An in-depth look at using heart rate variability biofeedback with slow breathing to reduce stress, enhance athletic performance and provide therapeutic support for some chronic health issues.

Heart rate variability biofeedback is being used primarily to reset the nervous system and thus as an antidote to different types of stressors. These include modern-day chronic stress, aka the all-time-on syndrome, or infections or other problems in our lives.

In this episode we compare the use of breathing techniques to other tools like meditation to improve HRV (Heart Rate Variability), and the use of biofeedback to optimize the benefits.

Biofeedback enables us to learn what yogis historically spent decades learning in a matter of weeks. And the applications are multiple. It can be applied to improving athletic performance, productivity, health issues such as headaches, irritable bowel syndrome, insomnia, asthma, inflammation and on and on.

It turns out that everybody has their own unique pace, where breathing in and breathing out at that pace produces the biggest peaks and valleys, the exact right phase angle between respiration and heart rate, and when you go into that particular rhythm, it seems to have tremendously beneficial effects. Again, we often see this as a brand new idea that’s 2500 years old because this is exactly what these yogis were doing.
– Richard Gevirtz

For the HRV biofeedback topic our guest is Professor Richard Gevirtz, PhD, professor of health psychology at Alliant International University. He has been working in HRV biofeedback for nearly 30 years and he’s published over 40 papers on biofeedback during that time in areas such as mind-body feedback, stress disorders, clinical protocols for the biofeedback, anxiety disorders and autonomic control. This was a great interview; I thoroughly enjoyed it. I hope you enjoy it too.

The episode highlights, biomarkers, and links to the apps, devices and labs and everything else mentioned are below. Enjoy the show and let me know what you think in the comments!

itunes quantified body

What You’ll Learn

  • The early days of biofeedback – key discoveries in conscious control over autonomic functions of the body (6:12).
  • How the science on the benefits and mechanisms of various yogi techniques needs to improve – to produce more quality studies and reliable data (11:05).
  • The degree of complexity in HRV biofeedback and the applicability of various beat-to-beat analysis in studying mechanisms of stress response (14:19).
  • Optimizing breathing and heart rate rhythms has beneficial effects on the cardiovascular system (19:26).
  • Why standard metrics do not apply for slow breathing, because this category is a low frequency range of approximately 4-7 breaths per minute (26:54).
  • Overviewing the ups and downs of available beat-by-beat biofeedback devices (32:25).
  • An average training session aimed at determining optimal breathing frequency during slow breathing. How to optimize measuring equipment and make people feel comfortable during the HRV tracking exercise (42:31).
  • Performance benefits of practicing breathing exercises, with examples in sports and music (46:33).
  • For optimal results, during practicing slow breathing you should be non-judgmental and self-observant at the same time (50:09).
  • How the brain and heart integrate physiological feedback in the body and how this system is negatively affected by anxiety and stress (52:35).
  • Positive effects on gastrointestinal health in kids with inflammatory bowel disorders, who practice slow breathing techniques (57:55).
  • In most studies on depression, improvements in HRV biofeedback are accompanied with beneficial effects (1:00:01).
  • Slow breathing training helps for anxiety and urge – control, by inhibiting stress response centers in the brain (1:03:52).
  • Data on cortisol (the stress hormone) indicates beneficial effects of slow breathing practice in fighting stress (1:04:30).
  • When practicing meditative slow breathing, it is important to measure EEG waves in low frequency ranges – in order to clearly demonstrate beneficial effects on heart performance (1:05:16).
  • Gratitude and compassion mindfulness exercises are broadly related to HRV performance, but optimizing slow breathing is a practicable and improvable skill to be learned and trained (1:08:47).
  • In the future, the team and Prof. Richard will continue to research outcomes of HRV studies, physiological mechanisms of slow breathing, and standardizing yoga breathing practices by beneficial effects (1:10:48).
  • How to best obtain information of Prof. Richard’s research and career (1:14:27).
  • People and lines of research related to Prof. Richard’s interests. Additional practical advice on integrating HRV biofeedback with your performance goals (1:14:27).

Prof. Richard Gevirtz

Tools & Tactics

Interventions

  • HRV Breathing: Modern science is increasingly focused on beneficial effects of meditation and slow or diaphragmatic breathing techniques – practiced at the pace of 4-7 breaths per minute. During slow breathing, heart rate and breathing rhythms synchronize – in a way that produces resonance in the autonomic nervous system. This concept is known as a meditators’s peak. The unique slow breathing pace at which it occurs in different individuals (for most people between 5.5 – 6 breaths per minute) can be determined using HRV biofeedback tracking tools. When tracking Low Frequency (LF) HRV ranges (see below), the meditators’s peak occurs as a single spike of great magnitude (in graphical form) and is followed by smooth overlaps between the peaks and valleys of waves representing breathing and LF HRV rhythms.
    Over time, slow breathing exercises produce flexibility in the autonomic nervous system. Essentially, practicing breathing at a specific, disciplined, rate synchronizes respiratory and cardiac systems to increase resilience to physical or psychological stress, improve autonomic balance, and sharpen mental clarity. These tools can be used to fight against stress related medical conditions such as Irritable Bowel Syndrome (IBS), hypertension, depression etc.
  • Acceptance and Commitment Therapy (ACT): Prof. Gevirtz has successfully applied this psychological therapy in his practice. A recent scientific review of all available research on ACT concluded that it is more effective than placebo, or standard treatment, in dealing with anxiety disorders, depression, and addiction.

Tracking

Biomarkers

  • Heart Rate Variability (HRV): HRV is the measure of the change in the heart’s rhythm over time based on changes between sympathetic and parasympathetic activation. HRV was previously covered in the context of managing stress using HRV in Episode 6 with Ronda Collier, in using hormesis to improve HRV in Episode 8 with Todd Becker, and in using HRV as a biomarker for longevity in Episode 20 with Dr. Joon Yun.
  • Time-Domain HRV

  • Standard Deviation of Normal to Normal R-wave Beat (SDNN): The most statistically simple measure of HRV – simply measuring beat-to-beat variability.
  • Root Mean Square of the Successive Differences (RMSSD): A measure used to calculate HRV that has proven to be reliable and is used in a lot of research studies. An integral measure that seems to be a little bit more dominated by the parasympathetic nervous system, compared to SDNN.
  • Frequency-Domain HRV

  • HRV may be broken into frequency components that compose the overall variability. Low Frequency (LF) is association with sympathetic activation; High Frequency (HF) is associated with parasympathetic activation. Frequencies of different rhythms can be detected over time in the heart rate. How much any of the frequencies is present in overall variability is indicative of heart performance and factors which influence this performance. For example stress is associated with high LF with respect to HF (high LF/HF ratio).

Lab Tests, Devices and Apps

    Biofeedback Devices

  • HeartMath: The company has developed products for tracking HRV. Devices include emwave2 and Prof. Gervitz’s preferred device – Inner Balance for iOS.
  • My Brain Solutions: The company offers products which track HRV including MyCalmBeat.
  • Muse: The Brain Sensing Headband: This device provides brain feedback data and allows users to determine when they are in a fully meditative state.
  • Breathing Timing Apps

  • MyCalmBeat App: Over 30 brain exercises for training slow breathing and improving HRV in managing stress.
  • Breathe2Relax: This is a portable stress management tool which provides instructions and practice exercises for using slow breathing techniques and managing stress.
  • Breath-Sync Music CD Suite: The suite includes six CDs with slow-breathing music, each at a different rate (from 4.5 to 7.0 breaths per minute).
  • Multi-Channel HRV Biofeedback

  • NeXus-4 by Mind Media: This instrument can be used to simultaneously track various biofeedback signals coming from photoplethysmogram (PPG) sensors. These sensors optically determine heart rate by illuminating the skin with the light from a light-emitting diode (LED) and then measuring the amount of light transferred to an opposite end of a finger – clipped sensor. Changes in light are indicative of changes in blood flow – which result from changes in hearth beat rhythm.
  • Stress Control Suite by Thought Technology: This software integrates information from multiple sensors relevant for tracking HRV and autonomic nervous system functionality. The Stress Control Suite works with the ProComp2, a physiological monitoring device which can be plugged to Temperature Sensors and Skin Conductance Sensors.
  • Multiple Channel ECG reader by J&J Engineering: This product connects to a computer and is able to monitor ECG, skin conductance, temperature, and respiration rates, at the same time. Price: $1,995.
  • HRV Analysis Software

  • Kubios HRV

Other People, Books & Resources

People

  • Peter J. Lang, PhD: A research scientist who was one of the founders in the field of psychophysiology (linking psychological phenomena with physical states of the body).
  • Our guest, Prof. Gevirtz, collaborated with Marks Schwartz PhD, Paul Lehrer PhD and with Dr. Stephen Porges during the early days of biofeedback.
  • Dr. Robert Freedman: Because of his interests in Raynaud’s disease, Dr. Freedman experimented with biofeedback as a way for people to learn to control blood flow in cold areas of the body – as a therapeutic means.
  • Neal Elgar Miller: An American experimental psychologist whose studies showed that animals and people could control all kinds of autonomic functions. Numerous studies of his have not been able to be replicated, leading to controversy. Regardless, Neal E. Miller’s legacy stems form inspiring future and current researchers to dig deeper into psychophysiology and behavioral studies.
  • Dr. Elmer Green has traveled to India and done extensive research on the physiology of yogis. He discovered that, through meditation and slow – breathing techniques, yogis could control a range of autonomic phenomena. Notably one yogi could warm one ear and then switch to warming the other, at will.
  • Laura Schmalzl PhD: Prof. Gevirtz recommends a recently published scientific review article by Laura Schmalzl on the topic of neurophysiological and neurocognitive mechanisms underlying the effects of yoga-based practices.
  • Dr. Ary L. Goldberger: A beat-to-beat heart rate is characterized by many different oscillators that are contributing to a healthy pattern. Dr. Goldberger is a pioneer of analyzing complex patterns in cardiology and in detecting how these vary in different heart diseases.
  • Lionel Messi: A world famous football player, currently playing for FC Barcelona. His coaches optimize his training using the gold-standard for HRV tracking – every morning in bed, right after waking up.
  • Prof. John Gruzelier: A researcher who makes use of brainwave feedback and slow-breathing techniques to bring benefits for recitals and dance performers.
  • Prof. Mihaly Csikszentmihalyi: A leading researcher in the psychology of flow (aka. optimal experience).
  • Tim Harkness: A club psychologist for FC Chelsea. His approach includes positive psychology, cognitive perception training, and psychophysiology.
  • Evgeny Vaschillo PhD: A Russian cosmonaut physiologist who started studying hearth rhythms in the very low frequency range – at approximately 3 breaths per minute.
  • Dr. Luciano Bernardi: At Italian cardiologist arguing that music offers beneficial effects in managing cardiovascular disease. Our guest shares the story of how Dr. Bernardi traveled to mountains in Bangalore accompanied by twelve yogi. He discovered the yogis’ slow breathing techniques had significantly increased their baro reflex (the ability to withstand high altitude without experiencing symptoms of altitude sickness).
  • Mark Stern: One of Prof. Gevirtz’s students who students who created a video to explain the basics of HRV Biofeedback and its Applicability.
  • Inna Khazan PhD is a clinical psychologist using mindfulness and biofeedback in her therapy. Prof. Gevirtz recommends her book on combining mindfulness with biofeedback (see below).
  • Dr. Kevin J Tracey: A neurosergant who is the president and CEO of the Feinstein Institute for Medical Research. His research focuses on inflammation and how neurons control the immune system.
  • Rollin McCraty PhD: Executive Vice President and Director of Research for the company HeartMath.

Organizations

  • Western Association of Biofeedback and Neuroscience: Formerly called the Biofeedback Society of California, was founded in 1974 and is the oldest and largest state neurofeedback biofeedback society.
  • Association for Applied Psychophysiology and Biofeedback (AAPB): AAPB’s mission is to advance knowledge about applied psychophysiology and biofeedback, to improve health through research, education and practice.
  • Mayo Clinic: Mayo Clinic is a nonprofit medical practice and medical research group based in Rochester, Minnesota.
  • The Wingate Institute: An interdisciplinary research unit focusing primarily on biofeedback and psychophysiology of gastrointestinal diseases. Notably, their research has shown that slow breathing exercises protects patients from lowered esophagial pain thresholds, thus lowering the conscious perception of pain.

Books

Full Interview Transcript

Click Here to Read Transcript

[DAMIEN BLENKINSOPP]: Richard, thank you so much for joining us today.

[RICHARD GEVIRTZ]: Glad to be here.

[DAMIEN BLENKINSOPP]: I wanted to get a quick background behind what you do. How did you learn to do what you do, these studies and this area; how did you first get into it and learn to do it?
[RICHARD GEVIRTZ]: Well I started as an undergraduate studying with a famous psychophysiologist named Peter Lang, who was one of the founders of the field of psychophysiology, which is basically different from neurophysiology because we’re looking at physiological measures indicating psychological parameters. In those days we were measuring heart rate, but not beat-by-beat heart rate, just average heart rate, and muscle tension, temperature and respiration.

Then I went to grad school and got waylaid a little bit into another topic, but eventually I came back to psychophysiology and began working. I was in Minnesota at the time and I was near the Mayo Clinic, and I ended up working with a guy who’s been a lifelong friend, Marks Schwartz, at Mayo Clinic and doing biofeedback. It was the beginning days of biofeedback.

In those days we were doing just muscle tension and temperature and breathing, not even heart rate in those days. That was interesting; we were doing work on chronic pain mostly, and then relaxation techniques with finger temperature. I did that for a number of years but became a little unhappy with it because it seemed very limiting.

I had a background in heart rate, and as the technology got better, we realized that we could measure heart rate in a much more sophisticated way. Actually, in the beginning, I was collaborating with Paul Lehrer, my colleague at Rutgers University, and we were fascinated by this. Also we were good friends with Stephen Porges, who is this Polyvagal Theory guy. We were fascinated by this idea that the action wasn’t in the sympathetic nervous system as much as in the parasympathetic nervous system for day-to-day stress. That went against everything we had been doing up till then, which was really calming down the sympathetic nervous system.

So, as the technology built, and we realized it was really an incredible amount of information in the beat-by-beat heart rate, he and I began developing this idea of looking at beat-by-beat heart rate and feeding it back to people.

At the same time, in cardiology, the measurement of the beat-to-beat heart rate was growing rapidly, and so we benefitted a lot from all of the cardiology research showing a healthy heart as a very complex, somewhat chaotic-looking pattern to them, and that represented mostly the parasympathetic nervous system.
(0:06:12)[DAMIEN BLENKINSOPP]: Great. To take a step back a bit, what is biofeedback and what are the benefits that you’re seeking through using that?

[RICHARD GEVIRTZ]: Biofeedback, in general, is feeding back physiological information to a client or a subject and having them try to modify their physiology based on what they see, based on either wiggly lines on a screen or some analogue – a rocket ship going up or a train moving, or some other visual or other signal.

In the early days, what we were doing was teaching people to relax their muscles more profoundly than they might be able to do naturally, and we did that by feeding back information from voluntary muscle activity from electromyographs. Then we used finger temperature because it turned out that by learning to warm your hands, you could shut down the sympathetic nervous system. The sympathetic activity produces vasoconstriction. As you learn to vasodilate, it generally accompanies relaxation.

[DAMIEN BLENKINSOPP]: People would focus on their hands?

[RICHARD GEVIRTZ]: Yeah, they would focus on mental techniques to warm their hands.

[DAMIEN BLENKINSOPP]: It’s interesting.

[RICHARD GEVIRTZ]: And it turned out that they could both cool and warm their hands at will. A colleague of ours, Bob Freedman, in Detroit, was interested in Raynaud’s disease, so he was starting to look at biofeedback as a way that people could learn to warm their hands, even without getting relaxed they could learn to vasodilate. He studied the mechanisms of that and actually found fairly detailed mechanisms of how people could warm and cool their hands with different mechanisms. But they could definitely do it; medical students, even while playing a game of bridge, they could warm or cool their hands when a signal told them to do it at, will. Not a lot, but to some degree.

Everybody was fascinated by the plasticity idea that people could really control these supposedly non-controllable autonomic phenomena. So actually the original impetus was Neil Miller’s studies in ’69 that showed that animals and people could control all kinds of autonomic functions, although most of that has not been able to be replicated, interestingly enough. But it’s a famous study in ’69 and we knew Neil Miller. He was a great pioneer in his field. So even though it hasn’t been replicated, it’s still got us all thinking about control of autonomic phenomena.

At the same time, a colleague, Elmer Green, went to India and studied yogis, and showed that yogis have remarkable control of autonomic function. Though he didn’t exactly know how they did it at the time, they certainly could do all kinds of things. They could warm one hand and not the other hand, they could warm one ear and not the other ear, and they could do a trick that looked like they were stopping their heart, which is actually just a muscle tension that hid the ECG.

[DAMIEN BLENKINSOPP]: So the ECG wouldn’t pick it up because of the way they were beating their heart?

[RICHARD GEVIRTZ]: Yeah. It looks like they’re actually stopping their hearts – they weren’t. But it’s still pretty amazing. And they also had great control over heart rate and they could control heart rate, so it looked like maybe people could learn to control heart rate, and that was our first foray into that idea.

[DAMIEN BLENKINSOPP]: Did you ever look into how the yogis had learnt that? Was it meditation or mindful?

[RICHARD GEVIRTZ]: Purely meditation, yeah. It was various kinds of yogic meditation with a lot of breaths, a lot of pranayama.

[DAMIEN BLENKINSOPP]: Was this like the fire breathing, the fast breathing and things like that?

[RICHARD GEVIRTZ]: All kinds of breathing techniques: fast breathing, nasal, alternation with nasal breathing, slow breathing, but the thing we eventually discovered was if we asked the yogis to do what they do to get calm and centered, whatever language we could use for that, they always did the same thing. They always breathed very slowly, somewhere between four and a half and seven breaths a minute – whatever breath rate they chose, they always used exactly the same breath rate, within a half a breath, and they could do it even during distraction.

One of our colleagues had this one yogi who had put skewers through his tongue and through his arm and his neck, and still maintained this exact breath rate through the whole thing.

[DAMIEN BLENKINSOPP]: Wow. Was he making new holes in himself with those?

[RICHARD GEVIRTZ]: Yeah, little tiny holes, but he could prevent bleeding. It wasn’t a fake because I was right there next to him and I felt those skewers and I saw him do it. I think he learned certain places to put them that didn’t bleed and would quickly close up again, but they could do this without any outward sign of pain, without any physiology changing, is just remarkable.

We realized that there was some potential for control and that set us off on this pathway.
(0:11:05)[DAMIEN BLENKINSOPP]: I actually used a machine where they look at the blood flow in your forehead. I don’t know if you’ve seen that it’s a biofeedback mechanism – you can play this little computer game and it will go in the right direction when you’re increasing the blood flow.

[RICHARD GEVIRTZ]: Yeah. The question about that technique is whether it’s really just measuring forehead and dura blood flow, maybe peripheral blood flow, or is it really going deeper into the brain to measure cortical blood flow, and I think that’s still to be decided. The claims are that you’re getting the first centimeter of the cortex – I don’t think that has been shown, myself. But something varies, there’s no doubt about it, and people can learn to control it.

Blood flow was one of those techniques that yogis could control. Remarkably sometime there was one yogi who could make one ear get very warm and the other ear stay the same and then he’d switch ears. How he did that, he could never tell us. He just willed it. But that’s pretty remarkable. Physiologically, you’re not supposed to be able to do that. There’s no evolutionary reason why we should be able to control an autonomic function like blood flow, so somehow the brain could learn to do this through some remarkable meditative techniques.

[DAMIEN BLENKINSOPP]: This is pretty spectacular. I’d read a lot of the yogi books and some of the books on the science of yoga, and I wanted to try it but I wasn’t sure there were actual benefits and I didn’t know what the benefits were, and it went through all the history and stuff – quite interesting to see that some of that matches up, that’s spurred on your interest in the area.

[RICHARD GEVIRTZ]: Right. Actually we’re trying to encourage better science, because they think they know it all and they can cure everything, and I think the chances are that they are definitely on to some very remarkable things, but others probably not.

[DAMIEN BLENKINSOPP]: Yeah, because it’s interesting because it’s split into different types of yoga and all of this, and which came from the actual practices. I understand that some people injure their lower backs and things like that, so there are some parts which are seen as not good and other parts, which as you say, could be good. So there’s a way to go to figure that out.

[RICHARD GEVIRTZ]: It’s very tricky for science because they don’t have standardized methods. We just got a paper from a group about a kind of a yoga called reflective exercise. It’s got some Indian name and it’s claiming fantastic results with athletes. Here it’s just a completely different one – they use reverse diaphragmatic breathing – and with all kinds of claims, with really not much science behind it.

I’m an associate editor of the journal Applied Psychophysiology and Biofeedback and we try to encourage people to send us some good scientific papers. We would love to see what the mechanisms are. There is just a recent paper coming out in Frontiers, looking at the neurophysiological mechanisms of yoga – a pretty extensive review by a woman named Schmalzl. There’s lots to be learned, that’s for sure, but I think it’s an area that will be studied more frequently.
(0:14:19)[DAMIEN BLENKINSOPP]: Great. Thanks for the reference on that paper, too. That will be interesting to read.

So you’ve been focused on the heart rate variability biofeedback for a while. What is that in comparison to the other stuff we’ve been talking about?

[RICHARD GEVIRTZ]: Firstly, the important point for the listeners is that heart rate variability measurement is completely different than heart rate variability biofeedback. The measurement is a very big field, very dominant in parts of cardiology, and the underlying idea is that healthy hearts have tremendous complexity in their patterns of beat-to-beat activity – and you have to actually look at a beat-to-beat to see this. If you go to the gym and do your average heart rate, that doesn’t pick it up at all.

A beat-to-beat healthy heart rate is characterized by great amounts of complexity – many different oscillators that are contributing to the pattern. For some heart disease things, you need a non-linear message to look at these really complex patterns. Ary Goldberger is pioneering this in cardiology and has amazing results with different heart disease, in terms of seeing how it varies.

The measurement is of interest to us because we do measurements on people with different disorders. The disorders we are interested in are more psychophysiological or stress-related disorders and they do show up with poor heart rate variability quite often.

[DAMIEN BLENKINSOPP]: Are we talking about RMSSD here?

[RICHARD GEVIRTZ]: Yes. There are three classes of measurement. One is called time domain measures, which are fairly simple, they just look at the beat-to-beat variability. The most common one is SDNN, standard deviation of the normal to normal R-wave beat. A little more sophisticated and one of the same type is called RMSSD, root mean square of successive differences. The difference between the two is that the second is an integral measure that seems to be a little bit more dominated by the parasympathetic nervous system. SDNN is simply all forms of variability, it’s just the standard deviation of beat-to-beat differences.

It’s quite simple really. You just get a column of interbeat intervals in milliseconds and take the standard deviation. That’s still very widely used and is a powerful epidemiological measure. RMSSD is a little bit more sophisticated because it picks up a little bit more of the parasympathetic nervous system.

Then there are frequency domain measures, a second class of measures, and that’s where you look at what the frequencies are of different rhythms over time in the heart rate. It gets a bit more complex then. So you have to print out a sequence of beat-to-beat heart rates and then look at the frequency characteristics of them, and those frequency characteristics then can be sorted by how much of each frequency. The advantage to that is that in one realm, what’s called high frequency power, is a pretty good analogue to the vagal tone.

The tenth cranial nerve is the vagus nerve, which is the parasympathetic nerve that controls heart patterns. At rest, it’s the dominant source of heart patterns. By being able to measure the amount of vagal tone, we can look at things that are of interest to us, especially psychophysiological disorders or anxiety disorders, depression, because those things are all diminished in those disorders.

[DAMIEN BLENKINSOPP]: So better vagal tone is better, more control?

[RICHARD GEVIRTZ]: Exactly, yes, good vagal tone is, in general. A rebound vagal tone, like in asthma, which is too much vagal tone and it shuts down the airways, but that’s just a poor amount of flexibility in the autonomic nervous system.

The goal is very flexible, resilient, autonomic nervous system; not necessarily more tone overall. We do see less vagal tone, however, in a number of disorders.

[DAMIEN BLENKINSOPP]: I think another scenario where high vagal tone may not be a good thing is adrenal fatigue – we’ve discussed it on the show before.

[RICHARD GEVIRTZ]: Yeah, that could be, and as I say, asthma, if you get a sympathetic surge followed by a giant parasympathetic rebound, it shuts down the airways and that’s not healthy. There are some situations like that. Some kinds of stress are vagal stress. For instance, if you show somebody a video of a fake shop accident, where the shop teacher is putting a piece of wood through a circular saw and we see him just about to saw off his finger, people rate that as very stressful, but they don’t get a sympathetic surge, they get a parasympathetic surge from that.

[DAMIEN BLENKINSOPP]: Interesting.

[RICHARD GEVIRTZ]: Similarly for a vasovagal response, people faint when they see blood or needles; that’s a parasympathetic response, not a sympathetic response. So the system is adaptive to what’s important. The vagal system is trying to preserve blood and shut things down, but that can be a stressful response too, so we don’t want you to just think stress is sympathetic.

(0:19:26)[DAMIEN BLENKINSOPP]: Right. In terms of the heart rate variability mechanism you’re looking at, which approach have you been using?

[RICHARD GEVIRTZ]: The measurements we use are the same as everyone else. I’ll tell you an anecdote – it’s a fun anecdote. Paul Lehrer went to Russia; went to visit his son who works for the state department, and there met some people doing some of this heart rate stuff. They had kids breathing very slowly and improving their vagal tone in front of computers in St. Petersburg. He couldn’t understand why that would work because it seemed like it would kill them if they had asthma. These are all asthmatic kids – but they were getting better.

He tried to understand that better and eventually that led him to a guy named Evgeny Vaschillo, who was the cosmonaut physiologist. He was observing heart rates and respiration rates in the cosmonauts. By some chance, one of the cosmonauts was a bit of a meditator and every day in space he would suddenly see these patterns of heart rate that were completely unusual. Big peaks and valleys, very slow big peaks of waves and valleys. Again, he called up and thought the guy was dying or something, and he said, “No I’m just meditating.” So, luckily he was also an engineer and a physiologist and he began studying these patterns.

At the same time, we were doing the same thing, but we didn’t quite understand it. But he helped us understand that at certain slow breathing rates there is a resonance produced in the cardiovascular system, between several different oscillatory systems. The main one is called respiratory sinus arrhythmia. It’s like a brake accelerator and every time you breathe in, the brake goes off; when you breathe out, the brake goes on. If you think about it, it makes sense: the brake goes off, heart rate speeds up; when the brake goes on, heart rate slows down.

Why wouldn’t you want heart rate to be speeding up when you have oxygen available for gas exchange, and then when you’re breathing out, there’s no oxygen available? Actually it saves you something like 350 million heartbeats over a lifetime. This rhythm is called respiratory sinus arrhythmia, RSA, and it’s a normal pattern that we can see in a normal resting heart rate. But when you breathe somewhere between four and a half and seven breaths a minute, that pattern becomes greatly exaggerated.

What Vaschillo figured out, and we’ve built on, was that at those rates, you’re getting the phase angle between the baroreceptor, the blood pressure rhythm in your body, and the breathing rhythm in your body at exactly a 180 degree phase angle. What’s happening is you’re breathing in and heart rate is going up, then it’s going up even further because blood pressure is at the exact right angle for blood pressure to go down to make heart rate go up; and then when you breath out, the opposite happens in the other direction. So, these unexplainable shifts in the cosmonaut, where it was going from 65 beats a minute to 95 beats a minute in each rest cycle – giant peaks and valleys.

[DAMIEN BLENKINSOPP]: So you can’t get that by – people would think based on the description you gave – I breathe in and it goes up? So I can’t take a really, really big breath, hold it for 20 seconds and breath out, and get a higher peak and trough.

[RICHARD GEVIRTZ]: No because the timing isn’t right. It’s like a metronome, and you have to push on both ends of that metronome to make those big peaks and valleys. You’ve got to get exactly the right pace to do that.

There is an artifact in there. When you breathe more deeply, you do produce an artificial pressure that does affect the heart a little bit. It’s not really the one we’re interested in. We’re interested in what happens during restful breathing at certain paces. That’s where the benefits seem to come. In fact, the danger of really deep breathing is people hyperventilate and then that has negative effects on them. So we really try to prevent hyperventilation at all costs.

It turns out that everybody has their own unique pace, where breathing in and breathing out at that pace produces the biggest peaks and valleys, the exact right phase angle between respiration and heart rate, and when you go into that particular rhythm, it seems to have tremendously beneficial effects. Again, we often see this as a brand new idea that’s 2500 years old because this is exactly what these yogis were doing.

These yogis have remarkable cardiovascular systems. None of them are hypertensive – we’ve never found one that’s hypertensive. If you take them to high altitude, none of them get altitude sick. A colleague Luciano Bernardi, a cardiologist in Italy – it’s a funny story – he went to Bangalore and found twelve yogis and got them to agree to go up to high altitude. The first thing he found out is that yogis are prima donnas, they wanted to be pampered. He thought they were going to be really stoic and not care what material – no, they wanted a certain kind of cot, a certain kind of food. So as they drove up to the Himalayas, the Italian crew was all getting altitude sick, having a tough time, and these guys are just complaining about the food!

We realized that what they’re doing is they’re strengthening the baro reflex tremendously, by 30 percent. Practicing every day, you strengthen this reflex in the cardiovascular system that has really powerful benefits for cardiovascular health, and that’s why they all have fantastic cardiovascular health because they breathe tons of time at these slow breath rates. They also do other breathing techniques too, but they do – do this as well.

[DAMIEN BLENKINSOPP]: Are there any studies on heart disease, cardiac issues in yogis?

[RICHARD GEVIRTZ]: These yogis don’t have heart disease, but of course they’re also vegetarians, who knows.

[DAMIEN BLENKINSOPP]: Right, there are other co-factors.

[RICHARD GEVIRTZ]: Yeah, lots of factors, but it’s unknown in these people that do this. There is a lot of evidence now in cardiac rehab that people that get a lot of vagal stimulation – nowadays the big money is in vagal nerve stimulators – that’s healing to the heart. There’s a study at Cleveland Clinic where they’re using the HRV biofeedback instead of left ventricular assist devices for people who are getting a transplant, and when they harvest the heart for the transplant, the old heart is much healthier than they would have expected. It’s well known that vagal input to the heart repolarizes the cells and is healing to the heart and overloading sympathetic system is very detrimental to the heart.

[DAMIEN BLENKINSOPP]: I don’t know if you have done studies, but we tend to be higher sympathetic basis? Everyone talks about it but I was just wondering about the studies and if we’ve actually looked at that?

[RICHARD GEVIRTZ]: The more chronically stressed your life is, the more sympathetic dominance there is. That generally plays out in poor cardiovascular health. The veterans coming back from the Gulf Wars have horrible looking cardiovascular systems. They look like they’re 70 years old – and they’re going through 18 months of chronic stress – and that’s really bad for your heart. So there are efforts underway to try to teach them techniques to prevent that.

(0:26:54)[DAMIEN BLENKINSOPP]: Coming back to the metrics you’re using.

[RICHARD GEVIRTZ]: The metrics don’t apply anymore when you’re doing slow breathing, that’s a hard thing for people to understand. So when you’re breathing normally, you want most of the activity to be in the high frequency – between 12 and 20 cycles per minute. That’s what’s called high frequency HRV. But when you’re breathing slowly, you’re purposefully moving out of that, into a lower frequency range. At rest, a low frequency range is indicative of poor vagal tone and high sympathetic activity, but when you’re breathing slowly, you’re artificially moving into that period of time during that slow breathing.

It’s like any kind of exercise. If you measure someone’s physiology when they’re exercising physically, they look like they’re quite sick during the exercise – their heart rates are flying high, they’re sweating – but, of course, we know that when they stop, then everything gets more resilient and more fit. The same thing is true for the autonomic nerve system. This is a kind of exercise for the autonomic nervous system. On a regular basis, you produce quite a lot of resilience, flexibility and health in that system.

The metrics fall apart completely when we do the biofeedback. We have to completely ignore them and start looking at a different sort of metric then. So then what we want is actually all the activity in the low frequency range, which is in the four to seven range. The activity we look at, there’s one known as meditator’s peak in that range – it’s a single peak of great magnitude in that low frequency range. If that was your normal breathing, that would be a sign of ill health, but during this slow breathing, it’s a sign of accomplishment, of being able to do the technique.

[DAMIEN BLENKINSOPP]: So it’s a specific frequency? Basically, nearly all of your heart beats are within this specific frequency range?

[RICHARD GEVIRTZ]: It’s exactly where you’re breathing. Let’s say you’re breathing in five breaths a minute, then it will be a little less than 0.1 Hz. If you’re breathing in at six breaths a minute, it will be exactly 0.1 Hz. If you’re breathing in seven, it will be a little bit higher than that, or something in-between those. That’s exactly what you see – breaths dominate that peak and then you want that peak to be the exclusive peak in the heart rate, and as high as it can be, during slow breathing.

[DAMIEN BLENKINSOPP]: Does it matter exactly where it is?

[RICHARD GEVIRTZ]: Yeah, for each person it matters because they have to find their resonance frequency. What heart math calls the point of coherence, we call resonance frequency. We think coherence is not exactly the right word because it means two things going together. It is two things aligning together – breath and heart rate – but they don’t measure breath, so we think really what you are doing is producing true physical resonance in the system between the baroreceptors and the breathing rhythms, and that’s where the big benefits come during that slow breathing.

[DAMIEN BLENKINSOPP]: Is it different for different people?

[RICHARD GEVIRTZ]: Yeah. We get some people at four and a half breaths a minute, that’s where their peak is; some at five; some at five and a half; some at six; some at six and a half; some at seven. We’ve done various studies to see where the frequencies are. They tend to be in the five and a half to six range for most people. Smaller people tend to have a little bit higher frequencies, very tall people have lower ones – it’s like a violin versus a cello, with different resonances. That’s not a perfect relationship.

What we do in the biofeedback is we test at every breathing frequency. With the other systems, what you do is just trial and error to try and find something that produces the most coherence. We actually systematically don’t do that; we systematically go through in some order. I like to start at seven and we do a few minutes of breathing at seven, then six and a half, then six. At some point, the pattern falls apart – it’s too slow – so we go back up another half beat until we find somewhere within a half a beat of the proper frequency for that person.

[DAMIEN BLENKINSOPP]: Where they’re getting their highest peak and trough?

[RICHARD GEVIRTZ]: Exactly, and the phase angles are correct, and it’s also the one with the smoothest heart rate patterns. That does show up – at our school they’re using a seismograph just to look at the pulse beats, but I think it does hold up that the smoothest, biggest peak-valley differences is usually where it will be.

[DAMIEN BLENKINSOPP]: Does that work with smooth breathing as well?

[RICHARD GEVIRTZ]: Yes, and we try to teach diaphragmatic breathing – smooth, restful, diaphragmatic breathing works better. If you overdo it, you hyperventilate and then you lose the effect. If you can breathe with your diaphragm, it’s much easier to breathe more slowly if you actually get your diaphragm in the action.

[DAMIEN BLENKINSOPP]: I think some people would know the heart math device, the M wave, already, in a sense, because that’s very consumer focused. With that one you have a score – basically, you get to 11, 16, if you’re getting higher. So mapping that to what you’re saying is the higher the S-score just the higher the peak and the trough.

[RICHARD GEVIRTZ]: Yes, well, what they do is actually measure the frequencies and then they take the low frequency that’s in the range of their breathing divided by all the other frequencies, so it’s just a percentage of activity in the low frequency range, which correlates very highly to the peak-trough difference as well.
(0:32:25)[DAMIEN BLENKINSOPP]: I see. If we compare that to what you do, do you use a specific device or devices?

[RICHARD GEVIRTZ]: Yeah, so we use one of many different biofeedback devices. The advantage we have is we measure four channels usually or five: we measure heart rate beat-to-beat, based on EKG not a PPG. So you can either do it based on a pulse – the problem with a pulse is that you have to decide when the pulse starts and stops – versus an R-wave of an ECG, which is a very distinct event to start and stop the clock. If possible, it’s good to use an ECG, which we do. So we use beat-to-beat heart rate, we use respiration – we have strain gauges for respiration. We look at finger temperature and skin conductance – that’s sweatiness on the palms of your hands. All of those are useful indices for what’s happening.

If you can, the devices that just use the single channel heart rate – the emWave, MyCalmBeat, a number of other ones that are out now–are fine, they work, but it’s certainly not as good an information as if you’re using devices that have the four channels.

[DAMIEN BLENKINSOPP]: Right. So you’re using clinical machines?

[RICHARD GEVIRTZ]: Right. But some of those clinical devices are getting down into the 600-700 dollar range now. The ones we use range from about 3000 dollars to about 11,000 dollars.

[DAMIEN BLENKINSOPP]: Very clinical!

[RICHARD GEVIRTZ]: That’s not for consumers. But, there are a number of devices now that are coming out that are going to be with those four channels, that will be ECG, that will be in the 600-700 dollar range. But for everyday people, the emWave device that really works well is the Inner Balance, the one that runs off an iPhone. It’s a beautifully designed device and you can have it on an iPhone and it’s tremendous to manage.

[DAMIEN BLENKINSOPP]: Yeah, because it’s convenient.

[RICHARD GEVIRTZ]: It works well but you’ve got to be sitting in front of a PC, which is a big difference, but it’s cheap and it works well.

[DAMIEN BLENKINSOPP]: I’ve had both the emWave and the Inner Balance – is it Inner Balance or the Inner Sense?

[RICHARD GEVIRTZ]: The Inner Balance is a Hearth Math device; it’s the one that goes on the iPhone. The other Heart Math ones either run on a PC or they have a handheld stand alone.

[DAMIEN BLENKINSOPP]: I find it so much more convenient, I basically keep it in my jacket pocket. I’ll be on a train or anywhere where I’ve got a bit of free time and I’ll just pop it on.

[RICHARD GEVIRTZ]: Right, absolutely. There are also some free apps. What we do usually is we don’t advise people to buy those devices because we find their resonance frequency with our instruments and then we give them one of three or four different ways of practicing at that pace.

MyCalmBeat has a free app for pacing. There’s another one we like called Breathe2Relax – these are free apps – or there’s a musical pacer, that does cost some money but it’s very nice, called Breathe Sync. It has five different musical tracks at your particular pace, so we have a separate CD for each person. We let people choose the ones they want, whatever is the most convenient. It’s really important that it’s something they can practice with.

[DAMIEN BLENKINSOPP]: So this isn’t biofeedback – this is once you have done the biofeedback, you’re just giving them the timer?

[RICHARD GEVIRTZ]: Exactly. And some people just count. I can do it now – I’ve done it enough that I can get exactly to my resonance frequency pace just by counting.

[DAMIEN BLENKINSOPP]: And then you become like a yogi basically, you’ve just learned a lot quicker to do it.

[RICHARD GEVIRTZ]: Yeah, I learned to do it but I don’t do it hours a day so I’m not quite like a yogi. I do it ten minutes a day.

[DAMIEN BLENKINSOPP]: Is there any danger of overdoing this, like if you did too much of it?

[RICHARD GEVIRTZ]: Not that we know of. Some people do get anxious when they try to do it, but usually that only takes a bit of practice until they get out of that. As far as we know, there doesn’t seem to be any ill effects of this, but people have worried about it and perhaps overstimulating the parasympathetic system. But it doesn’t really do that – it just gets you better balance in the system.

[DAMIEN BLENKINSOPP]: Right. Because when you said it was like exercise, like hormesis in a way, right? I’m just wondering as we can overdo exercise.

[RICHARD GEVIRTZ]: Well, the yogis are the ones who overdo it. They breathe many hours a day and they don’t seem to be in bad shape from it. I don’t know. There’s tens of thousands of the emWave devices that have been used and I’m sure some people must overuse them, but I know of no reports of any really ill effects of it. There might be but I don’t know.

[DAMIEN BLENKINSOPP]: It sounds like a very simple approach you have, just covering a slightly low and a slightly high and then just finding the optimum by moving around by testing. One of those devices – the 600-700 dollar ones – are there any names of those that are coming out?

[RICHARD GEVIRTZ]: The two companies that make them, they’re not quite out yet, they’re coming soon, one is J&J Engineering, which has a new device coming out in that range that will do those four channels, but it’s not a portable device – it’s a PC device. The other company is called Thought Technology, that’s a big biofeedback company. They’ve got a little device that’s coming out that’s a fingertip PPG, just a pulse amplitude but it also measures temperature and skin conductance, and it bluetooths it to a tablet. Then it has an accelerometer so you can put it on your chest and it will also give you the breaths measurement. So those two are in that range of price and they’re coming out fairly soon. I think one is out but not with all the channels yet, so I’m not sure where they are exactly.

The other company that doesn’t have a cheaper one yet is called Nexus, a Dutch software package. Thought Technology and Nexus have very expensive systems, but they do many more things than that – they do all kinds of bells and whistles.

J&J is a bit cheaper, it doesn’t have as many bells and whistles, but they also have a 3000 dollar device that measures many channels as well, but it doesn’t have as many displays, so probably for the consumer, none of these are of interest.

I’d say right now, the consumer device that is far and away the best for portability, is Inner Balance from Heart Math. They’ve mastered some things that nobody else has mastered. That system seems to work extremely well. I have yet to find someone that doesn’t get an adequate pulse from their earlobe, whereas we used to get a lot of problems with pulses and not everybody could get a good pulse.

[DAMIEN BLENKINSOPP]: The only problem I’ve ever had with – I think it was the emWave – was I was living in Spain – very, very bright sunlight – and if I was in the sun, it wasn’t working. I had to be in some kind of shade. That’s the only thing I ever came up with.

[RICHARD GEVIRTZ]: That’s true for any of the PPG devices. I haven’t ever really tried it in a really bright sunlight. So those are the devices, but we’re not sure that people need to spend the money on those things if they can figure out what their pace is and then just practice on a regular basis. Twenty minutes a day is ideal but people will practice ten minutes a day.

[DAMIEN BLENKINSOPP]: What are other ways? If I don’t want to buy the device, do some physicians have these kits or some other kind of specialist, so I could basically go for a session? I don’t know how long it takes to do this, an hour or something, and they would figure out my perfect?

[RICHARD GEVIRTZ]: Yeah, there’s a guy near you in St. Albans at the Open University who does it. There are people around who do this. We do a lot of trainings with people all over the world. I was just in Rome training people from all over Europe, so there are a lot of people who do this. And probably even more people who aren’t very well trained but who have the emWave devices who probably give close to enough to be quite beneficial.

[DAMIEN BLENKINSOPP]: For you, would it be worthwhile one session even if you’ve been doing emWave? Would it be worthwhile doing one session? It depends how extreme we are about these things.

[RICHARD GEVIRTZ]: Well you know what, it’s very convincing when you see it on the screen. So even if you were able to get exactly the right pace yourself, seeing the actual physiology change is amazingly persuasive.

With our clinical clients, we take a baseline at normal breath rates and then show it to them again after they’re done with the training, and they get emotional. They’re seeing that their physiology really has changed; their baseline physiology has changed dramatically over the course of six or seven weeks of training. That’s one big advantage of it.

[DAMIEN BLENKINSOPP]: And, of course, you’re cross-referencing lots of different data, so you’re seeing the change across the whole body. Is there ever a case where you see the change in just the EKG and you don’t see it in the other areas? Are you cross-referencing that data or is it more just to make sure?

[RICHARD GEVIRTZ]: We do cross-reference it with fingertip temperature and skin conductance. Sometimes we don’t get those, that’s true. Sometimes they don’t click and that may just be they’re being nervous in the session or something while we’re measuring them. And some people get very small changes in heart rate variability, especially older people. It’s actually a very small quantitative change, but they seem to get the same clinical benefits.

As we get older, those peaks and valleys definitely go down. Even if you’re quite fit – I’m a bicyclist, I ride 110 miles a week. I’ve been monitoring mine for twenty years – it’s going down despite my best efforts.

[DAMIEN BLENKINSOPP]: Even with all the training. So you’re not able to get the same peaks anymore?

[RICHARD GEVIRTZ]: Right. It used to be 15 – the value of the peak for me, 16. Now it’s 11, it just little by little by little it goes down. But, the good news is that in terms of the clinical benefits, it doesn’t seem to matter, as long as you’re training at that right frequency, you seem to gain the clinical benefits of it. It doesn’t necessarily mean you’ll live forever, but it seems to help with a lot of parameters.

[DAMIEN BLENKINSOPP]: So that’s similar to RMSSD, which declines over age as well.

[RICHARD GEVIRTZ]: Exactly, and that’s exactly why it does. Any of those indices would be measuring somewhat the same thing.
(0:42:31)[DAMIEN BLENKINSOPP]: So you spoke about people doing this for a number of training sessions. For someone wanting to do this, how long would it take? What’s the typical protocol you’d put them through to learn when you take them on?

[RICHARD GEVIRTZ]: We need one session to make sure we have the right frequency. Then we send them home with the practice techniques, any of the ones they want. Then they come back the next week and we just make sure we’ve got everything right, because sometimes one week of practice will change it a half a beat and we want to just fine tune it. Some people are very sensitive to that, others are not. The rest of the time is depending on what they’re coming in for, so if they’re athletes, we now start to use some sports psychology to integrate it into sports psychology.

I work with a lot of rhythmic gymnasts who get very nervous before they go on – those are the ones with the hoops and the clubs, that funny sport; these are little girls basically and they get nervous.

[DAMIEN BLENKINSOPP]: You mean they’re quite young?

[RICHARD GEVIRTZ]: Yeah they’re 11 or 12. The coaches are Bulgarian usually.

[DAMIEN BLENKINSOPP]: They’re quite tough on them.

[RICHARD GEVIRTZ]: So we teach them the technique, they come back, make sure they have the technique–these kids are fantastic at it, they get giant peaks and valleys. They’re so fit and good at this stuff. Then we sort of integrate it into the cues in their routine where they tend to get nervous, pairing them together with some sort of sports psychology intervention, so that might take a few more sessions.

[DAMIEN BLENKINSOPP]: Are you getting them to trigger it at just the right moment where they would normally get a bit more anxious, but you trigger it just before something?

[RICHARD GEVIRTZ]: Exactly, and we have to work out how to do that. But for somebody who just wanted to do it for their own benefit, we probably could do it in two sessions, as long as they keep practicing, they’d do very, very well.

[DAMIEN BLENKINSOPP]: So they come back for a session of half an hour, an hour?

[RICHARD GEVIRTZ]: They come back for an hour. That’s what our standard session is, but we usually talk about other things during that hour. We also want to get a baseline again and so we try to distract them and just get them breathing normally. One of the problems is that if people don’t breathe normally, you can’t get an adequate baseline from them. So if they breathe slowly, it messes up their RMSSD data. It messes up all their data, so suddenly they don’t have any high frequency data. You have to make sure they’re breathing at their normal breathing pace when you’re getting baseline or follow-up data, and then when they do the slow breathing, then that changes everything.

[DAMIEN BLENKINSOPP]: Right, just to make sure you’re comparing to that – you’re getting a real control basically.

[RICHARD GEVIRTZ]: Exactly.

[DAMIEN BLENKINSOPP]: This is how they are in real life or this is how they are just before they’re going to compete, in the other example.

[RICHARD GEVIRTZ]: Yeah.

[DAMIEN BLENKINSOPP]: So would you give them a heart strap and monitor their athletic when they’re actually doing it?

[RICHARD GEVIRTZ]: We do do that, and that would be just for research purposes. We don’t do it for them. They’re not usually allowed to have that in a real competition anyway. It depends how they are, and it depends on what we’re doing.

Another application that’s not biofeedback but it’s an interesting HRV technique is for detecting over-training. FC Barcelona has got Leo Messi every morning doing five minutes of heart rate variability measurements, right in bed in the morning, and the training director monitor that. When they see dips in heart rate variability, they decide that it’s over-training and they ease up his training protocol. So if he has a couple of games in a week, they’ll monitor that and try to see, because over-training generally produces poor performance.

[DAMIEN BLENKINSOPP]: Absolutely.

[RICHARD GEVIRTZ]: So that’s catching on like crazy. The sports psychologists are so competitive- if anybody gets anything, they all do it, just immediately.

[DAMIEN BLENKINSOPP]: They see it as a competitive advantage. I was thinking, you said they’re not allowed to wear those during competitions. Well I can understand why – if you’re getting biofeedback, it’s kind of like cheating. I don’t know if it’s cheating but you’ve got a competitive advantage.

[RICHARD GEVIRTZ]: Could be, yeah.
(0:46:33)[DAMIEN BLENKINSOPP]: What’s the performance benefit of being able to put yourself in this restful state? Say I’m just about to compete; is there a study showing there’s a performance benefit or another benefit, or is it just keeping their mental focus?

[RICHARD GEVIRTZ]: Yeah. It has to be for sports that are single action kind of sports, so golfing, gymnastics, baseball hitting, cricket batting, possibly penalty kicks in football; things like that. For aerobic sports, there’s no parasympathetic at all – they’re all in the aerobic range. It probably doesn’t make much difference for those, although it gives them a little bit of a psychological edge – it’s hard to detect the benefits there.

For baseball, one of my former students is in whole practice dealing with Major League Baseball players for hitting, because you’ve got a split second to make up your mind. The ball is coming at 95 miles an hour, and you have to be in exactly the right arousal level to be able to flow through that swing. It’s a way of getting an optimal flow state in things like that. Also in dancing and music, there’s a guy in London, John Gruzelier, who does it with dancing and music and combines it with brainwave feedback, and gets benefits for recitals and dance performances and things like that.

[DAMIEN BLENKINSOPP]: So it sounds like it’s eliminating nerves, is that the application?

[RICHARD GEVIRTZ]: Well, trying to get people into their optimal – to try to get them from over-aroused to the medium level. There’s a famous curve called Yerkes-Dodson Law, which is an inverted U-shape and the y-axis is performance, on the x-axis is arousal. Imagine an upside down U – people do the best in the middle, too high or too low isn’t good. We don’t want them to be relaxed, we want them to be psyched, but if they’re over-aroused then opposing muscles don’t work well, they began to get a certain choking mentality, they start thinking “What if I screw up?”, things like that.

[DAMIEN BLENKINSOPP]: I don’t know if you know about the science of flow and the books around flow. I can never pronounce the guy’s name, it’s very long and complicated – Csikszentmihalyi.

[RICHARD GEVIRTZ]: We think that we’re trying to go for the same thing. But it turns out, I was just at this conference in Rome and there were a lot of sports psychologists. One of the points they made, and it’s actually rare for athletes to be in the flow state during a performance, it’s definitely the ideal. These are people dealing with Olympic athletes, the most elite athletes in the world, and their experience is that maybe ten or fifteen percent of the time they actually get into their flow state. Now they’re saying the important part is if you don’t get into the flow state, don’t panic and go into the complete opposite quadrant where you’re really choking completely. But work on getting through the routine and the best arousal you can. That’s the first I’d actually heard that – I thought it was pretty interesting.

[DAMIEN BLENKINSOPP]: Right, so that’s more like limiting the downside, or focusing on not getting the troughs?

[RICHARD GEVIRTZ]: Exactly. There’s a guy working in London with FC Chelsea doing that, Tim Harkness. Chelsea has got a big room full of expensive biofeedback equipment, called “the Mind Room”. He works with all these multi-millionaire players. So it’s interesting to see.

Try to be self-observant, non-judgmentally observing your thoughts and breaths as you do it
[DAMIEN BLENKINSOPP]: One of the things I’ve done with Heart Math – you can tell me if this fits with exactly what you said – is I’ve tried many things to get my peak higher, of course, and get my highest score. I do think that what you’re doing with your mind seems… For me personally, I’ve had the biggest peaks and troughs over time by actually focusing on the wave in the device, so just watching the wave go up and down and then I breath at a specific point in that curve, which I found works for me.

[RICHARD GEVIRTZ]: Yeah, and I should have said that, so for some people, we don’t use the pacing at all – we do exactly what you do. We just show them their heart rate and respiration, we have the advantage of one more channel for them to look at, because you can see their breathing.

[DAMIEN BLENKINSOPP]: When you say one more channel, what would that be showing?

[RICHARD GEVIRTZ]: It’s showing a wave form of breathing, just a nice, smooth wave form of the breathing rate – so when you breathe in, it goes up; when you breathe out, it goes down.

[DAMIEN BLENKINSOPP]: In addition to the heart?

[RICHARD GEVIRTZ]: It could be smooth or jumpy and you want it to be smooth.

[DAMIEN BLENKINSOPP]: Right.

[RICHARD GEVIRTZ]: We would say exactly the same thing for a certain percentage of people: just make those two go up as high as they can, and down. Some people absolutely prefer that, they get their best results. I think partially because it takes away any performance anxiety, you’re just trying to match it as opposed to trying to breathe to a pacer. Some people really have a hard time breathing to a pacer, so we absolutely leave that as an opening – just do that, kind of thing.

We do try to promote a mindful mental set as well, so we try to say, “Try to be self-observant, non-judgmentally observing your thoughts and breaths as you do it.” I think there are some real benefits to doing that. I’m not sure it shows up exactly in the heart rate patterns, as we said earlier. I think that remains to be seen. If it does, it’s a pretty subtle difference.

[DAMIEN BLENKINSOPP]: If I started thinking about something stressful, like work, some problem I had at work, would that tend to put me off or would you think that would have a minimal impact compared to breathing, as long as your breath remained the same?

[RICHARD GEVIRTZ]: Right. It probably would be very hard to see as long as your breath stayed exactly in that same pattern. Oh, of course, it might interfere with your breath pattern too. Then you’d see it for sure; but if you maintained your breath pattern exactly the same, you’d probably have a very hard time seeing very much in there. Whatever it is – is subtle. If there is something to that, it’s probably quite subtle.
(0:52:35)[DAMIEN BLENKINSOPP]: What do you think about the connection between the brain and the breathing pattern in this case? By taking on this physiological breathing, do you think it will naturally affect the brain? I don’t know if there’s any research related to that, that it will put you in a different state of mind as well, as long as you maintain that.

[RICHARD GEVIRTZ]: We’re working on that now and we’re definitely finding pretty dramatic effects. Eighty percent of the vagal fibers are afferent – they go from the heart to the brain; only 20 percent of them are efferent – from the brain to the heart. This is something Heart Math has definitely pointed out and we agree with them on this completely, and it’s interesting. So the brain is listening to the heart more than the heart is listening to the brain, which seems counterintuitive. But they’re both part of a central autonomic system that integrates frontal lobe and some limbic system activities into the brain function. So really, it’s silly to treat them as separate systems – they’re an integrated system.

It appears that this technique has a powerful effect on the vagal afference going into the brain, so the brain states are quite dramatically affected. We recently published one study, and we’re just about to publish another, where we look at a brain wave called an evoke potential, it’s a very short – just for 800 milliseconds, and you do it for repeated stimuli. In this case, we take the filters off. Usually when they do EEG, you put a big filter on to get rid of that R-wave and the heart rate, because it messes up the EEG. But we take that off and let it mess it up, and you can see a very giant spike in the EEG for every heartbeat. Well there’s another wave that comes right after that – 250 milliseconds after. It appears to be the brain processing the information from the heart and it’s called a heart period evoked potential.

We measured that during positive emotions, negative emotions, baseline, slow breathing and resonance breathing. Resonance breathing had by far the biggest effect on it. Negative emotions did diminish that wave, so if your brain is busy thinking about the worst thing that ever happened to you, it doesn’t pay attention to your heartbeat anymore. During the slow breathing we got a dramatic improvement in this processing of the R-wave. It also correlates with people’s ability to be able to detect their heartbeat. There are some German studies that had people try to guess what their heart rates where. They were much better at it if they had that big wave at the 250 milliseconds.

So yes, I think the other powerful part of this is that we’re bombarding the parts of the brain that I think are beneficial to us with a very positive wave form – it goes up into the frontal cortex and the part of the brain we think that controls depression possibly – and this would be the basis for the claims of positive mental states coming from the heart rate itself. I think there’s a lot to that – we’re continuing to do more research on that. The results we got from both studies were very dramatic.

[DAMIEN BLENKINSOPP]: You mentioned a few use cases. What are the other most beneficial use cases that you have been working on over the years and you feel like the best applications for it are?

[RICHARD GEVIRTZ]: We mostly focus on autonomically mediated disorders, which are giant amounts of medical disorders. That would be things like functional gastrointestinal disorders like irritable bowel syndrome, reflux, functional abdominal pain, diarrhea, constipation. Those are massive familiar disorders and they’re greatly affected by the autonomic nervous system. There’s actually an institute right there in London, Wingate Institute (it might be a good thing for one of your podcasts actually), where they actually look at esophageal pain thresholds, with a nasal tube down the throat, and how they’re affected by autonomic function. They’re dramatically affected, and slow breathing changes the pain thresholds: it protects you from lowered pain thresholds. That probably is the low-hanging fruit in terms of applications.

We see about 15 kids a week with functional abdominal pain from our children’s hospital and we get tremendous results with those kids.

[DAMIEN BLENKINSOPP]: Is it therapeutic or is it just lowering the pain?

[RICHARD GEVIRTZ]: No, it’s therapeutic because the functional abdominal pain is actually caused by an imbalance in the autonomic nervous system. There’s no pathology that’s detected, these kids have been scoped, there’s nothing wrong they could find, but your gut needs a lot of parasympathetic input to function, and if you take that away… The kids that get this are all “internalizers,” they’re a little bit anxious kids – they’re great kids, they’re achievers, but they tend to be a little bit nervous, they worry about getting into a good university in third grade and things like that.

[DAMIEN BLENKINSOPP]: The famous insecurity overachievers.

[RICHARD GEVIRTZ]: Yeah, they’re lovely kids to work with, we love them, and they do very, very well. Adults don’t do as well but they still do well.
(0:57:55)[DAMIEN BLENKINSOPP]: You mentioned IBS as well. I think this is becoming a lot more common these days, a lot of people are getting these kinds of conditions and gut issues. Is it therapeutic also for those areas? Because a lot of people talk about probiotics, the microbiome, gut lining damage, gluten intolerance and all of these kinds of things related to these disorders, so I’m just wondering if you have had therapeutic benefits there.

[RICHARD GEVIRTZ]: Yeah, the relationship between the biome is complicated. I don’t think we know it, but it is definitely a parasympathetically connected system. We’re not quite sure whether we’re correcting it or whether it corrects us. The problem is the probiotics – there was a Cochrane Review on probiotics – apparently they are not near enough probiotics to have much effect, to really change the biome. But the biome definitely affects the brain, there’s no doubt about that, and probably through the autonomic nervous system. In fact we know it does through the vagal afferent system. So I think in the future, we will be pairing up with better techniques for improving the flora of the gut with these kinds of techniques that we use.

[DAMIEN BLENKINSOPP]: To kind of come at it from two different angles.

[RICHARD GEVIRTZ]: Both ways, I think that would be quite powerful.

(0:59:09)[DAMIEN BLENKINSOPP]: So you are seeing a permanent improvement in these cases, like IBS and stuff? But do they have to keep up the practice in order to maintain it?

[RICHARD GEVIRTZ]: We thought they did but then we did a follow-up and we asked them more in-depth questioning, and it turns out they just use the technique whenever they feel symptoms coming on – they don’t actually continue to practice very often. Some kids do, but a lot of them said, “Oh yeah, I keep on practicing,” and we asked them, “So what does that mean?” and they said, “Well, whenever my stomach gurgles, I do my slow.”

[DAMIEN BLENKINSOPP]: Okay, but that’s a good thing. That means that there is something that you’re fixing, basically, and so you don’t have to constantly – just maintain the practice in order to maintain it.

[RICHARD GEVIRTZ]: The kids with these disorders are at much greater risk for adult IBS – a lot of studies show that. We don’t know if we’re preventing that risk, but we think we are. We’ve had some five or six year follow-up with some kids and they seem to be doing just great at that point, so hopefully that will move on through their lives to be quite beneficial.
(1:00:01)[DAMIEN BLENKINSOPP]: Are there areas that you’ve looked at where it wasn’t effective? You mentioned depression – has it been effective in those kinds of neurological things?

[RICHARD GEVIRTZ]: I didn’t think it would be, but my students wanted to try it – I have a lot of doctoral students and we keep on consistently seeing beneficial effects on depression, probably through that vagal afference system. We are consistently seeing that and we’re doing more studies, and I think every study so far has shown a beneficial effect on depression. Sometimes they’re combined with psychotherapeutic techniques – in most of the studies they are. In one study they weren’t, they just did nothing but the biofeedback, and they got improvements, though there was no control group in that study. But the other studies, they are just adding it to cognitive behavioral therapy or one of the mindfulness-based therapies, and it seems to add a definite benefit to it.

In one study in China, they compared just slow breathing, without finding the right frequency, to finding the right frequency, and the frequency finding had better results than just slow breathing, even though that did help.

There are some indications that technique specifically might be beneficial. It probably is no more helpful than palliative techniques for chronic pathology like nerve pain, probably not very beneficial for people with Crohn’s or chronic IBD, inflammatory bowel disease. There is possibly an effect on the inflammatory system. There’s a guy called Kevin Tracey that has traced this cholinergic immunological system. There’s a lot of interest in that now, but we have not been able to show yet that it has any benefit on immunological function, but it may be.

There’s research coming out now that is indicating it might have an effect on one part of the immunological system. There’s a vagal part of that system that may help, and if it does work, it would probably be that it would be helping the system from going bonkers. Sometimes people’s immunological system turns on and doesn’t turn off again – autoimmune diseases – and nobody knows quite why that is, but it looks like strengthening this vagal system might prevent that. That would be that it might help to reset it; there are some claims of that. I would say the evidence is just beginning now.

Other disorders, it doesn’t seem to help for atrial fibrillation for some reason, that’s kind of a nerve induction of the heart itself. Pacemakers aren’t involved. At my age, all my friends are getting atrial fibrillation. I’ve tried it on all of them and it doesn’t seem to help very much. Then there are probably a number of physical disorders that it doesn’t really help. If it’s an autonomically-mediated disorder it seems to be quite effective.
(1:02:52)[DAMIEN BLENKINSOPP]: I guess what we haven’t spoken about is people’s emotional happiness and things like that. Are there any evidence that it improves satisfaction or happiness or stops angry outbursts?

[RICHARD GEVIRTZ]: Yeah, we have a couple of studies that show it helping with urge control. The pathway back up into the brain seems to go through the places that have inhibitory neurological control of emotion, so we have some reason to believe that if you can improve those inhibitory circuits, that would help a lot with anxiety, help a lot with urge.

We’re doing one now with smoking, people who are in smoking cessation programs, to try and help them with their cravings. There’s a food craving study that showed benefits for food craving and we’re doing another one of those right now actually. So there’s some reason to believe it might help with some of those kind of impulsive urge kinds of things.

I’ve used it with clients with anger control and they’ve reported the results, but there are no studies that I’ve seen, so it may be helpful for anger control. But we don’t just do it alone; we always combine it with a lot of other techniques. It’s going to be hard to show that by itself it’s a beneficial technique.

Heart Math has all kinds of studies on stress, self-reported stress, and self-reported life satisfaction that always show benefits but it’s hard to know how much of that is placebo and how much of that is the actual technique. I think it helps people, but the studies are hard to do and it’s self-reported – you have to put in a sham control of some sort to make them think they’re getting something that they’re not – but it’s hard to do those.
(1:04:30)[DAMIEN BLENKINSOPP]: Right, that is hard. Have you seen anything with cortisol levels or something like that, hormonal?

[RICHARD GEVIRTZ]: There’s a little bit of data in burned out cortisol patients with long periods of rehab – they do better. But there again, we don’t just do that, we do it with integrated exercise, with activity management, with sleep management. Those are the things that all go together in these syndromes and I would never just do the biofeedback. But biofeedback is the part they like the best.

[DAMIEN BLENKINSOPP]: There are benefits to that if they’re actually interested in coming into the physician’s office.

[RICHARD GEVIRTZ]: Exactly. We say it’s the “Trojan horse technique” – it gets people in, they don’t resist it. That’s true for a lot of disorders. With veterans we get them in by saying we’re doing biofeedback before we do any psychotherapy with them.

(1:05:16)[DAMIEN BLENKINSOPP]: The part you brought up about resisting impulses, so impulse shopping; we can think about lots of things we do on impulse. Personally, for performance at work and with my businesses and everything, I find that extremely important. Basically, in the morning, if I do some meditation, perhaps do some Heart Math, I do feel more in control and I’m less likely to work on something that is a waste of time for a couple of hours, rather than exactly the right thing that was going to bring the best results. So I find it from a performance perspective to be very, very important.

There’s a big trend in meditation. I also have a device which I can use – I don’t know if you’ve seen this – the Muse. It’s an EEG, you place it on your head and it tells you how calm you are in terms of alpha waves and so on. I’ve used both and I’m not sure, sometimes I’m left wondering “Which one shall I use today?” or “Which one shall I do this morning?”. I’m not exactly sure which one would be the most beneficial, so I’m just wondering if you have any perspective on it, or if it’s worth doing both, or one on one day and one the other day?

[RICHARD GEVIRTZ]: If you hook then both up, I think you would see that your optimal alpha state will come very quickly when you’re in resonance frequency, which to me is much easier to do. But, and I’m interested in your feedback, do you think the feedback on the EEG is as beneficial to you as on the emWave?

[DAMIEN BLENKINSOPP]: I feel like it’s different, honestly. I’m actually using Inner Balance on that now. I used to use the emWave before. With that one, I tested meditating, so I’m doing mindfulness meditation, and I didn’t get good scores in the Heart Math device. However, I definitely used breathing when I’m using the alpha wave thing and it definitely does help. So, it’s interesting, and I’ve heard that from other people using this – if they use their standard meditation, they don’t tend to do well on the Heart Math.

[RICHARD GEVIRTZ]: No absolutely. It’s because you’re not breathing in the low ranges with that. What is your standard meditation, is it a mantra-based one?

[DAMIEN BLENKINSOPP]: I’ve tried different ones. I’ve tried the mantra, and just the breathing mindfulness. The worst I would say, mantra is worse.

[RICHARD GEVIRTZ]: We get nothing from mantra people, even with years and years of mantra work – it doesn’t tend to train their breath. We did transcendental meditation with 30 year meditators and we were looking at brain scans at the same time. They had dramatic effects on their brain scans. Their mantras really affect their [unclear 1:07:45] a lot. But, we saw no effect on their breathing whatsoever, which is sort of good for the scanner because if you change your breath, it changes the BOLD response in the FMRI, which is an artifact. So then suddenly you don’t know what the heck you’re measuring. But in breath meditators, it just seems to vary a lot, so some of them do breath in the resonance range so they absolutely get both going together.

The Muse will definitely teach you how to get into an alpha state, independent of breath. Those are two separate things, so it’s interesting that you say that. To me though, if I hook myself up to an EEG, it’s so much easier for me to get into alpha by just breathing slowly than it is by paying attention to the EEG feedback that I don’t bother with.

[DAMIEN BLENKINSOPP]: Right, because you’ve potentially learnt. I’d love to run them both, but I need two phones because they both interface with the iPhone and you can only run one app at a time, unfortunately. So I’ll have to get an additional phone. It will be interesting to see how that works out.
(1:08:47) The last thing is–we did touch on it just before the interview – there’s a lot of people talking about gratitude types of meditation and empathy and that kind of thing, and that having an impact. How do you feel that connects or it doesn’t connect?

[RICHARD GEVIRTZ]: I think it only mildly connects, but I think it’s an independent, important thing to do. In our clinical training, we start with the biofeedback and we end up with mindfulness-based techniques, that’s pretty much all we do. We don’t do cognitive behavioral therapy at all anymore – the kind we like is called “acceptance and commitment therapy,” ACT. It’s another one of many, and it has a strong compassionate meditation, strong mindfulness component. I think most of those have the same kind of strong component.

I think it’s important for your brain functioning to learn those things. It doesn’t seem to have much impact on the heart rate variability, as we were saying before. I don’t see a ton of impact on heart rate variability and that’s mainly because breath is such a dominant factor in what we’re saying on that screen. As we get more sophisticated, we might be able to tease out some non-linear components or something once your brain is in a mindful state – it should show up somewhere.

The thing right now is like you walk into a room full of people talking loudly and trying to hear someone across the room whisper. It’s hard to pick it out because it’s a small component in the overall picture of heart rate. But, certainly there’s a lot of evidence now from brain scanning type techniques and EEG techniques that people do benefit from repeating it. It’s a skill, it’s very important to know it’s a skill, and the more you practice those mindfulness, compassion and forgiveness type skills. The evidence is strong that for instance forgiveness produces beneficial health outcomes, no doubt about it, and so does compassion. Those are things that we know are beneficial in some ways but probably in somewhat independent channels.
(1:10:48)[DAMIEN BLENKINSOPP]: Great. What’s coming next? You mentioned a few things, so in the future, are there any things you are looking forward to in this area or directions you’re moving in to? You mentioned a couple of things over the period.

[RICHARD GEVIRTZ]: I have a slew of students so we’re all doing this kind of research, so we generally focus on maybe three things. One is just outcome data from heart rate variability biofeedback. We keep on doing studies and trying to see what it works for, and we’ve got a bunch on those going so we’re always looking at how does it work compared to other techniques and compared to other controls, and we tend to get very positive results out of that. I just published a literature review on that and we have quite a number of applications where it looks like it works. We don’t have much big funding so we have to do little small studies – big pharma is not too interested in this technique, as you might guess, as “skills and not pills” is our motto.

The second one is mechanisms, so we make reference to how does it work? What are the other mechanisms here? There’s a whole bunch of new stuff on that. Vaschillo, that Russian guy, is looking at rhythms in the very low frequency range and seeing what happens to the blood pressure systems when you breathe at like three per minute, and there’s some really interesting data coming out on that. We’re trying to understand both psychological and physiological mechanisms of why this works, how does it work – we’re going to do many more studies looking at how the brain is affected.

The third one is, I’ve sort of been dragged kicking and screaming into this by my students, but looking at yoga and trying to standardize yoga and see what are the mechanisms by which yoga works. The other mechanism that I think is important but we have not been able to pin down, is the postures. We know the pranayama component of yoga is very important–that’s what we study, and it’s real easy to study that–but when we look at the postures, the body was evolved for movement so there are massive afferent pathways from muscles back to the brain and we’re quite interested in what are those pathways and how does the movement complement the breathing. The thousands of years of looking at movement-breathing complementarity – there’s probably something to it, but it’s very hard to study that and it’s very hard to figure out how to study those afferent muscle pathways. There’s not a good way to study it non-invasively – so that’s an issue.

We’re doing yoga studies for IBS right now, seeing how much heart rate variability changes. These are students who are very proficient in yoga, they were instructors and they beat me up until I let them [unclear 1:13:27] on yoga. There are assorted other topics that come up.

There are a lot of parametric things we don’t know, like [check 01:13:36] Hubbard inhalation-exhalation ratio: is it important to breathe 40% in, 60% out? That’s what everyone thinks but now there’s one study that shows that no that’s not very important, 50/50 is okay. Another study showed that 40/60 is better, so we want to look at that. We want to look at lying down versus sitting up. So these are little studies we do, parametric studies, so the students can get a scientific poster out of it and we present it at a meeting, and if it comes out, then we try to publish it. These are things that really nobody is studying and we really need to know those things.

Tight-fitting clothing – it looks like women who wear very tight-fitting waists don’t breath diaphragmatically at all, and it looks like it has a detrimental effect on them.

[DAMIEN BLENKINSOPP]: These are useful things. You find the answers to these, you can improve a whole bunch of lives.

[RICHARD GEVIRTZ]: Right.

(1:14:27)[DAMIEN BLENKINSOPP]: Mass market kinds of lives. I came across you first in a presentation video. I’m just wondering, what are the best ways to learn more about you and your work? Are there presentations you have got up online? Are you on Twitter? Do you have a website? Where’s the best place to connect with you?

[RICHARD GEVIRTZ]: We have some YouTubes out there. I avoid Twitter like the plague. One of my students, Mark Stern, did a very nice YouTube explaining heart rate variability biofeedback – it’s fairly recent. If you just Google “Mark Stern HRV BSC” (Biofeedback Society of California), it’s the first one that pops up as it’s got a long address. He goes through and explains how the biofeedback works and some of the stuff we’ve been talking about.
HeartMath has a lot of stuff too, so a lot of their stuff is really good.
(1:14:27)[DAMIEN BLENKINSOPP]: Great, so I’ll put all of that in the show notes.

Is there anyone besides yourself – you’ve mentioned a few people already, but is there anyone else you would recommend that people look up to learn more as well?

[RICHARD GEVIRTZ]: There are websites – the one you saw probably was from Thought Technology, because they keep on doing things with me and putting them up there. My website – I have a hard time keeping it recent, but there’s a lot of stuff from the Association for Applied Psychophysiology and Biofeedback, AAPB. We’re just coming out with another magazine, a whole magazine and all the articles on HRV, and they tend to be lower level, not quite as scientific. And we publish things in regular journals all the time.

There’s a woman named Inna Khazan in Boston who published a book of combining biofeedback with mindfulness techniques. That’s a really nice book. I hope to review it for the publisher, and she did a very nice job on that book. She’s using our techniques pretty much, she’s taken our workshops, but she’s quite an accomplished mindfulness-based therapist and she put that altogether in a book that she has published.

[DAMIEN BLENKINSOPP]: That sounds great. Thank you for that. So just a little bit about you and how you approach data in your life. I’m just wondering if there are any biomarkers or anything you track in your life – could be HRV, could be other things – and use it to make decisions or just to keep track of where you are at personally?

[RICHARD GEVIRTZ]: Well, I do check HRV but it’s kind of discouraging since it goes down as I get older. I do it sometimes because it’s easy just to hook myself up. I do the breathing on my own, I don’t need the devices anymore to do it so I do the breathing myself. I have a heart rate monitor for my bicycling, which is a little bit useful actually. By now I know exactly which hills produce which heart rates, so I actually don’t bother with it a lot of times. I know exactly where my heart rate is from my bicycling.

I monitor my blood pressure regularly, just because it’s a risk with aging. But that’s all I do; I don’t monitor any other biomarkers. I suppose I could do over-training, but I don’t think I’m in danger of over-training. Possibly I do; sometimes on Saturday I ride with a group that pushes me too far. I probably would have lower heart rate variability on Sunday morning, but I know that because I feel crappy.

[DAMIEN BLENKINSOPP]: We’ve talked a lot about HRV on this show, as you’ve probably seen, and there are some situations where I find I’ll have a low HRV in the morning and I feel okay and it will hit me probably at lunch or a little bit later. So at four in the morning I was okay, and my HRV says “You’re not okay.” There are a few times like that it’s been a – how do you say – a forerunning signal for me.

[RICHARD GEVIRTZ]: Yeah because what it’s picking up is vagal withdrawal. One of the implications of this is what makes people have ill effects, unless they’re in war or something, is not sympathetic over activation as much as vagal withdrawal. So the minute you get up and you have a big busy day of stressful things in front of you, you don’t get a big surge of sympathetic activity usually, and maybe during a presentation you might, but what happens is your brake goes off, so your vagal brake is off. If it’s off for about 90 minutes, your body doesn’t like that so it will show up in whatever the most vulnerable body system you have is.

For the gut problems, it shows up in gut problems for those people, but if you have a trigger point, it will show up in trigger point pain. Or if you have performance issues, it will show up with not feeling sharp in your performance. So I think that’s what you’re picking up. Probably it would be a good idea if you wake up with it to do some biofeedback, try to get yourself back on track. Or break up the morning sometime with ten minutes of slow breathing, maybe combined with some alpha, and just to do that as a middle of the day break is really powerful. That will put you back in balance and then you’ve got another 90 minutes of messing it up again before it will start to affect you again. 90 minutes is a total guess but that’s what we say.

[DAMIEN BLENKINSOPP]: That’s great, thanks. There are some very useful tactics there to keep me performing.

Just the last question here, what would be your number one recommendation for people if they want to use data in some way in their life to improve their health, what would be the one way you would recommend doing that?

[RICHARD GEVIRTZ]: Well, the Inner Balance actually has a – it’s tricky but you can get heart rate variability data out of it. If you wanted to monitor your heart rate variability on a daily basis, this would probably be interesting to some people; it’s a lot of trouble. There’s a free software program that you can load it into called Kubios HRV. It’s a Finnish program – it’s free, you can download it on your PC. Then you can actually export Heart Math data or any of those device’s data to that–for resting level data – and it will give you, actually a very respectable heart rate variability profile with all the measures we talked about and many more.

If somebody was really into it, they could do that on a regular basis. It’s a little tricky how to get the Inner Balance to output that data. You have to write to Rollin McCraty and he’ll give you something to load that’s not meant for that, but you can do it. Or if it’s one of the other devices, it will do it easily. That might be something that would be worth keeping track of, although I think really, in the long run, just how you feel, you know what’s going on and if you know what’s going on and you just intervene properly, you’d probably be just as well off.

[DAMIEN BLENKINSOPP]: Yeah, self-awareness. Great. Well thank you so much for your time. I’ve found it really interesting. There were some things I wasn’t expecting–the yogis, a great story as background to how you got into this and the 1000 year old knowledge was an input into all of this. Thank you so much for your time, it’s been a lot of fun.

Leave a Reply

A look at a collection of high impact endurance tools and tactics – and the top biomarkers to watch for optimization. Vetted by an endurance athlete with years of experiments and competitions behind him.

Today’s episode is about endurance training and using high-impact tools to get the most out of it. We look at self-tracking in diet and exercise when aiming to optimize your body to perform at peak capacity.

We discuss factors playing a role in improving endurance through a healthy progression. What self-quantifying strategies are useful for tracking overall performance and health?

This episode features actionable takeaways on dealing with a variety of obstacles commonly experienced by endurance athletes.

How to make use of ketogenic dieting in maximizing fat-burning efficiency during physically demanding exercise? Which biomarkers are important for tracking individual organ-systems functionality in the body? How to maintain a healthy hormonal status?

Overall, we look to beneficial and practical tactics for athletes wishing to upgrade their performance and discuss common pitfalls to avoid in cultivating endurance.

On this full-on ketosis diet… the endurance payoff was huge. The amount of focus that I had for long periods of time. My ability to just hop on a bike and ride for hours with no fuel at all, with just water. It was pretty profound, because you produce all these ketones as a bi-product of fatty acid oxidation, and they’re used as the preferred fuel… while you’re out exercising. And that’s a huge boon to an endurance athlete.
– Ben Greenfield

Today’s guest is Ben Greenfield who is a professional competitor in endurance-demanding events, including triathlon and Ironman races. Ben has 11 years experience coaching athletes and fitness professionals.

Throughout his athletic career, he has researched physiology of upgrading endurance using a quantified approach. He has performed numerous self-experiments targeted towards understanding his performance parameters, and towards optimizing his diet and exercise.

Ben is the author of a New York Time’s best-selling book titled “Beyond Training: Mastering Endurance, Health, and Life”, which was published in 2014. His top-ranked iTunes podcast is called BenGreenFieldFitness.

The episode highlights, biomarkers, and links to the apps, devices and labs and everything else mentioned are below. Enjoy the show and let me know what you think in the comments!

itunes quantified body

What You’ll Learn

  • Ben uses his biohacking experience to coach people on living healthy and attempting on-the-edge extreme exercise (4:46).
  • Ben’s interests in endurance training and research developed over time. No big eureka moments, just meaningful experiences (7:12).
  • Important biomarkers in endurance training specifically, and practical reasons for these picks in exercise self-tracking (11:24)
  • Why regulation of sex-hormones and cortisol (the stress hormone) are important to track in endurance training (15:50).
  • Why standard reference ranges for free testosterone are often not applicable to endurance athletes (16:48).
  • Liver enzymes, kidney parameters, Vitamin D, and digestive track inspections are also key biomarkers for healthy endurance training (18:20).
  • The digestive track plays an upstream role in multiple athlete pains and discomforts (21:18).
  • How to fight thyroid system dysfunction in endurance training (24:17).
  • The key lessons Ben learned from his 12 months ketosis dieting experiment (26:10).
  • The biomarkers for detecting adrenal fatigue symptoms (27:22).
  • Biomarkers and tests for autonomic nervous system functionality and distinguishing adrenal fatigue from thyroid system dysfunction (28:03).
  • Incorporating Heart Rate Variability (HRV) tracking in endurance training (31:39).
  • HRV is Ben’s ultimate marker for optimizing endurance training and quantifying overall health (33:23).
  • Success in endurance training requires optimization between high-volume achievements and short-duration precisely aimed tasks (34:29).
  • Dealing with negative effects of endurance exercise and ketogenic dieting (39:01).
  • Maximizing ketogenic dieting benefits and potentially useful supplements (44:34).
  • Breath ketones are an easy way to test for purposeful ketosis (46:20).
  • Tracking important biomarkers and avoiding excessive ketosis (47:20).
  • Why oxaloacetate can be used as a supplement with ketogenic dieting (48:25).
  • Why cold thermogenesis works for athletes’ bodies, for recovery and for overall performance (50:27).
  • The portal outlining Ben’s work and relevant people recommended by Ben (53:17).
  • Ben’s most-important advice on living healthy is being grateful several times per day (54:48).

Thank Ben Greenfield on Twitter for this interview.
Click Here to let him know you enjoyed the show!

Ben Greenfield, Greenfield Fitness Systems

Tools & Tactics

Interventions

  • Cold Thermogenesis: Can be achieved through a variety of cold exposure methods such as cold showers or dipping into cold water streams . In cold thermogenesis hormesis is used to promote positive adaptations in the body as we saw in episode 8. Amongst other improvements it can help to burn fat more efficiently and improve blood vessel functionality in part by promoting development of your Brown Adipose Tissue (BAT). BAT is a type of fat which is active tissue and able to generate heat.

Tech

  • Heart Math Gratitude exercises: The Institute of Heart Math promotes using specific gratitude exercises to optimize the HeartMath Heart Rate Variability (HRV) score. We’ve discussed the HeartMath form of HRV previously in episode 6. This exercise can be done with one of either of their two HRV feedback devices: Inner Balance for iOS or emwave2.

Supplementation

  • Thyro-Gold: Thyroid glandular extract produced by the New Zealand company Natural Thyroid Solutions. This supplement is used as a biohack to correct thyroid-system dysfunction, sometimes caused by ketogenic dieting – especially with very low carbohydrate intake and endurance exercise.
  • AndroGel: Although the use of testosterone hormone-containing products is illegal in professionally-sanctioned sports events, this supplement is sometimes used because free-testosterone levels often drop in a ketosis state.
  • Ketosports KetoForce: KetoForce contains the endogenous ketone body beta-hydroxybutyrate (BHB) in sodium and potassium salt form. The compound BHB can be used as an energy source by the brain when blood glucose is low. Ingesting KetoForce raises the levels of blood ketones for 2.5-3.0 hours after ingestion. (Note: A similar product from same company is Ketosports KetoCaNa).
  • benaGene: This supplement, oxaloacetate, was previously covered in depth in episode 30 in an interview with its creator Alan Cash.
    Greenfield uses this specifically to increase the rate at which his liver synthesizes new glucose molecules, during a low-carbohydrate ketogenic diet including exercise. The goal is to take advantage of its ‘glycogen sparing’ effect, since glycogen is less available in ketogenic diets, and thus get more intensity out of workouts.

Diet & Nutrition

  • Ketogenic Diet: A ketogenic diet is low in carbohydrates intake and high in fat intake. As such, it induces a state of ketosis in the body – the condition in which the body burns fats and uses ketones instead of glucose for fuel. Previously, we discussed measuring ketones and ketogenic dieting in Episode 7 with Jimmy Moore.
    To provide scientific support in favor of ketogenic dieting for endurance, Ben suggests the research of a University of Connecticut team investigating athletic training and human performance. For more information, see this recent scientific review authored by them on using fat as fuel for endurance exercise.
  • Cyclic-Ketogenic Diet: In some people, full ketogenic diets can lead to hormonal or organ dysfunction (e.g. thyroid). The cyclic-ketogenic diet is the solution often used to avoid these downsides. This is a low-carbohydrate diet with intermittent periods of high or moderate carbohydrate consumption (e.g. a refeed with carbohydrates every weekend). It is used as a way to maximize fat loss while maintaining the ability to perform intense exercise during a ketosis state.
  • Based on his 12 month ketosis self-experiment, Ben has concluded that eating anti-inflammatory food, as well as increasing intake of food containing medium-chain triglycerides (MTCs) and resistant starches, are all beneficial in reducing the potential negative side effects of ketogenic dieting.

Exercise

  • Polarized Training: Polarized Training is scientific terminology for the concept of easy-hard training. Researchers from the University of Stirling in Scotland have concluded that using an approach which excludes medium-intensity training is more beneficial for building endurance compared to an approach that includes medium-intensity training. The polarized training model (80% low-intensity; 0% medium-intensity; 20% high-intensity training) produces more positive results in endurance athletes, compared to the competitor threshold model (57% low-intensity; 43% medium-intensity; 0% high-intensity training).
  • Murph Workout: “Murph” is a CrossFit workout named after Navy Lieutenant Michael Murphy, who was killed in Afghanistan June 28th, 2005. He was awarded the Congressional Medal of Honor after his death. It first appeared on the CrossFit site 18 August 2005. This workout consists of (in order): 1 mile run, 100 pull-ups, 200 push-ups, 300 squats, and a 1 mile run at the end.

Tracking

Biomarkers

  • Heart Rate Variability (HRV): HRV is the measure of the change in the heart’s rhythm over time based on changes between sympathetic and parasympathetic activation. HRV was previously covered in the context of optimizing training workouts using HRV in Episode 1 with Andrew Flatt and using HRV as a biomarker for longevity in Episode 20 with Dr. Joon Yun.
  • Triglyceride to High Density Lipoprotein (HDL) ratio: Researchers have shown that using the triglyceride to HDL ratio is a better predictor of coronary disease risk factors, compared to tracking total cholesterol (which includes HDL and other lipoprotiens). A ratio of 2 : 1 or less is considered optimal.
  • High-Sensitivity C-reactive protein (hs-CRP): CRP is a protein that increases in the blood with inflammation and is used as a marker for cardiovascular health (high levels over 1 mg/l are indicative of higher cardiovascular risk). Both diet choices and overtraining can lead to high levels of hs-CRP (over 1).
  • Ketones: Ketone concentrations can be tested in blood, breath and urine samples to determine if you are in ketosis (burning ketones for fuel) and to what extent. We covered these markers extensively in episode 7 – how to measure ketones.
  • Creatinine and Blood Urea Nitrogen: These two biomarkers are often elevated above normal levels in endurance athletes, without being indicative of a health risk. In endurance training, creatinine levels lower than about 1.1 mg/dl do not pose a health risk. It is also relatively normal to have BUN levels over 20mg/dL.
  • Liver Function Tests: When excessive exercise is present, the blood levels of liver enzymes Alanine Transaminase (ALT), Aspartate Transaminase (AST), and Alkaline Phosphatase (ALP) are elevated above normal.
  • The 25-hydroxy Vitamin D Blood Test: The most accurate way to measure how much vitamin D is bioavailable to be used by your body is the 25-hydroxy vitamin D blood test. Optimum vitamin D levels range between 50-70 ng/ml.
  • Salivary cortisol to Dehydroepiandrosterone (DHEA) ratio: An increase in DHEA levels is highly suggestive of adrenal dysfunction because DHEA is produced exclusively by the adrenal glands. Excessive exercise stresses the body to produce very high levels of cortisol, which causes a depletion of endogenous DHEA. This results in an elevated cortisol to DHEA ratio. Testing for this ratio several times per day provides a more complete image of adrenal function, compared to a snapshot provided by simple monitoring of blood cortisol levels. A normal cortisol : DHEA ratio is approximately 5:1 to 6:1.
  • Thyroid Functional Test Panel: A TFT panel typically includes thyroid hormones such as Thyroid Stimulating Hormone as well as the thyroid hormones triiodothyronine (T3) and thyroxine (T4). Excessive exercise can stress the body to produce high-levels of cortisol (the stress hormone) which inhibits the conversion of thyroid hormone from inactive (T4) to biologically active (T3). This can result in lower levels of active thyroid hormone despite normal or up-regulated levels of TSH. Thus, testing for (active) T3 hormone concentrations is more relevant for endurance athletes self-tracking. Optimal reference ranges for TSH are 0.4 – 2.5 milliunits per liter (mU/L). Optimal reference ranges for free (bioavailable) T3 range between 350 – 780 pg/dL.
  • Sex Hormone Binding Globulin (SHBG) and free testosterone: The standard reference ranges for SHBG are 0.2-1.6 mg/dL for non-pregnant adult females and 0.1-0.6 mg/dL for adult males. Changes in SHBG levels affect the amount of free hormone that is available to be used by tissues, including the levels of free testosterone. In case SHBG levels are in abnormal ranges, then free (bioavailable) testosterone should be tested (reference ranges 1.0-8.5 pg/mL for females and 50.2-210.3 pg/mL for males).
  • Tests for detecting adrenal fatigue and thyroid system insufficiency

  • Iris Contraction Test: This test consists of you looking at the pupil of your eye in a mirror while shining a bright light at your eye. The light should cause the pupil (center black spot of your eye) to contract or become more narrow. The contraction should be sustained for longer than 20 seconds before the pupil starts to flicker or dilate. Otherwise, if the pupil starts to flicker immediately upon shining light, this is a good indication that you have adrenal fatigue – mainly because your adrenal gland is functioning properly in managing blood pressure.
  • Dizziness Test: If you lay down or you sit down and you stand up quickly and you get dizzy, then this is a sign of blood pressure mismanagement. Importantly, problems with blood pressure often accompany adrenal fatigue because one of the main functions of the kidneys is to regulate blood pressure via production of hormones in the adrenal gland.
  • Broda Barnes, MD Temperature Test: This test was developed by Dr. Broda Otto Barnes, who was best known for developing novel perspectives on hypothyroidism – a type of thyroid system disease. In essence, you do oral and armpit measurements every morning in bed upon waking up and keep a graph of the results. If your temperature is consistently low, then this is an indication that your thyroid system is dysfunctional even in the absence of a blood thyroid test.

Lab Tests, Devices and Apps

Other People, Books & Resources

People

  • Dr. Terry Wahls: Dr. Terry Wahls is a a clinical professor of medicine at the University of Iowa. Previously, Dr. Wahls was kind to participate in the third episode of our show, where we focused on linking mitochondrial health to autoimmune and chronic disease.
  • Alan Cash: Alan Cash is the CEO of Terra Biological. Previously, he has been a guest on our podcast in Episode 30, where we discussed the potential for using oxaloacetate as an anti-aging supplement.
  • Joe Friel: Joe Friel holds a masters degree in exercise science and is a USA Triathlon and USA Cycling certified elite-level coach. For Joe’s blog click here. For his Twitter click here.
  • Sami Inkinen: Sami Inkinen is a balanced person. He is a successful businessman and a top-age Ironman competitor. For his Twitter click here.
  • Dr. Peter Attia: Dr. Peter Attia is a scientist who is knowledgeable in healthy endurance exercise and self-quantification. For Dr. Attia’s Eating Academy Blog click here. For his Twitter click here.

Books

Other

Full Interview Transcript

Click Here to Read Transcript
[04:46] [Damien Blenkinsopp]: Ben, welcome to the podcast.

[Ben Greenfield]: Hey, thanks for having me on man. And I’ve got to ask you, is it Damien, or Damion? Or Dami-something else?

[Damien Blenkinsopp]: Or Damian? It depends where you come from, I guess.

[Ben Greenfield]: Okay. Just checking. I don’t want to stick my foot in my mouth.

[Damien Blenkinsopp]: Yeah. You can call me Dam. I tell people to call me Dam, just to avoid all those questions.

[Ben Greenfield]: There we go. I want to sound like I’m cursing the entire episode.

[Damien Blenkinsopp]: Yeah. But it even works in Asia, tried and tested.

[Ben Greenfield]: Nice.

[Damien Blenkinsopp]: I mean you’ve got a three letter name. That works well.

[Ben Greenfield]: Yeah, totally. Ben.

(05:12) [Damien Blenkinsopp]: So, Ben, you’re into triathletes, Ironman, and basically the way I look at you is you go around searching for tactics and tools to give you an edge in these areas that you’re interested in. Is that a fair kind of back story to who you are and what you’re doing?

[Ben Greenfield]: Yeah, I do a lot of that I guess n=1 guinea-piging myself. Going out and doing crazy things like training with the Navy SEALS or doing these Spartan Races or Ironman triathlons, things like that.

But then I also think I learn just as much via a lot of the coaching and consulting that I do, just because people typically come to me for one of two reasons.

They either want to do some crazy feat that’s completely unnatural for the human body to do, like they want to go run 100 miles in the wilderness or something like that, and figure out how to do it without destroying themselves. So my job is to figure out how to do that from a nutrition and a physiology and an exercise standpoint.

Or they come to me because they basically want to live as long as freaking humanly possible, and want me to manage how do you sleep when you want to do something like that, how do you exercise, what do you measure, what do you pay attention to in your blood and your gut. And so there’s that kind of biohackiness that I get into.

And I’ve got to admit, for me personally it’s a little bit of both, really. I certainly do want to live as long as possible. I also want to do as many crazy events as I can during the process, see as much of the world as I can at the fastest pace possible. And so for myself, personally, I’m doing a little bit of both.

But sometimes people come to me and want to do something that I know nothing about, so I’ve got to go and learn it. So part of it is that, too. That, or if it’s not coaching someone it’s writing about that. Because I’ve done a lot of writing recently. This morning [I] published a big article on my website about how to use marijuana to get performance enhancing gains.

And I never really would have delved into that if I hadn’t been asked by so many people, especially here in the US with the growing legality. It’s like, can I use this while I’m exercising? That type of thing. So it’s a little bit of everything.

[07:12] [Damien Blenkinsopp]:Yeah, great. So [what was] the event that started the whole Ben Greenfield fitness podcast, and the blog and everything? How’d you get involved in that? Because you’re obviously very passionate about it.

[Ben Greenfield]: Yeah. Well there’s, I mean I get that question a lot, and frankly – nothing against you – but it annoys me, because I hate when people go, “When did you decide to do this? When did you decide to do that?” I never make decisions. I don’t have a 10 year business plan. I don’t have some ‘Come to Jesus’ moment where I said, “Oh hey, I want to learn how to exercise.”

It’s just that I live my life. I do things that I’m passionate about, or that other people who I’m helping are passionate about and tend to fall into whatever I might fall into based on that. I’m getting into hunting right now – well specifically bow hunting and hunting competitions – before that obstacle racing, before that Ironman Triathlon, before that water polo, before that body-building, before that I was a collegiate tennis player.

It’s just like life is a series of chapters and moving targets. It’s never just like one commitment to do one thing. But I would say, to give you a rough answer to your question, the very first time I decided to something a little bit more endurance orientated – which I would define as something that has a nutrition rate.

You don’t see people dropping out of baseball or cricket games because of fatigue and heat stroke and lack of nutrition. That’s very rare, but you see it all the time in marathons and Ironman triathlons and things like that. So I would say the first time I started to get into that side of sports would have been my first Ironman Triathlon that I did back in the city of Portalane, Idaho in 2007.

And up until that point I’d been primarily an explosive power athlete. Like body-building and tennis and stuff like that. But my girlfriend, who is now my wife, was a runner. She ran cross-country for University of Idaho. So I kind of had to take up running, to a certain extent, just to be able to woo her.

And she dragged me to a triathlon one day and she actually had me run the running leg of the triathlon, which hurt like hell. I was a body builder; my boobs were bouncing up and down and my lower back was locking up and it was horrible. But it kind of got me interested in this high that you can get from endurance sports.

And so I wound up doing a few triathlons and doing, what I would say, is the biggest mistake for anyone who wants to avoid getting into endurance, that is I went and watched an Ironman Triathlon. And after watching Ironman and watching these intense feats of physical performance and the huge feeling of satisfaction and self-completion that these people were experiencing as they threw up their arms when they crossed the finish line I was like, I want that. I want to experience that.

And so I signed up for an Ironman and began taking everything I had been studying. At that point I had a Master’s Degree in Exercise Physiology and Nutrition and I was able to start applying that stuff to my training, and experimenting with a lot of what I was finding in research and sports science and seeing what worked and what doesn’t.

For example, all laboratory studies, or most of them, done by the white coats in their little labs will tell you that the body can take on about 200 to 250 calories of fuel during exercise. You can oxidize 200, 250 calories of carbohydrates while you are exercising. But for anyone, especially anyone who’s above about 150 pounds who has tried to go out and do an Ironman Triathlon, you completely bonk after about five hours on that number of calories, and you technically need about twice that in order to be able to get by in an Ironman race in most cases.

So, it’s a situation where what they’re saying in the lab and textbooks actually doesn’t work once you get out in real life and you try this stuff in the streets, in the trenches. So, that’s been kind of fun too, figuring out from research what works, and what doesn’t.

[Damien Blenkinsopp]: Right. Yeah, we often talk on here about n=1 experiments are often going to be different to the research, for a variety of reasons like the ones you brought up, and the use of averages, and other things like that.

[11:24] So, anyway, in terms of endurance training, since we’re there, what kind of biomarkers have you found to be the most useful to track your performance? Or what do you track around your capabilities for endurance training, and see as important?

[Ben Greenfield]: Oh, for endurance specifically?

[Damien Blenkinsopp]: Yeah.

[Ben Greenfield]: So for endurance specifically, that’s a great question. So one would be your level of HSCRP, which really that’s just for exercise in general. Or high sensitivity C-reative protein, just to make sure that your levels aren’t straying too high above 0.5. And the reason for that…

[Damien Blenkinsopp]: So that’s kind of your benchmark? You try to keep them under there? Where do yours tend to hover around?

[Ben Greenfield]: I actually fall below 0.2 now for HSCRP, probably because I eat a very anti-inflammatory diet, very clean. And I won’t insult your listeners’ intelligence by defining what a clean diet or an anti-inflammatory diet is, because it’s pretty easy to go out and figure that out with Dr. Google.

But I eat very clean. I also use a lot of anti-inflammatories. Like I make ginger tea, and I use a ton of turmeric, usually combined with black pepper to increase the efficacy of it, and I use percumin and I consume a lot of very dark and colorful vegetables with very limited amounts of dark and colorful fruits, and wild caught fish, and fats, and things that really help with inflammation.

And I’m also very careful with my training, where I do extremely focused and intense, but short, bouts of training with a specific purpose. I never go out and just pound the pavement for the hell of it, which is a great way to build up a lot of voluminous training based inflammation.

And so I have a very precise, dialed in training program that also includes things that help to mitigate inflammation, like foam rolling, and cold soaking, and these things that can help to remove a lot of these byproducts of metabolism that can create inflammation. So, inflammation is a biggie. Honestly, it doesn’t take a rocket scientist to figure out that if you keep your inflammation controlled, it’s a good thing.

So, a few others that I’ll pay attention to for endurance. When we’re talking about labs, as far as blood goes, TSH, preferably a full thyroid panel, is pretty prudent to pay attention to simply because high level endurance training can inhibit conversion of inactive to active thyroid hormone.

And because of the high amounts of cortisol that can potentially be produced through an improper training program can stress the body out enough to where you experience some hypothalamic pituitary adrenal axis insufficiencies, particularly high cortisol, creating a feedback loop that reduces the conversion of inactive to active thyroid hormone and thus an increase in thyroid stimulating hormone. So your body turns out a bunch more thyroid stimulating hormone to try and get more T4 present, even though a lot of that T4 isn’’t getting converted into T3.

And by monitoring TSH, if you see a pattern or a rise in TSH many times it’s concomitant with an increase in cortisol and stress, and often also accompanies a not enough eating period. Sometimes not enough carbohydrates is the biggest culprit, but in many cases just not enough damn calories, period. Damn, not referring to your first name but to the curse word. Just so we’re clear.

That’s another one is TSH. Cortisol, I alluded to, but when we’re looking at a hormonal panel, I also like to pay attention to sex hormone binding globulin. Because the body has this interesting mechanism where when it’s stressed out, when it’s in a time of famine, in a time of need, under high amounts of stress, doing a lot of migrating, a lot of moving with low amount of calorie intake, the last thing you want the body to do is produce a bunch of babies at that point.

And so sex hormone binding globulin often rises simultaneous to cortisol to keep total testosterone bound, and keep it from being available as free testosterone. So even if your testes are working just fine, or your pituitary gland is working just fine, –obviously talking about the males more than the females now– and even the leydig cells in your testes are producing testosterone just fine, if sex hormone binding globulin levels are really, really high that’s all for naught. And so that’s another really, really important one to keep an eye on. And that’s typically addressed by addressing cortisol.

[15:50][Damien Blenkinsopp]: Right. So, why would you look at SHBG versus free testosterone, or that marker? The [unclear 15:56]?

[Ben Greenfield]: Well, because if free testosterone is low, but if you look upstream perhaps it’s because total testosterone is low because the leydig cells in your testes are not producing enough hormone because you’ve got low levels of luteinizing hormone. In contrast to that, perhaps your luteinizing hormone production is fine, your leydig cells are producing enough testosterone just fine, your total testosterone is high, but it’s more of a cortisol issue than it is a central nervous system issue or a glandular issue.

So that’s why you test that versus just looking at free testosterone.

[Damien Blenkinsopp]: So basically, free testosterone could be many, there’s more reasons behind it, but the SHBG is more specific to endurance and specific dynamic.

[Ben Greenfield]: Yeah. Really, two reasons behind it. Either you aren’t producing enough total testosterone, or you are producing enough total testosterone but it’s not getting converted. So those are really the two main things to look at.

[16:48] [Damien Blenkinsopp]: So, are you looking at the standard reference ranges for that, or do you look for something a bit more precise?

[Ben Greenfield]: A lot of times you have to look at symptoms synonymous, because standard reference ranges are going to vary widely.

I’ve worked with a lot of endurance athletes who have very high libido levels, show no signs of over-training, have very robust nervous systems, high heart rate variability, low cortisol, and even low sex hormone binding globulin, but their total testosterone is in like the high 300s. Which, for a body builder they would scoff at that and say, oh that’s rock bottom low. Even though a lot of times hypogonadism is levels below 100.

And you’ll get many people who just feel like fricking crap at 300, and some people will be closer to 500, and some people will need levels of 700, 800, or even 1000. So it kind of depends. It varies widely, I suspect based on genetics as a big part of it.

So ultimately it’s really tough to hold things up to reference ranges. I mean, you can ballpark it. You can say well if total testosterone is starting to get below 300, that’s where we would really start to get a little bit concerned. But it really is kind of tough. A lot of times it’s a moving target based off of a cluster of other symptoms.

If someone’s complaining of low libido and low motivation, and lack of energy, etc, and their testosterone is at 400, well that’s a pretty good sign that 400 is not going to be adequate for them. So I know that’s one of those deals where it’s total soft science, but it does really depend. That’s one of those ‘it depends’ answers, but that is definitely a variable that I will look at.

[18:20] Liver enzymes is another one, like alkaline phosphatase, aspartate aminotransferase, the ALT, the AST, some of these liver markers just because a lot of times they can be elevated when excessive exercise is present. And so that’s another one to pay attention to. It doesn’t have to be excessive exercise; sometimes it can be alcohol, pharmaceutical intake, things of that nature. But liver enzymes are the one that I’ll look at.

Kidneys, a lot of people say to look at kidneys, but frankly it’s very rare for me to see an athlete who doesn’t have slightly elevate creatinine and blood urea nitrogen levels, which are two common markers in the kidneys that a physician will get concerned about if they see elevated, but that are very common to see elevated if an athlete is exercising anywhere in the 48 hours leading up to a blood panel.

So, as long as creatinine levels aren’t much higher than about 1.1, and as long as blood urea nitrogen isn’t through the roof and – I apologize, but off the top of my head I don’t remember the lab reference ranges for blood urea nitrogen. The reason being that I do most of my coaching for blood panels with a company called WellnessFX. It’s basically more like a dashboard with graphs, more than it is hard numbers, so occasionally I’m looking at graphs more than I am numbers.

[Damien Blenkinsopp]: And they just have those red zones.

[Ben Greenfield]: Yeah, exactly. They’ve got red, yellow, green, which actually annoys me some of the time. Because they’ll flag high LDL as red when I purposefully try to get my LDL high. So there’s some issues with the whole red yellow green type of quantification. But anyways, blood urea nitrogen and creatinine, even though a lot of people talk about those, they’re not super duper important in my opinion, because they’re always going to be a little bit elevated.

Vitamin D, that’s another one that I’ll look at just because of it’s importance. As you can suspect, a lot of these aren’t just specific to endurance, they’re specific to exercising period. Just as a hormone and a steroid, vitamin D is another important one that I’ll look at.

And then as far as other things, I typically will have most of the athletes I work with or the people I advise do at least once a year a full gut panel. You know, a comprehensive gut panel that includes parasitology, measurement of pancreatic enzyme production, measurement of yeast and fungus and any type of bacterial overgrowth in the digestive tract because I find that, especially when you’re jogging your body up and down for 10 plus hours while racing, having a really, really good gut and GI system and very efficient digestion is incredibly important.

And so I will look at things like presence of yeast or fungus, like Candida Albicans, or the presence of H pylori, or absence of hydrochloric acid, or absence of pancreatic enzymes, or overgrowth of specific bacteria, or lack of short chain fatty acids in the digestive tract, in the colon, and a lot of those things that tend to influence an athlete’s performance or their feelings of well-being. So that’s another thing I’ll pay attention to.

[21:18][Damien Blenkinsopp]: Right. A lot of people wouldn’t think of that as something performance related, more like a chronic issue related.

Have you got any case studies where you saw people, basically not performing but not having any negative symptoms in terms of GI distress or anything that they would have noticed, but when you put through these tests some negative results came?

[Ben Greenfield]: Sure. Now we’re delving a little bit more deeply. And I mean, obviously explosive diarrhea halfway through a marathon can be a good sign of digestive enzyme insufficiency, but so can, for example, vitamin B12 or vitamin D deficiencies, or even if you go more advanced and run like an organic acids profile, or an amino acid profile, severe imbalances of a lot of micro-nutrients.

Well if you’re not digesting your food efficiently, for example, if you’re not producing adequate hydrochloric acid, you’re not activating pepsin to break down proteins, beginning in the stomach an moving on to the small intestine, then you’re going to: a. have undigested protein fragments winding up in the bloodstream causing some auto-immune issues, and that can include fuzzy thinking, which no athlete wants.

But then you also can get amino acid deficiencies, like deficiency in the ability to create neurotransmitters, and also deficiencies in the ability to repair and regenerate skeletal muscle tissue, because you aren’t breaking down the proteins that you’re eating.

And the same could be said for something like inflammation in the digestive tract from wearing down of the microvilli. So perhaps you’re not producing adequate levels of lactase, so you’ve got some lactose issues and bloating and gas. Or you’ve got inflammation that is resulting in malabsorption of fat-soluble vitamins, so vitamins A, D, E, and K aren’t getting absorbed properly, or bacteria aren’t helping you to produce those, and so you experience hormonal deficiencies, or steroid deficiencies.

And so, yeah the gut is incredibly important, and that’s one of the things I’ve been kind of getting on companies like WellnessFX, for example, to do is to not just use the strategy of blood testing but also really pay attention to the gut. I mean, in an ideal scenario, what I would like to see is a done-for-you system.

And for me right now, what I do is just kind of string this together for the athletes who I work with. But a done-for-you system where you get your blood testing, you get your gut testing, and you get your genetic testing so we can look at everything from genetic snips to bacterial imbalances in the gut to all the blood and biomarkers, and have all of that done with either one panel or one service.

That would be really nice, because right now you’ve got to go to typically three different places. You’ve got to go to whatever DNAFit, or 23andMe, and you’ve got to go to DirectLabs, or Metametrix for GI affects, and then you’ve got to go to WellnessFX for whatever else. And then if you want to do food allergy testing, well then you’ve got to throw in a Cyrex panel, or something like that.

So maybe it’s a first world problem to want all this stuff to be available in one central location, but it certainly would be nice.

[Damien Blenkinsopp]: Yeah. It’s so near the early days from that perspective. There’s a lot of specialized, it’s still kind of specialized in terms of the labs. Each is in their little separate box and everything.

[Ben Greenfield]: Yeah.

[24:17] [Damien Blenkinsopp]: So, in terms of the kinds of decisions you’ve made, or you’ve advised a client based on some of these values, some of this data that’s come back, what have been the biggest changes that you’ve implemented to optimize training?

[Ben Greenfield]: You mean as far as training?

[Damien Blenkinsopp]: So, say the TSH came up too high, what would you do about that?

[Ben Greenfield]: Oh okay, so for high TSH, obviously it’s never a shotgun approach. It’s never a multivitamin. So for high TSH it may be looking at your carbohydrate intake. That’s the first thing that I’ll look at.

Even before you look at total amount of calories, you just make sure nobody is on some low, like 40 gram per day carbohydrate diet, because frankly a lot of the ‘low carb’ or ‘ketosis’ based diets that are out there were created for sedentary people. Even the bulletproof diet. I love the whole bulletproof philosophy, but it was written by a computer programmer, not by an athlete.

And so the levels of carbohydrate, and even the levels of calories in that diet, have to be adjusted and modified for a hard-charging athlete, especially an endurance athlete. So, otherwise with caloric depletion and carbohydrate depletion, you basically lose a lot of your ability to convert inactive to active thyroid hormone.

And in the case of calories, as you would deduce through common sense, when you send your body a message that calories are insufficient but you’re still requiring it to move a lot, your body down regulates metabolism. And one of the main ways it does that is by down regulating thyroid.

So, I look at carbohydrates, I look at calories, and then I also look at dietary intake of organ meats and fat soluble vitamins, which can also assist with thyroid health. So in my case, because I did an n=1 experiment about a year and a half ago where I did 12 months of ketosis.

Not cyclic ketosis, not cycling carbohydrates in and out throughout the day, but full on eating only 5-10 percent of my total daily intake from carbohydrates. Very low carbohydrate diet. Too low, in my opinion, for most endurance athletes who want to maintain optimal levels of health elsewhere.

[26:10] [Damien Blenkinsopp]: Did you see negative effects from that over the 12 months?

[Ben Greenfield]: Yeah, and that’s what I’m getting at with the thyroid. I started taking thyroid glandular extract. I took one called Thryo-Gold, which is made from New Zealand cows, that are like an A2 cattle.

A lot of A1 cattle has proteins in it that cause an immune reaction within the human body, but cattle that are breed via A2 are cattle that contain this A2 genetic profile that is more bio-compatible with the human body. And so I basically took a T1, T2, T3, and T4 combo, and that seemed to turn my thyroid around. But that was after I had already done a number on it.

So for thyroid, that would be an example of what I would do with something like thyroid, would be increase calories, increase carbohydrates, increase intake of organ meats and fat soluble vitamins. And then for a really hard-charging athlete who insists upon doing something like restricting carbohydrates to tap into the performance enhancing effects of ketosis, understand that you’ve got to get on extra help from the thyroid.

Since your body isn’t going to make T3, dump it into the body. And preferably get it from a whole source, like levothyroxine or synthroid. But a source that contains other elements of thyroid in addition to just T3, so you’re not creating an imbalance.

[27:22] [Damien Blenkinsopp]: Great. Well, connected with the thyroid issues, I was wondering if you’ve come across adrenal fatigue also. If that’s every come up with you or with anyone else.

[Ben Greenfield]: Absolutely. Adrenal fatigue, gosh. There’s like four chapters of my book on that alone. But adrenal fatigue, well what do you want to know about it?

[Damien Blenkinsopp]: Well first of all, have you looked at some of the tests? I’ve done some of the salivary tests.

[Ben Greenfield]: Oh yeah. Yeah, like an adrenal stress index is kind of gold standard, cortisol DHA. If you look at the cortisol DHA curve, that’s much, much better when you’re addressing something like adrenal fatigue versus a blood cortisol measurement, which is just a snapshot. You want to see a moving target of salivary cortisol levels, preferably matched to salivary DHEA levels, throughout the day.

[28:03][Damien Blenkinsopp]: I was just thinking, based on it’s endurance exercise, and it has this tendency to raise cortisol, that that would be more of an issue and something that you would keep an eye on. Or by monitoring TSH, does that kind of take care of itself? If the TSH is alright then you tend not to have an adrenal issue as well?

[Ben Greenfield]: No, not necessarily.

You can still have adrenal fatigue and have a thyroid that’s managed properly. Because what you would typically see in that case is someone is eating boatloads of calories and taking care of themselves from an energetic standpoint, but simply outputting too much energy. They’re just training way too much. Even though they’re supplying their thyroid with what it needs, there’s just too much training still.

And a lot of times you’ll see inflammation high, but yeah. Cortisol DHEA, and that adrenal stress index can be a good measurement. And there are less quantitative measurements. You could do a pulst test, where you look in a mirror and you shine a bright light at your eyes, and your pupils should stay dilated. But if it stays dilated and then just starts flickering rapidly.

[Damien Blenkinsopp]: Have you tried that one?

[Ben Greenfield]: I have, yeah.

[Damien Blenkinsopp]: Because I was just wondering. I did try it and I find it a little bit difficult to judge.

[Ben Greenfield]: Yeah, it’s certainly not as precise as a salivary measurement, but once you’ve done it a few times you can definitely see the pupil, and whether or not it’s actually flickering versus staying dilated. If you look at if for long enough, it’s just going to start flickering period, but if it starts flickering after just a few seconds, that’s typically a sign that your kidneys are not producing enough aldosterone, which is synonymous, or can accompany, adrenal fatigue.

The other one is just the dizziness test. If you lay down or you sit down and you stand up quickly and you get dizzy, that can be a sign of blood pressure mismanagement that often goes hand-in-hand with adrenal fatigue. And again, these are the super cheapo poor man’s methods, but it can give you clues.

And then there’s temperature tests for thyroid, the Broda Barnes Temperature Test, where you do oral and axillary measurements of your temperature in bed every morning, and keep a running graph. And if it’s consistently low, that can be a pretty good indication that even if you haven’t done a blood thyroid test that your thyroid might be having issues.

So, there are a lot of things. One of the best ones I like though is just pure heart-rate variability. Testing the interplay between your sympathetic and your parasympathetic nervous system by using something like a Bluetooth enabled heart rate monitor and one of these heart rate variability apps, and simply paying attention to whether heart rate variability is high or low on any given day.

And if it’s consistently low, and you see consistent suppression of both sympathetic and parasympathetic nervous system feedback, then that can be a pretty good sign that you’re on the cusp of adrenal fatigue illness or injury, and so that’s another really good one to pay attention to. And I do that one every day myself.

[Damien Blenkinsopp]: Do you do it in the morning as soon as you wake up?

[Ben Greenfield]: Yes, that’s gold standard, because that’s where most of the studies have been done on heart rate variability were five minutes resting in the morning.

[30:45] [Damien Blenkinsopp]: Right, right. I believe you use the HR…what’s the name of the company?

[Ben Greenfield]: SweetBeat?

[Damien Blenkinsopp]: Yeah, SweetBeat.

[Ben Greenfield]: Yeah, but because I want to build up that technology and add some features and stuff like that, I’ve actually white labeled their technology. And so I use the app called NatureBeat now, but it’s the SweetBeat technology.

[Damien Blenkinsopp]: Great, great. Yeah, she’s been on the show.

[Ben Greenfield]: Yeah.

[Damien Blenkinsopp]: So I was using that for a long time, and then I just recently started using iFleet, because I also talked to the guys at iFleet, and it does have this other thing that they just added recently. You might just want to check out.

It’s kind of interesting. It shows how high your energy levels are on a given day, so it kind of does this matrix thing. So it shows you if your in the bottom right corner, it means something a little bit different. So I’ve been checking it out. I’m still trying to understand what it means each day. But I do find that when I’m at the bottom, low energy, those days tend not to be good. Even if I have a high HRV.

[31:39] So anyway, out of interest, what is your HRV levels? Because you think normally endurance athletes have higher HRV, right?

[Ben Greenfield]: Yeah. Usually higher HRV, which isn’’t necessarily a good thing if you’ve got what are called HF to LF ratio imbalances.

You want your HF to LF ratio to be pretty close to one. That’s sympathetic and parasympathetic nervous system feedback. And if parasympathetic nervous system feedback, which would be your high frequency number, if that’s super duper depressed, and your LF is really high that can be an indication of aerobic based over-training, or vice versa.

So ideally you’ve got high HRV and a pretty close to a 1-1 ration between HF and LF. That’s what you want to go to. And you want both HF and LF to be up in the thousands. That’s a sign of a really robust nervous system.

So, my values tend to be between about 92 and 98, with HF and LF values that vary between about 4,000 to 8,000, around in there. Generally with a 1-1 ratio, depending on what my previous day’s training had looked like.

And I would expect, for example, this Tuesday I’ll do a CrossFit’s Murph and I’ll do that with a 20 pound weighted vest on, and just crush myself. And that will take me about an hour to do, and I guarantee my LF value will be tanked the next day. But I also won’t be doing any sympathetic nervous system training for like 48 hours afterward.

[Damien Blenkinsopp]: So you recover within 48 hours?

[Ben Greenfield]: 48 to 72 hours, depending.

[Damien Blenkinsopp]: These scores recover for you pretty quickly?

[Ben Greenfield]: Yeah, but I mean, if I were to do something epic, right? Like, usually something that gets you to the state of glycogen depletion. Or let’s say instead of Murph, I do double Murph, or I do a Murph with a 5k sandwiched on either end rather than just a mile, then it can take me several days to recover, for sure.

[33:23] [Damien Blenkinsopp]: If you had to pick one marker to optimize your endurance training by and make decisions on, which one of the ones we’ve talked about would it be?

[Ben Greenfield]: HRV.

[Damien Blenkinsopp]: Okay, great.

[Ben Greenfield]: Just because it’s easy, right? You don’t have to give blood.

And maybe at some point, once we’ve got the lab and chip technology finalized, and I can put a drop of blood onto a little dongle that will plug into my iPhone and I can measure, let’s say, testosterone cortisol ratios, maybe that will become a more valuable metric for me. But at this point, I would have to say something simple and easy to utilize and relatively inexpensive, the HRV would be the one that I’d choose.

If I had to choose an actual blood biomarker, tough to say. Tough to say. I guess I’d probably have to go with HSCRP, again. Just because inflammation is generally going to be high when cortisol is high. It’s generally going to be high when diet is crappy, it’s going to be high when triglycerides are high, it’s going to be high when omega-3 fatty acids are low. So, that’s a pretty good one to measure.

[Damien Blenkinsopp]: Yeah. So it catches a lot of things. Mainly whenever something starts going wrong.

[Ben Greenfield]: Yeah.

[34:29] [Damien Blenkinsopp]: Well so you’ve referred to over training quite a bit over this as something that you’d have to change. So HRV would be one of the first places you’d see over training.

Are there any other tell-tale markers, and what do you suggest, more to the point, because you mentioned earlier that you do very – is it short, intense kind of endurance exercises. And I think a lot of people when they’re thinking about endurance, they’re thinking about very high-volume, kind of long duration activity.

So how do you approach it, and avoid over training? What are the top things you’ve taken in over time?

[Ben Greenfield]: First of all, one of the common pitfalls that people fall into with endurance training is doing the long voluminous training every weekend. It’s very stereotypical that you’ll see in a lot of athletes these Saturday long bike rides and then Sunday long run, for example. Or in a marathon, the Saturday long run.

I’ve found that in most cases, you can maintain endurance really, really well. Unless you’re a professional athlete trying to perform at the peak of performance, most people can perform just fine. With doing digging into the well like that, really, really, deep for like a death march, a really long ride or something like that, you typically only need to do that one to two times a month. Not every weekend.

I’m a bigger fan of using shorter, very temporal based intervals. So to give you an example, for the Ironman triathletes that I work with, while their peers are out doing a five hour ride followed by an hour long run, my athletes will be doing two hours of 20 minutes at race pace followed by 5 minutes recovery. So a very focused activity with a specific goal in mind. And then they’ll finish that up with a 15 minute tempo run at a cadence of 90 plus.

So it’s all extremely high quality. And then once a month they’ll go out and do something big, something long, something voluminous that builds the mental tolerance to training, but that doesn’t dig so deep into the well as doing it every week.

And the reason for that is based off of the human body’s natural slow twitch muscle fibers. The human body’s ability to cool because we’re upright and not covered in fur and hair. Our ability to sweat, rather than pant, to reduce heat. And a cluster of other factors.

We’re pretty good at going for long periods of time. And when training for endurance, bigger limiters are things like power, speed, cadence, strength, the integrity of the fascia connective tissue, the intelligence to be able to use nutrients and calories properly.

And really pointing in one direction, and going for long periods of time is not that much of a weakness for the human body, but the problem is that it’s easy. And people take pride in it. They’re like, “Oh I persevered today. I did my three hour run.”

And my question to you is well yea, but what did you accomplish side from being on your feet for long periods of time? Which frankly I could stand up at my standing workstation and write an article for three hours and get the same amount of time on my feet as you just did out pounding the pavement. So it would be better in that case to do something with intervals at race pace for a shorter period of time.

Focus on cadence. Allow enough time before and after for a good warmup. Maybe some meditation and breath work. Some good recovery. And so that’s where the more intense, more quality, lower volume approach nine times out of ten trumps the voluminous approach.

The exception to that fact would be the person who has a lot of time on their hands to train: the professional athlete. Professional athletes, assuming they’re using this 80-20 approach, it’s called polarized training. 80 percent of your training is done aerobically, with about 20 percent done high intensity.

That approach works very well, and it is what a lot of the elite cross-country skiers and marathoners and cyclists etc. will use, but what is important to understand about that approach is it requires many, many hours per day.

That approach can require two to four hours per day of training, and even more than that, on weekends, for example. And the majority of folks simply don’t have the luxury of time available to utilize that approach effectively. That in a nut shell is my approach to training.

I’ve got a couple of athletes who I work with who are more, what I would consider to be on the professional level, who have that luxury of time. And I do train them with that aerobic approach, where they’re out doing long voluminous sets of training at a controlled heart rate aerobically, putting lots of time in the saddle or time on the pavement. But its very few and far between that I’ll recommend an athlete to train like that.

[Damien Blenkinsopp]: Great, great, thanks. That’s a great summary of it.

[39:01] I wanted to move on to, because I know you did this 12 months of ketogenic dieting. Could you talk a little bit about that? Give us an overview. What was your approach to that, what were you actually eating, and was there any specific goals to track over the year?

[Ben Greenfield]: Well yeah, for that specific diet, that was for a study at University of Connecticut that was done on, basically, a group of athletes who followed a high-carb/low-fat diet, versus a group of athletes who followed a high-fat/low-carb diet.

And it was basically a measurement of fat oxidation during exercise. And they also did muscle biopsies before and after exercise to see the rate of glycogen use as well as the rate of glycogen replenishment following the post work out meal to just see if the body does a better job at oxidizing fat, or at sparing glycogen during exercise when you’ve eaten a high-fat diet.

And it did turn out in that study that the athletes who followed the high-fat diet were oxidizing a lot of fat. The textbooks tell you that you can burn about 1.0 grams of fat per minute, and the group of athletes who followed the high-fat diet were burning 1.5, 1.6, 1.7 grams of fat per minute. Literally rewriting the textbooks when it comes to how much fat you can burn during exercise.

I haven’t seen the muscle biopsy data yet to see how much glycogen conservation actually took place, or whether or not the body became more glycogen depleted when using primarily fatty acids as a fuel. But ultimately, what that diet consisted of was really controlling carbohydrates.

Whereas I would normally – and this is what I do now – I would carb-cycle, or I would do cyclic-ketogensis or cyclic-ketosis, where I don’t eat carbohydrates all day long and at the very end of the day, typically in the post-workout scenario, with dinner I’ll eat anywhere from 75 to 200 grams of white rice, red wine, sweet potatoes, sourdough bread. You know, safe starches, not like pizza and ice cream, but good carbohydrates. And then the rest of the day just high fat and moderate protein.

Whereas on this full on ketosis diet, it was pretty much just things like bulletproof coffee, and high fat shakes and lots of coconut milk and coconut oil, and heavy cream and MCT oil and seeds and nuts, and just fats, fat, fats. Bone broth and avocados, and olives, and you name it.

And frankly, in my opinion, it wasn’t that enjoyable to have to not have sweet potato fries, and not have, even coconut ice cream has cane sugar in it. So you have to make your own with chocolate stevia. And so it’s a little bit laborious and a little bit tough, but I mean at the same time the endurance payoff was huge.

The amount of focus that I had for long periods of time. My ability to just hop on a bike and ride for hours with no fuel at all, with just water. It was pretty profound, because you produce all these ketones as a bi-product of fatty acid oxidation, and they’re used as the preferred fuel by the brain, by the heart, by the liver, by the diaphragm while you’re out exercising. And that’s a huge boon to an endurance athlete.

And like I mentioned, there’s some blow-back. Like the TSH could take a hit, the testosterone could take a hit. But ultimately, it’s a cool little bio-hack. If I could go back and do it over again, I would definitely start taking thyroid glandular earlier to stave off some of those thyroid issues.

I would,– it’s not legal – but I would really encourage folks to pay attention to testosterone. And I mean like, you can’t use testosterone in a WADA, or a USADA or like an NCAA sanctioned event, but my testosterone dropped so much during that experiment with ketosis, I would say if you’re not competing, use AndroGel or just some kind of testosterone support because your testosterone is going to fall to pieces.

And then the question becomes well is it really worth it to you if you’re doing this thing and you’re not even competing.

[Damien Blenkinsopp]: Yeah. Did you feel different?

[Ben Greenfield]: Oh, yeah.

[Damien Blenkinsopp]: Because we talk about testosterone with things like anxiety, your drive, your libido, of course. And so did you get any kind of low testosterone symptoms?

[Ben Greenfield]: Oh yeah. Absolutely. I mean even something as simple as only having to shave every four or five days, whereas normally I would just shave every one to two days.

[Damien Blenkinsopp]: That’s a benefit.

[Ben Greenfield]: I mean, little things like that, but you notice. Yeah, potentially. You save money on razors.

Yeah, the libido, sex drive, number of times having sex per week, desire to have sex, quality of the erection, all of those kind of things certainly they took a hit during ketosis. They weren’t good. But that was, mind you, ketosis in the presence of high amounts of physical activity. Even doing the ‘low volume approach’ it’s still a massive amount of work, right?

[Damien Blenkinsopp]: Right.

[Ben Greenfield]: You’re still working out 60 to 90 plus minutes every day, and longer than that on the weekends.

And you look at something like Dr. Terry Wahls and her ketosis approach for managing MS. Well sure. I mean, that’s going to work just fine for managing MS. I mean, going on a walk with your dog every morning, and maybe lifting easy weights, three sets of 10 for 20 minutes twice a week.

But once you jump into hard exercise, it’s a whole different type of ketosis.

[Damien Blenkinsopp]: Right, right. Just to be clear, were you getting better times? Did you feel like you were competing better?

[Ben Greenfield]: Oh, I was competing way better. Yeah. Absolutely.

[Damien Blenkinsopp]: Right. But it’s just the downsides to your lifestyle, to all the other things, were too great to do this on a constant basis.

[Ben Greenfield]: In my opinion, yes, because I don’t like being cold all the time, I don’t like not having libido. So again, I’m not saying you can’t do it properly, even though it’s way, way tougher once you get into training, but I think that you basically have to use supplementation pretty intensively.

[44:34] [Damien Blenkinsopp]: Did you kind of see the benefits evolve and get much better as the months passed, or is this something someone could do on a month basis, one month on and one month off?

[Ben Greenfield]: For exercise, you barely even see any benefits until you’ve been doing it consistently for about six months, and the real benefits start to manifest after one to two years.

But the other thing to realize is that right about the time I finished up the experiment, companies like KetoForce started coming out with beta hydroxybutyrate salts that could be consumed to elevate your ketone bodies, even in the presence of a lot of carbohydrates or glucose. And so it’s possible that now, since the experiment that I did, you could get the best of both worlds.

And I actually have some bottles of the beta hydroxybutyrate salts and the resistance starches, and a lot of the things that, if I had to go back and do it all over again, I would try to get the best of both worlds. I would eat more carbohydrates, but then I would also hack myself into ketosis by consuming actual ketones bodies.

The question there becomes a matter of long term health and gut health and how that actually manifests in terms of actual symptoms or the way you felt, or even I would definitely pay close attention to blood and biomarkers.

Were I to delve into that type of bio-hack? I potentially may. I could see myself, and obviously I’m at a point in my athletic career where I’ve still got a good eight years of hardcore performance left in my body, and I could see one of those years being spent utilizing a ketonic approach again, but with the incorporation of beta hydroxybutyrate salts, resistance starches, even higher amounts of MCT oils, particularly like the C8s and the C10s. And a little bit more attention paid to ways to get into ketosis that go above and beyond just carbohydrate restriction and exercise.

[Damien Blenkinsopp]: This is great Ben, this is a wealth of information.

[46:20] In terms of the biomarkers you would track, you said you would track some biomarkers if you were going to do this again what kinds of ones that we haven’t spoken about already would you look at? Did you track your blood ketones?

[Ben Greenfield]: Yeah. Breath ketones. I mean, urinary ketones become, many times, absent after a few weeks in ketosis just because you’re utilizing your ketones. Blood ketones are accurate but expensive and invasive to test, and breath ketones are pretty [easy].

There are breath testing monitors like the Ketonix device that, one breath and you know your ketones, and you’re good. So breath testing is a really good way to go as far as measurement of ketones. You look for values anywhere from 1.0 up to 3.0 millimolars. You’ll finish exercise as high as 7.0 millimolars.

You’ll rarely see ketoacidosis, which would be like 10 plus millimolars. It is a non-issue. I have yet to see any athlete I work with go under ketoacidosis, which would be an actual deleterious biological state. Not something you need to worry about unless you are letting yourself become severely hypoglycemic.

[47:20] [Damien Blenkinsopp]: So again, is that something you saw evolve over the months? Like your ketones ratings would get higher.

[Ben Greenfield]: Yeah. You get to the point where it’s just super duper easy to get into ketosis. Yeah. And your ability to go for long periods of time without eating just goes through the roof.

So ultimately, the biomarker I would say, in addition to what we’ve already talked about, would be breath ketones. And then pay attention to triglycerides too, because they’ve shown that compared to total cholesterol values, a better predictor of your coronary disease risk factors is your triglyceride to HDL ratio, specifically keeping that at one or lower in terms of your number of triglycerides versus HDL.

But I’ve found that some people will switch to a high-fat diet and have such a high intake of vegetable oils, and even an imbalanced high intake of animal based oils, like butter for example, versus olive oil and avocados. Their triglycerides go through the roof.

Pay attention to that HDL ratio. That’s my advice is make sure that that thing isn’t getting much above one, that would be another important thing to pay attention to, especially on a higher fat intake.

[Damien Blenkinsopp]: Great, great. Excellent points.

[48:25] So there are a couple of other things I’ve noticed you’ve done in your experiment. I read your book of course. One of the things that we’ve come across before – I spoke to Alan Cash from benaGene –oxaloacetate, and I was wondering what you’ve done with that and if you’ve tracked anything or learned anything about that.

[Ben Greenfield]: Yeah, obviously if you talked to Alan Cash your listeners can go back and listen to that to learn more about what oxaloacetate is. But in a nutshell, the reason that I used it was because it can increase the turnover rate of lactic acid into pyruvate, and increase the rate at which lactic acid is shuttled back up into the liver to be reconverted into glucose.

And so if you are eating a low-carbohydrate diet anyways, that by nature means you might not be taking as much exogenous glucose in, or might not even have as high a level of glycogen stores, but you can still take the lactic acid that you’re producing as a byproduct of metabolic activity anyways and have that reconverted into usable glucose sources to have a glycogen sparing effect and to get a little bit more intensity. And so the way that would be achieved if you’re going to increase the rate of that cycle, which is called the Cori cycle, would be via the use of oxaloacetate.

And so, I actually did use that. I don’t use it right now. It’s one of those things where it’s just like, I would benefit from it its just one more supplement to remember to take. But I certainly used it through that entire ketotic experiment with the oxaloacetate just to increase the conversion of lactic acid into glucose.

[Damien Blenkinsopp]: Right, it sounds like it would help specifically in that ketogenic diet state when you’re exercising.

[Ben Greenfield]: Exactly.

[Damien Blenkinsopp]: So you designed it that way? You decided to take it before, or was it something you came up with afterward to help?

[Ben Greenfield]: I talked to Alan at one of the Bulletproof bio-hacking conferences. We talked about the physiology of oxaloacetate, and then based on that I just kind of had a little light bulb moment, where I realized that if I was restricting carbohydrates anyway, that this was one more way that I could create endogenous glucose more quickly.

[Damien Blenkinsopp]: Great, great.

[50:27] Cold thermogenesis. Do you still play around with that? Is there anything like, for instance, have you seen your HSCRP any time, potentially when you first started it or did it a bit more intensively, change with that?

[Ben Greenfield]: Yes. I have not done a dedicated experiment with cold water exposure, cold temperature exposure, or the use of ice baths or cold showers to see the direct effects on HSCRP, although reduction of inflammatory cytokines has been observed in literature when it comes to cold thermogenesis and inflammation.

What I use cold thermogenesis for is increased conversion of white adipose tissue to brown adipose tissue. Simply because it’s very difficult to kill fat cells, but you can convert fat cells into energy utilizing and heat producing tissue. And that’s one thing that cold thermogenesis is good for. That would mean cold baths, cold showers, cold soaks, etc.

Also very useful for increased production of endothelial nitric oxide synthase, which can cause your blood vessels to dilate much more readily, which is good for everything from exercise to sex to heating your body when it needs to be heated. And then there’s also increased tolerance to the mammalian dive reflex, which is that activation of our sympathetic fight-or-light nervous system in response to stress.

And when you are able to withstand cold stress without taking that sharp influx of breath, that means that you have become more resilient and more resistant to subconscious activation of that fight-or-flight nervous system. You’re better at controlling stressful events that happen.

And so, what I do is I never take a warm shower. I do a cold shower in the morning, cold shower in the evening. I do once per week a 30 minute cold soak that gets me up to shivering level, typically needing to shiver for one to two hours afterward in order to regain warmth. And those are the ways that I use cold thermogenesis. I also keep my house relatively cold. My office is at about 55 degrees. In my home, typically I’ll sleep at 60 to 65 degrees.

It’s just a really, really good way to make yourself tough, to burn fat, and to increase blood vessel health. And it’s just super simple. And frankly, the other cool thing is when I go hunting or when I have long periods of time outdoors or when I’m at the beach and evening comes and I forgot my coat, I don’t get as bothered, which is just kind of nice. You’re just more tough.

[Damien Blenkinsopp]: It sounds like the only time it was an issue when you were doing you ketogenic thing. What was the issue there? Were you getting a lot colder, or?

[Ben Greenfield]: Yeah, but that was because of the thyroid. If you have hypothyroidism, cold thermogenesis is going to be very uncomfortable. Heck, even normal temperatures you’re colder during. So I was still doing cold thermogenesis then but it was quite unpleasant. It was hard for the body to get warm again.

[Damien Blenkinsopp]: Okay. Right, great.

[53:17] Some quick fly questions that I have just to finish off here.

First of all, if people want to connect with you and learn more about you and what you’re up to, where is the best place? Twitter, your website?

[Ben Greenfield]: Bengreenfieldfitness.com, because if you go there, you’ll find links to my Twitter, Facebook, Instagram, my blog, my podcast, etc. So that’s a good place to go as a portal.

[Damien Blenkinsopp]: Great, great. And who besides yourself would you recommend to learn more about endurance training, or some of the other topics we spoke about today? Ketogenic diets and so on?

[Ben Greenfield]: As far as people who have their head screwed on straight who are paying attention to the research, I’d say three people come to mind.

Number one would be Joe Friel. He’s coached a lot of professional cyclists, but also has just been in the sport a long time and pays attention to the science and the research and has a pretty good unbiased view of things.

Sami Inkinen, who is a top age group for Ironman competitor. He’s a higher fat diet, pays attention to quantified data, and is a smart, well spoken person who performs well.

And then Dr. Peter Attia, who I would not say is on the pointy edge of physical performance, even though he’s in much better shape than the average, general population. He’s not out doing Ironman triathlons or anything. But, as far as the science goes, he probably knows the science better than just about anybody else when it comes to being able to speak to these things, and he also does quite a bit of self-quantification himself.

So, those would be three people that would be good resources for this.

[Damien Blenkinsopp]: Great, thanks so much for that.

[54:48] Beyond everything, like all the biomarkers we’ve spoken about today, are there any other biomarkers you pay specific attention [to] on a routine basis, I don’t know whether it’s monthly –that you feel are important that we haven’t spoken about?

[Ben Greenfield]: I’ll finish with this because it’s important. And many times in our type of circles it’s not talked about, and it’s not quantifiable to a great degree, as far as I know. And that would be simply paying attention to your levels of gratitude every single day, and multiple times per day.

For me, I guess you could kind of quantify it – at least six times per day I’m grateful. Because I’m journaling, and at the beginning of the day I journal three things I’m grateful for, and at the end of the day I journal three amazing things that happened to me that day. So there’s at least six times per day that I’m being grateful for things.

And then I practice quick coherence technique, which is something you can read about at heartmath.org, which increases heart rate variability and decreases stress. And that’s where you simply think of something that you love or someone you hold dear, and you imagine intense feelings of gratefulness washing over your body and going into your heart after you feel those feelings of gratefulness.

Saying thank you to people, saying I love you to people, randomly calling up people and telling them how much you appreciate them. If you listen to my voicemail, I ask people to end their voice message by telling me one thing that they’re grateful for that day.

It’s certainly something that’s not super duper quantifiable, again, but it is one thing, not a biomarker, but certainly something I pay attention to every day is gratefulness for being alive, for the people in my life, for the experiences that I’ve had, and for simply being able to take one more breath.

[Damien Blenkinsopp]: Excellent. Thanks for that, that’s not the typical, but definitely something really important. So I can see how that would be useful. I do a meditation gratitude every morning too, and I find that really, really useful.

So Ben, thanks so much for your time today. It’s been really stock full of biomarkers and hacks and everything, so it’s really been a great episode. Thank you for your time.

[Ben Greenfield]: Awesome. Well thanks for having me on, Dam.

Leave a Reply

We strive for the best mental performance but how do you know if your routines (sleep patterns, coffee habits, etc.) are helping or hurting? The Quantified Mind is a web-based project that allows you to quickly check your cognitive function in a few minutes.

In previous episodes, we have discussed and identified ways to improve our mental performance. Most recently, we explored Brain Training with Adrian Owen in episode 27. Many people try to improve their cognitive function with interventions such as caffeine, Nootropics, and different sleep patterns to try and improve clarity of thoughts and performance of the mind.

How do we know that these things are paying off? We could just be misleading ourselves and wasting our time on something which may, at some point, be proven to have little or no benefit. In this episode, we look at a more usable, time efficient tool which could be used to decide whether or not the caffeine in this coffee is helping your mental performance. The Quantified Mind is a way to objectively check the value of our attempts to “boost our brainpower”.

[On using Quantified Mind to Check Mental Performance]
I’d say even just one minute [at a time] and pick one test or maybe two minutes and two tests, and that’s it.
– Yoni Donner

One of the people behind the Quantified Mind project is Yoni Donner. For years he has been interested in life extension and is searching for an answer using science and data. Therefore, he conceived, designed, and currently leads this web-based tool. Yoni and his team (including Nick Winter, developer, and Stephen Kosslyn, Former Professor at both Stanford and Harvard) have created numerous opportunities and experiments through their website which anyone can use to help them analyze their own mental performance and cognitive capabilities in a variety of different ways.
Yoni also works at Google on artificial intelligence and has published a few papers through his work with Stanford University.

The episode highlights, biomarkers, and links to the apps, devices and labs and everything else mentioned are below. Enjoy the show and let me know what you think in the comments!

itunes quantified body

What You’ll Learn

  • There are two stages to be used with the Quantified Mind testing: first a control of normal cognitive decline of an individual and then the effects of intervention on cognitive decline (8:01).
  • There is little to no practice effect involved with these cognitive tests (15:00).
  • Yoni Donner compares his tests with other mental performance tests such as Lumosity (16:35).
  • Yoni Donner shares his opinion on brain training (18:13).
  • The Quantified Mind includes tests that look at reaction time, motor speed tests, visual abilities, working memory, learning and executive functions (23:21).
  • Extra care has been taken to make sure the Quantified Mind experiments and tests are scientifically sound (26:24).
  • Yoni Donner explains the growth of the project and number of users who participate in the tests (27:30).
  • Within the tests, time of day cognitive differences and different intervention effects (such as coffee, etc.) can be analyzed while you test yourself (30:17).
  • Yoni Donner suggests that you only need to do one or two minutes of testing at a time (32:00).
  • Yoni Donner talks about his own personal experiments with the Quantified mind testing, including his suggestion to plan the activities of your day around your cognitive ability during different times of day (33:01).
  • Discussion of coffee as an intervention to improve cognitive performance (40:26).
  • Testing should be individualized for each user; many use these tests to track their aging process (46:04).
  • Discussion of Nootropics, especially Modafinil, and self-testing mental performance when using neuro enhancing drugs (49:20).
  • The Quantified Mind has been very active in the scientific community to help provide data and tools for researchers (51:25).
  • How Yoni Donner tracks biomarkers on a routine basis to monitor and improve his health, longevity and performance (54:37).
  • Yoni Donner’s one biggest recommendation on using body data to improve your health, longevity and performance (57:44).

Yoni Donner and the Quantified Mind

Tools & Tactics

Brain Training

Supplementation

  • Nootropics: also called smart drugs and neuro enhancers. These drugs and supplements are used to improve cognitive function and productivity.
    • Modafinil: A currently popular nootropic that is primarily sold under the brand name Provigil. It is a drug which promotes wakefulness and alertness in an individual and is rumored to be the inspiration behind the film Limitless with Bradley Cooper and Robert DeNiro. It requires a prescription, although generic drugs with alternative brand names are also being sold on the Internet.
    • Piracetam: Piracetam has also used to increase cognitive performance and protect the brain in diseases like alzheimers. It is one of nootropics with the longest history of use and the most research on it.

Diet & Nutrition

  • Bulletproof Coffee: Created by Dave Asprey, Bulletproof Coffee is a combination of low mycotoxin coffee beans, grass-fed butter, and MCT oil (or Brain Octane (a concentrated form of MCT) which is said to improve cognitive performance. In 2012, Dave Asprey and the Quantified Mind paired up to conduct a study to test the components of Bulletproof Coffee, as mentioned in this episode. Some information regarding the study can be found here. The outcome seemed to suggest that the butter had no impact, but that taking ‘low mycotoxin coffee’ as compared to standard Starbucks coffee did have performance benefits.

Tracking

Lab Tests, Devices and Apps

  • Quantified Mind: from this home page you can sign up to use these cognitive tests and join experiments that other users are also participating in through the project.
  • CANTAB: these are alternative neuropsychological tests, developed originally by the University of Cambridge, that were mentioned by Damien in the podcast.
  • Stroop Testing: the Stroop effect is used to process attention and processing speed. The Stroop test is a common tool in psychology used to assess reaction time.
  • Cambridge Brain Sciences: This website offers a battery of free mental and cognitive performance tests. These tests are designed to assess your state of cognitive performance at one point of time and to be done infrequently (requires 15 to 30 minutes to complete).

Other People, Books & Resources

People

  • Stephen Kosslyn: A former Harvard and Stanford psychologist, Kosslyn collaborated with Yoni on the creation of Quantified Mind.
  • Christine L. Peterson: Peterson is the co-founder and past president of Foresight Institute. She is an advocate for nanotechnology and life extension technology. She was an instrumental part of the Personalized Life Extension Conference mentioned by Yoni Donner in this episode.
  • Peter Thiel: Peter Thiel is a billionaire investor businessman. He is the co-founder of Paypal and one of the early investors of Facebook. He has recently taken interest in anti-aging solutions and life extension technologies.
  • Roy Baumeister, PhD: A social psychologist who is currently a professor at Florida State University. He was influential with his work on willpower and has been published over 500 times. In the late 90’s he authored a paper commonly referred to as the “cookie and radish” experiment. He was mentioned by Damien after Yoni Donner discussed ego depletion in the podcast.
  • Adrian Owen: Mentioned by Yoni as one of the first study authors on Brain Training. We discussed brain training with Adrian in episode 27.

Organizations

  • The Human Cognition Project (HCP): this is the home page for the Human Cognition Project which is also associated with Lumosity. This project aims to provide researchers with the data necessary to pursue research questions and hypotheses regarding human cognition.

Other

  • The Science page: this page offers a detailed description of the science behind the Quantified Mind project and cognitive testing. For further information, there is a list of references at the end of the page.
  • Lumosity blog: this is the blog hosted by Lumosity that provides up-to-date information about the science behind brain training and general updates about Lumosity itself.
  • HCP peer-reviewed published papers list

Full Interview Transcript

Click Here to Read Transcript

[Damien Blenkinsopp]: Hey Yoni, thanks so much for coming on the show.

[Yoni Donner]: Thanks so much for inviting me. It’s a pleasure.

[Damien Blenkinsopp]: Great. So, we before we get into it, I wanted to hear a little bit about your first got involved in your interest area. How did the Quantified Mind come about? Was this a mini project? Was it something you were interested in, at first, doing for yourself?

[Yoni Donner]: Yes. It started with a pretty different context. I always wanted to cure aging since I was pretty young.

[Damien Blenkinsopp]: Nice.

[Yoni Donner]: And I still do.

[Damien Blenkinsopp]: Yeah, I’m there.

[Yoni Donner]: Turned out to be a somewhat more difficult problem. But no, the original thought was that, perhaps, the most accessible part of aging that we can start working on is the aging of the brain. Especially since that sort of leads everything else and there were all of these reports of these things that might be useful.

And since I had lots of friends who were interested in this, and they often annoyed me when they massively consumed blueberries because they thought they would help, I really looking for some scientific backing of all these potential interventions. And it turned out there isn’t actually much. Most of the stuff that goes into newspapers is completely not validated, and we wanted to do it ourselves.

So, I just looked at “what can science tell us about how to measure cognitive performance,” and it turns out that they’ve been very good at measuring the differences between people, but they’ve done almost nothing to measure the inter-individual variation.

So, it’s very hard to compare a person to themselves under many different conditions for several reasons. So, the tests were not built for this purpose at all so I kind of have to adapt them to make them test the person several times. And also they’re very inefficient so sometimes you take a long time to get the data or you need a psychology student to get the data for you.

And it was a disappointing finding that I realized, if I really want it done, I have to build it myself. Especially since I’ve never really enjoyed building websites or anything of that kind. I really just like analyzing data and writing over convoluted algorithms.

But with some help from some friends in the first stages, we got this going, and since then it has actually been mostly used for other purposes. Namely for people to test more acute interventions rather than long term processes. And that’s fine. Whatever is useful is great.

[Damien Blenkinsopp]: So, you’re using it for the long – are you still using it for the aging? You want to maintain, or you want to improve over time, your brain responses?

[Yoni Donner]: There are several stages. The first one is simply to validate that we can accurately track the process of cognitive decline. This would be the control.

Once that is established, we want to start looking at the most promising interventions. So whether they be physical exercise or even jogs. Although I’m not generally a huge fan of jogs, simply because they seem to have more side effects than positive effects. But yeah, so we did make some progress.

Actually, only the last year, I finally managed to get some collaborators to recruit subjects and do a longitudinal study within person aging. So that is all very new now. Now, this is at this stage of trying to get more researchers for a slightly longer pilot study because this was sort of to establish the methods and verify that we get clean data and so on.

What I can say is we definitely have seen, on the data that’s been collected randomly with people who opted in to provide their age, that the classical effects of aging are very, very clearly seen. So, at least in that sense, all of the stuff that we’ve known has been replicated.

But now I mostly rely on working with researchers who can actually do the interventions. So it would be great, for example, to do a caloric restriction study in humans.

[Damien Blenkinsopp]: Right, and see if that has an impact. But I’m guessing you’re going to have to do this over five years or something to see anything significant?

[Yoni Donner]: So, that is a great question. So the whole point was to not wait five years. So Quantified Mind was built to be so precise that we could actually see effects given a reasonable sample size with a much shorter amount of time. Because, obviously, no single individual will reliably show decline over two months even if they’re over 70 or over 80 years old.

But it’s an average effect that is quite strong. So there is some effect size that you could say over a month of your life there is an average decline. It’s probably very, very small compared to, for example, random daily variation. That’s why, if you have a sufficiently large number of measurements, you could actually see that.

And I have a lot of data by now about the accuracy of this – how well [unclear 10:06] measures the actual observability. So, the reliability of the test is actually very, very high. And you got almost zero noise in the measurement itself so you’re just fighting against the noise in the actual cognitive function. So really people would vary more day to day more than they would on average over a month. But that’s fine since we average over that eventually with enough data.

[Damien Blenkinsopp]: Right. Well this is really cool because I didn’t know that this was the original purpose of it, and actually, this is what I’ve been interested in lately. I’ve been interested in mild cognitive impairment and I talk about cognitive decline.

And I’ve actually had some scans showing some nasty structural changes due to something I went through a couple of years ago. So I want to kind of repair that and get it back up to speed. So, it’s one of the reasons I’ve – and when you’re say anti-aging, you really think about the brain.

I’ve also thought, for me, the two areas that seem most important to me are energy and the brain. Brain so that we can carry on thinking and walking around. And if you don’t have energy you can’t really get stuff done either. Because once your productivity is gone you can’t work on any of this stuff.

[Yoni Donner]: Yeah, that’s true. Actually, what you said now is almost an exact quote from the first quote I gave in proposing this project in an aging conference four or five years ago.

[Damien Blenkinsopp]: Oh wow. Cool.

[Yoni Donner]: So yeah, completely agreed on this.

[Damien Blenkinsopp]: Well you’ll have to tell me afterwards about the anti-aging conferences. Are there any good ones that you like or prefer? Because I’m sure the audience is interested in this stuff too.

[Yoni Donner]: I don’t if it’s still going on. I have seen anything about this in a while, but it was called the Personalized Life Extension Conference. It was run by Christine Peterson who now does Foresight though. Maybe she doesn’t even do that anymore.

It was very cool. I got a slot there to just propose this project that was not even close to existing yet. It was just an idea, but I put on a spiel on all of my belief in why we need a new tool and what’s the problem with existing measurements.

And I have to say, at least I got one thing in my life right, that I did build it exactly the way that I proposed it. But it was nice. I got to talk to Peter Thiel about this right after my talk and –

[Damien Blenkinsopp]: Oh awesome.

[Yoni Donner]: He set me up with one of his people to actually discuss funding for the project. Of course that never materialized because I’m not a business person. So I never follow up on business talks.

[Damien Blenkinsopp]: Oh well it’s a great intro to Peter Thiel as that’s quite a big name. Might come in useful to you later maybe with the tool. So I’d like to talk about what future plans that you have for the tool later. But for now, could we take a step back? Because you’ve said that this tool is quite different to a lot of the others out there. And some of the ones, when I contacted you, I was thinking about, is things like the – we had Adrian Owen who developed the Cambridge Brain Sciences set of tests, if you know those. We had him on the podcast a little while ago.

[Yoni Donner]: They got really famous from publishing in [unclear 12:54].

[Damien Blenkinsopp]: Publishing, and with the study which showed the brain training wasn’t effective. Was it that one, or something else?

[Yoni Donner]: That may have been that. There was one study that was really famous that I think Adrian Owen was the first author on.

[Damien Blenkinsopp]: Yeah. It might have been that one. Anyway so, and in this CANTAB, which is supposedly the best validated tool, is the reason it’s not relevant to you as CANTAB is because it’s looking at the differences between people rather than a person in time, as you explained earlier?

[Yoni Donner]: Well each of the existing tools has some substandard features and some that are not. So, I should be more clear. There have been mainly three axes of scaling that the Quantified Mind is supposed to provide that have not been existing altogether in existing tools.

So one of them is just something that Lasuis Claviger [check 13:41] cross experiments. It’s very easy for a researcher to just set up a new experiment and get a very validated and standardized set of tests and tools for analysis.

So, part of this is, for example, providing easy access to the entire raw data through APIs, but in doing things like randomizing subjects into groups or very easily controlling how the experiment is applied. And they also provide all kinds of algorithms for making data analysis easier and distinct outliers very reliably. So this helps scale across experiments.

And then there’s the [unclear 14:13] in person component, which simply was optimized to begin with in this test. So, all the tests have been adapted to be very, very efficient and to be completely repeatable. When I say completely, you could even take the test one billion times if you wanted to, and it would still be effective. Not only that, it would be more effective because the practice effects get weaker over time.

[Damien Blenkinsopp]: That’s something we should highlight for people. A lot of these tests you can get better at them over time. So this is what you call the practice effect or the training effect.

[Yoni Donner]: Right.

[Damien Blenkinsopp]: And in this case, because you want to see if there’s decline or improvement, you wanted to eliminate that. So you’re saying in these tests there’s not very much of that. As I understand it, after you’ve played it a few times, you’ve done it a few times, there’s not much change in terms of practice or training effect.

[Yoni Donner]: Yeah, that’s generally true. I also have more precise on all of the tests of exactly the practice magnitude. In the worst case it takes about five sessions to get it down to manageable levels. By that I mean that it’s smaller than most of the hypothetical effect sizes that we’re interested in measuring. So just time of day variation and so on.

But I do have exactly the compositions of the variance for all the tests. I’ve got all of this data for my thesis. So, a lot of tests don’t even have practice effects at all. For example, reaction time tests are almost zero. And one way is if you can extrapolate the practice effect and eliminate it.

But I think it is generally better not to make any model based assumptions and not to fit additional parameters. So if it’s possible for any experiments to start with just a few practice sessions just to get this out of the way.

[Damien Blenkinsopp]: Right. Yeah so, in practice someone should do those tests a few times a few days in a row and then they could consider that in their baseline.

[Yoni Donner]: Right. Yeah. So that’s the protocol that we follow on most experiments now. Four for five practice sessions before.

[Damien Blenkinsopp]: Does it have to be the same day or could you just spread those out over a week or something?

[Yoni Donner]: Generally, I would say spreading them is a little bit better, but it’s kind of insignificant next to just the value of doing them at all. So often with this kind of thing, I think it’s better to make sure that just people do them and not be too strict about rules because that will just result in losing subjects and –

[Damien Blenkinsopp]: Right.

[Yoni Donner]: Or they wouldn’t do it at all.

[Damien Blenkinsopp]: Excellent. And then I just wanted to bring up the other tools and see how it compares in your mind. There’s Lumosity and there’s BrainHQ Posit Science. How does your tool compare to those?

[Yoni Donner]: Yeah. So Lumosity, we actually became good friends when I built Quantified Mind and we talked about this a little bit, and we really like each other because we are completely complimentary and non-competing at all because they are focused on brain training and also on user acquisition.

Obviously, the whole thing is a big game and they’re huge and they make something that appeals to everyone. We joked about this the other day. Almost everyone’s mother plays Lumosity.

That is very different. They don’t do a very precise measurement of the instruments, but they do try to make arguments about brain training, and they’re very, very good about the gamification effect and user retention.

Quantified Mind is completely focused on being a precise measurement tool and, even more so, a research instrument. So that’s a very different focus. But I should say, I just published a paper with Lumosity last month that used their data since they still have a lot more of it about human learning dynamic.

So, that was a lot of fun. And mostly I did the whole research and they provided their amazing data. But it was a great experience just collaborating with the VP of R&D there – is a great guy.

[Damien Blenkinsopp]: Yeah. Cool. And I as I understand BrainHQ Posit Science is pretty much the same as Lumosity, but just smaller.

[Yoni Donner]: Yeah. I think there are subtle differences. Posit does stay more focused on some pathologies or specific kinds of improvement. Lumosity, more appeal to the general public.

[Damien Blenkinsopp]: Great. And what’s your opinion on the whole brain training area? Like I said, we had Adrian Owen on and he talked about his study where they tested a lot of people in the UK and they found no effects at all after they’d been doing some training for a while with the Cambridge Brain Sciences test. Do you have an opinion on that?

[Yoni Donner]: I think it’s very hard to just put a binary result or to say for sure brain training does not work at all. But I think if we consider what work should mean to a reasonable person, we can kind of conclude this question anyway.

Because for something to work, it needs to have, not just a nonzero effect size, but also an effect size that’s big enough to be worth the effort. And even if you do something – I do a [unlcear 18:36] every day. And let’s suppose you even improve your working memory in the general transferrable sense, all the results that we have so far – even the most of the domestic ones, even the ones that say it works – show a pretty small effect size.

And it still takes a lot of your time and a lot of your energy. For example, people told me on Quantified Mind there is a single [unclear 18:58] test, which is not even as horribly annoying as to do an the Quantified Mind, and people still said they fight with their significant others after doing this. [Laughter]

So, it drains a lot of willpower, it drains a lot of energy to do those things, and you get a very tiny effect in the end. So, if you are dedicated enough to do something good for your brain, there is nothing in the literature right now that comes even close to physical exercise, and this has been documented so many times.

So I’d say do some effort to clean up your diet. I don’t know, ditch the caffeine addictions. But if you drink it, in small amounts. Sleep well and exercise a lot. It will be much better use of your time than brain training.

Of course brain training is just appealing to people who like playing video games. So it seems like if you like doing these engaging things with your computer, then you just don’t suffer that much. But it’s still very time consuming and the effects are quite small even according to the most optimistic results.

[Damien Blenkinsopp]: Right. I went through a phase of using Lumosity and I came to the conclusion that it was just a huge sink of my time and it wasn’t really providing any benefits. But what I did notice was, when I was sick, I would get a huge crash – [Laughter]

[Yoni Donner]: Oh yeah. That’s really true.

[Damien Blenkinsopp]: in my data. So that was interesting. But the amount of time to play the games is a lot when you’ve been playing it for a while, the games tend to start taking a long time. Some of them were taking – I felt like it was ten minutes, and that was just too much time at the beginning of the day, I was doing it for this.

So, that’s one of the things that attracted me to Quantified Mind because you said you had a focus on keeping it efficient and minimal. Before we get into that I just wanted to point out something you just said. You were saying the willpower. It drains the willpower. It sounds like we’ve both been thinking about willpower quite a lot and how that impacts. Could you explain what you meant in a bit more detail when you’re saying that doing these kinds of tests could drain willpower and that could have impacts on the rest of your life, right?

[Yoni Donner]: Yeah. Well so I don’t want to say things that are too conclusive in a field that I’m not an expert in, but I actually did – there was a master student who did his thesis project with Quantified Mind on exactly the thing called ego depletion, which is highly related to willpower.

So ego depletion is, for example, when I give you a stroop test and then you’re more likely to eat a cookie after. Because some hypothesis could be that it drains your willpower. And it definitely looks this way with the Quantified Mind test.

So, we actually did an interesting experiment where we gave people a 20 minute long stroop test, which is really torture. And you can definitely see that people just cannot, even within the test itself – within those 20 minutes – they cannot maintain their ability to answer the difficult trials.

So you can divide the test to easy, moderate, and hard trials to pretty rough division, and you could definitely see that they keep getting the easy ones correct. But there are points where they just collapse and they start messing up the hard ones.

[Damien Blenkinsopp]: That’s a matter of endurance – the longer you’ve been doing it?

[Yoni Donner]: So, we didn’t get longitudinal data on this, unfortunately, so we don’t know if the same people got better the second time they did the 20.

[Damien Blenkinsopp]: I meant in terms of if you’ve been doing the test for ten minutes versus one minute. Was there an endurance effect in terms of willpower potentially?

[Yoni Donner]: Yeah. So that was the main hypothesis. It turned that it’s a bit more complicated like everything in life. So then, in general, yes. You do get less likely over time if you average other people. But there are also times where people seem to sort of get it back together. Actually, towards the end. It seems like they suddenly notice they’re close to the end so they have another bout of energy.

[Damien Blenkinsopp]: Right.

[Yoni Donner]: But yeah, and we also had these results when people just report as qualitatively. They feel drained after doing a long [unclear 22:33] and it’s fine. I do personally believe that there is also a lot of this classical “willpower is not that important if you don’t believe that it is.”

[Damien Blenkinsopp]: You think there’s merit to that?

[Yoni Donner]: Well it seems to be partly true and partly there is something that does drain. And it also seems to be trainable to some degree. It’s just one other reason not to spend too long doing things that don’t give you much benefit. But there are many other reasons to not spend too long doing things that don’t give you much benefit.

[Damien Blenkinsopp]: Great. The cookie test you brought up – the experiment of, I think it was, Roy Baumeister?

[Yoni Donner]: Yeah. And actually one of the things really is the stroop test by the way. So this is direct evidence.

[Damien Blenkinsopp]: I understand. Could you explain what areas of Quantified Mind what areas of the brain are you testing or what cognitive capabilities are you looking at?

[Yoni Donner]: There are some tests that looking at reaction times and speed directly. So there are few reaction time tests and motor speed test. There’s some visual and spatial abilities. Which I’m going with a somewhat thematic order because these things are a little close to reaction times.

There’s a lot of executive function and working memory stuff. So there’s always the argument of whether working memory and shorter memory are the same thing or not. So there are things for both. There are some verbal learning stuff. So more long term learning. This is the main emphasis.

There have been other tests that people have put in who have collaborated with me on studies. Actually emotion regulation and decision-making, but we didn’t ever get a lot of data for those so I didn’t get to analyze their psychometric properties. But yes, so mainly those things. I’d say the most rough division –

[Damien Blenkinsopp]: Yeah. How do these relate to the people at home? If they’re thinking about working area and the executive function area, how is that going to impact their daily life?

[Yoni Donner]: So these are probably the most important ones. Actually more important than speed. Probably speed would correlate to what you’d think of as alertness or even energy – weakly correlate. And executive functions would more correspond to what people would think of as focus or attention, or really getting things done, or even flow, I would dare say.

[Damien Blenkinsopp]: Getting into flow. The ability to get into flow. Okay.

[Yoni Donner]: And working memory is the best correlator out of these things to intelligence in general. So to be efficiency of work. But again, these are all very rough generalizations in making things interpretable.

[Damien Blenkinsopp]: Yeah, right. So to connect to the day to day is a little bit difficult. But working memory is basically, roughly how many things you can keep in your mind.

So, I always thought if you’re solving some kind of puzzle or you’re trying to make some kind of decision, if you can have ten variables in your mind – I think it’s seven the amount typical for working memory. But if you can basically play around with those things more in working memory similar to a computer has ram, then it’s easier to make decisions and more complex decisions.

[Yoni Donner]: Yeah, exactly. And of course every kind of work in modern life is full of these multiple things that come at you and if you have too many of them. Even writing code, is one of the most obvious things that depend on working memory, right?

[Damien Blenkinsopp]: Well I think pretty much everything I can think of. When you’re problem solving, I think that’s very dependent on working memory. Is that correct?

For most people, if they’re going about their jobs. Most jobs these days, it’s troubleshooting, it’s problem-solving, it’s planning. Would you fit those into the working memory area?

[Yoni Donner]: Yeah. If we were take into just a generalization and not perfect [unclear 26:05], yeah, totally.

[Damien Blenkinsopp]: I like that you put the caveat out there. It’s good. [Laughter]

[Yoni Donner]: Yeah. Sorry, I just got my PhD so have to be an uberous careful scientific person. [Laughter]

[Damien Blenkinsopp]: No, that’s great. So in terms of the scientific validation between your tests that you’ve put up there, how strong is it?

[Yoni Donner]: It’s quite good. So, to begin with, everything is building on tests that have been very, very extensively used in the literature. That’s how I selected them to begin with.

But I also did many independent types of validation. First of all, reliability is extremely high. It was higher than I ever hope to achieve. The basic result on reliability in this data shows that a one minute test for almost all tests is sufficient to measure almost perfectly the skill which is being measured. Which is great.

And for validation, I looked at internal structure and external structure. So these mean how the tests relate to each other, and that behavior supports completely psychometric theory and psychological theory. So that suggested they are measuring the right thing.

And the external variables also look exactly correct, so the same we’d expect. There are extensive results on this. I am slowly working on a paper that, hopefully, will eventually bring all of these results out. But for now it looks really good.

So everything that we would predict does seem to behave correctly, and then, of course, there are new results that we had no predictions about so this gives us some confidence to believe in them.

[Damien Blenkinsopp]: So, when did this launch and how many users have you had using the system so far?

[Yoni Donner]: This was early 2012, and it grew fairly linearly. I never tried to get users, but it just happened so that’s nice. It grew fairly linearly. We have now over 40,000. I think most people, of course, don’t take many tests.

[Damien Blenkinsopp]: Right. They do a few and then disappear.

[Yoni Donner]: There was several jumps in the middle where some event happened and then a ton of people signed up overnight.

[Damien Blenkinsopp]: Great. Do you know how many tests have been taken to date?

[Yoni Donner]: Yes. It would be something like half a million tests. I think I even computed the number of individual trials and it was something like 660 in a million or –

[Damien Blenkinsopp]: Wow. I’m guessing you look at that. Do you sometimes look at that data to see if there’s anything interesting that comes out on the averages or -?

[Yoni Donner]: So looking at the aggregates, definitely that’s the way to do psychometric analysis. So without looking at who’s doing what and names at experiments, you can still look at relationships between tests and practice effects and complexity effects. These are real interesting things – and even time of day, which is always there.

I don’t just look at people’s data because that’s a big invasion of privacy. But there are cases where researchers are designing experiments that are run on the platform. Then I give them some access rights. Then everyone who signs to that experiment specifically opts in to having the data available only to that researcher, and often we do the data analysis together. So I do get to see a lot of cool stuff.

And yeah, it looks like these results are pretty encouraging. We definitely knew, to begin with, that the effect sizes to be expected with in-person variation would be rather small, but it’s very nice to actually find them.

[Damien Blenkinsopp]: Right. That’s cool. One of the things I’d like to make clear about this tool is basically that, in order to do experiments, you’ve added the ability to add variables. And there’s some basic variables you’ve already added in yourself, like “have I had coffee today, have I had chocolate today” that you have tested for. So it enables us to control for different things and see if they’re having an impact on us, on our cognition and at the different test areas.

[Yoni Donner]: Correct.

[Damien Blenkinsopp]: So, do a lot of people make use of that function and you can see the differences between say coffee and no coffee?

And you’re saying also the time of day. Do you track that with location? So, I’m in London right now, for instance.

[Yoni Donner]: Yes. People who are moving around and don’t update it in the time zone, I would lose that data. I do not take into account all the data from people who did not demonstrate that they were aware that a time zone field exists and needed to be updated. So, I only include people who explicitly change their time zone at least once to make sure that at least that part will be roughly –

[Damien Blenkinsopp]: So, I’m gone.

[Yoni Donner]: Yeah. There were cool results with the time of day because I think no one has looked at the time of day effects simultaneously across a wide variety of tests, and I’ve done exactly of this. Only a few weeks ago finally got to play around with this. It was cool.

So you can’t actually look at a uniform this time of day because different people have different chronotypes. So there would be owls and larks and all these other names. So instead of uniformly averaging across everyone, I used a nonparametric clustering algorithm to find, automatically from the data, what are the clusters that we can see. It was really cool because you could definitely see that almost all the people are worse at night.

But definitely some people get this afternoon dip and some do not. And some people peak in the late morning where as some others actually slowly improve throughout the day and only collapse late night. It was really cool to see this emerge from the data itself with no prior assumptions.

[Damien Blenkinsopp]: That’s interesting because I can make assumptions about those cases. You could probably too. It’s speculation, but a lot of people get slight adrenal fatigue so they could be more tired in the afternoon. I could imagine that it would. It’s said to affect cognitive.

So, it’s funny that your data has pulled out those scenarios, which would be very interesting. So what would be the minimal test? Because we’re talking about efficiency here and we talked about how doing a lot of testing might reduce our willpower and have some impact on our self-control during the day and some other impacts.

So, in terms of someone who wants to do some tests and basically see where they are – track some that are not having cognitive decline or potentially looking at days they drink coffee versus not or some other test – what would be the minimal test you could do once per day to track while experimenting like that?

[Yoni Donner]: Yeah. I’d say even just one minute and pick one test or maybe two minutes and two tests, and that’s it. So, two back or three back or a good test, cover a wide variety. It’s mostly working memory, but you’d also get a component of speed in that.

So if you do that I’d say you don’t really need to measure speed separately or choice reaction time or something. And it’s also valuable to put stroop or what is called sorting on the Quantified Mind.

But definitely one to two minutes and no more. There’s no need it and it just reduces the likelihood of doing this many, many times, which is far more valuable than adding more tests to a single measurement.

[Damien Blenkinsopp]: Right. So you could basically do this test once per day, control the variables and it’s basically a minute of your time to get potentially something useful.

[Yoni Donner]: Yeah. Or multiple times per day if you’re looking at something that changes across the day or the effect of coffee obviously are not constant across the day.

[Damien Blenkinsopp]: Right. Exactly. I know that you did a lot of tests in the past. I’m not sure if you’re still doing a lot of tests with this on yourself. What kind of discoveries have you made about yourself?

[Yoni Donner]: That’s interesting. So, I definitely agree with what you said before about getting sick. Fortunately – this is famous last words – that did not happen in quite a long time. So I didn’t get that data point. But last time I measured this the effect was huge. It was unbelievable. It was somewhat that I could compare this to, for myself, something like five days of pretty severe sleep deprivation.

[Damien Blenkinsopp]: Right. Exactly.

[Yoni Donner]: Awful.

[Damien Blenkinsopp]: Did you see kind of like a crash and then a slow recovery?

[Yoni Donner]: Even when getting better?

[Damien Blenkinsopp]: Yeah, right. Well for me, personally, it took it five days, seven days to get back to baseline after the initial day when you fall sick. Of course it depends on the sickness, so it’s a bit variable.

[Yoni Donner]: I think the recovery was a bit faster, but still we probably had different things going on. But yeah, it was a very strong effect. I actually did a [unclear 33:51]. One of the strangest things I’ve done on myself.

So I like doing things that they also keep me engaged by their own right. So an experiment which is not boring because it gets you to keep doing it. We had this funny discussion about a little odd result in the literature. You may know this one. Glycogen depletion followed by glycogen overcompensation resulted in a significant improvement in cognitive functions.

They did this on rats and this was a long, long time ago. I may not get the details right away. I think they basically let them run to exhaustion until the poor rat just collapsed. And then they fed them a ton of sugar, more than they needed to refill the glycogen. And then killed them and witnessed abnormally huge amount of glycogen in their range.

And then they hypothesized that this would also translate to a behavioral output. So I did this on my poor human self for like several days.

[Damien Blenkinsopp]: Okay. So could you explain how you did that to yourself?

[Yoni Donner]: Yeah. So without the killing part. So a lot of exercise. I think that was also a good excuse to get myself back into exercising. So, it was a lot of cardio and then some weight lifting.

I read what you’re supposed to do to do some glycogen depletion. So a lot of many, many, many sets with relatively low weights. That seemed, at least by subjective experience of wanting to diet, seemed to do the job. And then trying to do some calculations of what exactly would be the glycogen overcompensation, and then take cognitive tests about several hours later.

I don’t remember the exact numbers. It was a few years ago. But it was a hypothesis based on a minimal amount of existing data. That seemed to work great. It’s totally not worth it. It’s like brain training. But definitely I got some of the highest scores I’ve ever seen in my life.

[Damien Blenkinsopp]: Cool. That sounded like a huge effort actually. That sounded like it was a couple of days to do that.

[Yoni Donner]: Yeah. So I only did like five times, but it was pretty significant. This is definitely not something that I want to do in life, and it’s not worth it to get this benefit. But it was just interesting.

Again, this is the kind of thing you want to know or you or you want to test. And if there’s some open question, why not just settle it with science?

[Damien Blenkinsopp]: Right. And who knows? If you had a really, really difficult decision to make or some kind of planning session or something, you might to do that as a one off to solve that life decision that you have or –

[Yoni Donner]: It’s true. Or if you have an exam at 3:00 PM or something and you decide to waste your time on doing this crazy stuff instead of studying. You might at least know that you’ll be quite pumped up when you get there.

[Damien Blenkinsopp]: What other experiments have you done that have had some significant impact? Are there any you feel you’ve integrated into your life because they’re worthwhile because the time expense for actually doing these things isn’t too much to get some kind of benefit.

[Yoni Donner]: The biggest impact one is time of day and I think that would apply to a lot of people because you don’t really need to do strange manipulations or interventions for this. So just design the activities that you do such as they fit with your natural rhythms.

I’m currently at the point where I’m way more productive in the early part of the day. So, I leave all of the stuff that doesn’t require too much mental power to the later parts of the day. But that’s a very easy one.

And an interesting one that we’ve seen that’s not on me, but an actual study that was done quite recently was that the effects of temperature are not what people would expect. Which is also a little consistent with existing literature, but there’s not that much existing literature on this.

This was a great study where several hundred subjects and everything was perfectly controlled in terms of temperature and humidity. They did all the practice stuff perfectly so the data was very, very clean and very, very good, and it showed that people do not actually predict correctly when they function at their best.

So most people would report being more comfortable at a slightly lower temperature than the temperature which their brains worked the best behaviorally. This seems like a little counterintuitive, but I looked into this and it turns out that this is actually consistent with results that were previously known. But I think we brought a better resolution to this question.

[Damien Blenkinsopp]: It’s always interesting when it goes against our own sense of wellbeing. As you’re saying it’s a little less comfortable, a little bit hotter than maybe we feel is comfortable is when we’re working best.

I was also wondering if you think a lot of people might try to guess their rhythm during the day. I’ve always been a morning person and I’ve always told people I’m a morning person. Over time, I think I’ve got some more stamina now so I can work for longer periods. I can work maybe 10 to 12 hours and I don’t feel so bad if I’m not doing it too many times a week.

So basically, people should kind of test this kind of thing with the test. But would you expect them in [unclear 38:36] you mean speaking to people about their time stamp test and does it kind of reflect what they thought?

[Yoni Donner]: That’s interesting. I think most people have a good sense of this, especially who are workaholics because they actually try to use their brain at all times of the day. So they really discover what it’s like.

Of course you mix in all effects. Obviously you get a little tired just by doing mentally exerting work. So it’s not a perfectly controlled study because then you would have to be lazy the whole day and see if you still function not quite as good in the night.

But most people don’t do this and they are accurate. There aren’t that many people who have shared their results or given me access to their data explicitly.

But there’s at least one person who said he actually did change his routine based on these results. Because he used to do a lot of intellectually engaging work for the evening and it turns out his results were very strong biased towards morning strength.

So he moved everything around and moved, for example, his physical workouts to the evening because he found that he didn’t need much willpower to get started. So he would do the workout and didn’t feel that it matters too much if he lifts a little bit less weight because that also changes during the day and it might not be correlated too.

So that was a cool example of changing things accordingly. And that’s really, again, the easiest experiment to do. You don’t need an intervention at all. You just get the data.

[Damien Blenkinsopp]: Yeah. Great. Are there academic studies that you can talk about that have been done with The Quantified Mind? Because I noticed some of them are restricted.

[Yoni Donner]: Yeah. It’s true. So there are a lot going on. There’s always someone somewhere doing yet another kind of coffee study. Which is funny, but it’s nice because it always works.

[Damien Blenkinsopp]: Let’s talk about coffee because I think – did you do a bulletproof coffee study? Was that where it was done because -?

[Yoni Donner]: That’s not really academic, but it was a study. Yeah. It had problems. It was definitely not blind and there was a selection effect by the [unclear 40:35] class.

[Damien Blenkinsopp]: Just for the people at home, that means that the people had opted in big as like they like bulletproof coffee basically.

[Yoni Donner]: Yeah. They were actually recruited through the Bulletproof Coffee website.

[Damien Blenkinsopp]: Instead of being randomly given Bulletproof Coffee.

[Yoni Donner]: Yeah. And this in combination with not being blind means that the placebo effect would be huge. Because you’re exactly telling the people who would believe that this would work on them that they are currently under the condition that would work for them.

Having said that, the results were more interesting than just a pure monotonic improvement. So Bulletproof Coffee has this as a component of the coffee and the butter. So even in our data, butter had zero effect, but coffee had a large effect.

This means coffee, like Bulletproof compared to Starbucks, not Bulletproof compared to no coffee, which would obviously have an effect.

[Damien Blenkinsopp]: Okay. And the quality of the coffee basically or something about the coffee that was better. It’s interesting –

[Yoni Donner]: Or the placebo of the coffee, yes.

[Damien Blenkinsopp]: The facts that people were using the Bulletproof versus the other. Yeah, that’s cool. Well in coffee, in general, because everyone thinks of course that we’re performing better when we’re on coffee. You certainly feel good.

I’ve had an interesting – because when I started using this tool I thought coffee would make a difference. I’m drinking Bulletproof Coffee in the mornings because I feel like it gives me a ton of energy. So I’ve been doing that for a long time and I’v found that it makes no difference to my score so far.

[Yoni Donner]: Oh interesting. Even when you are slightly sleep deprived?

[Damien Blenkinsopp]: I really make an effort to sleep well. So I wouldn’t say that I’m – today maybe is the only day in a long time that I didn’t sleep great, and I know why that is. It’s because I took a few things yesterday. But that doesn’t really happen to me that I’m sleep deprived. So is that the one situation where coffee has the biggest impact? You’ve seen that?

[Yoni Donner]: Yeah. The literature definitely shows this that the effects of coffee are – I think there is still evidence to suggest they exist in non-sleep deprived individuals. But those are actually very rare in modern society.

It’s great that you take care of yourself, and I wish everyone did the same. But definitely the literature shows that the more sleep deprived you are, the more difference coffee would make.

There’s this famous study with Marines or Navy Seals or something where it showed that even the effect of the dose keeps improving after 300 milligrams, which seems like a gigantic dose to me. But that was still better than 200.

[Damien Blenkinsopp]: Wow. So, for the people at home, how many coffees is that?

[Yoni Donner]: That’d be like five espressos.

[Damien Blenkinsopp]: Wow.

[Yoni Donner]: I’m not a huge coffee expert really, but I think that sounds right. So yeah, this was still better than 200.

[Damien Blenkinsopp]: Okay. Yeah.

[Yoni Donner]: So I think it depends. But in general, whenever you use something chemical, even if coffee and it’s safe and it’s not that bad and it feels nice, you’re still playing with stuff that we don’t fully understand. I do firmly believe that, if you can first improve your life by sleeping better, then this is a better approach to do than optimizing coffee intake.

[Damien Blenkinsopp]: Right. I think one of the interesting things about this is when you feel good, you do more work. I find personally you tend to take on more bigger tasks and things like that.

And what I would say is I think coffee – I don’t know if I’m an addict – coffee makes me feel good. And so, I think I do more, but that wouldn’t necessarily show up in a cognitive test that I know of. Is that correct?

[Yoni Donner]: It might show in an indirect way if only by showing that you did more tests because this is a big effect when you’re not actually in a controlled study. You could just decide you don’t feel like taking the test now, and that would usually show that you’re a little weak on willpower or something.

[Damien Blenkinsopp]: You were saying it would show up for sleep deprived people. So, have you seen that coffee makes quite a big impact on people in general for the aggregate later? So, basically then you would be saying like a lot of people are sleep deprived who are taking a test to some degree.

[Yoni Donner]: Well so, first of all, you can never know. You can know if you ask every single person and if you believe all their answers, but that’s definitely not the case in an internet-based testing environment.

Coffee definitely seems to have a real effect in aggregate. It is not huge. I think it is the order of magnitude or time of day variations and then, of course, this is correlation that most people would consume coffee at this specific time of day. So these are confounded.

[Damien Blenkinsopp]: Right. A lot of people have it in the morning and, as you were saying, a lot of people, because of the time, that’s when they’re going to be performing better.

[Yoni Donner]: But we are now actually doing – this is happening this last week and this week. There’s a collaborator at Harvard who’s doing an in lab coffee study with Quantified Mind. So we’ve done a million coffee studies, but this is probably the most rigorous one.

So, they actually bring everyone to the lab and they randomize them. They don’t tell them what coffee they are getting, and they did the practice before and they have a crossover design. So hopefully we’ll see something.

[Damien Blenkinsopp]: Great. So when these studies are published, you list them on the site or you put references somewhere?

[Yoni Donner]: I would. I don’t think anything has been published in a journal yet because all of this stuff is fairly new in academic publishing takes years and years. There have been things I didn’t list that have been published informally. Like a student did a project and submitted it, and it was approved and they have a PDF somewhere. I guess I should look into putting some more of those.

[Damien Blenkinsopp]: Great. So are there other tactics that you seen, whether it’s the number of hours slept or anything else that you’ve seen, that people could think about testing?

If you had a priority list of tests worthwhile doing for people, experiments to see if it helps improve their cognitive capacities a bit, which ones would you list? If you were starting from scratch, which would be the top five you would start with having seen what you’ve seen that might have some potential uplift?

[Yoni Donner]: Right. I think this should be very individualized and people should start with their biggest suspect for, not what might make them better, but rather what might make them worse because these things have a much larger effect in practice. For example, someone who is good and sensitive would see a much stronger decline by consuming fruit than someone who just takes pure [check 46:28] to try to be a little bit better.

So, in general, effects of improving over the healthy well functioning baseline are much smaller than effects of fixing something that’s broken. I guess a lot of people do have somethings that they are sensitive to or that are broken in some weak sense. Like someone who is chronically sleep deprived, you could say that something is broken in their lifestyle.

And of course, this is not a moral judgement, but it just says that they might be able to see a larger improvement by fixing this and if they know that there is something they suspect. If someone suspects all kinds of food sensitivities, or even allergies, pathogens, anything that they feel hurts them, it will be useful to try to test exactly what it is using factorial designs and cognitive testing to fix this.

The other thing, I find it cool that a lot people are using this to really track their aging process. So this takes a lot of discipline to repeatedly take a test once a month, for example, for years and years. But this is admirable when people are doing this and it can maybe give you serious suggestions to when your brain is no longer that of a very young person and you should start taking more care of yourself because when you’re young you can get away with much more. So that seems also useful.

[Damien Blenkinsopp]: And I think sleep’s one of the ones that most people are guilty of. I’ve been guilty of it for a very long time. Especially driven workaholic type people. We just don’t want to sleep.

Have you seen any number of hours? A lot of those tests as you for the – well the standard ones I’ve been doing ask you for the number of hours you slept the night before. I’ve certainly noticed straight away – for instance, today, because I slept six and a half hours, it was lower. So for me, that’s low. Normally, I’m seven and a half hours.

Have you noticed anything in terms of the number of hours slept that you see some dips and dives or anything?

[Yoni Donner]: Yeah. So again, there is not that much data, and again, I don’t look into people’s data. So this is only people who ask me to look at their data and conversations with that and so on, which filters a lot.

But the most interesting result I can remember is that it seemed we actually did see a skip one day effect where the strongest effect would be with a delta of one day. Which was also interesting because one person also shared their result with me that suggested that it was the same with drug use.

[Damien Blenkinsopp]: So you’re saying there’s a lag effect,so it hits you the day after?

[Yoni Donner]: Yes. It’s a lag effect, yeah. It seems to be and it’s hard to say if it’s exactly two days, but it seems that the effect, when skipping a day, was stronger than the next.

[Damien Blenkinsopp]: Okay. Of course I have to ask you about Nootropics because it’s one of the biggest topics right now. You mentioned Piracetam and of course it is many others.

Have you got any anecdotal effects? Anecdotally have you gotten any information from it all about people taking Nootropics and getting any benefits based on the test results?

[Yoni Donner]: Yeah, a little bit. So people seem to like Modafinil, which is a strong one.

[Damien Blenkinsopp]: It is, yeah.

[Yoni Donner]: And you never know. You’ve seen the one where Dave goes on Nightline and talks about Modafinil?

Yeah. That was quite a while ago, right?

[Yoni Donner]: Yeah. So there’s like a minute there when they talk about Quantified Mind and the experiment he was doing. So I trust him when he says he got a strong result. But of course, one should always be careful.

For example, here’s a study design that I don’t like. You take Modafinil. You do cognitive testing, you get your scores. Then you stop taking Modafinal for a week and get back on it and you see that your scores during that week were much worse. This is controlling for practice so that’s fine.

But the problem here is that you might as well just show that you became addicted to Modafinil. You don’t actually know if this performance on Modafinil is better than what you had before you started. You just know that now it hurts you to get off it. So this, I don’t think they built control for.

[Damien Blenkinsopp]: Right. The other thing is people talk about Modafinil kind of feels like you’re running high speed gear or something and you get a lot done that day. But I wonder if maybe the days after you could pay for it with slightly lower cognitive capacities as in, when you come off of it, you’re basically trying to catch up or something.

[Yoni Donner]: Right. This is the borrowing from your future self.

[Damien Blenkinsopp]: Right. Basically, it is that thing you’d have to control for too.

[Yoni Donner]: Yeah. It would be great to have some other more controlled study or some more centralized resource of good practices when designing those studies. It is definitely something to look into and might be, and I asked before about, points for improvement for the future.

But definitely, self-explanatory limited by the fact that it is complicated and not complicated in an intractable way. But complicated in way which just in practice most people don’t take into account because it takes a lot of experience and thinking about these things.

[Damien Blenkinsopp]: You mean to set up a proper experiment?

[Yoni Donner]: Yeah. So, for example, the effects you just described are these lag effects and –

[Damien Blenkinsopp]: Great. Do you have any future plans to expand the functionality of Quantified Mind? It sounds like there’s quite a few academic projects starting to run with it.

[Yoni Donner]: Yeah. So this is great and I got a count quite recently since I put it on some presentation. It was around 30 that are either being done or have been concluded, and they’re either a stage of planning a follow up or writing up or just kept for internal use or something.

So I definitely want to figure out what gives researchers the most value and how we can improve that and provide that. I do want to also make users who are not researchers happier, but that’s just a slightly lower priority simply because it has a lower impact on the overall progress of science, which sounds pompous.

But I hate saying things like this, but it is in the end about impact and I do think that it will help more in the longer run if we have more general human knowledge about, even individual variations, but the effect of things we just don’t even know right now. And when people just learn something and they are the only ones who gain knowledge, it’s a small impact.

[Damien Blenkinsopp]: All right, I understand. If people want to learn more about this, where should someone look first? If they wanted to learn a little bit more about – we’re talking lament terms here. I don’t know if you’d have good references, like presentations or books or anything like that where people could learn more about cognitive, basically, testing and assessment and basically the tests that you have on the Quantified Mind.

[Yoni Donner]: That is a great question. You’re right, in predicting that I don’t often think about how to present information in lament terms. We still have the science page on Quantified Mind, which is kind of readable. Maybe even too readable because people might not get enough information.

This is a little silly, but there is my thesis which has two entire chapters about this and it’s probably also not very readable. It’s also not published yet. So this science page would be a good place to start and for specific questions, everyone’s always encouraged to write to me and it’s always fun to talk about cognitive testing and so on.

[Damien Blenkinsopp]: Great. What would be the best ways for people to connect with you? Are you on Twitter – Quantified Mind? Where are you most active?

[Yoni Donner]: The contact page on Quantified Mind is a good way. I’m a not a social media person.

[Damien Blenkinsopp]: Is there anyone besides yourself that you’d recommend to learn more about cognitive testing or running experiments for cognitive testing?

[Yoni Donner]: That is a good question. I know some people who are local and you meet them in all kinds of conferences. I don’t know if there’s one resource. Definitely Lumosity is not bad because, even though the main tool is the commercial game product, they actually have a large group of people who are more into the data analysis and resources.

They publish all the results in a human readable form as well on their blog, which is a good practice. So that’s nice to look at. There’s the Human Cognition Project which is to give more researchers access to this data and to generate more results. And then, of course, all the papers in science and nature also have popular interpretations.

[Damien Blenkinsopp]: All right, great. Thank you for those. Now just a little bit about you and what you’re doing these days. Are you tracking any of your metrics or biomarkers, like blood or cognitive tests or anything, on a routine basis?

[Yoni Donner]: Not really. My habits that are I start tracking something when I think there is something to learn. And I insist on not tracking it anymore when I’m not learning anymore. This is nice because sometimes you discover that you can predict.

You just know things that you didn’t know before. You know your heart rate. You don’t need to measure it. I’m sure you’ve experienced this after years of doing this stuff. And so it seems to be true for a lot of measurements.

I wouldn’t say that I can predict cognitive performance because that has that funny property, which is why we need this. As your brain changes, its ability to predict itself also changes accordingly so that’s why you have these wrong conceptions. So this I would still use, but I want an important question to have when doing this.

[Damien Blenkinsopp]: Right, yeah. It sounds like you basically do little projects on something you’re interested in and then you kind of move on. You’re just saying that basically builds self-awareness by doing these things with each one so you can kind of tell yourself where you’re at also.

[Yoni Donner]: Yeah. That’s exactly right. There’s a time cost and there’s an effort cost in tracking anything. So you’ll never track everything so might as well make sure that you track the things that count.

[Damien Blenkinsopp]: And what are the biggest changes you’ve made in your behavior over the years with experiments if any?

[Yoni Donner]: Yeah. I probably realized that I’m not actually built for short term rewards. All things that normal people call fun I don’t find them fun, and I don’t find them useful.

And for my longer term happiness, the things that make me the most satisfied are creating value. Being productive, learning, developing. So with time, I guess I put much more of an emphasis on really building my future self and not so much doing satisfying things in the short term.

[Damien Blenkinsopp]: Great. Because you find that satisfying as well.

[Yoni Donner]: Yeah. So there are two things.

[Damien Blenkinsopp]: It sounds like you find – the same way it makes you happy, the same way.

[Yoni Donner]: Yeah. And data can help you reach that conclusion in two ways. One is when you do this not very precise. But I try to make those subjective measures as precise as possible by just breaking them down to so many individual categories that can be scored and then getting numbers and doing something.

But also just, in the sense that if you are tracking things that matter to you in the short term, and you’re witnessing their anti-correlation with things that are supposed to be short term rewarding as opposed to long term benefits, then this is a good way of actually making change. Because you can’t deny from yourself a change that you can see in the numbers.

This was a very abstract thing so I’ll try to get more concrete. If you are tracking your fitness and you noticed that you are not paying that much attention to your stoop [check 57:15}, it goes down. This hurts.

If you know I lifted this much weights a few months ago and I can’t reach that anymore, it really sucks and this makes you change some things. And to me those health things, those performance related metrics have a huge impact in making me change behavior.

[Damien Blenkinsopp]: All right. So last question. What would be your number question – we ask this of everyone – to someone trying to use data to make better decisions to improve any aspect of their health, performance, or longevity? Just something about themselves.

[Yoni Donner]: So there are many aspects of using data. So definitely one of them is make sure that they are collecting the right kind of data, and in a consistent way, which makes for a valid experiment. But also not try to overdo it.

I’ve seen so many people just fail because they’ve tried to do too much and got lost in the details or in the process itself. Focus on the highest value thing at a time and do it properly and win, really win, and then move on.

[Damien Blenkinsopp]: All right. With the minimal effort, right?

[Yoni Donner]: Yeah. Passive tracking is great. Some people do a lot into tracking and getting data, but then don’t do the minimal effort in just learning data analysis. Some people still don’t actually feel that comfortable playing with raw data. I feel it’s worth learning for almost everyone because it’s not that complicated.

[Damien Blenkinsopp]: Thanks. That’s a great point. And do you got a tip? Where would you start? Would it being using Excel statistical correlation or what would be the first thing someone could try that would add a lot of value?

[Yoni Donner]: I think that is not bad. But if you’re at the point where you get weird files from tools then Excel won’t help you with this and you can’t always load giant data into Excel.

So, I would suggest try to learn Python OR. These are not so complicated, and they’re extremely powerful. And of course, this day, there are so many tutorials. All of this stuff is very easy with some reasonable effort. But people who can learn to play guitar can also learn to us Python.

[Damien Blenkinsopp]: Right. It seems really, really complicated when you look at programming languages. But I’ve done a bit of programming in my time and I’m not a programmer at all. I’m a business guy. But yeah, it looks much worse than it is. That’s what you’re saying, right?

[Yoni Donner]: Yeah. And also, trying to answer a very concrete question about your data is very different than building Gmail or something. You’re not building it. It’s not programming in the sense of building giant tools.

It’s really doing something very, very specific. There would be 50 lines of code maybe, if it’s complicated and involves reading files. But you just want to generate your graphs the way you like them.

And then throw out some bad data points and maybe combine data sources. It’s very hard to use some general tools that shield you away from programming. And often you get to a level of complexity, which is akin to actual scripting.

[Damien Blenkinsopp]: Well Yoni, thank you so much for your time today. Really enjoyed talking to you about all of these and setting some of the science straight on what we can’t really look at and decide that it’s going to work or not. So thanks for your time.

[Yoni Donner]: Yeah. Thank you! This was great and I admire what you’re doing. So good luck with all of that.

Leave a Reply

Can physicians improve health outcomes using new self-tracking tech with their patients? Or is the tech still too inaccurate or impractical? We take a hard look at the reality and potential with a physician testing quantified self practices in his clinic for the last 3 years.

This episode is about quantified medicine or the reality of cooperating with your physician using self-tracking and observation. Working with such feedback aims to bring fourth an integrated approach to health and performance.

Previously, we have looked at the value of a good physician on your team when looking to improve your health in episode 22 with Bob Troia, and at the potential of wearable measuring devices in episode 24 with Troy Angrignon.

Does the Quantified Self approach offer medical benefits? What is the potential of tracking your data and teaming-up with your physician during the healing or performance improving process? What are some simple ways to help yourself optimize yourself?

I think it is hard to take measurable insights and extract it in a medical, steady kind of way. And that’s why I continue to not be afraid of computers taking over my job, because ultimately I think there is a combination of metrics and data, and also presence and attention and experience that work together, and that’s why I think the medical profession has hope.
– Dr. Paul Abramson

Today’s guest is Dr. Paul Abramson who runs an integrative medicine practice in San Francisco. He earned his medical degree at the University of California in San Francisco (UCFS). Importantly, he also holds a degree from the Center for Integrative Medicine at the University of Arizona. As a member of the Clinical Faculty at UCSF, he is doubly board-certified in Family Medicine and Addiction Medicine.

Being a former electrical engineer, Dr. Abramson’s interest in patient self-tracking sprung early in his medical career. In 2007, he founded the My Doctor Medical Group – his medical practice institution offering customized coaching models for individuals. He has adjusted the Quantified Self Approach aiming to gain insight into specifics of patients’ health. He has seen the ups and downs of working with this type of quantifiable feedback. In his practice he cooperates with patients and asks them to be introspective. Given his originality and accumulated experience, Dr. Abramson is an important figure in shifting the paradigm towards personalized medical care and all-important patient involvement.

The episode highlights, biomarkers, and links to the apps, devices and labs and everything else mentioned are below. Enjoy the show and let me know what you think in the comments!

itunes quantified body

What You’ll Learn

  • Dr. Abramson’s interests in integrative medicine (4:04).
  • How Dr. Abramson defines integrative medicine (4:51).
  • The integrative approach means pivoting through the complexity of conventional therapy and the larger sphere around it (07:10).
  • Early on, Dr. Abramson pivoted towards a novel paradigm of patient self-measurement and observation (10:58).
  • Patient compliance is a problem for those who do not wish to continuously self-observe (14:24).
  • Using biomarker wearable meters provides knowledge important for informed behavior modification (16:39).
  • Dr. Abramson’s team places value on introspection and subjective observation of experience (20:02).
  • Patients are expected to self-explore and support their symptoms with subjective observations (22:53).
  • Determining useful metrics in medical practice requires careful deliberation over their reliability (27:14).
  • Simple subjective data on patient experience can be acted upon in complex medical conditions (29:16).
  • Patients with high intrinsic motivation are better-fit for using metrics in medical care (32:28).
  • Dr. Abramson has successfully applied awareness building exercises in individual coaching models (34:15).
  • Mobile apps can be used to track patient data and integrate it in could-sharing services (37:33).
  • The challenges of self-tracking broadly differ between lack of patient motivation and too-narrow hypotheses about undergoing causes (40:13).
  • Success with self-observation depends on developing optimized coaching matching individual patients (42:23).
  • There is less pressure on doctors’ medical authority positions when collaborating with patients in the context of team-care (49:50).
  • The more responsibility patients take, the more they acquaint themselves and the doctor with their health dynamics (52:16).
  • The biomarkers Dr. Abramson tracks on a routine basis to monitor and improve his health, longevity and performance (54:41).
  • Dr.Abramson’s one biggest recommendation on using body data to improve your health, longevity and performance (58:55).
  • Best ways to connect with Dr. Abramson, who is responsive on social media (60:00).

Thank Dr. Paul Abramson on Twitter for this interview.
Click Here to let him know you enjoyed the show!

Dr. Paul Abramson, My Doctor Medical Group

Tools & Tactics

Diet & Nutrition

  • Autoimmune Protocol Diet: The Autoimmune Protocol (AIP) diet is an elimination diet that works to reduce inflammation in the intestines caused by autoimmune triggers.

Tracking

Biomarkers

  • Continuous Glucose Monitoring (CGM): Promises greater accuracy than standard one point in time glucose monitoring by capturing the variance of blood glucose over time (Note: in Episode 22 we saw an experiment showing the detriments of just taking one point in time readings). Blood glucose is continuously recorded at frequent intervals such as 1 or 5 minutes depending on the device used. While not a widely established practice, Dr. Abramson claims that continuously tracking blood sugar levels offers insight into fine-tuning medication and behavior adjustments to optimize patient glucose-levels. It’s early stages, but there are a few Continuous glucose meters (CGMs) on the market. Current devices include the Medtroronic MiniMed 530G, the Dexcom G4 PLATINUM System and the Abbott FreeStyle Navigator II (available in UK only).
  • Blood pressure: Blood pressure is expressed in terms of the systolic (maximum) pressure over diastolic (minimum) pressure and its measure is in millimeters of mercury (mm Hg). Normal resting blood pressure in an adult is approximately 120/80 mm Hg. Among numerous indications, blood pressure is used as a biomarker to determine the risk of stroke and coronary heart disease.

Lab Tests, Devices and Apps

  • Zeo Sleep Manager: Zeo was Dr. Abramson’s favorite Sleep Manager (device and app combo) until the company went bankrupt. Zeo tells you how you really sleep, and helps you find ways to improve your sleep. It accurately measures sleep quality and quantity at home. It also discovers factors which harm your sleep cycle.
  • Withings WS-50 Smart Body Analyzer: The Withings company offers devices designed to monitor various aspects of your body. Tracking tools include weight and body composition, pulse, air quality screening, etc.
  • ResMed S-Plus: The company ResMed is focused on healthy sleep. To this end, it offers devices which monitor personal sleep parameters, room air quality, etc.
  • Beddit: The company Beddit offers devices which track sleep using a sensitive force sensor which detect small vibrations caused by your heartbeats, breathing, and movements to provide you with data regarding your sleep.
  • Evernote App: In the context of tracking subjective experiences regarding health, Damien suggests using this app to take notes in a form of a health-diary.

Other People, Books & Resources

People

  • Dr. Andrew Weil: Founder & Program Director of the Center for Integrative Medicine. Dr. Weil is an influential figure for Dr. Abramson’s interests in integrative medicine and his, overall, career.

Organizations

Full Interview Transcript

Click Here to Read Transcript
(04:04)[Paul Abramson]: I’ve been very imbued in the conventional science-based – I put science in quotes – world. I’ve also been very interested in alternative points of view and meditation, and what I would call consciousness and behavior, and the things that are, in essence, insubstantial in a material sense, but I think are often just as relevant to our lives and well-being.

So in that vain, I have individual interests and pursuits in those areas, and then I went to work for Andrew Wylie in Tuscon at the University of Arizona in his integrated medicine program there. I was a residential fellow for a year, and we swapped patients there and had case conferences with some of his…

(04:51) [Damien Blenkinsopp]: To take a step back, what does integrative medicine mean? Because we haven’t really talked about it on this show before.

[Paul Abramson]: Integrative medicine has 100 definitions, and it has been, I would say, used and corrupted by a variety of different people and interests over the years.

As I define it, and I think I’m pretty much in line with Andrew Wylie on this, integrative medicine is a way of looking at all of the available approaches, perspectives, tools, tests, treatments that are out there. And then looking at each individual as an individual, and trying to make a match between what’s going on for them and what is the best combination of approaches.

So in essence it includes all of conventional medicine and science-based, or whatever you want to call it, conventional medicine, and it includes alternative things. And it includes consciousness based things, and it includes mind and body and it can even include spirituality and things that are unknowable as part of the paradigm by which you try to help people both understand what’s going on for them and come up with a plan of what to do next.

So I think it’s completely non-exclusive, and I also apply a very discerning and discriminating kind of eye to it, in that of all the available options out there I’m going to evaluate each one on how useful do I think this is? And there are some things that do not need my sniff test, or my deep investigation that I do not… And once I’ve determined that I’m not really interested in something, or I don’t think it’s going to be fruitful for me as one of my tools, I leave it to the side.

So I do weed things out. It is not an indiscriminate approach of ‘all is good’. It is more like, I’m going to start with an open mind and then apply appropriate skepticism and investigation to choose what tools I think are going to be helpful. And they may vary depending on the individual.

So I do not apply a one-size-fits-all approach to anybody. There’s no one test or one treatment that I think is applicable to everybody. Nor is there one paradigm that I think is applicable to everybody. So, for some people that is dis-concerning.

(07:10) [Damien Blenkinsopp]: So in integrative medicine, is there an actual organization behind that, or is it more a term used for people who are dabbling in functional medicine, the alternative, and the…

[Paul Abramson]: Well, there is now a board certification in integrative medicine for medical doctors. There is a consortium of academic centers in integrative medicine that includes many of the big tertiary care centers in the United States that have integrative medicine centers and research programs.

And I think a lot of that comes into this kind of definition, where it’s consistent with the conventional medical world and a much larger sphere around it.

[Damien Blenkinsopp]: The functional medicine has an organization behind it, so does integrative medicine tend to relate to that more because there’s a big organization behind it? Versus some of the other things you were talking [about], which I imagine don’t have as much structure to them.

[Paul Abramson]: Well integrative medicine ultimately is, I think, integrated, meaning it’s not an either-or proposition. It’s, ‘whatever works’.

Whereas some of the other things out there are more alternative. Where it’s more of an ‘us versus them’ kind of situation, where we have a certain truth and those other people, especially either the conventional people or the alternative people, are biased, wrong, or otherwise not reputable in some way, and therefore you should pay attention to our perspective.

That is not, to me, integrative. But I think the conventional medical world falls into that trap, and I think the functional and alternative medicine world falls into that trap. Equally.

[Damien Blenkinsopp]: It’s kind of like Republicans and Democrats.

[Paul Abramson]: It’s kind of like Republicans and Democrats.

And in reality I would say my flavor of integrative medicine, or what I consider, is it’s not exclusive in that way. It’s like of all the things out there, some of them are valid, some of them are not, some of them work for some people, some of them don’t work for some people.

And you just have to be creative, and you have to be discerning and discriminating enough to not get overwhelmed by the complexity. You have to be able to take this, in essence, if you are not ready for tolerating ambiguity and dealing with massive complexity, then it’s easier to track into something that is simpler, where it’s more clear cut and there is right and wrong.

Whereas if you want to take the big picture, you have to help people weed through all of this complexity to come up with a relatively normal, simple approach that is going to work for them. And then you have to be willing to measure and then accept if it is not working out you’re going to back up and take another set of things and take another approach.

Then in the start-up technology world out here they call it pivoting, where you do something, you go full worth at it, and then you try it to the best of your ability, but you have to be constantly measuring your success. And if it’s not working out, you have to get over your ego and your attachment, and you have to back up and re-think and pivot, and keep moving.

Yeah, that is the [unclear 10:10] approach to medicine that I can think of.

[Damien Blenkinsopp]: That’s a very interesting point because – and you’ll know better than me – people when it comes to health, fitness, these diets, and these types of areas, they get very, very emotional about it. They tend to become fans of a certain approach rather than another.

I guess pivoting is, I understand because I’m an entrepreneur. My first company, I didn’t want to let go of it. I didn’t want to change it at first, until the pain in terms of profit loss got enough that I was like, “Okay, I have to be serious.” And I was taught to be able to pivot and make decisions based on data.

So I guess that probably happens a little bit in the medicine world as well. People eventually get to this point of pain, where they’ve been following some course because of interest, of love, and then they go, “Okay I have to try and get some kind of data.”

(10:58) Now, we first met, albeit kind of briefly because you were doing a talk, at the Quantified Self conference in 2013 – end of 2013 I think it was. And so that’s also one of the things you’ve dabbled in a bit in you integrative medicine. Could you talk a little bit about why you started taking an interest in that and have made that a part of your practice?

[Paul Abramson]: Well I think it does come back to what we were just talking about. You have to gather data about what’s going on for each individual to decide, is this working, is this not working. Or, are there things happening that are not good, that should trigger us, like your losses in your start-up.

The earlier you can detect and decide that things are not going to go down the right path, you should pivot. And yet if you’re not sure, you might continue to go on for a while and take more measurements. But you have to be constantly…

And so I was struggling in medicine with a lack of feedback on my patients. We were meeting and setting a treatment plan in place, and they were going off to do it. And I just was not getting enough feedback to know whether it was working, whether it needed to be adjusted, or whether we needed to completely pivot and try something else.

And so the promise with the Quantified Self approach is that it’s not so much that there is a new sensor or a new test that is interesting to me, but it’s a new paradigm, it’s a new concept that people are going to observe themselves, and then perhaps feed that back into a medical doctor or some other practitioner or some helper that they have, a coach.

But many people just decide to do it for themselves, where they’re moving along with a plan, and they’re measuring, and they’re questioning, and they’re constantly just trying to decide,” Do I keep going, do I add, do I subtract, or do I pivot?”

And I started doing these kinds of experiments with people where you can then take all of human behavior and make it an experimental approach, where, instead of saying, “You have to take this medication for your high blood pressure forever.” People hate that.

What I do is I say, “Wow. You’re blood pressure is really high. We’ve measured it over a whole month and it’s always really high. We know that’s going to wear out your blood vessels, and your kidneys, and your brain, and it ages you faster to have high blood pressure all the time. So, why don’t we lower it? And then, why don’t we start doing some experiments to see if we can find the cause, or reverse the cause, or come up with other approaches that are more agreeable to you, if you’re not really into taking pharmaceuticals every day.”

Which many people aren’t. And at such time as those thing start working, we can think about revisiting. I just say, while we’re doing those experiments, let’s limit the damage. And people respond much better to that. Instead of saying, “Oh, I’m just going to keep the high blood pressure going, and then in six months I will have lost 40 pounds.”

Maybe that happens, maybe it doesn’t happen. Maybe they lost 40 pounds and their blood pressure is still through the roof high. It’s a realistic approach that takes measurement into account, but also addresses what’s going on right now.

And the tools we have from Quantified Self, some of the technology but more the paradigm of self measurement and observation, gives us some hope that the culture could shift into that kind of approach.

(14:24)[Damien Blenkinsopp]: It’s interesting in a kind of work relationship. How does it change the work relationship between you and the patient when you introduce this? Do you work out some specific metrics with them, or is it really very different?

Have you seen this evolve in your practice? Because you’ve been doing this for a few years now, so I’m sure you’ve cut some things that didn’t work, and taken some things that did tend to work, and you’ve kind of got some type of best practice that you’re starting to put in place.

[Paul Abramson]: Well, it’s been humbling. People are very different.

They’re different in their background, they’re different in their medical and psychological situation, they’re different in their social circumstances and their family, and what the support is in their life to do things. And so some people actually just want me to say, “This is what you’ve got, this is what you have to do,” and to prescribe to them. And they go home and they take their drugs.

And we limit the damage, as best we know how with modern medicine, and sometimes that works out, and sometimes that doesn’t. But they don’t have time or interest or, even maybe the perspective, to take a different kind of, more proactive approach.

And for those people, after I challenge it a little bit and determine that it is in fact how they want to be.

[Damien Blenkinsopp]: That’s interesting. Are they not interested enough in their health to, or is it because they’re so busy with other things in life? What is the [reason]?

[Paul Abramson]: For whatever reason, they are not in a position where they want to do something that takes more work. What really sort of takes up more subjective view of reality, like there is a way.

There are many choices out there, it’s not really black and white. Some people really want the black and white. It’s easier for them psychologically, and it’s sometimes they’re just so busy, they’re like, “No way I’m going to have time to do experiments, or even to take my blood pressure twice a week.”

We’re just going to have to go without that. Especially diabetics. A lot of them just can’t check their blood sugar. Type 2 Diabetes, you know, it’s not really medically mandatory in many conventional settings for them to check their blood sugar at all time. You just take the medications and get some blood tests every few months and see how things are going.

That’s very unsatisfying for an engineer like myself. I really would want data and feedback and optimizing. But many people are really not into that. It’s either a cultural thing, or just a logistical thing. They just aren’t going to do that.

(16:39) [Damien Blenkinsopp]: Just out of interest, have you looked at the continuous glucose monitors?

[Paul Abramson]: Oh yes.

[Damien Blenkinsopp]: Have you been using those quite a bit? Or have found them useful?

[Paul Abramson]: Well, I mean they are generally able to be covered by insurance. They’re very expensive.

[Damien Blenkinsopp]: Yeah, about a 1,000-1,500 dollars, something around there.

[Paul Abramson]: The supplies are also very expensive. Each and every week you need a new implanted sensor that could be hundreds of dollars. So, it can really add up in a hurry per month and the initial costs. Such that many people aren’t going to do that.

Now if you’re a Type 1 Diabetic from a young age or even an older age where you have no insulin around, and insulin pumps are in the offing, then often they can be covered. But for Type 2 Diabetics it’s usually a completely out-of-pocket expense. And what I’ve found is that there are often incredibly great insights that one obtains from the continuous glucose model, but only some people get on-going benefit.

[Damien Blenkinsopp]: What kind of [insights]? Does it enable you to take some specific actions when you see some kind of behavior that they’re undertaking which is interfering with your goals, or…?

[Paul Abramson]: I’m not really offering generally to watch their data continuously.

[Damien Blenkinsopp]: Yeah.

[Paul Abramson]: What we are doing is having them get self-feedback, and then take notes in one way – electronic or paper – of their experiences with that data from the glucose monitor. Because you have to calibrate them with a finger stick multiple times per day, and you have to use it properly to try to get valid data. And then you get to see in real time if you eat something, or if you exercise, you get very quick feedback about how it affects your blood sugar, both immediately and later.

And so you can get pretty profound insights about that, and they are sometimes very unexpected. That some things lower your blood sugar and some things raise your blood sugar, and they don’t match what the conventional wisdom says should happen.

And then somethings people just have to get it in their face that, “Wow, if I exercise my blood sugar really is so much better.” It’s motivating enough that it’s going to make them exercise more.

But a lot of people, after they get those insights, if they’re Type 2 Diabetic, they can simply just use those wisdoms to change their behavior, and they don’t have to go through the hassle of calibrating and wearing an implanted monitor that has something go into their skin changed every week and calibrated several times a day. A lot of people don’t really want to do that on-going.

So then when you look at the up-front expense for something that they’re only going to use for a relatively limited period of time in most cases – because most people are not going to want to be doing that level of hassle if it’s not required because they’re not Type 1 Diabetic – a lot of people chose not to do the continuous model.

Maybe when we get the truly non-invasive blood-glucose sensor that is both accurate and possible. When I was an electrical engineering grad student at Stanford in the early 1990s, I was doing consulting for start-ups. Before there was the first technology, the first internet tech.

And I worked for a couple of different start-ups that were trying to get non-invasive blood glucose monitors, where they would shine a light through you, or they would use ultra-sonic. They would use various technologies to try to get, from the outside, your blood sugar. And the problem is glucose is such a small molecule, and so hard to differentiate from other molecules that really a lot of companies went belly-up back then, and they are still failing today.

(20:02)[Damien Blenkinsopp]: I think there’s a couple of watches. I’ve seen them around. I haven’t looked into them. I was concerned about the accuracy. I guess I’m a bit dubious about [them].

Because even the continuous glucose monitor, which you were just saying you have to calibrate it, right? And it’s got something actually implanted in you. So the accuracy of a watch with optical – I think they’re using optical – would seem kind of not achievable at this point.

[Paul Abramson]: This is the exact technology that they were trying to come up with in the start-up in 1992. And it ultimately did not kind of work out. And I think that at some point someone is probably going to do it, but to my knowledge it has not yet been done in a valid enough way that you could actually take action on the results.

But maybe there is something that I don’t know about that came out this year, and I will continuously watch that Weiner Chart. [unclear, 29:48-] at that, somewhere about 15 years ago after watching failure and failure.

So, I would just say that the measurement technology concept is something that you need to be very skeptical about, because if you’re going to take bold action based on the numbers, it better be accurate and reliable and reproducible and usable. So that is an on-going concern for me.

Now, more subjective measures, what we really came to in our self-tracking program here, one, is that we don’t apply a similar methodology to anybody. Everybody kind of gets a custom approach based on where they are in their readiness to do things, and what problem they want to solve.

But we’ve also really heavily weighted it toward, what I would call, subjective measures that require them to actually stop and pay attention to what’s going on in their experience. Because the objective measures that don’t take any [action], the passive tracking approach where I wear a monitor and it spews data out at gigabytes per minute, it does not require awareness and it doesn’t require self-knowledge. The learning is later when you look at the data.

Whereas if you aim to gather the data, if you have to introspect and think and become more aware of what’s going on about your pain level, or whatever your symptoms are, or your emotional state, or in any way something that you have to pay attention to measure – because we don’t have a measurement for headache except by your self-report – the data gathering itself becomes a therapeutic tool.

The act of tracking is part of the treatment in that they become much more aware of what is actually going on for them, so that when we start trying to change things or treat or affect things in a positive way, they actually have more basis on which to do that, and we can identify more potential targets for more interventions.

(22:53)[Damien Blenkinsopp]: So you think basically building their awareness so that you can create that feedback is one of the most important parts of it?

[Paul Abramson]: For us, it is. And I’m a behaviorist at heart. I like to have people try things overtime, and to see whether building new tracks and new behaviors in their brain can affect their body and their experience and their entire reality.

[Damien Blenkinsopp]: So do you then find that patients are able to come to you with insights more so than before? Because all traditional [unclear audio cut, 23:25]. I have some mystery problem. I’m coming to a doctor, and the first thing to do is talk about my symptoms. Go for a questionnaire, try and figure out what’s going on.

Do you find that sometimes that first picture, say compared to a second picture when you’ve had them self-tracking something you thought was relevant, could be quite different? Because it is a subjective experience, and they learn to improve their self-awareness and have a better hold of what’s going on. And maybe, do they sometimes come up with some insights like, “It’s funny. I’ve noticed that every time I do this, then I get these symptoms.”

[Paul Abramson]: Right. Well people often come to their doctor – and that’s my frame of reference, because I’m a medical doctor and people come to me – they come with symptoms, but they also come with conclusions. And they might be already having diagnosed themselves, or they might just have made some assumptions or conclusions about why they’re having the experience that they’re having.

And I think the self-tracking paradigm encourages them to back up to the raw symptoms, and also the circumstances that they find themselves in. You know, looking broadly at what are their circumstances and what are their symptoms in as concrete a fashion as possible. And not making any assumptions. And then we make some hypothesis. But we frame them as hypothesis and not conclusions, and that gets them into an exploratory mode.

Whereas if someone comes to me and says, “I have a urinary tract infection.” And I am a [unclear, 24:50] and I have eight minutes, I will prescribe ciprofloxacin to them for the urinary tract infection, and they will go away. Especially if they say, “Oh I’ve had them many times and I know what they’re like.” That is not my style of medicine.

I’m going to say, “Well what are you actually feeling?” And they’re going to say, “Oh, I have burning when I urinate” or “I have fevers” or “I have back pain” or whatever. It’s very likely in someone coming to the doctor that they are correct, in that circumstance, but sometimes they’re not. Sometimes they have a yeast infection and it’s not a bladder infection, and giving them antibiotics makes it worse.

So I think you should always back up. But then especially if it’s something vexing, they have probably been trying to figure out and fix it on their own for some time. Weeks, months, years, decades sometimes. So if it were something, if their conclusions were correct – not their diagnosis, but their assumptions and conclusions – I believe they would have figured it out, and they never would have met me.

So therefore, the fact that they are coming to me with the time and expense and the hassle of going to a doctor, it’s very intimidating for some people, it means they are probably ready for a pivot. It’s a sign that it is probably time to take a different approach.

So if I can get people to back up and look at the raw data, the raw symptoms, and then we can look at all the possibilities and start to make some hypothesis. And some of the hypothesis might be the conclusions they have drawn, but they have to be willing to have some flexibility about looking at other options. Otherwise, I might be a poor match for them.

If they just want someone to take their conclusions and follow their line of thought, then my view is, okay, they either don’t need me at all, or they only need me because I – in California – can order laboratory tests for them. Or I can order medications for them that they can not legally order on their own. So in essence I am just a proxy for them having gone through the license pathway that I’ve gone through, and I’m not really functioning as a physician as I define it.

And so I try to resist getting involved in just being a tool that they can wield, and I try to work with people who actually want to back up and really take a look at what is going on.

(27:14)[Damien Blenkinsopp]: So what kind of metrics have you typically found to be useful? You said the qualitative. Are these ratings from one to 10 for symptoms? What kind of things have you found that are useful?

[Paul Abramson]: A wide variety of things. With each metric we have a discussion about what is the, what are we going to track?

Let’s say for a headache, are we going to track mild, moderate, severe? Are we going to track zero to four? Actually, the numbers and bins of data collection that you define dramatically affect the results of your tracking. You have to all agree on what each bin means.

What does three stars mean? It can vary widely over many people, and that makes it useless. And then they have to have written down what each metric means so that they can apply it as consistently as possible over time. Because if they drift in what a headache of three means, then their data is going to be very hard to use.

So, we try to apply this sort of N of 1 controls as best we can to define things clearly, to re-visit them, to keep people calibrated. And then try to figure out is it a negative two to two scale, or is it a zero-four scale that’s going to be helpful. And try to make it as simple as possible so that people can actually do it in real life.

Sometimes you have to use subjective narrative data, and that’s why we’ve taken a coaching model rather than a computer analysis model. Because the most interesting things sometimes are the things that they write. Their observations about the process, or about the data. It could be a picture of something, it could just be a description of how they were feeling at the time that they had the high-blood pressure. That’s actually much more interesting.

[Damien Blenkinsopp]: So is that like a journal alongside whatever you’re tracking?

[Paul Abramson]: Yeah. And it could be an electronic journal, or a paper journal. My challenge with technology tools is they have to beat paper. If they do not win over paper, then you have to question why you’re using technology.

(29:16) [Damien Blenkinsopp]: It’s interesting that you’ve brought that up, because I struggle with my own problem, just figuring it out, and what kind of first worked for me was using EverNote as a journal.

[Paul Abramson]: Sure.

[Damien Blenkinsopp]: Just as kind of like a diary every day, one note for every day in a folder which was called ‘Health Diary.’ And then also tracking some metrics. And like, “Oh, that’s interesting. I wrote– “

[Paul Abramson]: Paper apps. It’s almost paper.

[Damien Blenkinsopp]: Right. Yeah. And it’s easy to search. I mean, that’s why it’s nice, because if you have some kind of hypothesis in your head, you can select that folder and you can search for that keyword, and you’re like, “Oh, look. It happened on four days, and maybe it coincides with the metric.”

[Paul Abramson]: Sure. And that’s what I would call primitive technology like paper. And sometimes it is the best approach, because something much more complicated will keep you from gathering the data, because it’s too cumbersome.

It’s very hard to apply machine learning and machine interpretation of data because the raw numbers rarely have the meaningful insights. And our basic model, we’ve gotten more flexible about exactly how we implement it.

Initially, we were doing a weekly coaching model, where people would track, the data would be shared with a coach who would meet with them – in person or virtually – every week to review their data and basically elicit their memories of what happened that week that they had not taken down as part of the data. So they would use the pictures or numbers or whatever they had tracked.

People remember a week. Most people. Whereas if you go back a month, people do not remember the moment to moment experience they were having. Which is probably why psychotherapy is typically a weekly model, because you don’t have to reinvent the wheel every time, you can build on the previous week because you remember.

And so the coaching model would allow people to tell the story around the data, and then the coach would concisely record the story and plug it into the project, or the experiment that we were running, and try to write down the story and the insights that could be taken. And then the insights and the summary of the story could be fed back to me, the physician, where very quickly I could think about it and apply my perhaps greater perspective or set of ideas, and make suggestions.

And so it became very time efficient for me. Rather than me going through the data for an hour every week, I can go through the coach’s notes for a few minutes and be almost as effective. And in some cases much more effective than I could be trying to be the coach myself.

The raw data was almost never the actionable. Now, that’s not always true. If we’re just doing a very simple tracking experiment where your blood pressure is 220 over 120, and we want it to get lower very quickly, and we’re going to track what you’re doing and what medications you’re taking, and how often you’re taking it, and track your blood pressure.

There you actually do have a much more concrete, discrete kind of experiment that you could apply some sort of automation to. But that’s not typically why people are coming to me. Most people are coming with much more complicated and murky problems where subjective data is really the actionable data.

(32:28) [Damien Blenkinsopp]: If we’re talking about the situations where you’ve found this most useful, is it it the more mysterious, people haven’t been able to figure out any[thing], the complex, multi-factorial potentially.

But as you mentioned, is there also something on the very hard side, nearly technical, where you have a blood pressure marker and it’s a very focused metric, that you are like, “We have to get that down.” From doctor’s experience and everything, this is the thing we need to focus on. So you know ahead of time what you want to focus on.

Are those the kind of two situations, or are there other situations where…

[Paul Abramson]: I would say it’s a whole spectrum, but the key factor is that if the tracking based on insights and memory and subjective recall are round objective data that you’re gathering is by it’s nature very labor intensive. Like this process, to really do a meaningful tracking experiment, is labor intensive and costly in various ways.

You have to hire help, you have to spend a lot of time, you have to think about it. You have to be involved in the process, and for that reason, that typically is applied to problems that are either very urgent or long-term vexing for people. They tend to be more complicated because they are at the end of their rope, and they need help, and they are ready to do anything just to figure this out.

[Damien Blenkinsopp]: Right.

[Paul Abramson]: And that’s a wonderful situation to be in.

[Damien Blenkinsopp]: For a doctor, yeah. Compliance.

[Paul Abramson]: Their intrinsic motivation is very high. The outcomes tend to be good in anyone who comes to a doctor with high intrinsic motivation to do whatever it takes. And we do select in our practice for people with that description. So our outcomes are phenomenal, but part of that is selecting some people who are ready to do whatever it takes to figure this out.

(34:15) So the other area other than complex medical mysteries that we’ve applied this to, well there are several areas. One, our awareness building exercises, where about half of our practice is also a complex addiction treatment practice for high-functioning professionals. And some very intelligent people, many of them in the tech industry, who have what I would consider very mundane addiction problem.

[Damien Blenkinsopp]: Is this like caffeine, or are we talking more…

[Paul Abramson]: Alcohol, cocaine, prescription opiates.

[Damien Blenkinsopp]: Okay. Is this quite common now? Because we all hear bout the performance culture, and everyone–

[Paul Abramson]: It is incredibly common now.

It has always been incredibly common, and yet it continues to be incredibly common. And the more fast and stressful and complex society gets, as we’re currently going through a little boom here in San Francisco, I would say it increases. And the number of people who go out of control increases, where it gets beyond the place where they can self manage, and they seek professional help.

So we are often trying to get people to do very basic tracking [endeavors]. Whether it’s their internal mood state, or their discomfort level, or interactions they’re having with other people. Or whatever triggers they encounter that trigger them to want to self-soothe or improve their performance by taking their substance or alcohol of interest. And it’s a very simple tracking model aimed at getting them to be more aware, so that they can then have more decision over their reality.

The other one is, like the blood pressure example. Where we are trying to achieve, or what’s been going on forever, is the diabetes blood sugar tracking model. Physicians have been asking people to track their blood sugars for a long time now, and it’s actually very useful.

The last realm, I would say, is in the performance improvement category. People who are okay but they want to be better, or they want to achieve a certain goal, whether that is in their body composition or it’s in performance at a triathlon, or it is in their work performance and their attention and their ability to accomplish things.

It’s more of a positive desire to improve by tracking and feeding that. That’s very motivating for me, and yet it is hard to find the people who want to do the self-tracking approach to that, because it’s pretty labor intensive and these tend to be busy people.

So if you’re an Olympic athlete and you have a whole team of people geared up at measuring you, at feeding back and changing your performance and changing what you do, and you have all that support around it, I think people can pull it off, if they’re a competitive high-level professional athlete.

For the regular person without that support team, we have had some challenges trying to construct a model that is both affordable and does not require an NFL team support staff to accomplish, and also doable by people who are also leading lives and not full time training. That’s an on-going exploratory area for us, and trying to find what is a model, in a manageable way.

(37:33) [Damien Blenkinsopp]: In terms of any tools you use, just kind of talking practicalities here, are you just asking people to use a little mobile phone app and put down a note in that, or is it sometimes Excel, or is it basically whatever they need, you’re like, “What would you find easiest to track this metric that I want you to look at.”

[Paul Abramson]: We have been using the mobile phone app that we’ve been working with a developer on called MyMe, which I have been on record has having mentioned over the years, which is a very simple way to just set arbitrary buttons up for whatever they want to track. And set whatever ranges of metrics you want to track, take pictures, etc. and then collate it on a central server where they account is owned by the individual, not by me, but then they choose to share their data with the coach or with me during the sessions.

Otherwise they hold they data and own the data, and we just keep in our files our observations of the sessions with them while looking at the data. And so that keeps it simple from a privacy standpoint and from a daily curation standpoint. And it’s worked fairly well.

We also, if they don’t like that tool or if they have different things they want to measure, we will take a whatever-works approach and try to get them to use other tools, most of which are not geared towards this. Most of them are geared towards other applications, most of the existing tools.

Amazingly, there isn’t a good, flexible generic tool that’s consumer available, where you can also involve a team. And maybe there is. Now, when you can share the data but it’s also designed at helping analyze things and helping collate and curate data.

And so MyMe is working on that. It’s not yet available to consumers, it’s just sort of for clinicians and doctors and people who are working with people who are self-tracking.

[Damien Blenkinsopp]: So there are other people like you working with MyMe?

[Paul Abramson]: Yeah.

[Damien Blenkinsopp]: Okay. Alright. All this stuff we put in the show notes.

[Paul Abramson]: Then there’s various companies that have tracking devices, and each one has their own cloud where they track the data from their own devices, and some of them will integrate data from other devices apps. And it’s coming together in some ways that I think might be good, but it’s been so slow to develop that I’m frustrated.

[Damien Blenkinsopp]: Yeah.

I used to be a telecoms consultant, and I worked in the interactive television market in the UK, which was one of the first markets in the world, and they had this walled-garden approach to it. And we were all talking about the open, like you have to open it up. And it took nearly a decade to happen properly.

And it’s always the same, except for the internet, luckily, which was pretty much open to start with.

(40:13) So, that’s great. What are the biggest challenges you’ve come across in trying to make self-tracking work? Have you had any failed, like – I don’t know how to put it – have you had failed self-tracking projects, where you’ve just been like, “Okay, after six months of tracking let’s just ditch this?”

[Paul Abramson]: Basically, they fall into two camps. One is where the self-tracking paradigm is too much work or isn’t intrinsically rewarding enough for the person to keep them going. Where the time and expense and hassle and all that isn’t worth it, and they drop out once they just get frustrated, or don’t continue.

The other is that their hypotheses are too narrow. The hypotheses they are willing to consider are too narrow. And we explore those deeply and broadly and do not find the answer in that narrow set of hypotheses, and they tire of doing the project, because it seems hopeless.

Whereas, I actually believe that there is always a way, but it may not be a way forward that people expect or desire.

[Damien Blenkinsopp]: So it’s basically like a process of elimination with one experiment, another experiment?

[Paul Abramson]: Well if the only hypothesis is that some food is causing my symptoms, and we just need to find what food, combination of foods, or other environmental physical inputs, are causing my symptoms.

And once we really convincingly do out that experiment, either they are willing to do the experiments, one, and the answer is not food – we believe that for a while. Or they are unwilling to do some of the experiments because they are too attached to certain things.

[Damien Blenkinsopp]: I love coffee.

[Paul Abramson]: Or marijuana, or [unclear 41:55]. Unwilling to give up certain things. But we look at everything else, and everybody gets tired. Those are the places where actually there’s a different paradigm that we need to apply. We need to do a pivot, but they don’t want to pivot.

And then you run into a dead-end in the start-up of events, or start-up company ends, ceases to be. And everybody goes off to do other things, and that is sometimes what happens.

(42:23) [Damien Blenkinsopp]: Great. And you referred to earlier that you had a lot of success with this. Could you share some of the success stories you’ve had? Has this improved your practice, would you say immensely, a bit?

[Paul Abramson]: I would say it has improved it measurably, but not immensely.

[Damien Blenkinsopp]: Immensely is a big word.

[Paul Abramson]: We are still working on optimal paradigms, to make the paradigm match the individual, and to try to bring it into a combination of energy and time and price that can match anybody. And we have not yet figured all that out. So that’s why it’s not immeasurably.

If we can apply these kind of concepts to every patient, and successfully because we can custom make it for each individual than it would be game changing. And that’s what we’re aiming for.

So I say this, successes are where either there is a simple answer, or a complex simple answer. It’s too complex for them to have figured out by introspection and their own tracking, but with some professional help we can get to that slightly more complicated insight that allows a dietary change or experiment or supplements or changes in their medications, or some other intervention to suddenly work. And then sometimes the tracking helps them to implement that intervention.

If it’s a food change, sometimes that takes a lot of time to change habits, behaviors, and family food production dynamics, etc. And sometimes the self-tracking is very supportive in that. Or, we exhaust one avenue of exploration and it gets them to the place where they are ready to consider other paradigms, where maybe it’s not food, maybe it’s, I don’t know, my relationship with my husband and son.

Maybe, as one patient found out, there was some very, very stressful, vexing, and long-standing family dynamics going on at home that clearly, once we got to know them, were contributory to the situation and symptoms.

[Damien Blenkinsopp]: What kind of symptoms, just to give people a reading on this?

[Paul Abramson]: The common classes of symptoms that people come to that are hard to diagnose are fatigue, pain of various kinds, neuropathic pain or muscular, skeletal pain, and gastrointestinal symptoms. And when those are accompanied by relatively normal tests and investigations from a conventional paradigm, many times they run into roadblocks with the conventional medical world, where they say, “Well you’re normal.”

So, you are plunked into a wastebasket diagnosis that doesn’t really describe why, it just describes what is going on in a very descriptive, but not very helpful way. Chronic fatigue syndrome doesn’t, in it’s current form, really help people to move forward, except weight and exercise, and similar things that are not typically very satisfying to people. And when they work, it’s great, but for some people that’s not the whole answer.

It could be very inflammatory conditions and rheumatological conditions that do have objective markers that are abnormal that don’t fit into any paradigm. So that I’m tempted to throw heavy drugs at them. And yet they just run into a diagnoses appended by the word NOS, not otherwise specified, meaning it’s not something that the conventional world takes a strong interest in, because they don’t have a discrete category to put it in.

And so that is one common class of people where sometimes it is what they think it is, because they have been reading blogs on the internet that say that food is the cause. If you change your food, you can cure anything. That is a common paradigm that you read about on the internet, especially people promoting a certain food paradigm, that basically all mystery illnesses should be treatable with food. Or are from some food trigger, that if you eliminate it or figure it out.

Hence the autoimmune protocol diet, which is an extreme elimination diet, or is very specific and very hard to implement, and may help some people, but for most is just, it’s not the end all answer. And so many people come very frustrated and wanting to find [some solution], but they’re still on the food path.

And once we kind of figure out that maybe there are other factors involved, even medical or psychological or social or spiritual, we can come up with a more integrative approach that is much more fruitful for them, either to fix their symptoms or to make it so that the symptoms are not as disabling, or that they can do everything they want to do in life because they’re able to mitigate the symptoms and improve their ability to function with those symptoms.

Because it’s of my opinion that getting the symptoms to go away, while it is always the goal, sometimes in this world there are mysteries, and being comfortable that sometimes there is a mystery and you have to work with it is the paradigm shift that has to happen.

Now, you don’t want to start with that, because ultimately people come to a doctor to get cured. And that’s really the cultural paradigm that we operate in, and I like to acknowledge that, and I like to participate in it, but I also like to continue to try to expand the paradigm to include other things.

[Damien Blenkinsopp]: So you’re saying you can improve the situation as well.

[Paul Abramson]: Yeah. And sometimes actually taking a more open-minded approach about what could be contributing and working on function rather than cure. Improving function rather than the functional medicine paradigm/vision that underline all illness, there is some root cause that you can discover, and once you discover the root cause, everything will get better.

And that is wonderful when it happens, and yet sometimes you have to take a more solution focused and practical approach to, “What do I want to accomplish in my life? How can I get there?” Sometimes that actually causes the symptoms to diminish, even though you never really find out what caused them.

So I think it’s helpful to keep an open mind about that, and yet most people in our society come in with a materialist obsession that it must be some biochemical or discoverable, testable thing that is causing my symptoms. And we have to work with that for a while.

And either it’s true and we cure them and we’re heroes – I get to be Dr. House every so often where I discover that mystery root cause, and it’s beautiful. But other times we have to take a more practical approach.

I think in the psychotherapy world, there’s the Freudian analytic perspective, where you find that one insight from your childhood and then your current problems will get better, or there’s the cognitive behavioral approach where, we’ll let’s just deal with what’s going on now and how you’re going to deal with it, and maybe what happened in the past will sort of take care of itself. And so I think that can be applied to human medicine, or physical medicine, as well.

But I always meet people at whatever level of the materialist spectrum their on, and I go there first. Because ultimately, they need to do the experiment for themselves. They cannot take my word for it.

(49:50) [Damien Blenkinsopp]: Right.

It sounds like a very team focused approach to the whole doctoring thing, which isn’t really traditional. It sounds more from the modern world. I mean, we’re seeing team building and team practices in a lot of what we do in the world now, thanks to corporates and so on. Would you say that it’s changed the way you approach the practice, and the way you work with patients?

[Paul Abramson]: I think I’ve always taken this approach to working with patients. It’s not new to me. And yet, I think you’re right, in the conventional paradigm, it is hard to find. There’s a lot more words and verbiage around this team approach in the healthcare world now because of the politics going on, but in practice it’s still really hard to find a collaborator, someone who is more focused on doing the process right than on the outcome.

And we’re going to really focus on improving the process and changing the process dynamically as we go through working with each individual. That comes from my engineering background in systems engineering and out of control system theory and designing things is that you have to constantly change your approach based on what’s going on. And that takes feedback and communication, and it takes two people who are aligned working together.

Now there is a power differential. I have an MD, I wear a stethoscope, there is some value to that role differential. Someone who is looking for help from a professional who, in theory, has maybe some things to offer based on my experience and training and insights. And at the same time I like to also align with whomever I’m working, and work together so that we’re focused on if the process isn’t working. We can talk about that and fix the process.

If we get to the answer and the conclusion, we can celebrate together. And if that is vexing and takes longer, or is more difficult to find, well then we can pivot together. Or they can separate from this, and they can move on to other paradigms or other people to work with, and that’s fine too.

So there’s less pressure, in a certain sense, on, “I’m going to throw this problem at the doctor and the doctor is going to spit an answer back at me,” because that’s an all-or-nothing kind of proposition. Either it works and you’re happy or, much more likely, it’s not exactly right and somehow there’s been a failure.

(52:16) [Damien Blenkinsopp]: Would you say you need the patient to take some responsibility? The example you just gave is basically where they are saying alright, I don’t have responsibilities, just give me the fix.

[Paul Abramson]: Well, the more responsibly the patient takes, the better. An extreme example is the patient who does not consult a doctor and just does the [unclear 52:31] on their own. And those people exist. There are many of them. They achieve great results and I never meet them, except at Quantified Self.

If you are doing it on your own successfully, then you never meet me as a patient. However, in many cases people get frustrated, or they need new ideas, they need new paradigms, they want to explore with someone who can meet them at their level and have a very, very quick and useful conversation, and then help them to implement.

And I have the tools of pharmacology and laboratory testing and other testing, and access to specialists. You know, I have all the medical tools at my disposal, if they are appropriate.

[Damien Blenkinsopp]: And the experience. It’s all good doing an n=1 experiment, but if someone has been overseeing hundreds of experiments they learn things from those experiments in themselves, which could be relevant to you case.

[Paul Abramson]: I think so, except I’m continuously amazed at how individual people are. Even in problems that are relatively, I would say, conserved among individuals, like alcohol and the human brain. It’s really not that, there are only a few different ways that that tends to manifest on an obvious level, how people relate to alcohol, and yet their individual circumstances and details are unique, which makes every approach unique.

And so I say, I have gotten some insights from the self-tracking that apply to others. I think it is hard to take measurable insights and extract it in a medical, steady kind of way. And that’s why I continue to not be afraid of computers taking over my job, because ultimately I think there is a combination of metrics and data, and also presence and attention and experience that work together, and that’s why I think the medical profession has hope.

If you can provide presence, and attention, and experience, and knowledge, and then integrate data into that, you can actually be helpful to someone more frequently. And so that’s why I do what I do.

(54:41) [Damien Blenkinsopp]: Paul, I also just wanted to find out a little bit about you, and what you do with yourself when it comes to the Quantified Self, or any kind of tracking of metrics or biomarkers. Is there anything that you track for yourself on a routine basis, or you’ve explored, potentially?

[Paul Abramson]: Right now I’m tracking sleep, mostly just sleep duration. I think I’ve gotten the insights about sleep quality from various previous tracking endeavors. More as a behavioral thing to try to get myself to lie down more, which is particularly vexing for me.

And I’m tracking weight and body composition as I do different dietary experiments. Partly for my own health, and partly just to experiment with different dietary approaches. And, I’ve done many experiments when I have had problems that I wanted to fix, or wanted to understand better.

And some of them haven’t been fixable, but I understood them better and that helped me to deal with them. Headaches, and other things that I’ve talked about in the past. So I would say I use my baseline as I’m not doing lots, and lots of time intensive of self-tracking, because I don’t have the time involved.

The investment of time and resources is more than my available disposable resources, and the problems aren’t serious enough to warrant giving up other things. But when something important comes up, I start to implement more tracking.

(56:03) [Damien Blenkinsopp]: Right, right. So, in terms of the sleep quality you mentioned, what do you use to track that? Because I know sleep is a bit of a tricky area to track. Are you using MyMe today to track your hours, or what are you doing for that?

[Paul Abramson]: It all started with the Zeo – rest in peace – which allowed you to get some, albeit not 100 percent accurate, EEG data out of your sleep and sleep stage, and it was very nice. I didn’t mind wearing a headband every night, which some people found objectionable.

Now there are better tools, some of which I’ve experimented with, from Withings and ResMed and Beddit, where they’re less invasive tools to track your sleep that don’t require a headband. I think right now I’m using just an app on the phone that lays on the bed and has an alarm built into it and tracks start and end time of sleep.

It also records sounds, so if you snore it will give you all the snippets of snoring through the night. It’s just a simple app on the Iphone. I think I use the simplest tool for whatever I’m actually interested in. So right now I just set my alarm, and when it wakes me up I know how much time I was asleep.

And I have some subjective notes I take about that, like how was my sleep. And I’ve found that those notes correlate pretty well with reality when I’ve used actual medical sleep tracking devices that you use for sleep studies on myself in the past.

I’ve found that Zeo correlated well enough that I could actually use that data. And now I don’t actually need the Zeo even to know what’s going on with my sleep, because I know what it feels like.

[Damien Blenkinsopp]: I actually do the same as you, I just track the number of hours I sleep with a little timer on my Iphone. I just click it when I go to sleep, and I click it when I get back up.

Out of interest, how many hours do you sleep? What do you consider good or bad?

[Paul Abramson]: My personal ideal is 8 hours, almost exactly. 7.9 to 8.1, somewhere in there. And when I get that much…

[Damien Blenkinsopp]: You feel better?

[Paul Abramson]: Everything improves.

[Damien Blenkinsopp]: That’s good.

[Paul Abramson]: Both subjective and objective.

[Damien Blenkinsopp]: And have you got any little tools that have got you there? Because I’m always at seven. I’m always trying to get to eight but it’s hard.

[Paul Abramson]: Right. Well my particular app tracks over the last 14 days what my cumulative sleep deficit is compared to eight hours.

[Damien Blenkinsopp]: That sounds scary.

[Paul Abramson]: It is. And so when I get up above 10 to 15 hours of sleep debt in two weeks, other people don’t behave as well. I mean, that’s my observation. I’ve found that I’m not performing as well, and it manifests as the external world not cooperating.

[Damien Blenkinsopp]: That’s interesting. That’s good, then it goes back to you saying not everything is about food, and sometimes it’s the other psychological or emotional things, which are probably harder to identify.

(58:55) What would be your number one recommendation to someone who is trying to use data to make better decisions to improve their health, performance, or longevity, or any aspect of themselves?

[Paul Abramson]: I would define a relatively simple goal that actually really matters to you. Either it’s something terrible that you want to fix, or it’s something really juicy and rewarding that you want to achieve, and then set up as simple a self-tracking experiment as you can. Most people cannot pull off complex self-tracking unless they have diagnosable obsessive-compulsive disorder, or some spectrum of that.

So you have to just start with simple things that are as easy to track as possible, and some goal that’s really motivating, so you have the best chance of actually doing it, and seeing if this modality, if this type of thing, works for you. Some people find it intolerable, some people find it absolutely fascinating and motivating. And you can always add complexity later.

And then if you try, and it’s a great modality for you but you can’t pull it off, you need more accountability or more insight or more help designing experiments, that’s when you involve a coach all the way up through a medical doctor who’s interested in this kind of thing.

[Damien Blenkinsopp]: Great, great. Thank you for that great recommendation. Totally agree with it.

(60:00) So what would be the best ways for people to connect with you? Is it Facebook or your website, or where do people usually [reach you]? Are you active anywhere, or how else would people try to connect with you?

[Paul Abramson]: I’m variably active on Twitter, at PaulAbramsonMD. We do have a Facebook page and Google+ page. I’m easily findable on the internet. I usually do respond to social media.

If people want to become patients at my documedical group, my practice in downtown San Francisco, they can just call us up and we can describe how it works and how people can come in. I usually don’t work as patients with people that I have not met and examined, for personal and professional reasons.

[Damien Blenkinsopp]: Yeah, isn’t that a legal requirement in California?

[Paul Abramson]: It’s subjective. And yet I find that my intuition and my ability to be helpful to people improves dramatically if I have sat in the room, if I have had sometime in a room with them, and if I have laid my hands on them and examined them. Things work out much better.

I have tried both ways, and so I’ve just decided that I’m going to meet with people who can meet with me here in San Francisco. And that does restrict my ability to work with some people.

Otherwise, I can have theoretical conversations with people. My time is pretty darn limited in terms of how much banter I can do on social media, but I do my best to be available.

(change)[Damien Blenkinsopp]: Excellent. Alright, so we’ll put all of those in the show notes, and your website of course. Is there anywhere else you would suggest people look to learn about Quantified Medicine, for want of a better term. Are there any resources you’ve come across that you found helpful, and might be helpful to people?

[Paul Abramson]: Well the Quantified Self movement – it’s really more of a movement than an enterprise – but it holds meet ups all over the world, in many cities, and it also has an annual conference, or semi-annual I think, in the Bay Area. And frequently there’s the one in Europe.

So that’s a wonderful community to connect to where there’s an inner sanction of people of all different persuasions. And so you can always find someone who wants to do something similar to you in that community, because it’s a very heterogeneous community.

As far as others, there are so many different things going on in medicine around self-tracking. I think the reason Quantified Self appealed to me is that it does not have a strong vested financial motivation or conflicts of interest. And so you can go there and everybody is pretty much there just to be there. There are some people tying to sell things, but they stick out pretty obviously.

And it’s very egalitarian and anybody can speak. So I like that, whereas everything else you have to filter through the business model perspective. If you can do that, especially here in the Bay Area and in Western Europe there’s a lot of enterprise going on around this.

So it’s more about finding things that speak to you. I don’t have any particular points of focus.

[Damien Blenkinsopp]: Great, thanks. Well Paul, thank you so much for your time today. I really appreciate it. It was a great discussion.

[Paul Abramson]: You’re very welcome, it’s been great to be here.

Leave a Reply

Oxaloacetate is an important metabolic intermediate in the energy pathway of the mitochondria. Recent case studies support the use of oxaloacetate as a nutritional supplement to help regulate blood glucose levels, potentially support longevity and protect the brain.

Can you get similar beneficial results from a nutritional supplement as you can from a water fast (previously discussed in episode 16 and episode 28)? Oxaloacetate supplements (also discussed in this episode with Bob Troia) are currently being studied for their use in improving blood sugar regulation and potential anti-aging properties.

…through the clinical trial that was done. We know that 100mg [of oxaloacetate] was effective in reducing fasting glucose levels in diabetics.
– Alan Cash

Alan Cash is a physicist who has spent years researching the effects of oxaloacetate. Through his efforts and travels he has seen great success for terminally ill patients and more who use oxaloacetate to supplement their health. Cash helped stabilize the molecule so that it could be used as a nutritional supplement and continues to advocate and study its use so that more research and clinical trials can continue to support its use.

In this interview we get into the nuts and bolts of how oxaloacetate works, the current studies underway, and some different ways you can use it depending on what benefits you are seeking.

The episode highlights, biomarkers, and links to the apps, devices and labs and everything else mentioned are below. Enjoy the show and let me know what you think in the comments!

itunes quantified body

What You’ll Learn

  • The implementation of a calorie restriction diet may work to consistently increase your lifespan and reduce any age related diseases (6:19).
  • Calorie restriction seems to affect the energy pathway of the cell (9:20).
  • We can essentially “bio-hack” our systems by tricking the cells into thinking that the NAD to NADH ratio is high so that fat production is reduced (12:50).
  • Human trials have shown that calorie restriction reduces fasting glucose levels and atherosclerosis (13:46).
  • Reducing age related diseases will increase the average lifespan and increase the maximum lifespan for every cell in the body (14:32).
  • Oxaloacetate is an important metabolite involved in one of the energy pathways in the mitochondria, the power house of a cell (16:20).
  • Oxaloacetate is used in the Kreb’s cycle to oxidize NADH to NAD (17:09).
  • A human clinical trial in the 60’s demonstrated that the use of oxaloacetate as a nutritional supplement reduced Type 2 Diabetes symptoms (20:00).
  • As the dosage increases from the minimum 100 mg other system processes occur, such as the reduction of high glutamate levels, which is one of the damaging factors for closed head injury/stroke victims (22:33).
  • A medical food called CRONaxal contains a large dose of oxaloacetate which, when used in conjunction with chemotherapy, can reduce tumor size and sometimes stop tumor growth completely in patients with brain cancer (26:07).
  • Fasting/a calorie restricted diet is another technique that has been shown to slow brain tumor growth (27:53).
  • Some cancer patients have already seen results with oxaloacetate supplementation and calorie restriction diets, however these are just individual cases and not clinical trials (28:46).
  • Recently, clinical trials have begun to study oxaloacetate as a treatment for different conditions such as mitochondrial dysfunction, Parkinson’s disease, and Alzheimer’s disease (30:13).
  • Oxaloacetate may also work well to reduce inflammation and increase neurogenesis in the brain (32:30).
  • Oxaloacetate may also become an important supplement for athletes who encounter severe head injuries during their sport (34:30).
  • Long term potentiation, the restoration of the ability to learn, may improve for patients after a stroke or closed head injury if oxaloacetate is used in combination with acetyl-l-carnitine (36:18).
  • Alan Cash spent years proving to the FDA that there do not seem to be any negative effects found with taking large doses of oxaloacetate (38:35).
  • So overall, oxaloacetate has an immediate pharmacological effect on the glutamate in the brain and a long term genomic effect on the mitochondria (46:30).
  • When trying your own experiment, take a daily fasting glucose level for a couple weeks to see the normal variability and then follow with oxaloacetate supplementation along with daily reading of your glucose levels (48:06).
  • The biomarkers Alan Cash tracks on a routine basis to monitor and improve his health, longevity and performance (55:29)
  • Alan Cash’s one biggest recommendation on using body data to improve your health, longevity and performance (58:49).

Alan Cash

  • Terra Biological: Alan Cash’s company which produces the stable form of oxaloacetate.
  • Oxaloacetate supplementation increases lifespan of C. elegans: The original study published by Alan Cash on PubMed.
  • : you can contact Alan Cash with questions using this email address.

Tools & Tactics

Supplements & Drugs

Oxaloacetate is available in a few versions in the market today – all of these come from Alan Cash’s company since he developed the proprietary method to thermally stabilize it and as such make it usable. A number of studies on Oxaloacetate were mentioned in this interview – see the complete PubMed list here.

  • benaGene Oxaloacetate: The nutritional supplement (100mg) version of Oxaloacetate to promote longevity and glucose regulation.
  • CRONaxal Oxaloacetate: This version of oxaloacetate is a medical food (containing oxaloacetate) which, when used with other treatments such as chemotherapy, has been shown to significantly improve outcomes and quality of life for cancer patients.
  • Aging Formula Oxaloacetate: Dave Asprey’s supplement is the same as the benaGene version of Oxaloacetate.
  • Acetyl-l-Carnitine: Mentioned with respect to a study where a combination of oxaloacetate and acetyl-l-carnitine reduced long term potentiation impairment in rats.
  • Metformin: A drug which is used to improve blood sugar regulation in diabetes. Researchers are looking at its wider applications as a knock on effect from improving blood sugar regulation to cancer and aging.

Diet & Nutrition

  • Calorie restriction: this dietary regimen involves a significant decrease in daily calorie intake and has been shown to slow the aging process as described in this review article. You can learn more about the potential benefits and the arguments against the anti-aging benefits of calorie restriction in episode 14 with Aubrey De Grey.
  • Fasting: The fasts referred to in this episode were complete water fasts that were also being used in combination with oxaloacetate in order to attempt to “stack” the effects and get better outcomes. The examples given were case studies of cancer patients (no clinical trials have been completed as yet). For more information on fasting as a possible cancer treatment see episode 16, and episode 28 on our water fasting self-experiment.
  • Calorie Restricted Ketogenic Diets: In a similar light to above, the anecdotal cases discussed for cancer were patients use of ketogenic diets (that put you into ketone metabolism, by restricting carbs and protein, and emphasizing fat) which were also calorie restricted. This involves stacking two nutritional strategies: ketogenic diets have been shown to be therapeutic for some conditions like alzheimers and blood sugar regulation related problems as has calorie restriction in general. Then some of these cases were also combining the use of oxaloacetate, again to try to stack the effects from these three tactics to further improve outcomes. See episode 7 for complete details on using ketogenic diets as a tactic to improve health.

Tracking

Biomarkers

  • Blood Glucose Levels (mg/dL): A measure of the level of glucose in the blood at one point in time. Fasting blood glucose levels are specifically taken when you have not eaten for at least 8 hours and optimally would be between 75 and 85 mg/dL. Health concerns with blood sugar regulation such as diabetes risk start to rise over 92 mg/dL. After taking oxaloacetate for many weeks Alan Cash suggests that your fasting blood glucose should vary less when compared with any control levels. These levels can be measured at home using a glucose monitor and glucose testing strips (an explanation for the use of glucose monitors can be found in this episode).

Other People, Books & Resources

People

  • Hans Adolf Krebs: Krebs is best known for his discovery of the citric acid cycle, or Kreb’s cycle, which is the main energy pathway of a cell.
  • Dominic D’Agostino: Well known for his work with ketogenic diets and performance.

Organizations

  • Calorie Restriction Society: This organization is dedicated to the understanding of the calorie restriction diet by researching, advocating, and promoting the diet through regular conferences, research studies, and forums.

Other

  • Kreb’s Cycle: oxaloacetate is one of the components involved in this energy pathway in the mitochondria of a cell.
  • NAD/NADH: the effects of oxaloacetate in the Kreb’s cycle changes the ratio of NAD and NADH in the mitochondria which in turn affects the energy available to the cell.
  • Orphan Drug Act: This law passed in the US in 1983 has provided more opportunities for researchers and physicians to pursue drug development for rare, or “orphan”, disorders.
  • Calorie restriction PubMed results

Full Interview Transcript

Click Here to Read Transcript

[Damien Blenkinsopp]:Alan, thank you so much for joining the show today.

[Alan Cash]: Oh, thanks. It’s always a thrill to talk about oxaloacetate.

[Damien Blenkinsopp]: First of all, I’d just like to get a bit of background story as to why you got interested in this at first. What’s the story, basically, behind how you got interested in oxaloacetate, and started getting involved with it?

[Alan Cash]: That’s a pretty weird story.

It turns out I had a brain condition where nerves sometimes grow very close to arteries. I had an artery that wrapped around my nerve. Every time my heart beat it acted like a little saw and eventually cut in through the myelin sheath that surrounds the nerve and protects the nerve, and went directly into a nerve bundle that was a major nerve bundle in my neck. And the result was instantaneous pain.

I found out that I was very lucky; I was able to get it corrected. They just went into the back of my head and followed the nerve until they could find where it crossed over, and they untangled it and put in a piece of Teflon. So now I don’t stick, but the pain is 100% gone, which is really nice. A miracle of modern science, because it was pretty terrible.

In looking up this condition, I found that it was really a condition of aging. As we grow older, your arteries get about 10 to 15 percent longer, even though we’re not getting 10 to 15 percent longer. So they have to fold over, go someplace, and it was just bad luck that it folded over next to this nerve.

As a physicist I thought I’d look into aging and see, whats the current state of what we can do about aging. And thankfully at that time there was a lot going on with the basic fundamentals of aging and trying to understand this, and looking at all the data that’s out there. That’s what physicists do; we take a huge amount of data and see where the kernels of truth are. We try to think of E=MC2, or F=MA, how much that describes about the universe.

And looking at the aging literature, the thing that stood out the most is almost nothing works, which is disappointing. The one thing we did find that worked consistently throughout the animal kingdom was calorie restriction. That was discovered back in 1934 in Cornell University.

It’s not just the diet. It’s essentially establishing a baseline of what you’d eat if you had all the food available, and then backing off that baseline anywhere from 25 to 40 percent. And when you do that consistently over a long period of time, we see several things. One, we see an increase in lifespan. Not just average lifespan of the group, but the maximal lifespan is also increased.

For small animals that live short times, that could be anywhere from 25 to 50 percent increases. In primates, we’ve seen an increase in lifespan of about 10 to 18 percent, depending upon the test. So we’re thinking in humans, we’ll probably see something in that range if you calorie restrict your whole life.

The other things we see though are a reduction in age related diseases, such as cancer. Our animal models indicate that incidence of cancer is 55 percent less in animals that calorie restrict. And that’s one of the most effective methods we have of preventing cancer, that we know of.

Incidence of neurodegenerative diseases such as Parkinson’s and Alzheimer’s are either reduced or greatly delayed. Incidences of any kind of autoimmune type issue, or inflammation issues. So it’s very, very powerful this concept of calorie restriction, and it wasn’t until just recently that we figured out molecular pathways of why it’s working.

[Damien Blenkinsopp]: So, in terms of the actual mechanisms for what’s going on in the body when we calorie restrict, what happens? What is it that creates these benefits and these changes in our biology, versus disease, and longevity in general?

[Alan Cash]: We’ve been looking at that for a long time as a question, and some of the things that we looked at were does it matter if it’s the calorie restriction with fats, or does it matter if it’s just carbohydrates or proteins. And what we’ve seen is it’s pretty much across the board ‘calories’.

There are various diets out there – there’s a new diet every week it seems like – that looks at restricting one form or another of calories, or fats, or proteins, or even specific components of proteins. But what we’ve seen in general in calorie restriction is it’s the number of calories.

So, based on that it seems like it’s an energy proposition, and looking at the energy pathways there’s been focus on the ratio of two compounds that are pretty much the same. Nicotinamide adenine dinucleotide, or NAD, and it’s reduced version NADH. So that ratio, which is also known as the redox of the cell, is looking at the energy of the cell. And when we have a very high NAD to NADH ratio, we see effects very similar to calorie restriction.

[Damien Blenkinsopp]: So in terms of what that’s actually doing, do we understand why the changes in NADH create this change in our biology?

[Alan Cash]: You know we’ve been able to trace this, and what we see is increasing the NAD to NADH ratio – and you can do that through a variety of ways – but that increase is measured by a protein called AMP protein-activated kinase, or AMPK. What AMPK does is it monitors, essentially, the NAD and NADH ratio, or the redox of the cell.

Think of it as a see-saw, so with AMPK as the fulcrum of the see-saw and NAD on one side and NADH on the other side. When the see-saw is in one position, AMPK will then act with other proteins that translate to the nucleus and turn on genes. When the see-saw is in a different position, AMPK will work with other proteins that translate to the nucleus and turn on different genes.

So let me give you a specific example. If you’ve had a lot to eat, your NAD to NADH ratio will be low. And AMPK will turn on genes that help with fat storage and production, because you’ve got all this extra energy, so hey let’s store some of it. So it will actually start producing proteins that deal with fat storage and synthesis.

On the other hand, if the see-saw is in the different position, if you haven’t had a lot to eat, there’s no point in storing fat. And so your genes will not be making these proteins that assist in making fat production. So how can we use that information?

For instance, when we trick the cells into thinking that the NAD to NADH ratio is high – or that the animal hasn’t had a lot to eat even if it has – we can slow down the rate of fat production, which could be interesting for people on diets. What we see is that you still gain some fat, but you just don’t gain it as fast.

So, biochemically, there are reasons why when you go on a diet and you lose all that weight, and you stop the diet and you rebound back very quickly. We can slow down the rate of rebound if we can keep the NAD to NADH ratio up high, because then the genes that are produced that create and store fat aren’t being produced. So there’s some really neat tricks that we can use to bio-hack into our systems that are existing systems.

[Damien Blenkinsopp]: Yeah, yeah. There are quite a few potential benefits to calorie restriction. We’ve come across some of these before. We’ve spoken with Dr. Thomas Seyfried about purposefully doing fasting for this kind of work as well.

What are kind of list the main big areas which people have seen this impact, like diabetes. What have you seen in your area, areas where people are meaningfully impacting this area with calorific restriction?

[Alan Cash]: We’ve actually done human trials in calorie restriction, and what we see is a reduction in fasting glucose levels. We also see a reduction in atherosclerosis, which, considering heart disease is the number one killer in America, if we can reduce that you’re going to have people living longer. That alone is huge.

[Damien Blenkinsopp]: So that just begs the question, when people are doing these estimates of longevity, is it because you’re reducing the risk of many of the kind of diseases that kill us – like cancer and neurological disorders, and heart disease – that people are living longer, and therefore you’re getting a higher longevity score? Or are they kind of separate topics?

[Alan Cash]: It’s both, actually.

Reducing these diseases is going to bring up the average increase in survival. So that would give you your average increase in lifespan. But there are certain people who don’t get these diseases, and they live a long time. But calorie restriction has been able to increase the maximal amount of lifespan. So that’s making every cell in your body live longer.

And we see that in our animal tests. For instance we started off working with these little worms called C elegans, which are used a lot in research because we understand, somewhat, the genetics of them. And one of the interesting things about these worms is once they go into adulthood, they don’t produce any more cells. That’s it.

They only live for about 30 days, but they live with the cells that they have. So if we can extend their lifespan, it means that we’re allowing each of their cells to live longer, and to be functional for longer. And when we increase the NAD to NADH ratio in C elegens, we see up to a 50 percent increase in lifespan.

So, as I said, it’s both. It’s eliminating a lot of these diseases that are associated with aging. I mean, think of all the diseases that you get when your old that you don’t get when you’re seven years old.

[Damien Blenkinsopp]: So, I’m sure you’re aware of Aubrey de Grey? We had him on the podcast previously talking about his seven areas of aging, which are basically diseases of aging. So he’s looking at it from that perspective. So, in terms of oxaloacetate, which is the mechanism you were using to generate that, where does it actually come from? What is it?

[Alan Cash]: Well, it’s a human metabolite. It’s in something called the Krebs cycle, which is what gives us power in our little mitochondria. So, mitochondria can be thought of like a little power plant. Glucose is the fuel for the power plant.

So the more mitochondria you have, the more power plants you have, but you have to also have the fuel, the glucose, to up-regulate that. So oxaloacetate is one of those critical components within the mitochondria. So it’s in every cell of your body already.

Now, when we give it to animals, the reason we started looking at oxaloacetate is in looking at our energy pathways, oxaloacetate can break down into malate, which is another metabolite. It’s found in excess in apples. And as part of that reaction, it takes NADH and turns it into NAD.

[Damien Blenkinsopp]: So it takes it from reduced into the oxidized form?

[Alan Cash]: Yes, and so in doing that, because you’re taking something from the denominator and putting it in the numerator, it changes the ratio very rapidly. The first person who measured this ratio change was Krebs himself, back in the 60’s. He added oxaloacetate to the cells and he saw a 900 percent increase in the NAD to NADH ratio in two minutes. So, huge changes with this human metabolite oxaloacetate.

Now, oxaloacetate has got some problems. It’s not very stable, it’s highly energetic. Commercially it’s available through chemical suppliers, but you have to store it at -20 degrees Celsius. If you want to make popsicles out of it, you could probably do that. But putting it into a usable supplement has been very difficult, and that’s why you don’t see it very often.

We came up with a method to thermally stabilize it so that it can be stored at room temperature for a period of up to two years without degrading. And that’s how we were able to introduce this into the market.

[Damien Blenkinsopp]: Great. So, in terms of where it comes from, in my understanding it’s also something that is part of foods. So there are foods which have oxaloacetate in it, so it’s basically a nutrient that’s found in the environment?

[Alan Cash]: Yes. Absolutely. Although it’s only found in very, very small amounts. There are some foods that have higher amounts of oxaloacetate, and these are foods that typically have higher amounts of mitochondria.

So, for example, pigeon breast has a lot of oxaloacetate in it because you need tremendous amounts of mitochondria to power flight. That’s what one of the most energy intensive things out there, is flying around. But you need about 18 to 20 pigeons breast to get the amount of oxaloacetate that we see as the minimum for seeing some of the gene expression changes we want to accomplish. So it takes a lot of pigeons.

[Damien Blenkinsopp]: So you’ve determined the minimum effective dose, which is around how much?

[Alan Cash]: So far – and this is from a human clinical trial – one of the side effects of calorie restriction in primates is it eliminates Type 2 diabetes, which is a good thing. And it turns out they, in trying to mimic calorie restriction – which is what we’re trying to do is turn on the same molecular pathways – we looked at oxaloacetate, and there was a clinical trial that was done back in the 60’s in Japan.

This was published, and it showed that oxaloacetate reduced fasting glucose levels in diabetics. So, we knew that this is one of the side effects of the calorie restricted metabolic state, and we could look at, in humans, what is the most effective dose.

And what we found is they did a range in this clinical trial of 100mg to 1000mg. There were no side effects in the 45 day trial. 100 percent of the people saw a reduction in their fasting glucose levels, which was good because they were all diabetics. We couldn’t understand why this wasn’t commercialized back in the 60’s.

So I actually flew to Japan to interview the department that was responsible for this clinical trial. The conversation went something like this, “Hi. I’m Alan Cash, your department produced this paper on oxaloacetate working in diabetics to reduce fasting glucose levels. Where’s the follow-on work?”

They said, “Well there is no follow-on work.” And I said, “Well why not?” They said, “Well because it’s a natural ingredient.” And I said, “Yeah it’s not only natural, it’s a human ingredient. So toxicity is extremely low.” And they said, “Yes, but we can’t get a patent on it.” And that was pretty much the end of the conversation.

So, as far as knowing the dosing and what’s effective, we already have a clinical trial showing where the minimum effect is, which is 100mg, which is where we set our sights to put out a nutritional supplement.

[Damien Blenkinsopp]: Yeah.

So, was there any advantage for the people, if we take the most extreme example, the people taking 1000mg in that study, was there any advantage to it? Did it impact blood sugar regulation differently?

[Alan Cash]: Yeah, well actually, as the dosage increases, we start looking at other reactions that oxaloacetate are involved in. And one of the main other reactions is the combination of oxaloacetate with glutamate. So, oxaloacetate and glutamate link together and that reduces glutamate levels in the brain.

Now that can be important for certain people. For instance, in a closed head injury, 20 percent of the damage to your brain is caused by the actual strike to the head, the damage to the tissue. 80 percent of the damage is caused by the aftereffects. And those after effects are in your brain it releases something called a glutamate storm.

Glutamate is one of those essential brain chemicals that you need to function properly, but if you get too much of it it excites the neurons to the point where they die. So this glutamate storm is responsible for about 80 percent of the damage.

And what they’ve been able to show now with oxaloacetate is primarily in tests over in Europe – the Weizmann institute out of Israel is doing a lot of this work, and there’s also some people in Hungary and Spain that are doing quite a bit of work with oxaloacetate. But they’re able to show that oxaloacetate, if you can get it to a stroke victim or a closed head injury victim within two hours, 80 percent of the damage is eliminated.

[Damien Blenkinsopp]: Wow. What, do they just take a small dose, or what does it have to be?

[Alan Cash]: No, you’ve got to take a lot, because you have to get it into your bloodstream, and if you take, let’s say, two 100mg capsules of oxaloacetate we’ve seen the data in the bloodsteam, only about five percent gets through. The rest of it is used up in the liver and intestines. That’s not a bad thing, because you want to keep those things healthy. But to get it so that it starts reducing glutamate levels in the brain you want to increase it’s supply in the bloodstream, and so you’ve got to take a lot.

[Damien Blenkinsopp]: So, basically after that is it always five percent? If I take 1000mg, is it just going to be 15mg?

[Alan Cash]: We don’t know. There may be a point where you start overloading the liver and more passes through. I can tell you that we have a medical food that is directed towards people with brain cancer, because if we can reduce the glutamate levels in the brain we see better results.

[Damien Blenkinsopp]: Because people, just to get back to it, is it that people with brain cancer tend to die from glutamate toxicity? Is that one of the main mechanism for their death? Or is it acting on other dimensions?

[Alan Cash]: Well, one of the main predictors of survival is the amount of glutamate that’s produced because what the tumor does is it produces tremendous amounts of glutamate, and it kills the surrounding tissues so that the tumor can grow into that area. So, if you can stop that, you don’t kill the tumor, you just stop it growing.

And this is essentially what we’re seeing with the product called CRONaxal, which is a medical food [that] is a high, high dosage oxaloacetate. So you may take the equivalent of 30 to 60 capsules of the nutritional supplement per day, and we’re seeing in animal tests a 237 percent increase in survival.

So FDA gave us an Orphan Drug designation for oxaloacetate for brain cancer. In the actual human work, we’re just doing case studies right now, but in the 17 case studies that we have MRI data on, the oxaloacetate was in conjunction with chemotherapy. So you use them together, it was able to stop tumor growth, or reduce tumor size, in 88 percent of those patients.

[Damien Blenkinsopp]: Wow, so that’s pretty great statistics there.

[Alan Cash]: Yeah, considering some of these people with glioblastoma, their tumors were growing at a rate of 80 percent per month. You can do the math there, it’s not a great equation.

And we were able to bring that growth rate to, in one guy’s case – he was 42 years old, two kids, a nice guy – we were able to bring that growth rate to zero for eight months. That’s very significant when chemotherapy alone only increases survival by a month and a half.

[Damien Blenkinsopp]: Wow, right. So, you were also saying earlier, we were just discussing you looking at combining oxaloacetate with fasting. We spoke to Dr. Thomas Seyfried about this recently, and you may be seeing potentially better results with that? Or it might be–

[Alan Cash]: Well what we’ve seen so far, fasting is one of the techniques used in brain cancer to slow or retard the growth of the tumor. It’s one of the few things that has been shown to work, especially a calorie restricted ketogenic diet, where you eat more fats.

And the thinking behind that is that you reduce glucose levels tremendously with the ketogenic diet, and glucose is one of the things that feed the tumor. Now, the other thing that feeds the tumor, according to Dr. Seyfried, could be glutamate. And so if we can reduce glutamate levels also with oxaloacetate, we may see some impressive results.

And we’re already starting to see that in anecdotal cases in patients. We had one young man who had a slow growing brain tumor that’s been able to stop it’s growth with a combination of calorie restriction and oxaloacetate supplementation with our CRONaxal product for a period of two years now.

[Damien Blenkinsopp]: Wow. And so is he taking around 6000…

[Alan Cash]: No, his tumor is slower growing, so he’s taking about the equivalent of 10 capsules a day.

We’ve also had recently a woman with Stage 4 breast cancer. Her latest report from her PET scan and her MRI data, they can no longer find the tumor, or tumors; she had like four of them. And all she was doing was calorie restriction and about 10 capsules of oxaloacetate.

There’s some real promise here, but it’s very early on. We don’t have the clinical trial data that supports this in a statistically significant manner, we just have individual cases. Although those individual cases are stunning, it would not be prudent to rely upon those cases.

[Damien Blenkinsopp]: Right. Well, have you got any plans to have any clinical trials? Was that something that might be occurring soon in that area?

[Alan Cash]: Yeah, well we’re actually in clinical trial for a variety of conditions. One is mitochondrial dysfunction. There are certain people that are born with genetic defects that affect the mitochondria.

We have one infant that’s been on oxaloacetate now for nine months that is showing normal development, whereas normally with this type of defect we would expect the infant to have passed away six months ago. So that’s pretty interesting.

We’re also in clinical trial for Parkinson’s disease because anecdotally we’ve seen some interesting cases where the oxaloacetate has reduced the symptoms of Parkinson’s disease. And lastly, we’re in clinical trial for Alzheimer’s disease, so we’ll see how those all play out.

We’re getting ready to start some clinical trial work in pediatric brain cancer, because if we can get away from doing chemotherapy, it’s just a whole better quality of life.

[Damien Blenkinsopp]: It sounds like one of the main mechanisms. So if you’re looking at Alzheimer’s disease, they also use ketogenic diets, and so it’s obvious that the glutamate is helping, but do you think it’s also the aspect of improving blood sugar regulation is potentially helping in all these diseases as well? Is that one of the factors?

[Alan Cash]: It certainly could be a factor. We just published a paper in human molecular genetics that showed that oxaloacetate increased the amount of glucose that the cells could uptake in the brain, it increased the number of mitochondria in the brain. So we not only built more power plants, but we’re now having a way to fuel those power plants.

The interesting thing is that oxaloacetate is also a ketone. So you don’t necessarily need glucose to fire off all those neurons in the brain, you can actually use oxaloacetate as a power source. So, the other things we’ve seen with oxaloacetate in the brain in animal models is a reduction in inflammation, and probably most exciting is we’ve seen a doubling of the number of new neurons that are produced.

Ten years ago we used to think that the number of brain cells you have is static, that those brain cells that you lost in college are forever gone by imbibing in too much alcohol, but now what we’re seeing is that there’s an area of the brain called the hippocampus which continues to produce new neurons. And as we age, this function decreases. So our ability to repair our brains decreases.

Well oxaloacetate in animal models doubled that rate of production, and not only did it double the rate of new neurons, but the length of the connections between the neurons was also doubled. So, if you think about, well if a neuron can connect to a neuron that’s further away you get more interesting connections, more interesting abilities to have different variables.

It makes your brain more plastic, is what we say. And oxaloacetate has been able to show both that increase in neurons and the length of the neurons. So it’s pretty exciting work.

[Damien Blenkinsopp]: Yeah, so brain injuries – you were talking about brain injuries before – I guess a lot of us think about brain injuries as a big thing, like maybe a car crash or something, you have a big serious brain injury. But now they are also looking at athletes, for instance in football where they’ve been heading the ball and areas like that, and they’re seeing there’s a lot of damage.

So could this potentially be a tool for sports? If you’re playing in football, would it make sense to be taking this stuff whenever you’re going to a match, or something like that, to reduce the kind of damage you’re getting each time you’re heading the ball, and so on?

[Alan Cash]: I think so. I mean, my daughters play volleyball at a very high level – one’s at Pepperdine, and the other is going to be at Hofstra next year – and occasionally they get hit in the head with a volleyball. They’re middle blockers, they go up, and they just get slammed in the face. So I always have a bottle of oxaloacetate in their gym bag, and if they get hit in the head they’re told to take 10 capsules right away and to continue taking 10 capsules for the next week or so.

I don’t want to suggest that you should use oxaloacetate for any kind of disease. Mostly it’s a nutritional supplement, there is the medical food also that’s specific for brain cancer. And I just want to make that clarification that the work really hasn’t been done in clinical trial.

Now, over in Europe they are working on that. They’ve done a lot of animal studies, and the interesting thing they’ve found is that if they can get oxaloacetate into these animals that have been hit on the head with a hammer within two hours, it reduces the amount of brain damage they experience by 80 percent. They’re looking at a lot of things in Europe, and it’s very, very exciting work.

[Damien Blenkinsopp]: Yeah, it seems like this is a really interesting molecule, because it seems to be having an impact in a lot of different things. Of course, it’s all early stages of research, like you say, but it seems to have quite a lot of potential.

I saw another study where they had combined oxaloacetate with acetyl-l-carnitine and they were looking at that. Could you talk a little bit about that? I believe it was long-term potentiation it was impacting.

[Alan Cash]: Yeah, long-term potentiation is a measure of how plastic your brain is, how well you can still learn. And when they go into the brain of animal models and give them a stroke, an artificial stroke, and then measure long term potentiation, the levels drop significantly.

When they use oxaloacetate or a combination of oxaloacetate and acetyl-l-carnitine, they saw 100 percent restoration of the brain’s ability to learn again, in very short order. And this could be very important for people with stroke, closed head injuries, that type of thing.

But again, this is early work, it’s been done in animals, it’s been very successful in animals. And both oxaloacetate and acetyl-l-carnitine have very low toxicity profiles, so the risks are low there, but we still need to do this in clinical trial and make sure that there are no unexpected results in humans.

[Damien Blenkinsopp]: Right. Yeah, so ALCAR or acetyl-l-carnitine, a lot of people I know have been taking it for a very long time. So in terms of toxicity for oxaloacetate, as you said there was the trials where you had 1000mg per day. Has anything above that been tested? Because it sounds like with some people you’re actually giving 10,000 or more in specific cases.

So, in terms of toxicity, is there any evidence to say that it could be harmful in any way if someone overdoses, or potentially someone in a specific situation?

One thing I was just thinking about while you were talking was in terms of glutamate, you say it helps to deactivate glutamate. In some people who are normal and have normal levels of glutamate, could that impact them in any way in terms of their brain performance, memory, things like that?

[Alan Cash]: That was a multiple question, and let me address them one at a time.

[Damien Blenkinsopp]: I’m sorry.

[Alan Cash]: As far as toxicity, in order to bring the supplement into the United States we had to prove to the FDA safety because this is considered a new dietary ingredient, even though it’s in just about every food we eat but not at the levels that we’re giving it to people at. So we had to prove safety, and we spent quite a bit of money and three years of my life proving safety to the FDA.

One of the things we had to do is feed animals as much oxaloacetate as we could stuff into them to see at what point in time 50 percent of the animals would die. And what we found out is we got up to about 5000mg per kilogram of body weight in animals, and we still couldn’t get any of them to die.

[Damien Blenkinsopp]: Did you get any negative reaction at all?

[Alan Cash]: We couldn’t find one. Now, what we are seeing in humans, especially in some of these people with brain cancer that are taking the equivalent of about 60 capsules a day, we do see an increase in burping.

[Damien Blenkinsopp]: That’s interesting. It’s kind of random.

[Alan Cash]: Yeah, well it relaxes the upper sphincter muscle in the stomach, and we see an increase in burping in some of the people.

[Damien Blenkinsopp]: That’s interesting.

[Alan Cash]: But that’s about all we’ve seen so far. So, from a toxicity standpoint, this appears to be a very safe molecule.

[Damien Blenkinsopp]: Well, that’s great. Do you remember the multi-part question, or shall I repeat it?

[Alan Cash]: Yeah, the second part was what if you take a lot of this and you’re just a normal person, what would you expect to see? Some of the things we’ve seen are really interesting.

We have an R&D project where we’ve developed an oxaloacetate tablet that goes under your tongue. And so we deliver a lot more oxaloacetate to the bloodstream, which preferentially reacts with glutamate. And what we see with that tablet is an increase in the ability to [unclear 40:04] because if you can turn down glutamate levels a little bit in your brain, you don’t have some of that repetitive cycling of questions, you’re able to focus more, you’re able to pay attention better.

It’s kind of like, the way I can explain it, it’s like you’ve been meditating for a half an hour, so you have this incredible focus but it’s not jittery. Like if you have 10 cups of coffee you can also have more attention, but your whole body is shaky. This is more, you’re very relaxed, and you just have that increased ability to focus. It’s pretty cool.

[Damien Blenkinsopp]: It sounds like you’ve been testing it yourself.

[Alan Cash]: Yeah I test it always on myself, because if I’m ever going to give it to somebody else you’ve got to feel confident enough in it’s effects to try it on yourself first.

[Damien Blenkinsopp]: Yeah. You know, it would be nice to hear, how do you use oxaloacetate yourself? Do you have some kind of routine, or what do you do with it?

[Alan Cash]: Yes, I use it primarily for anti-aging, because I’m after that [00:41:11 – 00:41:14:17 audio error repeated “we see an increase in burping in some of the people.”] I take like three caps a day, which is a little bit more than our recommended one cap a day, but I get it for free, so what the heck, right.

I’ve also started working with this sublingual dose whenever I’m tired. Like if I have to drive somewhere and it’s late I take one and immediately I’m awake and my focus is there. Or if I’m in a conference and its 4 o’clock on the third day of the conference I find that it helps quite a bit. So that’s how I use it.

A lot of athletes are using this now because we’ve been able to measure a decrease in fatigue and an increase in endurance. We don’t see an increase in strength, just an increase in endurance. So a lot of endurance sport people take one to two capsules about 15 minutes before competition, with about 100 to 200 calories.

[Damien Blenkinsopp]: So it sounds very quick acting, in terms of you’ve take it in and within a very short period it’s going to have that impact. Are you talking about it feeding the mitochondria, basically?

I mean, you spoke earlier about it basically being like a ketone. Do you think that’s the mechanism there, or is it because it’s stimulating the mitochondria somehow?

[Alan Cash]: Well there’s been some work out of UCSD showing that oxaloacetate activates pyruvate decarboxylase and allows the citric acid cycle to process faster. So you get more ATP production, which would tie with the endurance effect.

We’ve been able to measure the endurance effect almost immediately, and we published that in the Journal of Sports Medicine. We saw about a 10 percent increase in endurance. And you think, you know, 10 percent is not all that much, but in a lot of athletic competitions 10 percent is huge.

So that’s the short term effect, and that actually only lasts about two hours. And then if you want it again, you have to reapply.

[Damien Blenkinsopp]: Yeah. So a marathon runner would be dosing every couple of hours?

[Alan Cash]: Yeah, about every two hours.

The second effect though is longer term. We’ve seen that oxaloacetate supplementation increases the number of mitochondria, or the mitochondrial density in the cell. So it produces more of the power plants so that when you feed it more glucose, you can turn it into fuel faster.

But that takes typically, you know, anywhere from two to six weeks to see the effect on that. And you have to take it daily. What we’re doing is we’re increasing that NAD to NADH ratio, which then activates AMPK, and chronic AMPK activation has been shown to start the process of mitochondrial biogenesis, or producing more mitochondria.

[Damien Blenkinsopp]: Is there any reason we want that activated? Anything you know of like in the research, where it says like chronic activation of AMPK could lead to any downsides?

I have another question, just to kind of give you a bit of context to that. Is it worth cycling oxaloacetate? So having a month on, or a couple of months on, a couple of months off, or anything like that?

[Alan Cash]: Yeah, a lot of supplements that deal with stressing your cells in order to get an effect they work better if you cycle them. For instance, echinacea. Echinacea works because it’s an irritant. So you turn on your stress response and get a response, but if you take it all the time, your body gets used to it.

Oxaloacetate doesn’t work as a stresser, it works to turn on genes and turn on the development of more mitochondria. So no you want to take it all the time.

[Damien Blenkinsopp]: Great, and so we were discussing earlier, I was just asking you about potentially doing a lot of experiments with oxaloacetate, and you were saying that for most of the effects it’s really this aggregated, this cumulative effect.

We want to be using it for between two and six weeks before we see the effects. And then, if we stop it’s probably going to take that amount of time before those effects disappear. But they will disappear, so it’s something that you really kind of have to take on an on-going basis.

[Alan Cash]: Yeah, yeah. Because it’s, well there are two effects. One is a pharmacological effect, like for instance the reduction of glutamate in the brain. That happens almost immediately, so some people when they take this they get that feeling of peace because they’re just reducing their excitatory chemical in their brain.

But the other effect is a genomic effect, and while your genes start producing these proteins right away it takes a while for the proteins to be enough in number that we see measurable effects. We can see those effects in typically four to six weeks.

For instance, blood glucose levels would be one that we’ve been able to trace that down to activating AMPK, which is the same thing that the diabetic drug Metformin does but through a different pathway, and the up-regulation of a gene called FOXO3A, which deals with glucose stability. But that takes time, it takes usually four to six weeks.

[Damien Blenkinsopp]: So, for the people at home, if they were going to design their own little experiment, it would be basically measuring blood glucose stability, is that the main, is it the variant which is reduced, or is it actually lowered in general?

[Alan Cash]: One experiment that they could try is start off with a baseline. Go to the drugstore, get a glucose meter and some little paper strips, and take your fasting glucose levels for maybe a couple of weeks. You see the variability, because even in fasting glucose levels, you’re going to see the levels bounce all over the place.

And then start oxaloacetate supplementation, one or two capsules a day for a month, and take your daily glucose levels. You won’t see much change for about three weeks, and then what we typically see is a slight reduction – in non-diabetics – in fasting glucose levels.

And more importantly, a reduction in the swing. So you don’t see as high a high, and as low a low. And that reduction is typically on the order of 50 to 60 percent, so you have better glucose regulation. And in normal people, that’s not a bad thing.

[Damien Blenkinsopp]: Right. Just if we’re talking in terms of performance, just throughout the day I think people’s performance goes up and down. Some of the reasons people try new diets such as Paleo and Ketogenic and so on is to try and even out their blood sugar a bit more so they don’t have these typical dips people get after lunch when they need another shot of caffeine to get through the afternoon.

So I’m sure probably you can see how that could impact their performance in that way. That would be interesting.

[Alan Cash]: Yeah. Absolutely.

[Damien Blenkinsopp]: So how would you recommend someone takes oxaloacetate? Would it just be 100mg one capsule? Would it be in the morning, once daily?

What would be the recommended way to try this out, for someone who is just normal and healthy, and they’re just more interested in the long term benefits, and so on.

[Alan Cash]: For the long term benefits, we looked at the minimum amount that you could take – I believe in small measures for big effects – the minimum amount over time, and we know that through the clinical trial that was done. We know that 100mg was effective in reducing fasting glucose levels in diabetics. We’re turning on those genes that we want to turn on.

So, one capsule a day. It doesn’t matter if you take it in the morning or the evening, what does matter is that you take it every day, because we’re trying to increase that NAD to NADH ratio and keep it pretty steady, so that we continuously activate AMPK. And that continual activation is what turns on the genes and gives us the gene expression that we want to see to see extended lifespans.

[Damien Blenkinsopp]: Great, great, thank you. Are there any situations where you would recommended people – because you’re taking 300mg yourself, and obviously you don’t have the costs that other people would have – but are there other situations where you would think it would be interesting for people to take a slightly larger dose?

[Alan Cash]: Yeah, but I really can’t recommend that, as I’m not a physician, I’m a physicist.

[Damien Blenkinsopp]: Right, right. We’re getting outside of the nutritional realm again.

[Alan Cash]: Yeah, and that [can] be a dangerous thing for us to do.

[Damien Blenkinsopp]: Absolutely.

[Alan Cash]: Definitely our CRONaxal medical food for [treating] cancer, they would take a lot more oxaloacetate.

[Damien Blenkinsopp]: Great, great. If someone wanted to learn more about the topic of caloric restriction and oxaloacetate, where would you say, are there any books or presentations or is there any other resources people could look up that would help them to learn more about this?

[Alan Cash]: Absolutely. There’s quite a bit in PubMed, so they could go to www.pubmed.com, or .gov, and just type in ‘oxaloacetate’ and ‘calorie restriction’. We’ve got some papers in there that we’ve published.

And they can also look at oxaloacetate and other things like Parkinson’s, Alzheimer’s, cancer, you know, if they’re interested in that, and see what animal data there is out there right now. There’s not a lot of human clinical work done yet.

We’re in the middle of some of that ourselves. They can also email me. My email address is acash@benagene.org. I typically get back to people in a couple of days with questions.

[Damien Blenkinsopp]: Great, and I can attest to that, because we’ve been in contact before and I know you make yourself very much available, and that’s really appreciated.

Are there other ways that people could connect with you? I don’t know if you are on Twitter. You have a website, of course, which is benagene.com?

[Alan Cash]: Yeah, we have a website benagene.com. There’s not a lot of information on that because the FDA discourages that. For instance, we can’t legally put any animal data on our site, even though I consider humans animals. I think it’s relevant, but the FDA does not.

[Damien Blenkinsopp]: Right, right. Of course. So, is there anyone besides yourself that you’d recommend to learn about this topic? I don’t know, calorie restriction, longevity. Is there any interesting stuff you’ve read over the years, or have you referred people’s work?

[Alan Cash]: There’s tremendous amounts of data on calorie restriction. And there’s a society, the Calorie Restriction Society, where these people have been restricting their own calories for years, seeing tremendous results, especially in reducing atherosclerosis. In human clinical trial we’ve seen a major drop in atherosclerosis and blood pressure.

[Damien Blenkinsopp]: Do you know if that’s reflected by the CRP? The C-reactive Protein biomarker? Because you spoke about inflammation earlier, I wasn’t sure if that was that marker or another one.

[Alan Cash]: I’ve seen a decrease in inflammation in our studies really through the M4 pathway. I don’t know if C-reactive protein levels are down. We did have a case where due to a genetic dysfunction an 11 year old girl, she was in critical care, her CRP levels were up around 20,000.

[Damien Blenkinsopp]: Wow.

[Alan Cash]: Yeah, yeah. She was…

[Damien Blenkinsopp]: That’s insane.

[Alan Cash]: Yeah. Yeah. She was eating herself alive, essentially. And she was in critical care. They tried just about everything. And this was work done out of University of California San Diego Mitochondria Dysfunction Department. They’re doing some breakthrough work there.

They ended up giving her some oxaloacetate and in two days her CRP levels dropped to zero, and she was released from the hospital and went home. Once again, that’s a case of one person and specific genetic anomaly.

[Damien Blenkinsopp]: Yeah, yeah. Interesting. That’s pretty impressive.

In terms of your own personal approach to data and body data – because we’re always talking about data on this show in terms of our biologies and so on – do you track any metrics or biomarkers for your own body on a routine basis?

[Alan Cash]: Glucose levels. And for a guy, I’m 57 years old, my blood glucose levels are typically in the low 80s, which is pretty good. That’s about the only thing I track regularly. I mean I track my weight, which is very stable. I don’t count the number of hours I exercise or anything like that. I should.

[Damien Blenkinsopp]: I guess. Have you tracked your blood sugar over time? Before you started taking oxaloacetate, or is it since, so you probably wouldn’t see the effects? I’m just wondering if it would be a cumulative effect from you having taking it, I assume, for years now.

[Alan Cash]: I have been taking it since about 2007, which is when we introduced it into the Canadian market. Basically it just dropped. Initially I was up in the upper 80s to low 90s, and over time I’m just pretty much consistently in the low 80s now.

[Damien Blenkinsopp]: So you have seen some kind of steady decline, or did it decline when the genes turned on and then it stayed there?

[Alan Cash]: It pretty much declined when the genes turned on and stayed there, yeah.

Now there’s ways to lower it even further if I went to a ketogenic diet. I know some people who have been doing this, like Dominic D’Agostino. I think his blood glucose levels are down in the 40s.

[Damien Blenkinsopp]: Wow.

[Alan Cash]: Yeah. But he does a very strict ketogenic diet, and he’s feeding his cells with ketones instead of glucose.

[Damien Blenkinsopp]: Yeah, so I was interested – just before we started the interview – also in just cancer prevention, so we had Thomas Seyfried on here and he recommended a five day water fast twice a year.

So it would be interesting to combine that with the oxaloacetate. It might have a potentially beneficial upside, you know, combining those two rather than doing them separately.

[Alan Cash]: Yeah, we’re seeing that in patients now. Hopefully we’ll be able to get some funding for some clinical trials to combine calorie restriction with oxaloacetate in some of these patients. To take the science from our animal data, which is very promising, but it’s not human data. And so hopefully we can continue our research and help some people here.

[Damien Blenkinsopp]: Yeah. I’m guessing it takes quite a while to get these clinical trials going. Would you expect this to be done over the next 10 years? Is there anything that could help you with that, in terms of getting funders, or what could help to push that along faster?

[Alan Cash]: We’ve taken the unusual step in brain cancer of making oxaloacetate available for a disease through the Orphan Drug Act in the US. So this allows for various medical conditions that have scientific basis to be used for a specific disease. In this case, we’re using it for brain cancer, which is an orphan disease.

So that’s helping get the word out, get some anecdotal cases, which I’ve discussed with you a little bit, and increase the interest in getting a clinical trial out there. We’ll see how that all evolves.

[Damien Blenkinsopp]: Great, great. Thank you. Well, one last question Alan. What would be your number one recommendation to someone trying to use data, in some way, to make better decisions about their health and performance, or their longevity?

[Alan Cash]: I think that’s a great place to start. You know the benefits of calorie restriction, and so just counting calories and reducing calories where you can would be one strategy of using data to improve your health. If you keep track of that information.

Keeping track of blood glucose levels, because having lower glucose levels rather than higher glucose levels is going to positively affect your health. The amount of time you exercise.

One of the ways we’ve seen to increase the NAD to NADH ratio is chronic exercise. So calorie restriction is one way, chronic exercise is another way. A drug such as Metformin can increase your NAD to NADH ratio, or activating AMPK anyway.

And oxaloacetate as a nutritional supplement over the long term. So there are quite a few ways that you can use data and monitor your data to positively affect your health.

[Damien Blenkinsopp]: Alan, thank you so much for your time today. It’s been really amazing having you on the show with all of these interesting stories about these case studies about the work that you’ve been doing.

[Alan Cash]: Yes, and just as, again, as a disclaimer, we don’t want to recommend this nutritional supplement, which we manufacture, called Benagene, which you can get at www.benagene.com, for any disease.

Not to diagnose, treat, prevent, or cure any disease. It’s primarily, we developed this to keep healthy people healthy.

[Damien Blenkinsopp]: Great. And I take it myself too, so I’m kind of following in your footsteps there.

Well Alan thanks again for your time today, and I look forward to talking to you again soon.

[Alan Cash]: Alright, thank you very much.

Leave a Reply

Mitochondria, the power plants of our body, get damaged through aging and other stressors. Lipid Replacement Therapy (LRT) is a tool being used to repair part of this damage to mitochondrial membranes, and can help people recover and optimize their energy levels.

The mitochondria is often described as the “powerhouse” of the cell and it supplies the energy the body needs to function properly and efficiently.

Previously, we have discussed mitochondria as related to cancer, in episode 16 with Dr. Thomas Seyfried and in episode 3 where Dr. Terry Wahls described mitochondrial health and the link to autoimmune disorders.

This episode will focus on mitochondrial function and the symptoms we experience when our mitochondria have sustained damage from either environmental factors, natural aging, or other exposures. Often this leads to general fatigue, cognitive decline, or physical decline and the effects can be seen in patients who suffer from chronic fatigue illnesses, neurodegenerative disorders, cancer and various other diseases.

Lipid Replacement Therapy (LRT) has been shown to repair the mitochondrial membrane damage and improve symptoms for many patients suffering from these chronic diseases and other natural aging symptoms.

One of the things we’ve done with the aging process is we’ve taken people that were fatigued, 90 years old plus, we’ve improved their mitochondrial function to a 30 year old. And they’ve gained all kinds of function in the process. Mental function, physical function, you name it.
– Garth Nicolson PhD

Today’s guest is Dr. Garth Nicolson who is an extremely accomplished research scientist best known for his work with Gulf War Syndrome, and Lipid Replacement Therapy (LRT). He is the president, founder, chief scientific officer, and researcher at The Institute for Molecular Medicine in Huntington Beach, CA where he conducts most of his current research.

He was the leading authority serving the United States House of Representatives on the study of the cause, treatment and prevention of Gulf War Syndrome on suspicion of biological warfare. For his service he was conferred honorary Colonel of the US Army Special Forces and honorary US Navy SEAL.

He has published over 600 peer reviewed research papers and served on the editorial boards of 30 scientific journals. In 2003 he introduced LRT and its benefits for the first time, shedding light on the importance of mitochondrial function and repair of damaged membranes and its benefits for aging, cancer and chronic disease states.

The episode highlights, biomarkers, and links to the apps, devices and labs and everything else mentioned are below. Enjoy the show and let me know what you think in the comments!

itunes quantified body

What You’ll Learn

  • Mitochondrial function decline is the underlying problem in many chronic diseases (6:43).
  • Mitochondria are the powerhouse of the cell providing energy – like a battery – which fuels the cell’s function (7:43).
  • Oxidative damage to the lipid membrane of the mitochondria is the most universal cause of damage (8:38).
  • Damage to the lipid membrane harms the phospholipid molecules causing “leakiness” across the membrane (11:30).
  • If you don’t produce enough energy in a cell, you lose the function of that cell (13:15).
  • Damage to the energy process in a system can occur during aging, chronic illness, viral/bacterial infection, toxic exposure, etc. (13:55).
  • Some patients have restored their endocrine systems by repairing their mitochondria in some way (15:53).
  • Chronic fatigue illnesses (chronic fatigue syndrome, fibromyalgia, etc.) are directly related to loss of mitochondrial function, which is mostly true for many other diseases as well, such as cancer and neurodegenerative disorders (16:45).
  • Much of the mitochondrial function decline occurs because of the natural aging process (18:46).
  • For instance, improving the function of a 90 year old, fatigued patient greatly improves mental and physical functions for the patient (19:01).
  • Repairing the mitochondrial function for patients who have any of these diseases is not a cure-all, however it is a step in the right direction and definitely supports the overall recovery for the patient (21:21).
  • Dr. Nicolson discusses the importance of lipid replacement therapy (LRT) as a way to replace damaged membrane phospholipids to improve mitochondrial function (22:48).
  • LRT also functions to detox and repair chemically damaged cells as the lipids delivered to the system can soak any chemicals out from the membranes and remove them from the body (27:11).
  • Dr. Nicolson works with populations who have had particular exposures however everyone has been exposed to various chemicals throughout their lifetime (31:05).
  • Using both LRT and infrared saunas can speed up the long, slow process of detoxification and recovery (32:47).
  • LRT can reduce the symptoms of detoxification and recovery; for example LRT used in conjunction with chemotherapy for cancer patients helps the patient manage the side effects of the cancer treatments (34:50).
  • Patients generally see improvement of symptoms between 10 days and 3 months after the start of LRT but when therapy is removed the mitochondrial function declines again and symptoms return (36:39).
  • Mitochondrial function can be measured directly by testing the mitochondrial membranes in the white blood cells (38:38).
  • LRT is becoming more popular especially with naturopathic doctors and individual people as you do not need a prescription to obtain these natural supplements (40:37).
  • An increased dose of lipids is crucial for patients with severe chemical damage or mitochondrial damage so luckily no one has reported negative side effects yet as lipids are natural substances of the body anyways (44:37)!
  • Cholesterol markers and homocysteine levels have been shown to improve when using LRT (45:48).
  • LRT is proving to be effective as an anti-aging treatment, a therapy for various diseases processes, and as a co-treatment option for cancer patients to reduce negative side effects and fatigue related to traditional therapies (46:29).
  • LRT works well at improving energy systems however dosages, etc. do have to be optimized to work with each person’s unique system (50:26).
  • LRT is a lifelong solution and a long term treatment because we are constantly exposed to new toxins, infections, and traumas throughout our lives (52:17).
  • The minimum supplement needed for LRT is NT factor lipids. (55:32).

Garth Nicolson PhD

Tools & Tactics

Interventions

  • Lipid Replacement Therapy (LRT): Used to restore and repair mitochondria function by replacing damaged lipids in the membrane and restoring the mitochondria’s ability to produce energy for the cell. (See relevant lipid supplements below).
  • Infrared Sauna: Used to remove fat soluble toxins in particular from the body. Garth Nicolson recommends using this along side LRT to help with the removal of chemicals from the cells, which tends to improve results.

Supplements

  • NT Factor EnergyLipids: NT Factor is the lipid based supplement that is the main component used in LRT. There are a variety of products including this one, which contain NT Factor. Read more about these on NTFactor.com, as recommended for use by Dr. Nicolson.
  • NT Factor Energy Wafers: The specific NT Factor product that is “child friendly”, as the wafers easily dissolve in the mouth and do not need to be swallowed.
  • ATP Fuel: In addition to NT Factor, this supplement also contains NADH and coenzyme Q10 which also aid in the energy production cycle in a cell.

Tracking

Biomarkers

  • Cholesterol: A cholesterol panel covers a number of markers related to lipoproteins (such as HDL and LDL) in the blood. LDL and HDL are standard markers used to track cardiovascular risk. Dr. Nicolson has seen LDL drop and HDL increase with use of LRT – which typically indicates improvement and lower cardiovascular risk.
  • Homocysteine: A marker often used to assess cardiovascular risk. Higher values relate to increase cardio risk. This marker is often related to methylation SNPs like MTHFR as discussed in episode 5 with Ben Lynch. Dr. Nicolson has seen homocysteine levels drop with LRT also.
  • Mitochondrial Membrane Potential: An approach to assessing the health and functioning of a cell’s mitochondria by looking at it’s potential or voltage. In the same way as with a battery, if it is functioning, the outer membrane of mitochondria has an electric output and thus a voltage.

Lab Tests, Devices and Apps

  • Inner Mitochondrial Membrane Potential via Rhodamine 123: The status and functioning of the mitochondria are assessed via analysis of mitochondria inside white blood cells with the dye rhodamine 123 and a fluorescence microscope (see study here). The test provides a quantitative fluorescence value indicating the health of the mitochondria and integrity of the membrane. This test is not easily accessible and is used for research purposes.

Other People, Books & Resources

Organizations

Full Interview Transcript

Click Here to Read Transcript
[Damien Blenkinsopp]: Garth, thank you so much for joining us on the show.

[Garth Nicolson]: Well it’s a pleasure to be on your program.

[Damien Blenkinsopp]: To start off with, I was really interested to find out how you first started working with mitochondrial function. Where it first came up for you, and you started taking an interest in it.

[Garth Nicolson]: Well this really goes back to our work on Gulf War veterans. And from that we did work on civilians with Chronic Fatigue Syndrome, Fibromyalgia Syndrome and related fatiguing illnesses. And one of the underlying problems in all of these – and it turns out any chronic disease – is mitochondrial function. There’s just not enough energy around to provide all the necessary high energy molecules in a cell to perform all the functions necessary.

Then you get into energy deficits, and if the energy deficits are systemic, well you can have a chronic condition with lack of energy, lack of mental alertness, all kinds of other additional problems. Because basically every cell requires energy to perform. And some cells, such as the nervous system, require a lot of it – six times what most cells require – and so they’re particularly sensitive to losses in energy function.

[Damien Blenkinsopp]: It sounds like there’s a wide variety of symptoms that could be reflecting some kind of mitochondrial function damage, or interruption. Is that the case? Is it quite a wide variety of symptoms?

[Garth Nicolson]: There are a wide variety of symptoms associated with loss of mitochondrial function. And as I mentioned before, the mitochondria provide energy to your cells. In fact, almost all the energy is provided by mitochondrial function in our cells.

If you’re breathing oxygen, you’re using that oxygen to provide it to mitochondria, so they can convert it to energy, along with other molecules that they use in the process called Electron Transport System. And it’s a complicated conversion system which converts, essentially, stores that you have in your cells to high energy molecules that you need for doing a number of different functions.

Now in different clinical conditions, we find that these people have given signs and symptoms, but often they’re also related to mitochondrial function, because a lot of these problems arise when there isn’t enough energy left for cells to perform their functions necessary, and consequently this can have profound effects.

[Damien Blenkinsopp]: Right, and what kinds of damage can interfere with mitochondrial function?

[Garth Nicolson]: Well there are a variety of different types of damage. We’ve concentrated on damage to the lipid membrane of the mitochondria, because this turns out to be the most sensitive form of damage, or the most universal form of damage that we find in mitochondria. They’re particularly sensitive to oxidative damage.

And oxidative damage can occur, for example, during infection, during high performance issues, if you get run down – for example, physically, mentally, you name it – or because of infections or other damages, disease associated damages, mitochondrial function suffers. And in order to recover from all of these, you do have to have mitochondrial function available, because you can’t repair and recover without it.

[Damien Blenkinsopp]: So are we all constantly repairing the lipid membranes, as you are talking about? Is this a constant? Because when you mentioned, for instance, high performance, could that be someone like an athlete, or someone who’s heavily into fitness? Are they constantly causing this type of damage with oxidative stress, which then has to be repaired?

[Garth Nicolson]: Well, that’s true, but it’s also true during aging, for example, where our membranes normally get damaged during aging processes. And mitochondrial membranes are particularly sensitive to aging, and as we age, they get more damaged. And so if you look at a 90 year old, many of these 90 plus year old people have lost almost half their mitochondrial function.

And a lot of that is due to accumulated damage in the mitochondria, and a lot of the damage is due to the damage to the mitochondrial membrane. And the inner mitochondrial membrane is integral to our production of energy, and if that’s damaged, they become leaky, and lose function, and they can’t maintain the trans-membrane potential, the electrical potential across the inner mitochondrial membrane, which is absolutely necessary to produce high energy molecules.

[Damien Blenkinsopp]: Right, right. Well to take a step back, when you’re talking about trans-membrane, what’s the function of the membrane in terms of generating electricity? Because basically the mitochondria are a bit like our power cells, you know our batteries, which feed our cells and the rest of our body with energy. But how do they do that, and what’s the role of the membrane in that process?

[Garth Nicolson]: Well I always liken mitochondria to the little batteries inside our cells. And like any battery, it has to be insulated to selectively permit a trans-membrane potential across different membranes in our mitochondria. It’s a biological membrane instead of a synthetic membrane that we have in batteries, but it provides the same kind of insulation necessary to separate electrical charges.

And so when this separation of electrical charges occurs, you can make a battery out of it. Essentially that battery drives the production of high energy molecules in the mitochondria just as it does in a normal battery.

[Damien Blenkinsopp]: Great. And what types of damage are we talking about when we’re talking about this membrane getting damaged?

[Garth Nicolson]: Well there’s certain molecules in the membrane. It can be the phospholipids that make up the matrix of the membrane. But when they’re damaged, there can be enhanced leakiness across the membrane. So it’s like you get a leakiness if you take the insulation off a battery it will leak, and you’ll lose the charge of the battery.

The same thing in the mitochondria. If they become leaky, and the inner membrane becomes leaky, you can lose the trans-membrane potential, and then you can’t form the high energy molecules. There are also some critical lipid molecules, like cardiolipin, that are exquisitely sensitive, in fact, to oxidative damage. And when they’re damaged, this results in loss of function. So these different types of things are very important, the direct function and the trans-membrane potential.

[Damien Blenkinsopp]: So these are different types of fat molecules that we need in the membrane for it to function optimally. And it’s kind of like holes have been punched in the surface of the membrane, and molecules have been knocked out of it? Is that a way to look at it?

[Garth Nicolson]: It’s a little more subtle than that. When oxidative damage occurs, think of the lipid chains that are going into the membrane, into the hydrophobic matrix of the membrane, you can think of kinks getting in those chains after they’ve been oxidatively damaged. And those kinks mean that the lipids can’t fit together as well, and there’s a certain rate of leakiness across the membrane.

[Damien Blenkinsopp]: Great. Is this something anyone should be concerned about, in terms of the type of damage? You just referred to a 90 year old, the damage that’s gone on to them.

What kind if symptoms could someone think of if, maybe they don’t have a chronic disease like some of the ones you referred to, but are there other indicators that potentially they have some aspect of mitochondrial damage, in terms of some symptoms they could look out for which might identify that?

You were referring to, like brain fog, or other symptoms. Are there obvious ones, or is it always very different, and it’s kind of difficult to differentiate this to other things that might be going on?

[Garth Nicolson]: Well, obviously a number of different factors can cause problems with your central nervous system, for example, your peripheral nerves and other systems of your cells, but one of the things that can happen is that if the energy systems inside the cells get run down, they don’t function as well. It’s as simple as that.

So if you don’t produce enough energy in your cells, your cells can’t function as well. So all the different functions that cells do, of course the nervous system, the function is to transmit nerve impulses, if they’re not functioning properly then the nerve impulses can’t be transmitted properly. And so that leads to a loss of function.

Now this can occur when people get run down. And they can get run down for a variety of reasons. They can lose their energy stores, for example, or they can have them damaged through the mitochondrial damage that I was talking about. Some of this occurs naturally, and it’s reversed by rebuilding things like the membrane as it’s damaged.

And if there’s some process that prevents that rebuilding of the membrane, then this will persist. For example, during infection we know that a variety of different types of infections – viral, bacterial and so on – cause an increase in the what are called reactive oxygen species, or ROS. And these damage the membranes of the cell, and in particular they can damage the inner mitochondrial membrane and cause loss of function.

So these are things that can happen. So it can happen during infection, it can happen during aging, it can happen during a chronic illness. It can happen when you get run down, for example, or you have exposures of various types that are toxic. So under a variety of different conditions you can have damage done to your mitochondria, which means loss of function, and your body cannot repair itself as well without that energy that’s necessary to do it.

[Damien Blenkinsopp]: Great. And I guess an important differentiation I just wanted to point out here is a lot of people talk about adrenal fatigue, and if one of the symptoms is fatigue, basically having low energy – which I guess would be one of the outputs of mitochondrial damage – how do you differentiate it, or is it possible to differentiate it, to something which someone would diagnose as adrenal fatigue? Or how do you look at that?

[Garth Nicolson]: Well they go hand in hand, because for the adrenal gland to function, it requires energy. So if there’s an energy deficit in the adrenal gland, then that’s not producing the correct hormones and everything that your body needs. Cytokines and so on. So this sends up the deficit, and this can cause a problem. So they’re inter-related.

[Damien Blenkinsopp]: Right, right. And it sounds like you’d think mitochondrial damage might be a pre-cursor to adrenal fatigue, often.

[Garth Nicolson]: It could be a pre-cursor to adrenal fatigue. And so we’ve seen people that have managed to repair their endocrine systems by repairing their mitochondria. So at least we know, and at least in some patients, that’s reversible.

Now in other patients they may have either genetic defects, or toxic exposures, or something like that, that’s damaging specifically those particular adrenal glands. So that’s a different issue. But we do know that these things are inter-related. If you don’t have the energy, you can’t repair.

[Damien Blenkinsopp]: So you’ve worked, in your clinical studies and your patient population, you’ve worked with Gulf War illness and Chronic Fatigue Syndrome and some others. Could you give us a brief explanation, for the audience, what are the issues that these people have? How critical are they, what kind of situation are they in? Before we talk about the lipid replacement therapy and what it was able to do.

[Garth Nicolson]: Well there’s quite a bit of variation on the signs and symptoms of people with chronic illnesses, and a variety of different sorts. We started working with what are called Fatiguing illnesses, because Chronic Fatigue is the hallmark of those illnesses, and that’s directly related to mitochondrial function. So that was a good place to start.

A lot of other diseases, mitochondrial function may be thought of as a side issue; although it’s important it may not be the primary clinical manifestation of the disease process. Nonetheless, it’s still important [for] practically any chronic illness.

If you take something like a neurodegenerative disease, for example, mitochondrial function is intimately tied up with neurodegeneration. You cannot repair your nervous system if you don’t have the energy available to do it. So if mitochondrial function goes down, you’re particularly susceptible to neural damage. And to have that process going on, it can exacerbate it.

So this is one of the things that we are trying to work with, how to improve mitochondrial function, how to help people with a variety of chronic illnesses.

So we started with the fatiguing illnesses, and Gulf War Illnesses are really one of the fatiguing illnesses, but Chronic Fatigue Syndrome is another one, Fibromyalgia syndrome is another. Fibromyalgia syndrome is a little different because it’s also characterized by widespread pain, in part, we think, that’s due to mitochondrial function problems as well. The nervous system not operating properly. But there are some other factors as well.

So all these issues have as an underlying commonality loss of mitochondrial function. In a variety of different diseases, that’s true. And it’s true in infections, it’s true in toxic exposures, it’s true in a wide variety of different diseases. Cancer, you name it, practically every disease you can think of has a problem with mitochondrial function. They can’t keep up the repair process.

[Damien Blenkinsopp]: Are there other, beyond the ones we’ve already discussed, are there other types of patient populations, or other use cases you’ve looked at for lipid replacement therapy? You mentioned anti-aging as well. Have you worked with people for that area also?

[Garth Nicolson]: Exactly. Well, anti-aging is probably the normal manifestation of mitochondrial functions. I mentioned as you age you lose mitochondrial function naturally. And there’s an increase in the oxidative damage that occurs in all of our cells, so we need to reverse that process.

And so, one of the things we’ve done with the aging process is we’ve taken people that were fatigued, 90 years old plus, we’ve improved their mitochondrial function to a 30 year old. And they’ve gained all kinds of function in the process. Mental function, physical function, you name it. Every system that seems to be important improves.

[Damien Blenkinsopp]: In terms of the studies you’ve done, are these all based on studies, or is some of this based on patient population, other studies? Because I’ve seen some of your presentations, looking at your studies and work on the fatigue cases and the Gulf War Syndrome. So are all of the studies basically based on those patient populations versus the anti-aging, or have you also done studies on anti-aging also?

[Garth Nicolson]: Well we’ve done some studies where we’ve included older people in our studies, and that’s where we see the anti-aging effect. So with those older cohorts of patients – well they really are, they’re subjects, not patients, because their main problem is they’re elderly and they have fatigue issues. So we can’t categorize them as a disease process, because it’s a natural process of aging.

So they are fatigue subjects. So they have chronic fatigue, but they don’t have a disease called Chronic Fatigue syndrome, or Myalgic Encephalopathy, or something like that. They have fatigue problems. So we work with people like that as well.

We’ve also worked with cancer patients, we’ve worked with people with chemical exposures, we’ve worked with people with infections. For example, there are a wide variety of chronic infections that we work with, like Lyme disease, mycoplasma infection, so on and so forth. Were, again, in the chronic disease process, it’s always an issue. Mitochondrial function is always an issue.

[Damien Blenkinsopp]: Right. Would you say it’s going to be helpful in most situations to have some kind of lipid replacement therapy as a support for your mitochondria? In terms of the disease process, to give an idea, what kind of results do you get from people? Can you get people back to resolution? Or is this basically managing symptoms, managing the damage of mitochondria, kind of therapy?

[Garth Nicolson]: Well it depends on the situation. If we take normal, healthy people that can get run down for one reason or another, yes we can bring them completely back by repairing their mitochondrial function.

If you take people that are in a disease process, usually these processes are much more complex than just mitochondrial function. Mitochondria being one part of the problem that they have. And we can repair that part, but there are other elements that have to be taken care of as well. For example, if you take somebody with a neurodegenerative disease, does just repairing their mitochondria reverse the process? No. There’s some other elements that are involved.

Does it help? Yes, it seems to help people with cognitive loss and so on and so forth. But it doesn’t reverse it or completely cure the problem. That would be a pretty simplistic approach to these complex, multi-factorial issues. But, we do know that this is an important element in all of these processes.

[Damien Blenkinsopp]: Do you feel like it provides a support to get people to recovery? That it’s an important ingredient in your practice? You feel like it helps people to recover by giving them that mitochondria energy, thus supporting things like the immune system, and other systems of the body?

[Garth Nicolson]: Absolutely. If you’re talking about the immune system, for example, it requires energy to function. So if your energy goes down, your system might be less capable. So, it’s absolutely important there.

And it’s absolutely important for any type of recovery, because what is recovery? Generally it’s repairing our cellular processes and our system processes, our organ processes, and that requires energy. That just doesn’t happen naturally without energy.

[Damien Blenkinsopp]: Okay, so let’s get kind of concrete here, for the audience listening at home. What is lipid replacement therapy? What does that actually involve, what do people do when they’re taking lipid replacement therapy?

[Garth Nicolson]: Well this is a particular type of lipid, this is not just the normal gross lipids that people might think of. These are very particular membrane lipids, so these are lipids that make up the membranes of all our cells. And of course as I mentioned before the membrane is an integral part of the mitochondria, but they’re also an integral part of other organelles within the cell.

Membranes, in fact, are absolutely essential for the function of all of our cells. And they get damaged, they get run down, we have to replace the molecules and the membrane occasionally. And some of the most sensitive molecules are the lipid molecules, because they’re very sensitive to oxidative damage, which can occur in any disease process, infection, or whatever.

So this is something that has to be replaced. And we came up with this idea, well we need to replace the membrane lipids, which are primarily a class of lipids called glycerophospholipids, that don’t need a lot of other things. That’s what we need to help repair the, more or less the matrix of the membrane.

So if we supply that in purified form, undamaged form – which is very important – then we should be able to help repair this process, because we have natural systems in our body to replace these lipids as they’re damaged. Because we evolved with the mechanism to help repair and replenish our membranes.
The problem is we can’t keep with the damage, and that’s when the disease process can occur. So to help it along, if we provide the lipids, well we can help that process.

Now people say well, you can buy all kinds of different stuff at the store. Well, the reason it doesn’t do it is a lot of those lipids are already damaged, they’re already oxidized, they’re not the right kind of lipids, and so on. So they’re not very helpful. And even a lot of supplements that people buy in the store are not very helpful, because even if they have lipids they’re not the right kind of lipids, or they’re already damaged, or they’re damaged during the shelf-life.

These are very sensitive issues, which we’ve tried to overcome with the products that are designed to survive and provide our bodies with exactly the right lipids that we need to repair our membranes and restore function.

[Damien Blenkinsopp]: So, would it be correct to, because you provide these in pill form. So is it these are things we can get from food, but we get them in very low quantities, so it’s like having a very high dose of the reduced form? The active form versus the oxidized form of these lipids?

[Garth Nicolson]: Well that’s part of it, but a lot of the lipids are damaged already by the time we take then in in the foods, and unfortunately, our transport systems, they can’t readily acknowledge a damaged lipid from a properly pristine, undamaged lipid. And so a lot of these things might get transported in as well. Or at least they’re transported in, too much of it is transported in if it’s damaged.

So we kind of flood the system with undamaged lipids, and that helps the whole process move very smoothly. It also helps remove the damaged lipids, which is one thing we’re working on now, is how to take people who are chemically damaged – and I can talk about that later – help them remove those damaged chemicals from their bodies.

And it turns out that the replacement therapy can help do that, because it’s an energy driven process, so it helps provide energy, but it also is very dependent upon moving what we call hydrophobic molecules out of the cells. And the lipids that we provide have a very important part of their structure, a hydrophobic part of their structure, which helps remove these molecules.

So if they’re present in quite a bit of excess it can help remove these damaging chemicals from our system. And that’s one thing we’re working on right now.

[Damien Blenkinsopp]: That sounds very interesting. We’ve spoken about detoxification before. So, just to take a step back, when you say chemically damaged people, what kind of things has happened to these people?

[Garth Nicolson]: Well often people with chemical damage due to illness could be anything from herbicides, for example, to very industrial chemicals, and so on and so forth. Often damaging chemicals are chemicals that we would classify as hydrophobic chemicals. That is, they don’t like water. They like fat, essentially.

So they concentrate in our membranes, they concentrate in the fatty parts of our cells and lipid droplets, and so on. And they can remain there indefinitely. And they can bleed out very slowly and cause problems with the cellular mechanisms. So to get rid of these, we need a system to remove them.

But the system that we have for detoxification is an energy dependent system, at least one of the most important ones. So by providing mitochondrial energy, that helps in that process. But it also helps remove them because, it turns out, the lipids that we provide kind of soak up these molecules, because it will bind to the lipids and it helps them be excreted from our cells and from our system, so they naturally come out in the GI system.

[Damien Blenkinsopp]: So that sounds like the new molecules that you’re providing are basically replacing the ones which have absorbed the toxins, the chemicals, the fat soluble chemicals, and are thereby displacing them and allowing the body to remove them.

[Garth Nicolson]: Well that’s basically it, but it’s providing a different store, or different storehouse for these chemicals to move into, but a storehouse that we can eliminate. And that’s the important thing is to do that.

One of the mechanisms for moving chemicals that’s most important for these very damaging chemicals that concentrate in our cells is that there are enzymatic mechanisms, to conjugate the offending chemicals with other hydrophobic molecules within the cells, to make them more easily removable.

Well when that happens, if we have somebody’s undergoing lipid replacement therapy, there are a lot of these lipid droplets around and lipid carriers around, which could help soak these conjugated chemicals up and remove them from our systems.

So it’s a process, it’s a very slow and steady process of removal. It doesn’t, of course, happen over night, but it’s a natural system for removal of damaging offending chemicals from our bodies. And this just takes it to a maximum advantage by providing some of the things necessary for it to operate in the first place.

[Damien Blenkinsopp]: So out of interest, because we’ve spoken quite a bit about detoxification, and also the kinds of tests involved in measuring things like mercury, lead, and other toxins. Are you able to test these chemicals in fats and see the change, and how long does it take? Does it take a month, two months?

[Garth Nicolson]: Again, we’re not talking about heavy metals, because that’s a different process of removal. We’re talking about chemicals that partition themselves into the fatty portions of your cells. Well these chemicals, and they could be, for example, herbicides or any number of different chemicals.

[Garth Nicolson]: Yeah, a lot of the chemicals that damage our cells are very hydrophobic, and they partition into the fats of the cell, the fat systems and the membranes of the cell. They have to be removed or eventually they’ll interfere with the function. That removal process is slow. It does not happen over night.

So it’s a very slow process of bleeding them out and removing them from the stores, and so on and so forth. So one of the first things that you can see, for example, if you give somebody lipid replacement therapy, is you might actually see an increase in the number of these chemicals that are being excreted, that are being at least mobilized as well.

So there may be an increase in the blood levels of these, because they’re being brought out of the cells and being transported to the brush border cells in the intestines, and then secreted there. But again, there are a number of different mechanisms, this being just one of them.

[Damien Blenkinsopp]: I’m guessing this is a new area, it sounds like you’re more focused on this recently?

[Garth Nicolson]: This is a very new area of ours that we planned to get very focused on because it’s so important, so necessary to help these people, many of whom have been damaged for decades without much help at all.

[Damien Blenkinsopp]: So just out of interest, are there any specific exposures? And is it people working in factories, or is it people who have detoxification systems which aren’t functioning, or perhaps they have some methylation or other issues, which they’ve lived a pretty normal life, compared to most people. It’s not like they’ve been in any specific situation which could have exposed them to more chemicals.

What kind of populations are you dealing with here?

[Garth Nicolson]: We work with the populations that are sick in general, although a variety of different individuals may be exposed to chemicals, because they are all over the place in our modern environment. And people will have tremendous variation in their sensitivities to these chemicals.

So you may have somebody that’s been normally and naturally exposed who’s becoming sick because of it, and other people not at all. Because there’s such a range of sensitivities to these.

So we’ve worked with people who’ve had specific exposure. For example Vietnam war veterans who’ve had exposure to Agent Orange, which is a particularly nasty chemical that takes a long time to remove from the body. Or Gulf War veterans that are exposed to petrochemicals in the forms of fumes, and exhausts, and oil fires, and so on and so forth, during the first Gulf War, and some during the second Gulf War.

So these are people that have had chemical exposures above and beyond the normal types of exposures that we might see. But in the industrial environment that we’re in, there are a lot of people that get exposed to various chemicals.

If you work in the petrol-chemical industry, for example, you could be exposed fairly easily, and it may not cause any problems with you but there are other individuals who have severe problems because of it.

So again, there’s a wide range of different sensitivities to these different chemicals that are seemingly in our population.

[Damien Blenkinsopp]: Great. I just want to bring it up, because I know a lot of people talk about infrared saunas, and saunas in general when it comes to fat detoxing from the fat soluble toxins like the ones we’re talking about. So, do you have a viewpoint on that, on the effectiveness of infrared sauna? Is it something you’ve ever gotten involved with, and could you compare it to your process?

[Garth Nicolson]: We’ve looked a bit into that, and yes the use of infrared saunas to actually bring the chemicals out in your sweat, which is what it really does. But if you do these at least a minimum two times a week, you’ll slowly start to deplete some of the chemicals from your body.

What we found is if you add our lipid replacement therapy on top of that, you can accelerate the process of removing the chemicals from your body that way. So again, this can be an adjunct to a variety of very well established methods for detoxification.

[Damien Blenkinsopp]: Great. Have you seen complete recoveries, or to what degree have people recovered from their health? Because we’re talking about people that are quite sick.

[Garth Nicolson]: Well, we’re in the beginning process of this right now. So this long term goal of ours, but again, this is just the beginning, and we’re seeing some responses. We’re seeing people that are feeling better, getting better. But again, it’s a long, slow process for recovery.

And again, there may be other types of damage along the way that we discover that these individuals have. Most of these chronic illnesses are multi-factorial. There’s not just one problem, generally these people have a number of problems, this being one of them. But this is something that we can approach.

[Damien Blenkinsopp]: Absolutely. So it sounds like an on-going process of a year. We’re talking really long term, just to give people an idea.

[Garth Nicolson]: We’re talking long term. Particularly when it comes to removing offending chemicals from your body, it’s a long term process. Same thing with removal of heavy metals from your body, it’s not a short term process.

It can take years to remove heavy metals from your body, and the same thing is true with chemicals that build up in your body. It can take a long time to really get rid of them. And in fact, if you mobilize them too quickly, you can really make people feel sick in the process. So it’s better to do it naturally and slowly.

[Damien Blenkinsopp]: So, I’m glad you brought this up, because we’ve spoken about these kind of topics quite often on the podcast before. It’s nice to get that. Is there anything you have to do in terms of supporting them?

Because you mentioned that some people can get sick if it comes up too fast. Is there anything else that you do for them while you’re using the lipid replacement therapy to support detox, or as long as you go at a reasonable rate, which I imagine is a reasonable dose?

[Garth Nicolson]: What we have found is that lipid replacement therapy actually reduces the symptoms of detoxification, reduces the symptoms, for example, of cancer chemotherapy. So it is very significant in our studies with the cancer patients. They’ve showed really quite a dramatic decrease in the side effects due to chemotherapy, because it causes a lot of damage to our normal systems, and the lipid replacement therapy helps repair those normal systems.

So you get a reduction in the associate problems, very adverse events that occur during cancer therapies. So, you could figure that is, again, when you’re repairing the normal mechanisms of the cells, the tissues, and this helps the overall process.

[Damien Blenkinsopp]: Right, right. So you’re saying a lot of the symptoms people have when they’re going to a detoxification process, or, as you’re saying, chemotherapy or exposure to other toxins or when they’re ill, is due to mitochondrial damage, right?

So when you’re supporting the mitochondria with lipid replacement therapy, it helps to manage the symptoms as well in that process and reduce them, because there’s not as much damage going on.

[Garth Nicolson]: Well it does, and not only that, it helps accessory systems as well, because a lot of the signs and symptoms that we see that are associated with damage are release of chemical messengers like cytokines, that cause all kinds of problems in the body, and so on.

And damaged tissues can initiate this whole process. So if you reduce the damage, you can reduce these accessory damage response systems from exacerbating the signs and symptoms in these patients.

[Damien Blenkinsopp]: Great. One thing I wanted to kind of make clear to people, what kind of results, because when I was watching some of your clinical studies you were looking at. Over the few months you were giving lipid replacement therapy, could you talk about what kind of impacts it generally has on the people?

If we’re talking about say the chronic fatigue, or in the Gulf Syndrome cases, the ones I saw, what kind of time-lines did you walk through in your clinical studies? And also, it was interesting what happens when you stopped the therapy.

[Garth Nicolson]: This is a process that takes time. You don’t repair your mitochondria overnight. It takes days to weeks. The process can begin fairly soon after you take the lipid replacement, but it takes time to fully repair the mitochondria.

And we’ve seen, again, that it can take, depending upon the different formulations of lipids, anywhere from 10 days to three months, depending on the formulation, depending on the patient type, to reach an equilibrium of repair. And these people see a maximum benefit in that time. But they do see benefit fairly, fairly soon.

[Damien Blenkinsopp]: And then what happens when you stop the therapy? Depending on the condition. So when it’s in a chronic condition, like Chronic Fatigue Syndrome, or Gulf Syndrome, where they have some kind of infection or some underlying cause, then what happens when you stop the therapy?

[Garth Nicolson]: Well then it slowly returns back. As the mitochondria get damaged again, it will slowly go back to the way it was before you started the therapy. And one of the trials that we did was called a cross-over trial, where we take patients, and they’re on part placebo and part the lipid replacement therapy, but they don’t know when they get it.

And what we found was when they get the lipid replacement therapy, they improved. They had reductions in fatigue with 35 to 45%, enhancement of mitochondrial function was a little bit less than that in terms of percentage, but very significant. But when we switched them to placebo, it slowly started to go back again.

[Damien Blenkinsopp]: Yeah.

[Garth Nicolson]: And they wondered what was going on, because it wasn’t having the same effect. So we could prove that it was in fact the lipid replacement therapy that was giving them the benefit, not a placebo effect.

[Damien Blenkinsopp]: Great, thank you very much for that. And so, what were you using to assess mitochondrial function in terms of tests?

[Garth Nicolson]: Well what we do is we take a blood sample from patients, we isolate the white blood cells which have mitochondria – the red blood cells do not have mitochondria – and we can measure the mitochondrial function directly.

And what we’ve done actually, more recently, is we’ve measured the membrane potential of the inner mitochondrial membrane using a special redox dye, called rhodamine 123, and see that fluorescent dye in the mitochondria. If the mitochondria are fully functioning, they will reduce that dye and it will fluoresce.

And if they’re not functioning, they can’t reduce it, and the mitochondria won’t fluoresce. So you can see it visually in a microscope and you can quantitate the fluorescence so we can get a quantitative value.

[Damien Blenkinsopp]: Great, great. So this is your own lab tests that you developed for this purpose?

[Garth Nicolson]: Well other people really developed the tests, we just adapted it to what we were doing.

[Damien Blenkinsopp]: Great. Well I guess what I wanted to say is it’s a pretty unique [test], like we wouldn’t expect to find it outside of research, apart from potentially your practice, and some other specific areas.

[Garth Nicolson]: This is a very specific research type of test, and you won’t find it in your normal doctors office, that’s for sure. Because it requires some complicated machinery, like a cell sorter and fluorescent tools, fluorescent light sources, and so on and so forth. So, it’s a bit complicated, but it works in a research environment.

[Damien Blenkinsopp]: So it’s not something you use on your patient population, I guess it’s cost prohibitive. It sounds like quite complex.

[Garth Nicolson]: Well it is, and speed is very important. So you have to have a very fresh sample. Often if you’re not doing the test immediately or soon, you could get variable results. So to get the best results, speed is very important. So, generally you have to have this complicated equipment on hand to do it. And the technical expertise to do it.

[Damien Blenkinsopp]: So, how well accepted is lipid replacement therapy? We’ve spoken with functional medicine doctors here, and we’ve looked at functional medicine quite a bit, contemporary medicine is there of course also, and in the research studies.

Is there a lot of support for it right now, or is it still something quite niche that basically there’s not very many people using?

[Garth Nicolson]: Well more and more are using it, because more and more people are finding out about it. And we published some 28 papers on this process. So, it’s well-known in the literature. We published a number of reviews on it now.

Less known in the general population of physicians, more in the naturopathic medicine areas, mainly because I get around and talk to these people, and then they get informed that way, through conferences and so on. So it’s becoming more and more well-known, and even people outside the medical area will find out about it through broadcasts like yours, for example.

They can buy this stuff over the counter, it’s not something they need their physician’s prescription for. These are natural supplements. It’s the lipids that are in our membranes all along. So, it’s not a drug, it’s not anything but what’s there. We just have to provide it in a way that’s not damaged.

[Damien Blenkinsopp]: Well so I’ve got to ask you the question, are you using lipid replacement therapy yourself?

[Garth Nicolson]: Absolutely.

[Damien Blenkinsopp]: Okay. How long have you been using it?

[Garth Nicolson]: Well, I’ve been using it for years now. It was very effective for me in terms of reduction of fatigue. And for example, recently I got an influenza virus, unfortunately. It kind of knocked me down, and this helped the repair process. I recovered much more quickly than normal, and so I think it’s very useful for that.

[Damien Blenkinsopp]: What kind of dose are you taking? Let’s talk about practicals here. Because I’m taking ATP Fuel, for example, because I’ve had my own issues and it was recommended to me. And your research was recommended to me, so that’s kind of where I came into it.

So I’ve been taking that for a while, the ATP Fuel. And you have the NT Factor, which is a part of that. Is that actually your company who supplies that, or is that another company?

[Garth Nicolson]: I’m in a non-profit organization. We’re not really a company, but we do consult with companies like Researched Nutritionals that makes the ATP Fuel, [and] Nutritional Therapeutics in New York which makes the NT Factor, the lipids.

In fact, the Researched Nutritionals uses the NT factor product in their own product. They add some other things as well. So, ATP Fuel is an excellent product for these chemical exposure patients. In fact, I’ve just been going back and forth with the President of Research Nutritionals because we need to increase the amount of NT Factor, which is the lipids, to that product to really help these individuals.

So what we found is that more of the NT Factor is actually better. You might want to supplement your ATP Fuel with some NT Factor Lipid Wafers. By the way this is an excellent product.

We use these with children, for example, that have autism spectrum disorders, and these children have mitochondrial function problems. They readily take these wafers, and they don’t take pills. You can’t get them to take a pill.

[Damien Blenkinsopp]: Right, right.

[Garth Nicolson]: But these wafers are very tasty, and they’re creamy, they melt in your mouth because they’re lipids. So they like these creamy things, and so we have no problem with the compliance, even with difficult cases like these autistic children.

These are things that we work with on a daily basis, and we’re trying to improve our products as we go. Recently we found that although ATP Fuel is a really good product, I’m saying for the chemically exposed individuals that we need to increase the amount of NT Factor with the lipids in that product.

[Damien Blenkinsopp]: So just for the audience, the ATP Fuel has co-enzyme 10 and NADH added to it. Obviously, say that the dose of the lipids, which you say is the most important, this is kind of the innovation here, the lipid replacement therapy.

[Garth Nicolson]: That seems to be the most important thing because if you leave that out, it’s not very effective. If you put it in, it’s very effective. So it is a combination, but it’s a critical part of that combination.

[Damien Blenkinsopp]: Let’s just talk downsides here. Are there any downsides you know to this, and are there any safety issues? I just want to make that clear in terms of, maybe if you overdose it. You’re talking about increasing a dose for chemically exposed people. Is there any downside or risk to taking a lot of this?

[Garth Nicolson]: We’ve never seen any safety issues with the NT Factor lipids. As a matter of fact, we’ve given approximately 40,000,000 doses of this to patients without any recorded evidence of a real side effect.

And the reason for that is these are natural molecules that are in our cells and our systems all along. So we’re not giving our systems anything that’s different. We’re not giving them a drug, we’re not giving them something that they don’t see all the time anyway. I don’t know that it has any toxicity.

There are some studies that had been done in animals, where they’ve been given tremendous doses, without any effect at all. And we’ve had patients that have been on, oh, up to several grams per day of the NT Factor lipids without any [negative], as a matter of fact more positive effects. Their blood lipids had more normalized, they’ve had a lot of really positive things happen to them.

[Damien Blenkinsopp]: So that’s interesting. What kind of quantitative changes have you seen in terms of, are you talking about cholesterol markers?

[Garth Nicolson]: Yes.

[Damien Blenkinsopp]: Have those changed as well?

[Garth Nicolson]: Cholesterol markers and bad and good lipids. For example, lipoproteins, we’ve seen a move in the right direction. We’ve seen reductions in a product that’s associated with Heart Disease, homocysteine.

We’ve seen in elderly patients a reduction over time in homocysteine levels, which are directly related to coronary, artery disease and heart attack. So these are some of the beneficial things that we’ve seen in patients taking this long term.

[Damien Blenkinsopp]: Great, great, thank you for that. So, are there things that you’re looking for in the next five or ten years, where you think there’s going to be some more changes or innovation? Or is there anything you’re kind of excited about the opportunity of this, to help more people or to improve it?

[Garth Nicolson]: Well we’re doing an anti-aging study right now, which I’m very excited about. It’s actually going on in Uruguay. A colleague of mine who is there is a specialist on sperm function, and he takes care of men with fertility problems. But as we age, our sperm function declines, and that’s what I’m interested in as a test model for anti-aging.

So far what we’ve seen is that even in vitro, if you take sperm they have a certain lifetime. So if you take older men they have less of a lifetime, that is they can be for a while, but then they start losing motility more rapidly than younger men. But if we put in the NT Factor in it, we can help restore the function of the sperm even from older men.

So the next step is that we’re going to go from these in vitro experiments, which are very interesting, sperm motility, to in vivo experiments where we look at actual men with fertility problems that have functional problems with their sperm motility, and see if we can help repair that process.

But in terms of it’s anti-aging, which is what I’m really looking for, long range, this is an interesting model to look at. So whenever we have systems that undergo slow degeneration, like sperm function over time, if we can reverse that process, that means that we’re having an anti-aging effect, and it’s very clear, it’s very specific, and very quantitative effect. And so that’s one of the systems that we’re looking at, and I’m very excited about.

And we also have a number of different diseases processes that we’re very interested in, and we’re trying to intervene and see if we can help. Neurodegenerative diseases is one thing I’m very interested in. That’s obviously a very long term and slow process to eventually recruit patients in that area.

Another thing is reducing the adverse effects of cancer in cancer therapy. So there are two aspects of this. If some person has cancer, often they have what’s known as cancer associated fatigue, in the absence of any therapy. And of course the NT Factor will help patients with that.

We’ve seen a 30% reduction in that fatigue with patients with long-term cancer, that have had cancer associated fatigue. But it’s really reducing the side effects of cancer therapy that is most interesting, because we’ve seen reductions in side effects to chemotherapy that are really dramatic. So there’s reductions, for example, not only in fatigue but in vomiting, and malaise, and a number of other side effects – headaches, for example, and so on – associated with chemotherapy.

I think the reason for that is we’re helping repair the normal systems very rapidly in these patients after their burst of chemotherapy. So you might ask, well does this interfere with the therapy? And the answer is no, because it turns out there’s a window of therapy which is very short for the cancer, but it’s very long for the normal systems.

So these chemotherapeutic drugs attack the cancer very quickly, but then they have lingering effects on our normal systems for months, literally, after the therapy is over. So, what this does is the NT Factor helps reverse that process of damage after the therapy.

[Damien Blenkinsopp]: It sounds like you’re saying that there’s no risk of them providing a protective effect to the cancer cells themselves, provided that you introduce a timing?

[Garth Nicolson]: Well what we do is we put it in after the therapy. Because we know the damage to the cancer cells occurs very quickly. Generally, within hours after the therapy is administered. Whereas the damage to the normal systems occurs for weeks, or even months later. So we allow the therapy to occur and then next day, the following day, we start the lipid replacement to help repair the normal systems.

[Damien Blenkinsopp]: This is really interesting work. You must be really excited about all of these projects you’ve been working on.

[Garth Nicolson]: There’s something new every day!

[Damien Blenkinsopp]: And luckily you have lipid replacement therapy to keep your energy up, so you can keep focused on them all.

[Garth Nicolson]: Well I’m taking it, and so far it’s been a real help. I know that personally. But every individual will have to see what’s optimal for them. Some people will find they have to take a bit more of the lipid replacement than other people, and that may have to do with their transport systems that bring these lipids into their bodies and cells, and everybody’s different in that regard as well.

So, the same thing with detoxification. We have systems in place to help detoxify us, but it’s working so poorly for most people, or their systems are swamped out with these dangerous chemicals and they can’t keep up with the damage, and so this helps accelerate the removal of chemicals.

And also, we know that’s an energy dependent process. So it helps rebuild the energy systems that are necessary for detoxification. Because detoxification just doesn’t occur naturally, it requires energy.

So if you don’t have the cellular energy necessary, you can give them all kinds of different things, and you’re not going to see much improvement, or at least you could see much better improvement if you repair their energy systems at the same time. So I think for any detoxification, mitochondrial repair is really important, because it really helps accelerate the detoxification process.

[Damien Blenkinsopp]: Great, great, thank you. There is a cost side of this kind of therapy.

So, in terms of monitoring, how do you assess whether someone should remain on the treatment? Is it purely based on symptoms resolution, or whatever they’re trying to achieve, or do you have any markers? You brought up the homocysteine, for example. So if they had raised homocysteine and it leveled out, you could say, okay now I can take you off the therapy, because you’ve got to that critical [point].

[Garth Nicolson]: Well, actually, here’s the problem that we have in the modern environment. We don’t stop people from being exposed. We don’t stop people from getting sick, we don’t stop people from getting into automobile accidents, or whatever. We can’t do that, but what we can help them do is repair once it occurs.

We can help repair and accelerate the healing process due to trauma. We can help the healing process due to infection. We can help the process due to long term treatment of a chronic condition. All of that means that this is a long term solution, not a quick fix. And that’s why I’m taking this for the rest of my life.

And I put my father on it when he was 92, and he had much better cognition, he had less fatigue issues, and was more ambulatory, and clearer thinking, and so on and so forth. And he lived another eight or nine years. He was a coronary patient and he was on his last legs when he started.

So I think it’s never too soon. Just like it’s never too soon to stop smoking, it’s never too soon to start taking lipid replacement therapy. And yes, you may have to take it for the rest of your life if you want the benefit.

[Damien Blenkinsopp]: Well, I think I’m certainly going to stay on it. And I’m very glad to have you on the show to spread the information about this. It’s been very useful to me.

In terms of other people who, besides yourself, you would recommend to talk to about mitochondria, or lipid replacement therapy. Is there anyone else who’s done work which you would reference which is interesting, that have done a lot of work in this area?

[Garth Nicolson]: People can go to our publications, because they can see what we’ve cited in terms of the references, and the groups, and so on. Yes, there are other people working on different aspects of it. For example, there are some groups in Europe that are using intravenous lipids – similar type but not the same – and they’re getting very good results with that.

We prefer the oral supplements because obviously you can’t go in every day for an intravenous lipid replacement therapy. So, we prefer people take it orally, because we know we have the mechanism in our brush border cells lining our guts to bring these lipids in naturally, because they’re essential lipids. So, this is a very natural process that we’re supplementing, essentially.

And I think people need to find out about this. The ATP Fuel that you mentioned is primarily available through physicians and naturopaths, and professional health people, but there are also a lot of people out there maybe listening that want to know where can I get this stuff on my own.

And there’s a website called NTFactor.com, where they can buy all these products over the counter, because they’re just natural supplements. And so, that’s where they can go, NTfactor.com to find these lipids replacement therapy products, and find out more about it. And they can go to our website, the Institute for Molecular Medicine, which is www.immed.org. It’s like a media .org, and they can see the scientific results and the clinical trials.

[Damien Blenkinsopp]: Great, thank you so much. We’re going to put all of this in the show notes so people have all the references to everything we’ve spoken about today. Would you recommend they take the straight version of NT Factor? Because there’s these different combinations of things.

[Garth Nicolson]: Well it depends on what people want to do, and it also depends in a lot of cases on what people could afford if they’re buying supplements and stuff. The minimum thing they need is the NT Factor lipids.

Now, the more complex formulations like the one you’re taking cost more because they have a lot of other ingredients that are very costly. But if they want the initial punch, they need to take at a minimum the NT Factor lipids.

[Damien Blenkinsopp]: I see, that sounds like the big lever.

So Garth, thank you so much for your time today. Just on a personal note, are there any data metrics that you track for yourself? Either on a routine basis or a once yearly basis for your health, longevity, or performance?

[Garth Nicolson]: Well of course we look routinely at membrane lipids, for example, in our blood. We look at things like homocysteine and so on – and my levels are very low. I find that I feel better on NT Factor and, by the way, I have gone on a trip recently and I forgot to take it along, and I suffered because of it.

[Damien Blenkinsopp]: Oh no.

[Garth Nicolson ]: I feel very strongly about taking it on a daily basis. So I’ve seen it in myself. I mean I know that I can recover much faster from travel associated problems, for example, from illnesses and so on and so forth if I take the NT Factor.

And that’s what other people reported back to us as well, it’s not just my own personal results. We get a lot of feedback from a lot of people who are taking this, and now tens of millions of doses have been given to patients and subjects and so on, in various forms, and so far we haven’t had any complaints. And that’s a good news.

[Damien Blenkinsopp]: Its great news, it’s amazing news. Thank you very much for your time today, Garth. Its been great to have you on the show.

[Garth Nicolson]: Sure. Thanks for having me.

Leave a Reply

Have you been using Dual-N-Back or other braining tools? A look at failed brain training experiments and how to assess real mental performance improvement with Dr. Adrian Owen.

In today’s fast paced, technologically advanced world strong mental performance is of utmost importance. From our abilities in the work place to our interactions in social situations we are expected, and constantly asked, to be able to perform with the highest level of mental function. Therefore, it is important that we both protect and improve our minds in order to get the most out of life and increase our overall satisfaction.

In the last few years, brain training apps, such as Lumosity and Dual-N-Back, have become increasingly popular as a way to improve cognitive performance and working memory abilities over time.

However, there is a bit of controversy surrounding the use of these apps:

Does brain training improve mental performance?

This episode addresses this question and more as we discuss some of the research that has been conducted to try and assess our mental performance. Whether it is brain training, diet changes or just sleeping better, these tools might help us decide if we are actually getting the bang for our buck so we can make a positive impact on our lives and mental performance.

Just because a lot of people believe in it and are sure that it is true, if it hasn’t been scientifically proven, then it’s very likely not the case…I think that the commercial brain training is a very good example of that
– Dr. Adrian Owen

Today’s guest is Dr. Adrian Owen who has looked specifically at the effectiveness of brain training on a broad population to see if it is actually having an impact on our mental capabilities. Currently, he works as the Canada Excellence Research Chair in cognitive neuroscience and imaging at the Brain and Mind Institute, University of Western Ontario, Canada. Previously, he worked at the Cognition and Brain Sciences Unit at Cambridge, UK and has published more than 200 peer-reviewed scientific papers over time.

The episode highlights, biomarkers, and links to the apps, devices and labs and everything else mentioned are below. Enjoy the show and let me know what you think in the comments!

itunes quantified body

What You’ll Learn

  • The Cambridge Brain Sciences was set up to research and assess brain training tools (06:59).
  • Previously, brain function was researched by testing brain damaged participants (10:30).
  • In the 1990’s brain imaging techniques (PET scans and fMRIs) became important tools for brain assessment (11:40).
  • Dr. Owen explains further the definitions of fluid intelligence and crystalised intelligence (17:56).
  • Research using these brain training tasks, games, exercises, etc. usually focuses on fluid intelligence (20:22).
  • Dr. Owen describes further the brain-based tests used by Cambridge Brain Sciences (20:52).
  • Damien and Dr. Owen discuss the use of these cognitive tests to assess your own brain performance on a regular basis (22:43).
  • Cambridge Brain Sciences is hoping to encourage people to use their tools to assess whether brain training and interventions (such as coffee, etc.) can affect their own cognitive performance (25:12).
  • If you are going to run your own “experiments” to test the training or interventions, be your own scientist and carefully employ “good” research techniques (26:16).
  • Remember, what works for you may not always work for another (27:24).
  • Dr. Owen begins discussing “transfer” of training: to improve upon many aspects, not just the one (29:06).
  • The Cambridge Brain Sciences study also compared the lifestyles of the participants as related to their performance on the different tests analyzed in the study (36:18).
  • Damien and Dr. Owen discuss the damage that occurs to the brain from aging, injury, etc. and the fact that these cognitive declines are specific to each individual person (41:07).
  • Neuroplasticity is defined and discussed as a “change in the brain” following the learning process (45:04).
  • Dr. Owen discusses the use of EEG, a cheaper alternative, to analyze aspects such as consciousness that have previously been assessed with an fMRI, a more expensive machine (51:51).
  • Dr. Owen shares his thoughts for the future of cognitive performance including brain training and a short description of neuroenhancers, often called “smart drugs” (55:00).
  • Dr. Adrian Owen’s one biggest recommendation on using body data to improve your health, longevity and performance (1:00:10).

Thank Dr. Adrian Owen on Twitter for this interview.
Click Here to let him know you enjoyed the show!

Dr. Adrian Owen

Tracking

Biomarkers

  • Electrical activity: is assessed by electroencephalogram (EEG). When enough concurrent electrical activity is generated by neurons firing, simple periodic waveforms are distinguishable. Rhythms generated by electrical activity are measured by their frequency and amplitude. Frequency is expressed in the unit Hertz (Hz) while amplitude is recorded in microvolts (μV).

Labs and Tests

Tools & Tactics

Interventions

  • Brain Training: This episode is all about evaluating the effects of brain training, and more specifically the daily effects that may occur after the use of cognitive games. There is an incredible variety of these types of exercises available, produced by a number of companies and organizations.

Other People, Books & Resources

People

  • Jessica Richman: Dr. Richman studies citizen science and crowd sourcing. She did a podcast about the microbiome and crowd science with The Quantified Body which can be found here.
  • Aubrey de Grey: A scientist, author, and activist who was featured on a recent episode on The Quantified Body where he discussed longevity and anti-aging techniques.
  • Randy Engle: A research scientist known for his work with brain training.
  • Barbara Sahakian: Dr. Sahakian is a researcher who studies “smart drugs” and neuroenhancers.

Other

Full Interview Transcript

Click Here to Read Transcript

[Damien Blenkinsopp]: Adrian, thanks so much for joining us on the show.

[Dr. Adrian Owen]: Thanks for having me.

[Damien Blenkinsopp]: Excellent. How did you yourself get into this whole of area cognitive science—assessing performance, Brain Training and all these areas? What was the thing that first stimulated you to get interested in this area?

[Dr. Adrian Owen]: Actually I’ve been interested in cognitive assessments since my PhD. Back in the late 80’s, I was working on assessing frontal lobe function. In those days, it was pre-brain imaging; we just used to test patients who’d had part of their brain removed and then designed cognitive tests to try and work out what it is that they couldn’t do, so I’ve been in the area of assessing cognition for 25 years now.

The move into Brain Training actually came much more recently, in about 2009, I got very interested in the amount of attention that was being paid by the general public to whether Brain Training could make you smarter and I got in involved with a study with the BBC to test that.

[Damien Blenkinsopp]: Well, give us a quick overview of that so that everyone can hear about it because it was quite a big project at the time.

[Dr. Adrian Owen]: It was. It started because the BBC came to me and said, “Well we want to do a programme, we’d like to do a huge study to promote public understanding of science. Could we get a lot of people involved in this, and obviously Brain Training works, right?” I stuttered, “Well hold on, stop. What do you mean ‘Obviously Brain Training works’? Let’s talk about that,” and they said, “Well, this company or that company have sold a 100,000,000 units this year, the whole world is training their brains,” and I said, “Well, is the whole world getting smarter?” I was very intrigued by this idea because I thought it’s funny, out there in the world we’ve got perhaps one of the largest public science experiments running right now—at the time I was living in London, England, and there were people sitting on trains with their handheld devices all training their brains and I thought, “Well, I haven’t seen any evidence that any of them are getting any smarter,” and certainly looking around among my friends, it wasn’t the case that those who were super smart would say, “Well, it’s because I’ve been using this device.” So I thought, “Well there is something interesting in there that a lot of people believe it and trusted in it and it would be a fun thing to try and test.”

So we set up a BBC programme called Bang Goes the Theory. We advertised this as a way of assessing whether Brain Training worked. We got people to log into a specific website that we’d set up; the website had a lot of training games on it.

[Damien Blenkinsopp]: So is this the current website that is up today or is it different to the Cambridge Brain Sciences website?

[Dr. Adrian Owen]: That is actually entirely different but did feature in that study. What we use Cambridge Brain Sciences for, was to assess whether the training had worked because we wanted something truly independent to look at pre-imposed testing scores. Cambridge Brain Sciences is not a training site; it’s a cognitive assessment site that I’ve set up with one of my colleagues out of Hampshire. We got everybody to log into Cambridge Brain Sciences to get a sense of their cognitive performance before they started training and then everybody would log into one of the BBC sites.

I split them into three groups, basically. There was a group who trained specifically on reasoning tests, things to improve your ability to reason and think through the solutions to problems. Another group, a second group, which were randomly assigned obviously, would log in and do memory tests and attention tasks, things that emphasised other aspects of cognition that weren’t necessarily problem solving and reasoning. The third group, basically, just had to do a simple exercise that involved using a computer for about the same amount of time. They would look up the answers to complicated questions on the web and that was just to make sure that the control group used the computer for the same period of time over the six-week training period. We had people log in several times a week for at least ten minutes per session for six weeks, and a lot of people took the challenge. We had tens of thousands of people logged in; only about eleven and a half thousand people survived, did the distance, did the pre-testing and the six weeks of training and the post-testing, but nevertheless, twelve thousand was a fantastic result and an enormous uptake.

[Damien Blenkinsopp]: So we have discussed a bit previously on this show about crowd sourcing of science, like crowd science and citizen science, so this is basically like an early example of you leveraging the crowd to get some science done and some validation.

[Dr. Adrian Owen]: It was great. Actually it was a lot easier than I thought it would be. We’ve used the same method subsequently to connect a number of scientific studies. The secret I think really is if you can engage people in something that they are actually interested in, and clearly there was a lot of public interest in Brain Training and whether it worked. Having the BBC, obviously, was enormously helpful because it was a popular science programme and they used it as a vehicle to promote this, but I think it’s great if you get people interested and they feel like they are part of something and they’re helping to answer a question.

[Damien Blenkinsopp]: We had Jessica Richman—I don’t know if you know her work? She is really into citizen science and crowd sourcing of science. She gets up in presentations and talks about that. A new biomes project looking at the microbiome: they are getting lots of data from lots of different people around the world and feeding into that to try and start understanding the microbiome.

We discussed it and seems like it’s going to be an exciting time for crowd science. It’s already started; it’s the internet; it’s also that people, as you said, are interested in these things now—whether it comes to cognitive performance, which is a big thing when it comes to everything in our lives; if you think about it, it’s your work, your relationships, everything.

Just to take a step back, how would you look at our brains and what areas would you split it into in terms of performance? It’s also been a little while since you did that study, what do you see as the important aspects of performance for us cognitively in our lives?

[Dr. Adrian Owen]: I think that’s a really great question and actually, it speaks to a much bigger question about how psychology and brain science have evolved over the last fifty years. When I started working in this area, doing my PhD, 25 years ago, we didn’t have any direct ways of accessing brain function. We would basically assess behaviour, and as a consequence, we had many so-called cognitive models that were based on things that we all think we can do. We know that we can remember stuff, so we would have memory models; we know that we can attend to different things and some of us can attend to multiple things at the same time, so we would have models of attention. The only way we had of actually testing these models in terms of the brain, was to assess patients who had damage to one or more of the modules that were assumed to be involved in these models. So we would test brain damaged subjects, participants who had had tumours removed from their brains, for example, and a bit of healthy tissue had gone at the same time and we could try and work out whether the model really worked. Looking back, it’s a rather awkward way of investigating brain function because you are continually looking at people who are impaired in order to try and work out how the rest of us actually work.

In the late 1990’s, brain imaging really took off. In the beginning it was a technique known as positron emission tomography, or PET, and that soon gave way to FMRI or Functional Magnetic Resonance Imagining, which has absolutely exploded and is really the tool of choice for many now-called cognitive neuroscientists. Many psychologists now think of themselves as being what we call cognitive neuroscientists because they take brain-based models on board as well as cognitive models.

Brain imagining has allowed us to access the brain in a different type of way, which is principally to look at the brains of healthy participants. So now, instead of trying to work out how healthy brains work based on how unhealthy brains work, we can actually look at healthy brains doing their thing, and what this has done has changed, in many ways, how we think about behaviour and how we think about cognitive functions. Certainly, in my lab, a guiding rule has really been, “Well, let’s only really start to stress about this or fret about this if this is biologically plausible.” Even if there are things that we feel that we have in life and we can achieve in life, if it’s not something that by looking at the brain you could see how that could be accomplished, then my first guess is usually that we are barking up the wrong tree.

[Damien Blenkinsopp]: Could you give an example just to clarify that? It seems like something a little bit harder to visualise.

[Dr. Adrian Owen]: Well, unfortunately most of the examples I would give you would be things that I don’t work on and I don’t work on them because they are good examples of this. I suppose an illustration of the sorts of thing I’m talking about is that there are many things that people have attempted to look at with brain imaging that I think probably are not easily explained in terms of networks within the brain, like how we fall in love or why we trust each other or where do we get a sense of justice from, these big, squishy, emotional things that are not easily reduced down into measurable components within the brain. Whereas memory, how is it that we lay down memories for words or how is it that we acquire language, or how is that that I can attend to two things at the same time, these are things that are much more easily thought about in terms of what we know about the structure of the brain and networks within the brain. Not everybody agrees with me: there are certainly a lot of people out there that think we are going to solve the riddles of love by using brain imaging, but that’s not the way I work.

So, this is a very long-winded answer to your original question, but it’s just to really tell you about how we tend to think about cognition now, and it’s almost a bottom-up approach, we use the brain: we use the brain; we look at the brain and we say, “Let’s look at different areas within the brain and try and work out what they are doing,” rather than trying to explain what it is we are able to do in the world in terms of areas of the brain. That is an interesting approach because it turns out that the brain isn’t really organised how we imagined it would be organised. There isn’t a bit of the brain that lays down your memories, so spending a lot of time looking for that area of the brain isn’t a very rewarding thing to do. There are certainly many areas of the brain that are involved in laying down memories, and they work together as a network, and they play really quite different roles and some of those roles are overlapping. As you have probably guessed, it’s really complicated.

[Damien Blenkinsopp]: It’s a lot more complicated than some of the jargon we have learnt. When we think about cognitive performance and the standardised testing and also some of the apps like Dual N-Back, which was the brain training app that we’ll come back to which was supposed to increase working memory and so on. So we have things like working memory, fluid intelligence versus crystalised intelligence; for you, do those things still exist today? Are they still effective ways of explaining our performance in the real world—Whether it’s work or whether it’s problem solving?

This world is getting more and more complex and faster and faster and, obviously, some people are pushing the edge, some people are taking new tropics or they are trying to do all sorts of things to stay on top of where they are in performance, in their jobs, and everything. Are these still terms that we can think about or is it moving away from that? Because we’ve taken the lid off the brain and we realise that it is much more complex that we thought and we can’t really reduce it to these ideas anymore.

[Dr. Adrian Owen]: The answer is yes and no. To take your question backwards, we definitely can’t reduce the brain in terms of those ideas anymore. I don’t think that thinking about the brain in terms of fluid intelligence is a very sensible way to go about it.

We actually had our most recent large-scale study, which we published in a journal called Neuron at the end of 2012, that involved 44,000 members of the public, and there we specifically addressed this question. We got everybody to do a fairly large number of cognitive tests online and then we tried to look at whether we could estimate people’s fluid intelligence, or IQ as it’s often referred to, using these different, specific cognitive tests. It turns out that you cannot explain the variance; you cannot actually explain everybody’s performance in terms of a single factor. Whichever way we cut up the data, there was no way of explaining or reducing people’s data to a single factor, say an IQ factor or fluid intelligence factor. It turns out that there are at least three different components in performance, I’m sure it’s not just three but there are at least three.

That paper was really designed to take a swipe at the community who are still looking for evidence of fluid intelligence or IQ in the brain, because we accompanied it with a brain imaging study that produced exactly the same results. It said that if there is something like IQ, there is a way of comparing one person to another person in terms of a single measure then we should be able to find evidence of it in the brain somewhere, but actually we weren’t able to do that.

[Damien Blenkinsopp]: So it’s really the dynamic relationship between different parts of the brain, so just focusing on developing and aspect—if we can actually do that—is potentially erroneous.

I just wanted to make sure that people at home understood the difference between fluid intelligence, IQ and crystallized intelligence and how it relates to their lives. Can you just give a quick overview of what that means when people are talking about that?

[Dr. Adrian Owen]: I’m certainly not an IQ expert and I think maybe the best way to think about this is that these are measures that are out there in the world that clearly measure something, but they measure something in the same way as having a driving test measures something: you take a driving test and you pass or you fail, but you probably get a score on it as well. That score means something but it doesn’t tell you everything about somebody’s ability to drive. If I got a 94 and you got a 96, how much would that really tell us about the likelihood of you causing a collision on the road or me causing a collision? That doesn’t mean it’s useless having a driving test; it’s a measure that we have constructed to measure something out there in the world that, an aspect of people’s abilities, and we use it for a purpose, which is to determine whether people should be allowed out on the road in a dangerous vehicle or not. IQ is a little bit like that. It is a measure that has been around for many years. It’s often divided into two components: crystallized intelligence and fluid intelligence. Crystallized is really the stuff that you’ve learnt, the stuff that you have acquired since your childhood, stuff you know.

[Damien Blenkinsopp]: So is it that the harder you studied the more you tend to have?

[Dr. Adrian Owen]: Well, that may be true; it may be that the more of it you had to start with the harder you study, I don’t know. But fluid intelligence is more related to problem solving, reasoning, our ability to work through problems, plan for the future; that is assumed to be something that is not necessarily as related to what we have learnt and the knowledge that we have acquired over time, but it’s—I’m going to choose my words very carefully here—something that many people think of being an innate ability that some people have a very high fluid intelligence, an ability to reason their way out of problems, and other people have a rather lower fluid intelligence.

The whole concept of IQ is often divided into those two things. I think for obvious reasons, most people are more interested in fluid intelligence than they are in crystallized intelligence because fluid intelligence gets wrapped up in arguments about genetics and whether one person is better than another person. It’s not just because they have had more education, it’s because they’re somehow inherently smarter. All these arguments about brain training and smartness and how intelligent you are, are actually usually referring to some measure of fluid intelligence, rather than crystallized intelligence.

[Damien Blenkinsopp]: That is the thing people tend to work on. These brain training aspects are trying to change that because we already know that crystallized intelligence can be changed.

[Dr. Adrian Owen]: Exactly, you can learn more stuff.

[Damien Blenkinsopp]: Yes, exactly. So to look at what you did at Cambridge Brain Sciences, what were you actually looking at in terms of assessing people there? Was it relating to these concepts we have been talking about?

[Dr. Adrian Owen]: You mean the study with the 44,000 people?

[Damien Blenkinsopp]: Yes, what is the assessment that Cambridge Brain Sciences does when you take that test or when they did it?

[Dr. Adrian Owen]: I think what’s interesting about Cambridge Brain Sciences, and is perhaps a little bit different to many other online testing studies, is that, basically, it’s brain based. These are all tests that we’ve either devised or have been based on tests that other neuroscientists have devised to assess specific brain functions; these aren’t tests that are set up to assess a cognitive ability. We don’t have a memory suite thats designed to test your memory; we have essentially groups of tests that are assigned to assess specific brain functions. Most of these tests now have a 25-year history of being used in my lab and in other labs around the world. A lot of them were based on patient studies that we did in the late 80s and early 90s, or on non-human studies that other neuroscientists have conducted to look at how the brains of monkeys perhaps compare with the brains of humans. So all of these tests have been used in many neuroscientific studies, so they are genuine scientific tools, if you like. We’ve dressed them up slightly to make them a little bit more appealing to the person in the street, but basically, what they are testing is something that addresses a specific scientific question about the role of particular brain regions’ in cognition. In that context, I think they are very useful for trying to understand how different people’s brains function compared to one another.

[Damien Blenkinsopp]: Before we spoke—I took the test about a year ago—so I just wanted to revise it and I took it again today, and was horribly disappointed to see that one of the areas had declined quite specifically.

[Dr. Adrian Owen]: Well, you are obviously getting a bit older, you are just going to have to deal with this.

[Damien Blenkinsopp]: Does that actually mean that my cognitive… sometimes will it be an off day? Let’s talk about practice first; what would you suggest people use these for? From my own perspective, if I’m hoping, as you just brought up, not to have an aged brain, you know a brain that’s aging too rapidly, I might want to do it once a quarter, once every six months, just to check where things are. Is that a reasonable use of that?

[Dr. Adrian Owen]: It’s perfectly reasonable use of it. I think it’s a very good way of assessing your current cognitive performance based on using the same tools that cognitive neuroscientists are using these days. I think you have to be very careful, there obviously is variance. We try and take account of practice effects by making sure that novel problems are served up each time. So in all of those tests, you won’t have seen exactly the same things that you saw a year ago, they’ll be different and there are algorithms built into that to make it infinite; you could test yourself as many times as you want and you won’t encounter the same problems. But saying that, there is obviously an initial practice effect. The first time you sit down and do them, the entire concept is novel. You’re sitting and doing an online test you’ve never seen before, you’re trying to work out where the instructions are, so there is going to be a difference between your very first time and your second time. We generally suggest that people have a go once and then start testing themselves once they are familiar with the environment.

[Damien Blenkinsopp]: I think I’ll just put my bad score today down to that then.

[Dr. Adrian Owen]: I think that would be entirely reasonable; that’s something that we can deal with. But people also need to be careful about the circumstances in which they test themselves: if you didn’t get any sleep last night, then the chances are that your cognition is going to take a hit. You’re going to be less attentive, less able to focus, your memory might be slightly impaired. In some senses, the downside of having people test themselves at home is that they could be intoxicated, they could have had a few beers beforehand, there are all sorts of things that might have affected.

[Damien Blenkinsopp]: Or you could be a bit under the weather, as you said not having slept. I actually experienced that with another tool, Lumosity; I don’t know how similar it is to Cambridge Brain Sciences, or if you are up-to-date on that, but it is a brain training tool that is quite widely used.

[Dr. Adrian Owen]: It is. Lumosity is actually very different to Cambridge Brain Sciences, in that they have gone much further in trying to turn things into games and entertainment, and of course their focus is on training. Although you can use Cambridge Brain Sciences to train, we’ve never made any claims about training, we are not encouraging people to try and train their brains using Cambridge Brain Sciences; we are trying to encourage people to use it to assess whether training works or assess whether any form of intervention works. If somebody wants to know whether a cup of coffee in the morning makes an effect, take Cambridge Brain Sciences twice, once before your coffee and once after and see if there has been a change.

[Damien Blenkinsopp]: So you think it could be useful for those small interventions? A lot of people are taking nootropics or coffee—you’ve heard of bulletproof coffee, where you put butter in it? All sorts of people are trying different things at the moment, including myself. If we have a standardised tool to assess ourselves and you think it can make the difference between one… could we test ourselves once each day at the same time? Are there are a lot of things we have to control for if we were going to run our own little experiments, in terms of getting realistic information out?

[Dr. Adrian Owen]: I think it’s the perfect tool for doing those sorts of things; it’s extremely sensitive, by that I mean it will pick up small changes. Because of the way that we measure performance in these various tests, it’s designed to pick relatively small changes. I would encourage people to try their own experiments at home with it but, of course, you should try and do it scientifically. Try and do it the way that we would do it in the lab, which is control as much as you can except the variable that you are looking at. So, try and do it at approximately the same time of day, try and make sure there are no huge confounding factors like you haven’t had any sleep for one test and you did for the other; keep as much as you can the same and then vary what it is you are interested in, whether it is in drinking coffee or taking your regular sleeping pill or whatever it is that you are particularly interested in, then do it.

Repetition is the corner stone of scientific enquiry. I don’t think that one single participant performing one manipulation pre-imposed coffee does not make a Nature or a Science paper, I can tell you that. If you are interested in it and see that you have promising early results, then try to repeat it, maybe try it on somebody else to make sure it works on multiple people. But these are all basic principals in science really.

[Damien Blenkinsopp]: I think there is an interesting aspect here when it comes to an n=1 experiment, is that we have personal biologies which are different: caffeine is metabolised differently, for instance. Some things, which in the world of science, because we are not aware of them, they won’t work; when we test ten people, we get a variance of results because we aren’t aware of a specific aspect of biology which varies in people quite differently. But when we’re doing an n=1 experiment, if we do control it well and we do it at the same time of the day, and we try to control for these things, we can see some repetitive thing that happens in us, and maybe it’s not going to happen in our friends, but we have that ability to see, “I wanted to improve my brain performance; this apparently does. I don’t know why it doesn’t work for other people but there you go.”

[Dr. Adrian Owen]: That is a very interesting point. The problem is when people then make claims based upon things like that. This is the problem with the whole brain training literature really is that people are making extremely broad claims, and I think that if you really boil it down, what the person in the street is hearing or is interested in is brain training—whatever that is—makes me smarter—whatever that is—and actually, the devil is in the detail, because brain training obviously works in a sense that if I teach myself to ride a bicycle, I have trained my brain. My brain is now able to operate all my limbs to ride a bicycle when it wasn’t able to do that before, so in that sense, brain training works; but that’s not news. If I practice long division, I’m going to get better at long division; again that’s not news, that’s learning. But in a sense, it’s brain training.

[Damien Blenkinsopp]: You’ve touched on basically the aspect of why everyone focuses on brain training. The point is not to get better at one thing; it’s to improve your ability to deal with new things.

[Dr. Adrian Owen]: It is and actually, that’s where the science gets really complicated and controversial because a lot of people, and I don’t think it’s uncontroversial to say that a lot of people with commercial interest, would like to claim strongly that there is so-called transfer: if you practice this one test, you are going to get better at all of these other things. Scientifically, that’s actually been something that is extremely difficult to demonstrate unequivocally that you really do get better at all those other things, because often all of those other things are quite closely related to the thing you’ve been training on, which is a bit like learning to ride a bike and then suddenly finding out that you are also better at spin class; it is not that surprising.

[Damien Blenkinsopp]: The biggest example that I can think of, I don’t know if you know other ones, is the Dual N-Back, or even the N-Back applications, which you will find on iPhones. I think a lot of people have come into contact with them these days. I played around with it for a while until I started reading some of the conflicting research and I thought I’m not sure this is such a great use of my time. The idea there is that you play this game and then it increases your working memory and your ability to solve problems and, basically, we are talking about the fluid intelligence that we mentioned before, which everyone wants to be able to do. What is your viewpoint on the effectiveness of these types of things and what kind of brain training did you test when you were looking at this?

[Dr. Adrian Owen]: I’ll answer the second part of your question first, so we actually used various types of brain training tests and some of them were similar to the N-Back tasks, they certainly involved a lot of working memory and, as you know, we didn’t find any significant transfer effects. Even when people had trained for six weeks for ten minutes several times a day, they clearly got better at everything they trained at, every single test that was trained people got better at, but they didn’t transfer to other tests, and actually in our hands, they didn’t transfer to other tests that were quite similar.

So for example, we had what’s called a spatial span task, where you simply remember the locations of various boxes on a computer screen, and in many ways that is very similar to a commonly used psychological test known as digit span, where you just remember a series of digits, in the sense that these are very discreet things that you have to remember one after the other and you repeat them in the order that they were presented—one of them are blobs in different places on the screen and the other one are numbers.

I think it would be reasonable to hypothesise that if you got better at one of those things, you might be improving your performance at the other one because there is quite a lot of overlap between them. Lots of brain processes are likely to be the same in both, but actually that wasn’t the case. We found that even with tests that were reasonably closely related to one other, like that, working hard at one didn’t actually improve your performance at the other. But again, that is one study; that’s the study that we conducted, that’s the results that we reported; other people have certainly reported other results and have suggested that training on working memory is beneficial.

I think one of the really big problems here is working out what is working memory, and what tasks do and don’t involve working memory. It’s very easy to say, “Well, this is a working memory task that has been designed by cognitive neuroscientists to assess working memory. We’re going to assess the effects of training on this other task, which is not called a working memory task; it’s called a fluid intelligence task. That must mean that if there’s an effect, there’s transfer,” but what people need to understand is these are just names that we assign to things. For a very simple example, working memory is involved in absolutely every single aspect of our life. You and I having this conversation, a working memory is absolutely essential to have this conversation because you are listening to what I’m saying and you are trying to accommodate what I’m saying in order to generate your next question, and I’m doing the opposite to you, and all the time we are remembering what each of us is saying and that’s how we are having a conversation.

[Damien Blenkinsopp]: It’s a bit like a computer ram. Everyone’s got computers; they need ram to have things working. It’s like working cash flow, working ram and it’s actually being used versus the stuff we have stored in long-term.

[Dr. Adrian Owen]: Exactly, that’s a perfect analogy. But would we, based on that comment I’ve just made, conclude that language involves working memory. Most people who work on language—psychologists and cognitive neuroscientists—don’t think of working memory as being a component of language, but they recognise that in the process of using language, and us talking to one another or even just generating speech, we need to use our working memory system. So, that is just an example where you need to look very carefully at the test because just because it’s called a fluid intelligence test doesn’t mean that it doesn’t involve working memory, and certainly it does; any cognitive test involves working memory because you have to remember the instructions of how to do it. You have to implement those instructions, you typically have to remember where you are in the test—Am I half way through? Am I near the end? It doesn’t matter what the test is about. I can’t easily think of a cognitive test that wouldn’t require working memory. That’s not a complete answer to the question, it’s not a complete explanation to why it is that training on working memory appears to improve fluid intelligence, but it’s just one example I think of the problems that arise when people try and make claims about transfer from one thing to another without really exploring the components of the individual test and saying, “Have I just trained up something that’s helping this person to do this other test?”

There is a lot of discussion/argument in the cognitive literature about exactly that. That’s why we’ve taken the Cambridge Brain Sciences’ approach, which is to not just rely on one test, but to have a whole array of assessment tools. Now, I guess our position on brain training would be that if brain training works, then you should be able to train on this one test, whatever it is, this magic brain training task and, in general, your performance on this whole slew of other tests, which brain sciences should get better. I honestly think that is what most members of the public would expect and are expecting from what they read about brain training. It’s not that if I train on my working memory, my performance on this one test of fluid intelligence is going to improve; they are thinking, apparently, if I train on working memory I’m going to get smarter. The best way we have of measuring am I smarter is to do an entire battery of different cognitive tests that assess planning and memory and attention and all these different aspects, so I think you do have to look at the big picture and when you look at the big picture, the data are really far from equivocal. It’s not clear that training on any one test or even any one battery of tests will generally improve you on most aspects of cognition.

[Damien Blenkinsopp]: Is that to say that every time say I’m doing the Cambridge Brain Science test, or you are, you’d expect to get roughly the same scores, unless you’ve had some injury, something negative, you would expect some age decline as you referred to earlier, but you wouldn’t expect there to be jumps? Even if beyond brain training we’d been exposed to new environments perhaps, a new job, perhaps we’ve taken on a new course, we’d taken on some new studies, a PhD, whatever it is, I’m assuming that you wouldn’t really expect those measures to change much?

[Dr. Adrian Owen]: Actually, in the study we published in Neuron in 2012, we looked at a lot of these different components. Because we had 44,000 people logged in, we also asked them a lot of questions about their lifestyle. That obviously doesn’t directly address your question in that people weren’t assessed at different time points, but we had an awful lot of people that had an awful lot of different lifestyle and behavioural characteristics. We had young people, we had old people, we had smokers and non-smokers, drinkers and non-drinkers, gamblers and non-gamblers, brain trainers and non-brain trainers. We could do some of these comparisons and try and look at what difference things make, and it’s actually surprising. A lot of things that I wouldn’t have thought would necessarily affect performance really did make a difference: your general level of anxiety, for example, affected performance, but it didn’t affect the performance across the entire battery; it had selective performance on a subset of tests. Similarly smoking, whether you were a smoker or not I should say, didn’t affect cognitive performance across everything; it had specific effects on clusters, on known groups of tests. I think that’s more likely what people are going to see if they repeatedly test themselves, perhaps pre and post to brain injury or using one of these interesting manipulations we discussed earlier, like whether you had a cup of coffee or whether you’ve lost a night’s sleep. They won’t see a global deterioration of cognition; they’ll see specific problems in various areas. Perhaps your memory would be affected or your ability to attend or problem solve would be affected.

[Damien Blenkinsopp]: One of the main things I’m interested in looking at is a lot of the things are hyped. A lot of the things that we consider spending time in, so some of the big things at the moment are mindfulness meditation. You’ll see most executives today doing some form of mindfulness or transcendental meditation, basically repeating a syllable versus just focusing on being mindful. Me myself, I try these things and my friends were all trying these things to increase our performance because we are all entrepreneurs and we are just trying to do better at life and get more out of life and so that’s what everyone wants these days.

But the question is, really, could we potentially test what you just said about anxiety because I’ve always of anxiety as like a distraction. If I’m trying to problem solve on a test or problem solve at work, I know for a fact that if I’m distracted I feel more anxiety and it feels like it’s harder work because I’m not really focused. It is like half of my working memory is taken up by whatever the distracting mechanism is. Meditation, yoga, things like this are supposed to improve that, so it would be interesting for people to do interventions at home and for people to do scientific studies on this to see if this has far more impact than brain training if you want to enhance your cognitive performance.

[Dr. Adrian Owen]: I come from very much the same philosophy that you do. I am always intrigued by what the current trend is; what is it that people are doing and believing. I would strongly encourage people to go out and try these things.

I think the problem is the best tool that we have for assessing anything is science and we have a scientific process, and we have a very well worked out system for what is acceptable science and what is not acceptable science and what scientists have to do to make sure that their peers agree with this, and these sorts of thing. People do need to be slightly careful I think on relying too much on just running their own experiments and finding out about stuff and assuming that it’s the whole story. But I think as long as people try and remain scientifically rigorous and go out and test these things, I think they are all perfectly plausible things to investigate.

A rule of thumb I always have is just because a lot of people believe in it and are sure that it is true, if it hasn’t been scientifically proven, then it’s very likely not the case, for whatever reason. I think that the commercial brain training is a very good example of that, where tens of millions of people clearly believe in this because the large manufacturers of these things sell tens of millions of units of these things, so there are a lot of people who think it might work, but the scientific evidence doesn’t support it and most people should be able to see that by looking around them in the street. Talk to your smartest friends and find out why they think they are smarter, I bet you can’t find somebody who says, “Oh, it’s because I’ve been using this brain training system for six months.” It’s not that all of our smart friends are brain trainers and all of our less smart friends are not brain trainers. The evidence is out there in society that brain training in a commercial big sense clearly doesn’t work, that all the smart people aren’t the brain trainers and the less smart people the non-brain trainers. Again, that doesn’t mean there’s nothing in there and no type of brain training could have any effect, it just means that the sorts that most people are buying into at the moment, it isn’t doing what they believe it’s doing.

[Damien Blenkinsopp]: We don’t have any concrete scientific studies saying, without conflicting studies coming up a couple of years later, “Well, actually this isn’t repeatable.”

An aspect I wanted to relate back to is, because I hear this a lot, I hear about the brain aging and how we have got to protect ourselves. A lot of people are concerned about Alzheimer’s of course, it’s is one of the biggest fears of people, and losing our brain is something that obviously we care about a lot. When we are talking about aging of the brain, what does that actually mean? What’s going on there?

[Dr. Adrian Owen]: Again, it really depends on who you are; if you are dementing, by that I mean you have something like Alzheimer’s disease, then your brain is generating abnormal clusters or groups of cells within the brain that are seriously detrimental to performance and are affecting your memory and your attention, your ability on many tasks. If you have Parkinson’s disease then basically you have a reduction in a particular neurotransmitter known as dopamine, which we know is important for many tasks and for the normal functioning of many parts of the brain, and that again will have really rather specific effects. For the rest of us, maybe a lot of us have had small strokes during our life that we are not aware of. We are all very familiar with people who have had a major stroke that may have affected a large portion of their ability to move a part of their body, but there is a school of thought that over the course of our life, many of us have small strokes that don’t have measurable effects, but by the time you get to your 70s and 80s, that stuff is all adding up, you’re starting to see impairments.

Head injuries; I spend a lot of my time working with very severe head injuries, but of cause concussion is very much in the news these days. Over the course of most of our lives, most of us sustain a fair number of bangs on the head. It may not have resulted in a clinical concussion, but the brain, in spite of the fact that it is well protected by the skull, is an extremely vulnerable organ. We know that a blow to the head can have a serious effect. So I think all of these things, along with what most of us assume as aging, this non-specific atrophy of the brain, brain cells just shutting down or dying; all of these things can add up to the aging process and this is why aging is such a mystery because of course it’s all so different in each and every one of us, because we’ve all had different experiences and been exposed to different things in life.

[Damien Blenkinsopp]: What you’re saying is that it is very complex. Aging is this name we give to lots of biological changes, like damage accumulation. We’ve recently had Aubrey de Grey on, and he talks about aging and he splits it into seven different areas, so it’s quite interesting for him to break it down and say well, actually, it’s because you have cellular garbage building up and to actually break it down and describe it. So it’s interesting to talk and clarify a bit because everyone talks about brain aging, and as you say, it can be different for different people. If we are trying to prevent this, since you brought up the injuries, have you been able to improve the situation of people with injuries beyond just kind of assessing what stage they are at? Are you able to at least get them to recover somewhat, so it kind of gives up some hope for the aging process as well?

[Dr. Adrian Owen]: There is obviously a big difference between mild brain injury and severe brain injury. Some of the work we are trying to do now is to look at concussion, and again we are using Cambridge Brain Science; we are assessing concussion in people like American football players, who often suffer many serious concussions within the course of one season, and looking at whether by carefully measuring their cognition pre-imposed concussion and we’re coupling that in some cases with brain imaging studies to see what the actual impact of the brain is. We are trying to look at ways in which that sort of damage can be mitigated.

For very, very serious brain injury, I do a lot of work in patients who are in coma or a vegetative state, and there the damage is often so severe that it is very hard to work out where to start as far as rehabilitating people is concerned, or getting them back to a normal life. That doesn’t mean that there won’t ever be any answers or that there aren’t any potential answers on the table, but it’s a much harder problem to solve.

[Damien Blenkinsopp]: So when people talk about neuroplasticity, because that’s one of the things that gave people a bit more hope there, what does that refer to?

[Dr. Adrian Owen]: It’s a very broad term which has slightly been taken out of context. Two ways in which it is used often is in studies of healthy participants who are taught to do something that they couldn’t do previously. There was a very well publicized study a few years ago about people being taught to juggle. They were non-jugglers to start with, they were scanned at various points during the learning process, they were expert jugglers at the end, and there were changes in their brain that had occurred as a result of them learning to juggle; those changes were, I suppose, why they were able to juggle. Neuroplasticity had occurred in the brain and they had acquired a new skill. It’s a great study; it’s very well carried out and they use some beautiful new technical methods, but in a way, the result isn’t surprising because of course the brain has to change to do stuff and to learn stuff and that is how we retain these abilities to do things for many years. Once you have learnt to juggle you can usually do it for years and years after, even if you don’t continue to practice. So there is that kind of neuroplasticity, which I think, again, some people have taken out of context and said, “Okay, so the brain is totally plastic. We can all just move things around and learn to do new things,” and it’s not quite as simple as that.

The other way is, again, very good studies that have looked at the results of things like strokes, patients who have had a stroke and have learnt to do things that they lost as a result of the stroke. Perhaps they couldn’t move an arm, and through a process of continued rehabilitation, they regain the ability to move that arm. In some cases it’s been shown that it’s not that the bit of the brain that was damaged has been fixed, it’s that a different part of the brain has taken over the role that was carried out by the damaged part of the brain. Things have shifted around and, again, it is another example of neuroplasticity. There is no doubt that this happens; I don’t think anybody is questioning that this is something that the brain is able to do, the question is how widely can it be applied? It doesn’t mean that any of us can just reallocate resources within our brain, because we happen to have a large frontal lobe, let’s shove it all up the font and do it with our frontal lobe; things aren’t quite as easy as that, but neuroplasticity is an interesting idea and it is, as you, say something that is gaining a lot of attention.

[Damien Blenkinsopp]: It sounds like it’s potentially a zero sum game, the reallocation of what you have rather than being able to re-build capacity that was lost for whatever reason.

[Dr. Adrian Owen]: I think so, certainly in the case where there has been a specific type of brain damage. It is very rarely the case that part of the brain that has been seriously damaged can be repaired. I can’t think of examples where that part of the brain has been made to work again. It is usually about reallocation of existing resources, but there’s a lot of truth in the old saying about how much of our brain we are using at any given time. We have quite a lot of brain and it is an extremely complex organ that is very, very well interconnected, so I think most of us do have a lot of potential for neuroplasticity, as long as the damage that you’ve received is not too severe. So although it’s a zero sum game, I think there’s plenty of potential there.

[Damien Blenkinsopp]: I just did want to bring up one study that I saw recently, which was a bit more optimistic. You might have heard of it, I’m not sure, it was a reversal of cognitive decline. A novel therapeutic programme, it was in September 2014, and it was basically a multidisciplinerary approach. They had ten people do ten different things at the same time, so it wasn’t one of these controlled experiments where you’ve just got one thing going on. They just wanted to see if we throw everything at these people, can we help them? And it seemed like it was pretty positive: nine out of ten had some objective and subjective improvement and six out of six who had stopped working, went back to work. I don’t know if you saw that study, it was on Alzheimer’s and other patients; it was published in the Journal of Aging.

It’s with things like that you wonder, potentially, there are way to improve our situation. Maybe it’s not regrowing capacity, but there are ways of allowing our brain to work better in the conditions that it is in and continue to live the life or improve our performance as per whatever we are looking to do.

[Dr. Adrian Owen]: I think that is a really great example of where the point is to just not move too far away from the data. So I don’t doubt for a minute the results of the study, but what’s important is that you stick to that result and you say, “Okay, so when people of that kind, patients in this case, perform multiple tasks at the same time, their lives improve and they go on and live better lives than they did before,” and that’s the important message; that’s what that paper measured, that’s what it set out to measure, that was the result that it demonstrated and that’s what you should take away from it. Rather than say thinking, “Ah, so brain training works then!” which is, as we have been discussing, it is just a much bigger issue and, actually, that study doesn’t show that brain training works; it shows that a specific group of tests in a specific type of patients can improve their lives in specific ways. So that suggests that some aspects of brain training work, but one shouldn’t take away from that that if, “Okay, I go and buy this product to make me smarter, it’s going to make me smarter.”

[Damien Blenkinsopp]: Maybe I should have been clearer here. It wasn’t brain training; it was ten different interventions in terms of exercise, meditation and yoga to de-stress, basically doing everything you can think of that people say we should do to live healthily. So that’s what I meant when they threw everything at them, they were just like, “Have a programme and you have to do everything that we are supposed to do to be healthy. Now, is this going to make any impact in terms of your brain cognitive performance?” Again, I guess the same point remains: are you an Alzheimer’s patient? But it might be an interesting test to do yourself, if you are willing to do ten little interventions and then to use something like Cambridge Brain Sciences test to see if it has had any difference after a month or something.

[Dr. Adrian Owen]: I think so. I think you would get a pretty good pre-intervention assessment and a post intervention assessment with something like Cambridge Brain Science, it would be a perfect way to test that. As you say, it could be different in healthy participants. We know a lot about the difference between patients and healthy participants. Patients, in a sense, have much more to gain. There is an argument that those of us who can claim to be healthy are already doing as good as we can, we’re working at our cognitive optimum levels and maybe we can’t get any better, whereas somebody who is already declined 20% from their best, has that opportunity to climb back up to the top again. These are all important factors that may produce differences in the so-called healthy population versus any kind of patient.

[Damien Blenkinsopp]: Great, great, thanks for that. Just to bring up, it is interesting that you have been looking at EEG and the use of that. We spoke about functional MRI technology, which of course is extremely expensive and limited to research studies primarily because there is not so many of them. So you have been doing some work with EEG, which is interesting because it means that potentially some of those applications could be used broader because EEG is more accessible. So could you give us an overview of how you used it and where it could be applied potentially, this kind of approach?

[Dr. Adrian Owen]: Again, just to sort of qualify something that you have said, although EEG is much cheaper than FMRI, there’s EEG and there’s EEG. The EEG systems that we use actually cost more than 100,000 pounds each, so these are not things that you are going to be able to go and buy down at Radio Shack or Best Buy; these are extremely sophisticated, expensive pieces of scientific technology. But of course, the potential of EEG is that if we get it right with these expensive tools, we can make it cheaper; one could reduce the number of electrodes—instead of the 128 that we use, perhaps you can answer that question with just five or six. Those are all scientific and technical questions that we are trying to solve. FMRI, for various technical reasons, is not going to get a lot cheaper at any time soon. We’re not going to be having portable MRI scanners that we can all take home with us very soon, so there isn’t the potential for things getting much cheaper or more portable with MRI in the way that there is with the EEG.

What we have been trying to do is to use the EEG systems to achieve many of the same things that we have done with the MRI, mostly this is with the very serious brain damaged patients, it’s trying to determine whether some patients who appear to be in a vegetative state might actually be conscious but locked inside their head. We’ve had quite a lot of success with that over the last ten years using FMRI, and we are now pretty good at detecting something like one in five patients who appear to be entirely vegetative, and sometimes have been that way for many years, when we put them in the scanner we can detect that they are actually there, they are conscious, they are aware of what is going on around them, they are laying down memories and if they could, they would probably express opinions about the situation that they’re in. That is something that we have been trying to replicate with the EEG, and technically, it’s much harder, it’s proved to be much harder with the EEG. We’ve done it, we’re about at the same stage with the EEG that we were with the FMRI. But even though it’s simpler, it’s a portable technology, you can take it to the patient in their hospital, scientifically in terms of what you are measuring in the brain, it’s a little bit harder to actually analyse the data and interpret the data, so it’s had it’s own difficulties, but we are continuing to work in that area to try and improve things.

[Damien Blenkinsopp]: I wish you success there, it sounds like a very useful application that is going to help a lot of people.

So to round off the interview, what are you expecting in the next five or ten years in terms of our ability to assess cognitive performance or cognitive abilities? Are you expecting any big exciting changes or interesting things that might be helpful in this area?

[Dr. Adrian Owen]: I’ll tell you what I’m not expecting, I don’t think that we are going to suddenly get a brain training magic bullet. I really don’t think we are suddenly going to find that doing a particular task three times a day, six times a week is suddenly going to improve cognitive performance. The reason for that is you just have to look out there in the world and we would have worked this out by now if that was going to be the case. If there was some reasonable thing that one could do to boost one’s cognitive performance in terms of practice or brain training, then I think we would know about it by now. So that’s not what is going to happen.

We are learning an awful lot of information about things like the effects of drugs on the brain, how drugs affect different brain regions; there’s a whole area that we haven’t touched on here about so-called neuroenhancers, drugs that one can take to up your performance, to improve your cognitive abilities, and we are starting to learn much more about how those drugs work, the neurochemical systems that they work on in the brain, and I think it is entirely plausible that new drugs, so-called smart drugs, will be developed that will have specific and perhaps reasonably large effects on cognition.

I think the other thing is that people are waking up to the importance of trying to keep your brain healthy, trying to preserve what cognitive function you have, and we are seeing changes in society. Society is generally getting healthier, people are stopping doing a lot of things that are now pretty clear weren’t good for us and are affecting our brain in various ways, so I think that will also feed into public knowledge about ways of preserving function during aging for example. I’m not anticipating any huge revolutionary changes except, potentially, in the smart drug area.

[Damien Blenkinsopp]: Great, thanks. That’s good to hear. Is there anyone besides yourself you would recommend to talk about these subjects, like cognitive assessment or potentially, the brain training area, that they have looked at it in detail and assessed the potential of it?

[Dr. Adrian Owen]: Randy Engle in Georgia has published a lot on the so-called brain training, and he is an extremely smart and approachable individual who has a lot of very intelligent things to say about some of the statistics that have been used, some of the controls that have been used. His is a largely negative view, I would say, about the effects of brain training. You won’t have to go very far to find somebody who would be happy to talk to you about the positive aspects of brain training, so I won’t promote that by dropping any names in.

As far as smart drugs are concerned, somebody like my former PhD adviser, Barbara Sahakian in Cambridge, UK, is doing a lot of work on smart drugs and the effects of cognitive enhancement. She is certainly very knowledgeable in that area and I’m sure she’d be happy to talk to you.

[Damien Blenkinsopp]: Great, great. Thank you very much.

Just to round off, I’d like to get a view into your personal life and if you are using any type of data. Are you tracking any type of data in a routine manner or looking at anything in your life from time to time, maybe once every six months, or anything to assess your health, your performance or your longevity?

[Dr. Adrian Owen]: I’m just afraid to do that. I do, of course, log into Cambridge Brain Sciences every so often just to check how I’m going.

[Damien Blenkinsopp]: Out of interest, did you get a decline similar to me?

[Dr. Adrian Owen]: Well, when you get to 48 years old, it is inevitable that some things are just not working quite as well as they used to. Sometimes I’m surprised that I’m as cognitively preserved as I am, but I’m not the sort of person that monitors my performance on a regular basis. I, of course, get to scan my brain very often, and I guess that’s one answer to your question. Because of the context of my brain imaging research, I get to go inside the MRI scanner to test out various new things we are trying and to test new sequences in the scanner, etc., so I do get the opportunity to see my brain really quite frequently. I’m always on the look out for anything that looks a little bit abnormal, any sort of accelerated atrophy or lumps and bumbs here and there. It is impossible not to be intrigued by these things if you are a neuroscientist.

[Damien Blenkinsopp]: Right, especially if it’s your brain you’re looking at. I guess it is like the whole medicine thing, when you start googling stuff, you get the whole placebo effect of, “That sounds like something I have.” We’ll call it the anti-placebo effect, you should never start googling if you have some little random symptom because you’ll end up that probably google will say you have cancer or something.

[Dr. Adrian Owen]: Google always says you have cancer.

[Damien Blenkinsopp]: One last thing; we have spoken a lot about data today and controls, what would be your one big recommendation to people that are using data in their lives—they are trying to make some sort of decision, use data to improve their lives on any dimension, whether it’s longevity, performance or health—what would be your one recommendation in terms of what they do with data or how they use it?

[Dr. Adrian Owen]: I think there’s a scientist in everybody. We are all interested in questions about the world, about our lifestyle, about the effects of our lifestyle on our brains or on our ability to think. I think my one recommendation would be for people to try and stick to the scientific method. We’ve homed this idea over hundreds and hundreds of years now, we know how to conduct rigorous scientific experiments; you don’t have to be an expert in statistics, you just basically have to follow a few simple principles. Make sure when you test something, you are controlling as much as you can about other factors, try and make sure that the effect is reproducible, try and make sure that it’s reliable. There are many fairly basic scientific principals that one can apply to everyday life. Don’t just google something or read about something in a newspaper and assume it’s true. Go out and test it, but when you do that, test it using as many basic scientific principals as you can and I think you won’t go far wrong if you do that.

[Damien Blenkinsopp]: That’s a great bit of advice. I don’t know if you know if there’s a book or something that would give someone a basic introduction to the scientific method? I don’t know if that exists.

[Dr. Adrian Owen]: I’m sure it does exist, but off the top of my head I can’t think what would be a good place to point people, but I can send you something that you can accompany this podcast with.

[Damien Blenkinsopp]: That would be great, I’d really appreciate that, that would be very helpful.

Adrian, thank you so much for your time today and all the questions and answers you’ve been giving us. It’s been really interesting.

[Dr. Adrian Owen]: That’s my pleasure. It was a lot of fun. Thanks very much.

Leave a Reply

How well are you aging? We look at an attempt to make an aging biomarker index accessible to consumers that tracks their true biological age and provides feedback recommendations to improve how they age.

In this episode we take another look at longevity through the lens of aging biomarkers. This time taking a look at some of the most well research-supported biomarkers to predict how well we are aging. Or more to the point, how badly we may be aging, and get some early warning indicators, about having to intervene to assure we avoid shortening our lifespan.

Specifically we look at InnerAge, a new panel of aging biomarkers developed by the consumer blood testing service InsideTracker.

The panel provides an index estimating longevity based on a combination of biomarkers, and based on the results, makes recommendations to improve your longevity (AKA put the biomarkers back in the optimum zone, reducing the associated risks of shortened lifespan).


“…for each of those biomarkers, we have an intervention that you can take in order to optimize your InnerAge, and it’s very important for us to take markers that you can [have an impact on]. For example, we are not taking a marker of a disease like BRCA1 or other markers that show whether you have cancer or not, as you cannot do an intervention for that.”

– Gil Blander, PhD

Today’s guest is Gil Blander, the founder, president and chief scientific officer of InsideTracker. Gil has 18 years of experience in systems biology, computational biology, aging, metabolism and caloric restriction research.

During his career he has worked at MIT, the Weizmann Institute, and several systems-biology and computational biology companies. In this interview he walks us through the new aging panel, InnerAge, and the research and thinking behind why the company chose each of the biomarkers in the panel.

The episode highlights, biomarkers, and links to the apps, devices and labs and everything else mentioned are below. Enjoy the show and let me know what you think in the comments!

itunes quantified body

What You’ll Learn

  • Gil’s interest in biomarkers arose at the age of 12 when the death of a close family member made him think about age and longevity. (5:12).
  • Gil founded InsideTracker, with the aim of having a way of doing a monthly health check-up with optimal values for various biomarkers that are tailored to each individual (8:06).
  • When we look at biomarkers in the blood, they can show us where we are in terms of health and based on that, we can find optimal zones for each biomarker. (9:30).
  • The team of scientists and two year research process it took to cut down the aging biomarkers from hundreds to the top five (12:55).
  • How InnerAge uses an algorithm to estimate your chronological age, and recommend interventions based on your biomarker results (17:06).
  • Examples of some of the interventions including food supplements, exercise and lifestyle changes used to push biomarker values back into their optimum zones and reduce risk of shortened lifespan. (18:58).
  • Other biomarkers included in InnerAge are vitamin D, testosterone for males, CRP (22:35).
  • Why testosterone was included for men in the panel and why they have used different optimum ranges according to age and fitness activity (23:03).
  • InsideTracker is building its own database with information from athletic populations that do primarily strength or primarily endurance training. They are mining the database to determine optimal biomarker levels for each population. The benchmarking tool can be used to tell you how you compare with the rest of the population For example, a large percentage of the population has low vitamin D levels, but InsideTracker can tell you what percentage of the population shares those levels (25:47).
  • For benchmark levels of the biomarkers, InsideTracker shows the optimal range, which is their range, the normal range, which is what is used by the diagnostic companies and out of normal. For some biomarkers, even more ranges are shown (28:55).
  • An interesting biomarker not included in the panel is cholesterol. There are no scientific papers that have shown the correlation between cholesterol, or LDL and longevity. New guidelines by the American Heart association state that cholesterol is not as important as was once thought (30:00).
  • Cholesterol is a building block of testosterone, so if cholesterol is low it will be harder to make testosterone. If you have good metabolism, you can metabolize cholesterol (31:50).
  • CRP is another biomarker included in the InnerAge panel to capture the inflammation dimension of aging. (32:38).
  • InsideTracker should be used repeatedly so that you can see the trends in your values. Samples should be taken at least a couple of times a year for average users (35:09).
  • Other scientists working on aging is Nir Barzilai from New York City and Cynthia Kenyon from UCSF (37:29).
  • Currently, InsideTracker is developing an app that will help you maintain weight, biomarkers and activity (41:46).
  • InsideTracker uses LabCorp request to send samples, but it also uses home kits. They hope that in the future, home kits will improve. (42:18).
  • Theranos’ innovation in finger prick blood samples for a wide range of blood tests. (44:20).
  • Gil Blander’s own personal routines for tracking his own biometrics with InsideTracker and other tools, and the current devices and other services he uses.

Thank Gil Blander, PhD on Twitter for this interview.
Click Here to let him know you enjoyed the show!

Gil Blander, PhD

The Tracking

Biomarkers

  • Fasting Glucose: One of the most commonly used biomarkers. It is used as an indicator of blood sugar regulation and can be indicative of longevity as blood sugar disregulation lies behind many common health issues such as diabetes and obesity. Gil mentions that while blood glucose should be between 65 and 99 for everybody, his aim was to find optimal levels for different populations.
  • Total Testosterone: Low testosterone has also been linked to depression and decreased cognitive ability. Since testosterone levels decline with age, it can be used as a biomarker of aging. Gil Blander included testosterone as one of the biomarkers in the InnerAge panel.
  • Vitamin D (25 Hydroxy Vitamin D): Also referred to as Vitamin D 25-OH. InnerAge panel includes vitamin D as a marker of longevity. This is measured in ng/mL and InnerAge uses ranges of between 40 and 50 ng/ml depending on your profile.
  • Total Cholesterol: Has long been thought to contribute to cardiovascular disease. However, re-evaluation of scientific evidence has shown that cholesterol is not harmful for most people. Cholesterol is a building block for steroid hormones, such as testosterone and estrogen and is an integral part of cell membranes. Since recent scientific data do not support the idea that high cholesterol causes heart disease, Gil Blander has decided not to include it in the InnerAge panel.
  • High Sensitivity C-Reactive Protein (hs-CRP): We’ve discussed this common biomarker of inflammation often on the show. As a general rule, the closer your marker comes back to 0, the better. InnerAge includes CRP in its panel because they implicate higher inflammation as a dimension of aging. Gil Blander notes that because exercise increases inflammation, the test should not be taken for approximately one week after vigorous exercise.
  • Alanine Amino Transferase (ALT): This biomarker of liver function is also included in the InnerAge panel. Normally, levels of ALT in blood are low, but increase if there is liver damage, which may be chronic and ongoing. The Liver is looked at for longevity in this case as its role in detoxification is considered an important predictor of health and longevity.

Lab Tests, Devices and Apps

  • HRV from ithlete: This is an app for iPhone and Android that tracks HRV. It can be used to maximize athletic performance and maintain good health. Gil Blander uses this to track his HRV, as does Damien.
  • MyFitnessPal: This is an app that is used to track nutritional intake. It can be used to track intake of calories, macronutrients and micronutrients as well as energy expenditure. Gil Blander uses MyFitnessPal to track his food intake
  • Nutrino: Nutrino is a “virtual nutritionist” app that connects to wearable devices like Whitings and Fitbit and makes personal meal recommendations. It includes information on what to eat and when to eat it. Gil Blander uses it to track his nutrition.
  • Withings WS-50 Smart Body Analyzer: Gil Blander uses this scale to track his weight and store the data daily.
  • Fit Bit Charge: FitBit is a wearable tracker used by Gil Blander. It monitors physical activity and sleep quality.

Other People, Books & Resources

People

  • Simon Wegerif: was mentioned in the context of his interview on QBP and his app and HRV platform ithlete.
  • Lenny Guarente, PhD: One of the leading researchers on aging and is considered to be the father of the new aging research.
  • David Sinclair, PhD: David Sinclair is a professor of genetics at Harvard Medical School is one of the leaders of aging research. He is also involved in the biotech community and has started several companies.
  • Bob Troia: Bob Troia is known for his n=1 experiments in self-tracking and biohacking. He was a guest on episode 22 of QBP and is a user of InsideTracker.
  • Nir Barzilai: Nir is one of the scientists involved in developing the InnerAge. He is the director of the Institute of Aging Research at the Albert Einstein College of Medicine. He is studying the effects of the environment, especially nutrition, on extending the lifespan.
  • Cynthia Kenyon: Cynthia Kenyon is a professor of biochemistry and biophysics at UCSF and is one of the scientists who has helped develop InnerAge. She is one of the pioneers of research in genetics of aging.

Organizations

  • LabCorp: Laboratory Corporation of America provides lab testing and services. InsideTracker currently uses LabCorp for its lab processing.
  • Theranos: A lab testing service that tests on very small amounts of blood, taken from the fingertip. Their tests promise to be a lot more affordable, convenient and faster than tests from traditional labs.

Full Interview Transcript

Click Here to Read Transcript

[Damien Blenkinsopp]: Hi Gil, thank you so much for joining us today on the Quantified podcast.

[Gil Blander]: Thank you so much for inviting me. It’s a great pleasure
and I already listened to a few of your guests and I really appreciate it because the
quality is very good.

[Damien Blenkinsopp]: Thank you, that’s a great compliment coming from
you. As we’re going to see, you’ve been pretty busy yourself doing some good stuff.
So, could you share first why you got involved with your interest area—what is the
story about why you do what you do at InsideTracker today?

[Gil Blander]: It’s a great question. Apparently everyone is asking me this
question. My scientific journey started at the age of 12 when one of my closest relatives
passed away, triggering my quest and a thirst for knowledge in our body age. Basically,
at that time I decided that instead of being a physician or physicist, what I wanted to do,
I decided to become a biologist. The reason for that is that one of my relatives passed
away and I started to realize that I’m not immortal anymore, and I realized that one day I will be gone. I wanted to live forever; I wanted to stop the clock; I wanted to try to delay the aging-related diseases. So that basically pushed me to become a scientist and to focus and to have my lifetime goal in aging research.

So I’ll fast-forward a few years: I decided to study biology, graduated from Tel Aviv
University with an undergraduate in biology, PhD from the Weizmann Institute of
Science studying aging, and then I came here to MIT in Cambridge, Massachusetts,
and I joined the best lab that studied aging in the world. I studied aging there for five
years, published a lot of interesting papers, did very cool research, but very early when I arrived here to Cambridge, I started to be exposed to what we call “the Kendall square
environment.” There are hundreds of start-ups in biotech, pharmaceutical, and high-tech. I started to be exposed to them and I started to talk with a lot of founders. I started to do some partnerships with them and I very soon realized that I will contribute much more to humanity if I would start my own company than to be a professor in the academia that publishes a paper once a year and maybe five people will read the paper. I realized that that should be my next step.

Even having realized that, it took me some time because I really like the work in the lab
and I did a very cool experiment. So after five years at the MIT, I left MIT and I joined a
couple of biotech companies and worked there just in order to learn and understand the
industry. Also, I really wanted to learn more about systems biology. So I spent a couple
of years there and then, during that time, I was exposed to two other PhD scientists that were really intrigued by the aging process as well, but also were trying to change the equation between healthcare—basically that the healthcare is taking care of the sick and not of the healthy.

We came at that time with the basic of InsideTracker. The basic is very simple. First of
all, all of us are a machine and like a machine, we need to take care of ourselves.
Today, we are not taking care of ourselves. If you look at that, you go to the physician
mainly when the machine or “us” is broken down. When we are breaking down then we
go to the physician. So we decided to find a way to have once a month to have a
check-up that we can basically check ourselves, find what is not completely optimized
with ourselves, then intervene, and then have our body good for a few more months.
I really like the analogy of the car: so every 5000 miles, you take the car to the
technician. The technician plugs a computer into the car, the computer tells the
technician exactly what should be done in order to make the car good for another 5000
miles, should he replace oil or the oil filter and so on. The technician does that and then
the car is good for another 5000 miles. There is a lot of research that shows that since
the time that this routine schedule of maintenance for the car was introduced, in the
80s, the lifespan of the car increased from around 100,000 miles on average to around
200,000 miles on average.

So we said let’s do something similar. We cannot obviously plug a computer into our
body, but we can plug a needle into our vein and extract the liquid gold that we have in
our veins, called blood. Then when we extract the blood, we can look at the biomarkers
that show where you are staying and based on that, you can find optimal zones for each biomarker. I can give you an example; let’s look at the most boring, maybe, biomarker that you know, which is glucose. For all of us, the optimal zone is between 65 to 99. It doesn’t matter if you’re male or female, young or old, Olympian or couch potato, someone that is obese or someone that has a BMI of less than 15; all of us should be between 65 to 99.

We said that that’s wrong; let’s find an optimal zone for each of us based on age,
gender, ethnicity, and athletic activity, and other criteria. Let’s find an optimal zone that
is matched, and then find whether you are within your optimal zone, above or below. If
you are not in your optimal zone, we can subscribe you an intervention that includes
food, supplements, exercise, and lifestyle changes, that basically will help you to bring
yourself to the optimal zone, and when you bring yourself to the optimal zone there is a
good chance that you will optimize your health, your performance, and hopefully, your
longevity.

So that’s basically the background of InsideTracker. I just want to say that all of our
recommendations, the zones, everything, is extracted from peer-reviewed scientific
literature. We have a team of scientists that do that, so we are looking at it very
seriously and taking it very seriously.

[Damien Blenkinsopp]: What are the most common use cases you have
today? You mentioned a few different things like athletes. What are your clients today?
What are they mostly using it for?

[Gil Blander]: We have three main segments of clients: we call them the
train, the gain, and the pain. The train is, as you said, is an athlete: someone that wants
to shave two minutes off his marathon time; someone that wants to play at the fourth
quarter; someone that wants, basically, to approve his athletic performance. The gain is
an interesting segment. People—that are more like me—that are trying to reach to their
forties, trying to stay in their peak performance, trying to reach the afternoon and have
enough energy and enough patience to play with their kids; people that are trying to
perform better in their work, so a lot of executives; those are the gain population. The
pain are people that are sick.

Currently we are mainly trying to serve the train and the gain, because we feel like the
pain, which are sick, have already someone taking care of them—that’s the physician,
and wishing that the physician is doing a good job. We also don’t want to get into all the
regulation—when you are sick, there is more regulation. We are trying to have a proof
of concept or to show to the train and the gain that we can help them a lot, and maybe
in the future, we’ll go also for the pain, but currently, the main customer segment that
we are trying to approach are the train and the gain.

[Damien Blenkinsopp]: Thank you very much for that. You have just
created this new panel, which is called InnerAge, and it’s specifically targeted at aging,
whereas the rest of your platform, as I understand, is a bit more general. When you
were looking at the criteria for selecting biomarkers, how did you go about that? What
kind of criteria were you looking for in order to select the biomarkers that you’ve put
into that panel?

[Gil Blander]: First of all, we built a team of scientists, and actually we
recruited new scientists and we work with our scientific advisory board. I want to
mention that two of those scientific advisors that we have, one of them is Professor
Lenny Guarente from MIT, who is considered to be the father of new aging research
era and is by far considered to be the initiator of the aging research in the world and
considered to be one of the five top researchers of aging in the world.

Another scientist is Professor David Sinclair from Harvard Medical School. He actually did his postdoc at the lab of Lenny Guarente. Now he’s also considered to be one of the leaders of aging research. He’s also extremely involved in the biotech community; he’s started a lot of companies, and one of them called Sirtris—which use what they call resveratol (which I assume that you’ve heard of), a small molecule that is in high concentrations in red wine and has been shown in a lot of studies to increase longevity—was sold to a big pharmaceutical company a few years ago for $720 million. So both David Sinclair and Lenny Guarente help us to do that.

As to your question, we basically spent almost two years looking at hundreds of
biomarkers and trying to see what is the effect of those biomarkers on aging or
longevity. Basically, we were trying to pinpoint, looking at the scientific publications,
which are the five that are the most related to longevity.

[Damien Blenkinsopp]: So, just to take a step back—when you’re talking
about longevity and aging, are we referring to mortality here? Some people when they
think about aging, they’re thinking about their skin and how they look and things like
that. Are we talking about longevity in terms of how long we’re going to live, or is it
other aspects also?

[Gil Blander]: It’s a good question, and the answer is yes. I can give you
again the example of glucose, which is one of the markers that we have in the
InnerAge. We looked at the data and we found a lot of data that showed, not surprisingly, that when your glucose is high, you might compromise your longevity. But
we were looking for better data and we found it in the scientific publication that was
published based on the Framingham Heart Study. I don’t know if you’ve heard about it?

[Damien Blenkinsopp]: Of course, yeah.

[Gil Blander]: It’s basically a study that was done here in Massachusetts,
in a small lake town next to Boston. They followed up the population of this town for
tens of years and measured some biomarkers. What they found is that there is a strong
correlation for the level of glucose at a certain age and your final longevity. Let me give
you an example: if you are 40-years-old or 35-years-old and your fasting blood glucose
today is 70, you have a good chance to reach your 90s; if your glucose is a bit higher,
let’s say 80, you have a better chance to live to your 80s; and if your glucose is in the
90s, you have a better chance to live to your 70s; but if it’s 100 plus, you have a better
chance to live only to your 60s. So based on that, we took the data, we compiled it, and
then you can basically take a person and say, this person’s age is 40, his glucose is X,
so basically based on the glucose, the predicted longevity will be 80. He’s now only 40
so he has, just by the glucose, 40 more years to live.

Now we’re looking at a few other markers, so each of them show us what the effect is,
then we compile it all together using an algorithm and that’s what we show you as the
InnerAge. We show it to you in comparison to your chronological age, meaning what is
your age today.

[Damien Blenkinsopp]: So it’s an estimate of your longevity based on an
average person? The trendline I guess you’re showing is chronological age against this
biological age, and it’s showing it against, say an average 80-year-old or if you’re doing
better than the average, maybe you’re going to live to 100?

[Gil Blander]: Yes, so it uses the average but also, I want to say that it
shows what is happening with you today. It doesn’t say, and we’re not trying to say that
if you’re a 40-year-old male and your InnerAge is 30, we’re not trying to claim that you
will live 10 more years than what you’re supposed to or than the average. What we are
saying is that if you continue to stay like that, you have a chance to live ten years less
or ten years more. So that’s a very important point.

What is also very important is that for each of those biomarkers, we have an intervention that you can take in order to optimize your InnerAge, and it’s very important for us to take markers that you can intervene. For example, we are not taking a marker of a disease like BRCA1 or other markers that show whether you have cancer or not, and you cannot do an intervention for that.

[Damien Blenkinsopp]: Right. We don’t have any ideas about what exact
tool we could use to change the fact that, apart from having surgery and having your
breast removed in that case, but there’s no specific intervention that you have linked to
those. So you stick to things that are actionable, which is great; that’s what we like to
hear on this show.

[Gil Blander]: They are actionable and more than that, they are simple
interventions. So it’s a food supplement, exercise, lifestyle changes, so similar to Inside
Tracker but a bit more simple. And the simplicity comes with the next feature that we
have in InnerAge, which we called “focus foods.” So focus foods are basically nutrient-
heavy foods that will help you to optimize all the biomarkers that are related to InnerAge that are not optimized for you. So basically, focus foods are foods that are personalized just for you based on the level of the biomarkers that you have and they will help you to optimize all the biomarkers that are not optimized just for you.

For those foods, you don’t need to change completely your routine. What you need to
do is pick a couple of them and start to integrate them into your diet. So for example, if
you need to consume more oatmeal, eat it every day; that’s it. You don’t need to
change completely your behavior. Or if you need to eat strawberries, just try to integrate strawberries. Don’t change all your diet. So what we’re trying to do here is very simple because, as you know, it’s very hard for us to change our diet completely. You have a lot of influence on your diet, you are at home or at the office, you are commuting, you are travelling—it’s not easy. But when you have only a few food items that you need to incorporate all the time, it’s much easier to do that.

[Damien Blenkinsopp]: Could you give us an example—you gave us a
blood glucose example—as to what kind of recommendations the tool would make: I’m
40-years-old and my blood sugar is currently at 95. My fasting blood sugar I guess
we’re talking about.

[Gil Blander]: First of all is nutrition. To optimize your blood glucose, it’s
very important to consume foods that are rich in fiber because the fiber helps our body
to absorb the glucose and then the level of the fasting blood glucose decreases, and
that has been shown to increase your longevity. So one thing that it’s very important to
do is to try and consume more food that is high in fiber. Another thing that it’s good to do is to exercise more. Again, depending on the person; if you are a professional athlete, don’t exercise more. But if you are not, exercise more. Also maintain a healthy weight. There is a lot of data that shows in the literature that if you are overweight, you tend to have higher blood glucose. So there are a lot of interventions like that.

Each of our users receives the intervention based on this information. So if you have a
high BMI or you are heavy, you will receive the intervention of lose weight. But if you
are not, you won’t receive it. Or if you are exercising five times a day, you won’t receive
a recommendation to exercise more. But if you are not exercising at all, you will receive
it. So there are a lot of interventions that are personalized and coming to you based on
your profile and based on what will help you to optimize yourself.

I just want to add that we are also taking into consideration your dietary preferences. So you can tell us that you are on the Paleo Diet; you can tell us that you are a bachelor, live in town and don’t know how to cook; you can tell us that you are gluten-free; so we have a list of a few kinds of dietary requirements that you just need to click and then the algorithm will provide to you the food that is good for you and will help you to optimize yourself.

[Damien Blenkinsopp]: Which other biomarkers have you looked at for the
InnerAge panel? Which other ones have you included today?

[Gil Blander]: We discussed the glucose, we also added vitamin D, we
added testosterone for males, we added CRP, which is a marker of inflammation, and
ALT, which is a marker of liver function.

[Damien Blenkinsopp]: Vitamin D, a lot of people talk about that today, so
that’s common about the benefits to the immune system and so on. Testosterone, I
think, is not so obvious for a lot of people—what’s the issue with testosterone? Why’s
that important when it comes to aging for men?

[Gil Blander]: That’s a great question. What we have seen, and I assume
that you’ve heard about it, that the level of testosterone is decreased by 1-2% every
year when we are getting old. Testosterone is important for our muscle tone, it’s
important for our sex drive, it’s important for our mood. So it’s very important to maintain a healthy testosterone in order to maintain the health and longevity.

What you eluded in your question is, is testosterone as important as glucose? and my answer is definitely not. So each of the biomarkers that we included has its own value or its own weight. So, if you ask me if you have low testosterone and have a high glucose, what is more important to take care of? I would say definitely start with your glucose, and then move to the testosterone. But the testosterone is also very important and there is a lot of data in the scientific literature that shows that.

[Damien Blenkinsopp]: I believe there’s a lot of research on strength and
muscle: the higher the levels of muscle you have going on older in life, the better your
longevity chances. So that correlates also with the testosterone.

In terms of testosterone, what kind of ranges are you looking at? Because there are
obviously the lab ranges we often talk about here—you have the LabCorp range for
example—which isn’t necessarily, and I imagine is probably, not the same as the range
you’re looking at, so what kind of reference range are you looking to get people into?

[Gil Blander]: As I mentioned before, we have what we call the optimal
range or optimal zone, and that’s calculated exactly based on the papers, like I told you
before, looking at the population of thousands or hundreds of people and seeing what is the level of testosterone at specific ages. Then we can from that come with an optimal zone based on your age, based on your gender—obviously, because males and females are completed different—also based on your athletic activity. Those ranges come in based on all the demographic information and then we subscribe to you the optimal zone that is good for you. Your optimal zone might be completely different for a person completely similar to you but in a different age or ethnicity or so on.

[Damien Blenkinsopp]: That’s interesting. Do you look at the difference
between someone who’s doing endurance training versus heavy-weight training, the
different approaches?

[Gil Blander]: Yes, we are extracting the information that we can from
the peer-reviewed scientific literature. For some of them we have data, so we are doing
that; for some others, we don’t. Basically, we are trying to extract the most that we can,
but I want to admit that we don’t have everything because not everything is published in
the scientific literature. In order to try to fill the holes of that, we are building our own
database and we are mining the database. We have a lot of athletic active population
who are doing either strength or endurance, so we are starting to extract information
from there and then help our customers to compare themselves more to their peers
than compared to a couch potato doing nothing.

[Damien Blenkinsopp]: Great, I understand. So I’m guessing it’s early stages
in terms of mining the information from the client base. When do you expect to bring in
the first bits of information from that and analysis to help improve the tool?

[Gil Blander]: We are actually doing that already. We have what we call
a benchmarking tool that shows how you stand compared to InsideTracker
community. So for example, we can see that a high percentage of our community have
a low vitamin D. But you want to know whether it’s 5% or 20% or 40%, so we are
showing and sharing it with our community. They like it a lot because sometimes people say, “Oh, I have low D but it’s 50% of the population. It’s not so bad.” So some people like to see, “Oh, everyone’s having this issue so I’m not…”

[Damien Blenkinsopp]: Right, yeah, it’s not so bad.

[Gil Blander]: “… I’m not going to die tomorrow.”

[Damien Blenkinsopp]: Are you able to tunnel down and say, it’s athletes
like me, say I’ve put into your system that I’m an athlete and I’m eating Paleo, would it
be able to position me compared to that population, or is it early stages for that still?

[Gil Blander]: We are doing it currently just for specific customers; we
are basically tailoring it for them. We have what we call an InsideTracker Pro, which
we’re working with some professional athletes, teams, some gym chains, and others.
For them, we are doing what we call a tailoring solution for them. But we don’t supply
that yet for the person that comes to our website. We are working on that and we hope
to have it soon.

[Damien Blenkinsopp]: In terms of the number of users you need to make
this really useful, how many users do you have today and how many would you think
would be important to have to really make lots of statistical analysis? I guess you have
ideas about doing data mining and a lot more exciting and intricate things.

[Gil Blander]: We have many thousands of users. Obviously I cannot
expose the number. I have a statistician on the staff that helps us to analyze and to
evaluate each of them, so basically we are doing rigorous scientific work and statistic
work, and based on that we decide whether we have enough power to share it with our
users.

[Damien Blenkinsopp]: In terms of the benchmarks you’re using, we’ve
already discussed that they’re different to the lab reference ranges, so when I go into
the system would it also show me for instance the normal reference ranges and how
yours are different? Or will people just get your reference ranges? So that they can
compare—say they’ve had tests outside of your system in other places before, when
they’ve been given other numbers.

[Gil Blander]: Yes, it’s a good question. We are showing base, what we
call the normal and out-of-normal, and then we are showing the optimal. For some
biomarkers, we are showing even more ranges. I can give you an example of
cholesterol. There is an optimal, then you have a normal, then you have a near-normal,
you have high, and you have very high. So, sometimes it’s more complex than just
optimal, normal, and the out-of-normal. But in most of the biomarkers, you see the
optimal, which is our range, you see the normal, which is the range of the diagnostic
companies, and then you see the out-of-normal, which is out of the diagnostic
companies. Most of the time, our optimal range is consumed by the normal so it’s a
subset of the normal.

[Damien Blenkinsopp]: Right, I understand. So out-of-normal range means
the standard labs like LabCorp or based on the research and so on; thank you. Which
other biomarkers did you look at that you decided not to include in your panel?

[Gil Blander]: In the InnerAge panel?

[Damien Blenkinsopp]: In the InnerAge one, yes.

[Gil Blander]: One interesting biomarker is cholesterol, which when we
started to work on that I was sure that cholesterol would be part of the panel. I asked the
scientist that worked on this marker after a couple of weeks that he was working on
that, “Okay, show me the papers.” He said, “Gil, I cannot find any papers.” So I told him,
“Are you kidding me?” Well, you have cholesterol, you have statins, and you have
lipidol, and a business of, I don’t know, ten billion dollars. So I told him, “You know what,
I will spend.” I spent four weeks on that and I couldn’t find anything. You could find old
papers but old and new papers haven’t shown a strong correlation between cholesterol,
or LDL, and longevity.

Very interestingly, exactly a year ago, the new guidelines of the American Heart
Association came out, and basically said that cholesterol is not as important as it used to
be. It is important if you are overweight, if you have high inflammation, if you are not
athletically active, if you have a family history of high cholesterol, or if you have blood
pressure, but someone that doesn’t have most of those, it’s not as important as it used
to be. That was a big surprise for me, but apparently we came to the same conclusion
that other agencies or all the scientific community came to, so that was a very big
surprise.

[Damien Blenkinsopp]: There is definitely a lot of movement going on
around the cholesterol markers. One interesting thing with that in relation to your
testosterone is I found it’s easier to get my testosterone raised when I have higher
cholesterol. So I think if you’re on a lower cholesterol diet, it can be more difficult to
raise your testosterone, which you’ve included in your panel.

[Gil Blander]: Yeah, it makes a lot of sense because if you look at that,
testosterone is a derivative of cholesterol. So basically, cholesterol is one of the building
blocks of testosterone. So when you have low building blocks, it’s harder to build the
building. Actually, a couple of weeks ago, another news about cholesterol came out,
and what they’re saying now is that cholesterol is not evil. You can eat cholesterol as
much as you want if you have a good metabolism and your body can metabolize the
cholesterol. It’s not like everyone needs to run away from cholesterol. Again, don’t eat it
like crazy, don’t eat 50 eggs a day, but if you eat one or two eggs a day, you should be
all set, other than someone that has all the risk factors that we discussed.

[Damien Blenkinsopp]: You’ve included CRP. The reason everyone was
focused on cholesterol was for heart disease, but it turns out that hs-CRP is a better
marker, correct? Is that why you’ve included it?

[Gil Blander]: Yes, but CRP is not only for that. CRP is basically a
marker of inflammation and it’s related to cardiovascular diseases, but it’s also related to
a lot of other diseases, including cancer, and even diabetes. So, CRP is a marker of
inflammation, and inflammation is more and more considered to be a big, big problem,
not only for after athletic activity that your inflammation is increased but also for the
average population. Definitely inflammation is very important.

[Damien Blenkinsopp]: As you just mentioned, with athletic activity the
marker would go up, so I guess your tool comes in pretty useful in this situation because
you’re looking at those different populations and saying what’s normal for them.

[Gil Blander]: Exactly. It’s normal that your inflammation will go up after
athletic activity. For example, after a marathon run, I would suspect that your CRP
would be high. But it’s not normal that it would stay high for a week after that. So what
we are doing is we are asking our users to test themselves at a certain time when they
haven’t been running a marathon the day before, or maybe haven’t been highly
athletically active for a week before, and do it also after a day of rest. Then, if your
inflammation is high, that means you have some issue. It could be that you over-
exercise, could be that you have some injury, and it helps us and it helps our users to
pinpoint what the issues are that they have.

[Damien Blenkinsopp]: Great. It sounds like you’ve put a lot of controls in
there. Have you done the same thing with blood glucose? I’m just curious because we
had someone else on the show before, Bob Troia, “Quantified Bob,” and he’d been
tracking his fasting blood glucose daily and I was quite surprised to see how much it
went up and down most days. He was doing football practice some evenings, so he had
some correlation differences between the mornings after the night he’d been in football
practice and exercising versus a normal day when he hadn’t been exercising the day
before.

[Gil Blander]: Yes. First of all, I know Bob very well; he’s a user of
InsiderTracker and he’s a very interesting person. I completely agree with you. A blood
glucose, even fasting blood glucose, can change based on what you have done the
night before. What we are reaching or trying to do with our user or trying to explain to
everyone, it’s not only one time point and InsideTracker is not a tool that you should use
once. You should use it and use it again and again and again, and then when you start
to use it again and again, you see where is your field—Is it running between 80 to 90? Is
it running between 90 to 110? Or is it jumping all over? And usually it should be more or
less flat. And you can also start to see the trend if during the aging process or when you
are becoming older and older, you’re starting to see a trend of increasing it. So I
completely agree with what Bob has showed, but what we are trying to do here is not
looking at one point, not even two points, in order to see a trend you need to have at
least a few points.

[Damien Blenkinsopp]: How often do you recommend people take the
blood samples for the tool?

[Gil Blander]: We recommend that you do it at least a couple of times a
year. We have some users that are doing it four times a year; we have some athletes
that are doing it even once a month in order to really keep them in top performance, but
the average users that we have are doing it around twice a year.

[Damien Blenkinsopp]: Okay. That sounds about similar to me, actually—
what I do—so I’m glad to hear that I’m average in terms of how often I do these panels.
To learn more about InnerAge and any resources of our aging that you’ve come across,
first of all, where can we get information on InnerAge itself?

[Gil Blander]: Everyone can come to our website, it’s insidetracker.com,
and there we have a link to a page that we developed that shows what is InnerAge, an
explanation about focus foods, an explanation about the science, why those
biomarkers, and about the scientists who developed it. We developed a lot of
information for that because we know that it’s the cutting-edge and people need a lot of
information to understand what we are doing, so we devoted a page with a lot of
downloads that you can read PDF after PDF and spend maybe a full afternoon learning
about InnerAge.

[Damien Blenkinsopp]: So you’ve mentioned the scientists you’re working
with on this tool. Is there anyone else you would recommend to get more information
about aging, or are there any references like books or particular presentations that you
found useful in your research?

[Gil Blander]: Yeah, there are a lot of good scientists that are studying
aging. I mentioned Lenny Guarente and David Sinclair. There are a few other leading
scientists that are studying aging. One of them, which is a very interesting person, his
name is Nir Barzilai, located in New York City, and he’s studying mainly long-lived
humans and trying to see what are the changes in their genome and their proteome
compared to the average human, so that’s an interesting person to look at.

Another very interesting scientist is Cynthia Kenyon, who is from UCSF in San Francisco. She’s
focused mainly on the insulin pathway, which is very related to glucose—insulin and
glucose. She started with the model organism slow worms, and now she’s also working
on other model organisms. So I think that if you are looking at, or your audience will
look at those four, you can find a lot of very interesting information.

[Damien Blenkinsopp]: Great, thank you very much for that. What would
be the best ways to connect with you personally? And you on Twitter, Facebook?
Where do people connect to you? Where are you most active?

[Gil Blander]: I actually like Twitter a lot so I’m on Twitter. They can find
me, it’s GBlander1 and they can find me there. If someone has any questions, they can
contact us via our website. On our website there is contactus@insidetracker.com and I
would be more than happy to talk with them.

[Damien Blenkinsopp]: Great, thank you, Gil. I just wanted to learn a little
bit about you before you go, are you using your tool every month? What are you doing
in terms of tracking your biology at the moment?

[Gil Blander]: It’s a great question. I’m using the tool at least four times a
year. There are some months that I’m maybe testing every day. There was one day
that I was testing myself like four times because I’m all the time trying to find new tools.
So we are using home kits and different labs, and often my arm is completely dotted
with blood stains.

On top of that I used to use other Quantified Self tools. I used in the past the HRV from
Ithlete, which you interviewed Simon, and I think that it’s a great tool for the athletically
active population. Currently what I’m testing every day, or all the time, is my activity,
and my weight. I’m trying to use some other tools, so we’re trying to develop now a new
nutrition tool for our users, so obviously I’m using some nutrition applications,
MyFitnessPal, Nutrino, and others. So I’m using a lot of different tools but in the day-to-
day and in the last year, I measure my weight every day by Withings, which is a
European company, which have a great wireless scale. And I’m measuring my activity
using Fitbit, but I did test it from the 23andme to measure my genome, so I’m trying,
because I’m working on that, I’m trying a lot of different tools.

[Damien Blenkinsopp]: It sounds like you’ve got involved in a lot of them. Is
there any key insight; what have you learnt about yourself so far? Is there one important
thing that you’ve learnt from these activities?

[Gil Blander]: Yeah, I leant about myself that data is the key for me. For
example, when I’m measuring my weight, every day I’m measuring it here in the office,
after that I make a decision, should I eat that or should I eat that? Because it’s showing
me every day whether my weight went up or went down. So I succeed to maintain my
weight more or less stable. When I’ve seen that my weight is too high, I use some tools
to see if it’s helped me to decrease it. For example, I did an experiment when my weight
went up after the holidays. I started to log my food in MyFitnessPal and I lost like eight
pounds in a week and a half. The issue is that you cannot continue with it forever
because it’s very time consuming and annoying to add what you ate every day. So it’s a
good intervention but it’s for the short-term.

What we are trying to develop here in InsideTracker currently is find a tool that will
help you to maintain your weight, maintain your biomarkers, maintain your activity,
which is more seamless, and it’s not easy. We have a team of scientists, exercise
physiologists, coaches, and nutritionists who are trying to do that. But it’s definitely not
easy.

[Damien Blenkinsopp]: Yeah, great. Well keep me updated if you’re
coming out with something interesting; that would be great. So one thing you did
mention right there, which I forgot to mention, is I think that InsideTracker, currently
you use LabCorp request to get people’s samples. So you give them some requisition
forms and the person runs down to LabCorp and it gets sent to you, but you said you’re
also using home kits. Is that something that’s going to change in the future or is that just
for you in experimentation?

[Gil Blander]: No we have home kits. So if someone wants to use the
home kits, we have them; we are using home kits. The problem with the home kits is
that we tested a lot of vendors and most of them haven’t had the precision of the
measuring of the biomarkers to be good enough for us. Because we are giving you an
optimal zone, you should have the precision. So we came with two vendors that are
precise enough, but the number of biomarkers is limited. So for one of them we have
only five biomarkers; the other we have seven. But we are still using it because some
people are too lazy to go to the lab, some others don’t live in the U.S., and currently the
lab availability is only in the U.S., so they can use our advanced home kit and we are
sending it all over the world. So because of those reasons we are still using the home
kits.

We also hope that in the future, the quality, the precision of those home kits will be
better, then we could use more and more biomarkers. I really hope, and I think that it
will happen that in the next five years, we won’t need to go to the lab at all, we can use
our iPhone. Basically we are saying that you can bleed on your iPhone, spit on your
iPhone, pee on your iPhone, and then receive a lot of information, so that’s our goal. I
think that it will happen and what is nice about InsideTracker is that we are a
technology diagnostic. We don’t care where the information comes from; what we care
about is the quality of the information because we are running it via our analytic and
then providing to you the ranges and the recommendations. So as soon as the
technology will be good enough, we will integrate it.

[Damien Blenkinsopp]: I’m sure you are aware of Theranos and what
they’re doing. I don’t know if you know, but would you think that their services would be
accurate enough for you when they get to market? Or do you think they’re still focused
on being in or out of normal range and it’s not necessarily sharp enough for you?

[Gil Blander]: Theranos is very interesting. What is interesting is that
instead of taking the blood from the vein, you take it from the finger like the home kits
that we’re using. What is also interesting is the volume: because you’re taking it from the
tip of your finger, you cannot extract a milliliter; you are talking about microliters. What
is also interesting, that they promise, is that you can do it on time. So you receive the
information immediately, while when you do it at the lab it takes a couple of days, and
when you do it with the home kit it might take a couple of weeks. What is happening
with this—at least today, and I don’t know, I hope it will improve—is that even though
that they have a machine that can do it in place, they are sending it to a central lab. So
basically you go to one of the clinics of Walgreens. Currently only in…

[Damien Blenkinsopp]: I think it’s Arizona.

[Gil Blander]: Only in Arizona.

[Damien Blenkinsopp]: There’s one in San Francisco I think, as well.

[Gil Blander]: There should be one in Palo Alto, yeah. So you prick your
finger, they fill a small vial, and then they courier it to the lab. The lab do their analysis
and then you receive the result, I assume a day later, I’m not sure I haven’t tested it. So
you lose the value of the immediate response, that we don’t have, but it sounds like (at
least what they claim is) it’s accurate, which is great. Also, another advantage that they
have is the price: their price, at least the sticker price—what they show on their
website—is much lower than the price that a biophysician would do it, which is great
value. But again, it’s only available in Arizona; it’s not immediate. I think that it’s still an
intermediate solution. So it’s nice progress but it’s not the end product. The end product
will be the…

[Damien Blenkinsopp]: The iPhone.

[Gil Blander]: … your iPhone, yeah.

[Damien Blenkinsopp]: Thanks for the commentary on that because it’s
hard to know actually what’s going on and how far the progress. So it’s still in a trial
stage, Theranos.

[Gil Blander]: I assume so but my knowledge is the same as your
knowledge. I don’t have any internal knowledge about that.

[Damien Blenkinsopp]: Great, thank you. Well Gil, thank you so much for
answering all our questions today. You’ve given us some great insights into how you’ve
constructed your aging panel there.

[Gil Blander]: Thank you so much and I’m looking forward to really cool
entrepreneurs in your future podcast.

Leave a Reply

What is the best biomarker to track your oxidative stress burden? Joshua Fessel explains why F2-isoprostanes provide the best assessment of our ongoing oxidative state.

Today’s topic is understanding your oxidative stress levels via lipid peroxidation. We previously took a broad look at measuring and lowering oxidative stress in episode 4 with Dr. Cheryl Burdette.

Now, we are going to take a look specifically at one of the more accurate and reliable markers: F2 isoprostanes, a measure of lipid peroxidation. This is an important marker for the fact that every cell membrane in the body is comprised mainly of lipids and damage to these delicate structures can lead to a host of degenerative health conditions, including cancer.

“…I have a personal sort of one-man crusade to actually get rid of the term oxidative stress because I think it’s too nonspecific. It sort of carries with it the idea that every free radical that’s produced in a living system is bad and we know that’s not right.”
– Joshua Fessel

Our guest is Joshua Fessel, Assistant Professor of Medicine and Pharmacology at Vanderbilt University. His research interest focuses on pathways that control molecular metabolism looking at the Krebs cycle. For example, mitochondrial function and interactions between oxidative stress and cellular metabolism is what we’re looking at today.

Dr. Fessel has done 49 studies on these subjects and he’s worked on research in isoprostanes directly with L. Jackson Roberts, one of the researchers responsible for the discovery of isoprostanes in 1990.

He’s also the founder of Vanderbilt’s Mitochondria Interest Group, which is the multidisciplinary group of nearly a hundred investigators who study all aspects of mitochondria, biology, and metabolism. Obviously mitochondria is another thing that comes up in his show quite often.

The episode highlights, biomarkers, and links to the apps, devices and labs and everything else mentioned are below. Enjoy the show and let me know what you think in the comments!

itunes quantified body

What You’ll Learn

  • Dr. Fessel distinguishes between “good” oxidative stress (oxidant signaling) and “bad” oxidative stress (oxidant injury) (7:15).
  • The site of free radical production within a cell or within the body may determine lifespan (12:35).
  • Current relevance of tracking levels of F2 isoprostanes and other biomarkers of lipid peroxidation products (17:15).
  • Lack of reliable intervention for slowing the aging process at this time (17:15).
  • Study that found caloric restriction decreases F2 isoprostane levels (20:15).
  • Types of markers that exist today and relative usefulness of F2 isoprostane (22:35).
  • Measuring the byproducts of free radical reactions vs. measuring actual free radical levels helps distinguish between signal and injury (23:30).
  • Chemistry of F2 isoprostane formation is well-known and the molecule tends to be stable and measurable compared to other biomarkers (24:49).
  • Biomarkers of Oxidative Stress (BOSS) studies established isoprostanes as among the most robust biomarkers for oxidative stress (26:55).
  • Distinctions between in vivo (within a living organism) and in vitro (in a test tube or petri dish) (27:55).
  • Lipid oxidation products are useful to study because lipids are present in every cell of the body (29:57)
  • Effects of dietary antioxidants and exercise on isoprostane levels (33:27).
  • Single high-fat meal doesn’t significantly raise isoprostane levels (36:06).
  • Most advantageous times of day to collect blood and urine samples (37:50).
  • Seasonal variation with regard to sample collection (38:56).
  • Effects of acute illness or injury on biomarker levels (39:38).
  • Ability of supplements to lower TBAR and MDA levels (41:10).
  • Dr. Fessel’s tips on how to weed out poor-quality studies when reviewing research on a supplement (43:42).
  • Dr. Fessel describes the Feeding Danny Project: a year-long case study on an organic, whole-foods dietary intervention for a morbidly obese man that is being made into a documentary (47:03).
  • Baseline metabolic functions and biomarkers Dr. Fessel will be testing on Danny: cholesterol, HbA1c, blood sugar, triglycerides, kidney and liver function (52:56).
  • Dr. Fessel’s wish list of comprehensive testing he would do in the absence of budgetary constraints: thyroid function, isoprostane levels, malondialdehyde levels, TBARS, hsCRP, plasma ascorbate, vitmain E and other antioxidants (53:42).
  • Discussion of health parameters that can improve in response to dietary or lifestyle interventions before weight begins to change: blood sugar management, cholesterol levels, LDL particle ratios, inflammatory markers, correlating fitness tracking data with lab biomarkers (55:15).
  • Dr. Fessel’s personal weight loss journey (61:25).
  • Biomarkers Dr. Fessel tracks on a daily basis and his recommendation for the one best way to use data to improve health, longevity and performance.

Joshua Fessell

The Tracking

Biomarkers

    Lipid Oxidization Levels

  • F2 isoprostanes: Inflammation-promoting byproduct of lipid peroxidation. A byproduct of cellular aging and a more direct marker of lipid peroxidation levels in your body than TBARS and MDA. F2 isoprostane levels in urine should be below 8.4 pg per ug creatinine. Pubmed lists 1330 studies that include F2 isoprostanes.
  • Isofurans: Byproducts of oxidation of arachidonic acid. Exert similar effects to isoprostanes. Used as a measure of mitochondrial membrane damage.
  • Lipid Peroxidation

  • Malondialdehyde (MDA): A naturally-occurring byproduct of fatty acid oxidation and arachidonic acid metabolism. A highly reactive free radical used as a biomarker for oxidation. Can be monitored but doesn’t provide actionable information.
  • Thiobarbituric acid reacting substance (TBARS) Assay: A method for measuring free radical activity, that is commonly used but problematic. It is difficult to obtain accurate values because the test itself causes free radical formation. As with MDA, this marker has been used extensively in the research.
  • DNA Damage

  • Guanosine: Nucleic acid base that forms part of the structure of DNA. A biomarker that can be monitored but doesn’t provide actionable information.
  • ADO DG guanosine: Analog of guanosine and a byproduct of cellular aging.
  • 8-OHdG: 8-hydroxy-2′ -deoxyguanosine: Byproduct of free radical interaction with DNA. A potential biomarker for oxidative injury vs. oxidative signaling. Tested via a first void urine test to show levels of oxidative stress in the body. This marker is supported by over 2000 research studies. See the Pubmed entry here.
  • Cardiovascular Risk

  • High Sensitivity C-Reactive Protein (hsCRP): A gold standard measurement for inflammation that other inflammatory biomarkers, such as F2 isoprostane, can be measured against. This is an inflammation marker that is used to also track cardiovascular risk. Values of below 1 are shown to represent low cardiovascular disease risk, however the most desirable level is close to 0 (e.g. 0.1 or 0.2 mg/dL). Pubmed currently contains over 2,900 research studies on hsCRP.
  • LDL-P: Measures the density of your LDL particles. Research shows that small LDL particles are the ones that play a role in cardiovascular disease. This test is not yet routine, but provides the most accurate evaluation of cardiovascular risk today.
  • Biomarkers Used on Feeding Danny Project

  • Cholesterol: The cholesterol panel covers a number of markers related to lipoproteins in the blood. There are standard markers that all doctors and labs will run, and some newer specialist labs that are more specific and accurate.
  • Triglycerides: Should be below 100, optimally under 70.
  • Fasting Blood sugar: Typically taken first thing in the morning after an 8 hour fasting period. Ideal healthy levels are around 73 mg/dL. A cut off point to keep below is 92 mg/dL as an indication of blood sugar disregulation.
  • Hemoglobin A1c (HbA1c): Measure of glycated hemoglobin, or hemoglobin to which glucose has become attached – a process that occurs when blood sugar levels become excessively elevated. A proxy measure used to assess your average blood sugar over a period of time. Since haemoglobin is part of the red blood cells it is exposed to blood sugar over the lifetime of the red blood cell, thus giving a measure. As such this measure is used to identify blood sugar control issues. Levels of 5% or higher can be indications of blood sugar disregulation. HbA1c has been well researched and has been included in more than 34,000 studies published on Pubmed.
  • Basic Kidney Function Test: Blood screen for basic kidney function that Dr. Fessel plans to monitor in the Feeding Danny project. May include uric acid, blood urea nitrogen, creatinine and albumin.
  • Basic Liver Function Test: Blood screen for basic liver functions that Dr. Fessel plans to monitor in the Feeding Danny project. May include bilirubin and liver enzymes such as alkaline phosphatase, LDH, SGOT/ALT and GGT.
  • Basic Thyroid Function Test: Can include thyroid stimulating hormone (TSH), T-4, T-3 uptake, Free Thyroxine Index. Dr. Fessel noted these as nice to have, but too expensive for the project’s funds.
  • Other Biomarkers of Oxidative Stress Mentioned

  • Glutathione: Major antioxidant enzyme used by the body. Dr. Fessel has seen that this is depleted in smokers. The optimum range Christine Burdette’s Dunwoody Labs (from episode 2) uses is 658.3 – 988.5 µM, sample report here.

Lab Tests and Devices

  • NMR Lipoprofile Test: LDL particle number testing was mentioned. This lab test is currently the gold standard of cardiovascular risk assessment which it does by looking at the LDL particle number and size.
  • Precision Xtra Blood Glucose and Ketone Monitoring System: Pinprick blood sugar and blood ketone measuring device that you can use at home.
  • Fit Bit Charge: Fitness tracking device. Suggested by Damien as a way to monitor progress in the Feeding Danny project.

The Tools & Tactics

Supplements

  • Curcumin: Bioactive compound in the spice turmeric. Works as an antioxidant in part through the process of hormesis – a low-dose form of stress that stimulates the stress adaptation response in a healthy way. The most effective forms of curcumin are Curcumin BCM95 and Liposomal Curcumin. Learn more about hormesis in episode 8 with Todd Becker.

Other People & Resources

People

  • L.Jackson Roberts II: Medical researcher who discovered isoprostanes and founder of Vanderbilt University’s Mitochondria Research Group.
  • Aubrey de Grey: Mentioned by Damien regarding his research on longevity. Listen to Aubrey deGrey discuss his longevity research here.
  • Bob Troia: Tech entrepreneur mentioned by Damien regarding his long term experiment in which he tracked his own blood sugar levels for an extended period of time. Damien’s interview with Bob Troia on his n=1 experiments.

Resources

  • Biomarkers of Oxidative Stress Study (BOSS): Series of studies sponsored by the National Institute of Environmental Health Sciences and NIHS to determine the best markers of oxidative stress or oxidant injury in a living system. Mentioned by Dr. Fessel in regards to establishing isprostanes as the gold standard.
  • Feeding Danny: Documentary of a year-long dietary intervention that Dr. Fessel is involved with.

Full Interview Transcript

Click Here to Read Transcript
[Damien Blenkinsopp]: I just want to thank you so much for joining us today.
[Josh Fessel]: Sure. Thanks for having me. This is really fun for me. This is a new thing for me, but I’m really looking forward to it.
[Damien Blenkinsopp]: Excellent, Dr. Fessel. I really enjoy these too, so we’re both coming at it with enthusiasm.
[Josh Fessel]: Absolutely.
[Damien Blenkinsopp]: First of all, I always like to hear people’s stories a little bit about how they started working with what they’re working with. How did you get interested in the subject of oxidative stress and start working on that?
[Josh Fessel]: Oh, that’s a great question. I’ve been thinking about oxidative stress for the last almost 16 years and it really started when I was in graduate school or looking to start graduate school. I started a training program to train both as an MD – so it was clinical – a clinically trained physician – but also to get a PhD to do a research degree in some area. I was casting about, looking for what I thought would be an interesting area of study for my PhD research and I ended up talking to a guy named Jack Roberts, goes by Jack. His full name is L. Jackson Roberts, II. If you looked for him in the literature, that’s how you’d find him.
I sat down to talk to Jack and found out that he and I – the important part of the conversation was that he and I were very much of a like mind when it came to thinking about science. That the idea was that you could take the fundamental principles of chemistry and physiology and apply those to living systems in a way that you could learn meaningful stuff. It turned out that what Jack studied and still studies actually – he still has a very active lab – is oxidative stress and free radical injury in biological systems. I was really drawn to the approach that the lab took, basing things in organic chemistry and biochemistry and then going all the way to studies in living people. So that’s how I first got interested in it and what was going on in the lab. It was one of those things that I thought it would be fun when I started and it turned out to be even more fun than I thought it would be.
[Damien Blenkinsopp]: That’s great to hear.
[Josh Fessel]: Yeah. So that’s really how I got started and things really took off. We did some work to discover a new class of biomarker for oxidative injury and that led to an interest in mitochondrial function and how oxygen is regulated dynamically in a living system. That kind of led to what I do now, which is more focused on a broader perspective, looking at mitochondrial function and molecular metabolism, carbon source utilization in living systems. What are the fuels, how do they get used, and how do those decisions get made.
[Damien Blenkinsopp]: Great. So does that still involve oxidative stress that you’re looking at?
[Josh Fessel]: Absolutely, yeah. The two are very closely linked. I think about it like a car engine and if a car engine runs perfectly with perfect efficiency, every drop of fuel is converted to motion to useful energy. But we all know that that doesn’t really happen and that you get leaks in the system. Some of that from a car engine leaks out as heat – sometimes it leaks out as an actual sort of fuel or other things and the human body is really no different. And so if the cellular engine runs perfectly, every molecule of fuel is converted to carbon dioxide and water and useful energy, but that doesn’t happen perfectly and the byproduct – the leak – is free radicals and that gets you right into oxidative stress.
[Damien Blenkinsopp]: Right. Why do you feel this is an important subject? Oxidative stress. Are these leaks? And maybe we could talk about the broad strokes of where the leaks are bigger and smaller. But, in terms of oxidative stress, why do you think that’s something worth looking at? And would it be worth tracking, for instance, in people as they age or as they through different health conditions or even, perhaps, when they’re looking at performance.[Josh Fessel]: So, I definitely think it’s something worth looking at. I’ll tell you, I have a personal sort of one-man crusade to actually get rid of the term oxidative stress because I think it’s too nonspecific. It sort of carries with it the idea that every free radical that’s produced in a living system is bad and we know that’s not right. Some of them are quite useful and serve signaling roles, bacterial killing roles. Some of them, under particular circumstances, are harmful and I think that’s what we really worry about. So, I talk a lot of times and I’m trying to be more rigorous in my scientific writing talking about oxidant injury versus oxidant signaling and teasing those two apart. But I definitely think it’s something worth studying, quantifying, tracking in detail because fundamentally, I think, we still don’t really understand all of the concepts that tease apart useful oxidant production from harmful. And so one of the ways I think that we can start to get at that is collect data and be careful about how we define the conditions that we’re studying and then from there you can begin to kind of back calculate and figure out okay in this situation a little bit of stress to the system maybe was actually useful; whereas in this other situation, it was clearly harmful. So I think in spite of the fact that people have been studying free radical biology and oxidative stress for decades now, there’s still a lot we need to learn before we really can translate those findings into something actionable.
[Damien Blenkinsopp]: Alright. Yeah, there’s still many different theories. I guess you’re juggling and trying to prove and disprove different ones. Let’s take a step back. It’s always interesting to see how someone, especially someone working in this area and doing the studies and everything, it’s interesting what they do themselves. Have you tracked your own oxidative stress or you follow that? Do you ever look at that in yourself and have you compared it over maybe a few years or anything like that?
[Josh Fessel]: That’s a great question. So, I have measured my own levels of – I probably shouldn’t admit this. We aren’t really supposed to do this, but we all do in science where you need a so called normal sample and so a lot of times that ends up being you. So in some small studies, yeah, I have actually done that. On a routine basis, there’s nothing that I track as far as oxidative stress or products of redox reactions. This question always comes up as to what would a person track. I think in a research setting there are a lot of things that are useful to look at and I’ve certainly participated as I say in research studies of, for example, looking at products of lipid peroxidation and looking at oxidized lipids that float around in the plasma. And I think that’s really useful, but when it comes to what I would recommend to a person or what I do myself, I tend to be a little more conservative because I really – hang up isn’t exactly right – but I focus on that word actionable because I might be able to tell you that on any given day [unclear 10:47: oh [ axles of] isoprostanes] are this, and my levels of guanosine are this and my levels of malondialdehyde or whatever the product is. But I don’t really know what to do with that and so when it comes to a person in the real world – whether it’s you or me or a patient of mine or whoever – I tend to focus on pretty low level stuff and this is true in my own life. I tend to focus on pretty low level stuff that we know has a pretty clear impact on health and wellbeing.
[Damien Blenkinsopp]: By that you mean that you like to focus on biomarkers which are being used consistently for a longtime of 20 years of research behind them, a link to specific disease conditions or aging?
[Josh Fessel]: That’s exactly right. You got it.
[Damien Blenkinsopp]: My understanding is that – I’ll maybe start calling it oxidant injury. Maybe that would be the correct term. But as I understand it, like F2 isoprostanes and Ado DG guanosine – I always have a problem with pronouncing that one – but these are linked to aging as one byproduct, just as we get olderthese tend to correlate where they’re kind of sloping and steadily get higher. Is that true?
[Josh Fessel]: In general, that is true. In a broad sense, most products of oxidant injury will tend to increase with age and this gets at the whole free radical theory of aging. The idea that at the molecular level, one of the things that drives the aging process is that slow leak of free radicals that’s just part of the normal process of being alive and having an active metabolism in an environment that is or an atmosphere that’s 21% oxygen. And I think there’s some core validity to that idea. In general, I think its right. In the specifics, I think there’s still a lot more learning. I was just reading a paper this morning, for example – it was just published – that where in a given cell or organism free radicals are produced can have a pretty profound impact on lifespan. Now this was in a very simple model organism and how this actually maybe applies to you or me – that’s anyone’s guess. But I think that’s what makes it fun that in general I think the theory has validity and that’s evidenced by the fact that somebody that’s 80 years old, by and large, is going to have a higher circulating level of F2 isoprostanes than somebody who’s 20. But there are a lot of variables that come into play and we’re just teasing all those out and I think it’s really fun to do that.
[Damien Blenkinsopp]: Yeah, I guess there’s like two things we’re often trying to do. Sometimes we’re trying to diagnose or basically zero in on something we can act on. [Inaudible] is actionable. Here at The Quantified Body we’re all about action. Exactly the same like idea. If we’re measuring it and it’s not actionable, we’ll there’s not much point especially as a lot of these tests of devices or things out there are relatively expensive and we talked about that on shows before. So you have to really be careful about which measures you’re wanting to invest your time in because it also takes times, conveniences, all sorts of pay offs in our equation in terms of your lifestyle and the benefits you’re getting out of it. So, in terms of the payoff for these, would it be interesting, for instance, to relate that to age? If you’re interested in longevity, would it be interesting to track? You’ve focused a lot of your work on F2 isoprostane and the benefits of that marker. So, based on your knowledge, would it be something useful? If I started tracking it right now and continued for the next 10 years, would it be possible to compare myself to benchmark people of the same age? And then also maybe get concerned if it tended to go into an upward trend that I felt was sharper than I’d want at this stage of life?
[Josh Fessel]: That’s a really interesting question and I’m trying to think if I know of a study where anybody’s done that where they’ve actually looked over time of a cohort of people to see what happens. I can’t call one to mind, which is not the same thing as saying it hasn’t been done. It might be very interesting. You’re exactly right when you say that the way that you’d want to think about that, the first thing you’d want to know is fairly large group of essentially normal people or more or less normal people of varying levels of fitness and varied diets and all that kind of thing. What does the population look like with respect to any biomarker be it F2 isoprostanes or whatever? And then that gives you a basis for comparison. And then it might be very interesting to see what one’s individual trend over time was with regard to that some markers would be easier to do that with than others. There are lots of ways to measure these things and some of those – some of the methods are more robust than others and that kind of thing. And so, for example, we’ve talked a little bit about F2 isoprostanes and related lipid peroxidation products that I’ve studied over time. Those are really, really robust markers. They’re chemically stable. They’re detectable in every biological sample type you can think of. They’re detectable at pretty small levels, so you don’t need a huge signal to confidentially say okay the level of F2 isoprostanes in the blood or the urine or whatever was this. The problem is that they are expensive to quantify and for a really robust measurement it requires a pretty sophisticated setup. It’s mass spectrometry and blah, blah, blah. So, it sort of fails that aspect or it fails on that criteria and for an ideal test which should be easy, cheap, reliable, robust, [and] applicable to a wide range of situations. So I think we’re still – in terms of what a person would do on a day to day basis, I think we still don’t have the perfect thing to look at and I’ve had people ask me, “Well should I send in a sample for this array of tests for oxidative stress or whatever?” And my general answer is if you want to know and you’ve got the disposable income to do it, yeah that’s probably okay. But it shouldn’t be the top thing on your budget because there are lots of simple things to do that we know are going to have a positive impact on oxidative stress and on every other aspect of health. You know dietary things to think about, regular exercise, [and] all that kind of stuff. So in that regard – the other thing is that as far as the normal aging process goes, I don’t yet have an intervention that I can tell you to try that will reliably slow down or modify the aging process. There are few things that look promising, but I couldn’t say oh you seem to be aging rapidly. Why don’t you try this?
[Damien Blenkinsopp]: That’s an interesting discussion and longevity is one of the things we look at and we recently had Aubrey de Grey on the show. If you’ve heard of him or you follow some of his work, he’s very focused on longevity and promoting ending the aging equation and investing in research. He actually wrote a book about the mitochondrial theory of radicals and so on. So I’m sure you’ve connected there. So, he’s looking at a whole bunch of markers every year – 160. But I think he feels like you do, he’s really looking for something that goes perhaps an extreme, I think. I think maybe this is like an angle that could be interesting. It’s like if something goes extreme in terms of its nearly off the normal curve. It’s in the top 10% or the top 5%. Then he gives you reason to kind of look at it. But while it’s remaining within a range, which has been detectable, then I think what you’re saying is like it’s not like it’s very actionable or you already can think of something. And I guess oxidative stress – there’s still a lot of controversy around it – oxidative injury. So, when it comes to vitamins – vitamin C, vitamin E, succinate, and other interventions that people use to try to increase their antioxidant levels and lower oxidative stress, I guess in terms of the actual research supporting that and evidence that’s not really there yet. But we were just talking about it before this chat and we’ll talk about it more is the diet. And there’s obviously a lot of people doing different diets today and it’s a subject we’ve discussed before and we’ll keep coming back because there’s so much confusion over which diets work and which don’t and what they’re useful for. But I think it does come to mind that your diet could have an impact on your oxidative stress levels. So, potentially tracking F2 isoprostane once per year and changing your diet for a year and seeing what happens or perhaps a shorter amount of time, might be something relevant just to see if that has an impact in terms of how would you compare it to say inflammation such as high sensitivity CRP, which is a bit very common standard measure of inflammation. So you can often see an impact in CRP when it comes to diet – pretty substantial. It varies. I’ve been following mine, for instance, for a very, very long time and as I’ve changed my diet and optimized it, like it’s virtually zero at this point where it started at closer to 1, like around .8 – it was somewhere around. Which isn’t high, but it’s just you can see the difference over time. So, I’m wondering if you could see that kind of change over time if you feel that you might be able to see that. I know maybe in the research it might not exist, but sometimes if we’re looking to kind of go ahead of the research and just see – it’s like then it equals one experiment and maybe we can inspire someone to do some research if we go ahead.
[Josh Fessel]: Absolutely. I think that kind of thing could be very valuable and in small studies those sorts of interventions have been done where people have been transitioned to – for example, Jack Roberts – the guy I mentioned – the guy that discovered isoprostanes did a small study where he took young, relatively healthy – in other words, no chronic diseases – nonsmoking adults, but who were overweight and measured F2 isoprostane levels and they were increased and had them participate in a program of caloric restriction. So they did and it was pretty robust. It was about a 40% caloric restriction. So 60% of their typical core needs average over like a 3 day period or something like that.
[Damien Blenkinsopp]: So, could you just specify? Is that caloric restriction based on normal human needs or was it based on their original intake?
[Josh Fessel]: If I remember – I got to think about that. It may have been based on normal dietary recommendations. I’m trying to remember the specifics of that.
[Damien Blenkinsopp]: We can check that. We can link to the study or whatever.
[Josh Fessel]: Yeah.
[Damien Blenkinsopp]: It’s not essential, but I thought it was interesting. I imagine they probably did it at normal human intake.
[Josh Fessel]: I think that’s probably what they did actually. Although, as I recall, they did sort of do a food diary and the caloric intake that these people had, while they were overweight, it wasn’t wildly off what the normal recommendations were. Maybe 10% different or something like that. But the only intervention of this short period of time was a caloric restriction and there was a rapid fall in plasma F2 isoprostane levels well before there had been any substantial weight loss. I think the average weight loss at the time of the nadir of F2 isoprostanes was something like a pound or two. So it was not a significant percentage of bodyweight, but there was this really pretty impressive effect on this marker of oxidant injury and so I think what you’re describing – tracking over time within and individual and modifying diet in some way, be it increased antioxidant intake or even somebody had weight to lose and they wanted to try a more calorically conservative diet and then track markers like that, I think that could be very informative if the means exist to do it and all that kind of thing.
[Damien Blenkinsopp]: Well so let’s talk a bit more about the isoprostane because you’re work has kind of shown, as I understand, that it’s one of the better markers compared to the ones that are used more popularly, we’ll say today, still because they’re kind of the ones – I don’t know how you say it – the ones that have been in place a long time. So, what kind of markers exist today and why do you feel the F2 isoprostane has been a more useful marker?
[Josh Fessel]: That’s a great question. So there are tons of markers that you can look at and most of them are some byproduct of free radicals reacting with some large class of biological molecules. So you can look at the products of free radical reactions with sugars or lipids or proteins or DNA or – and depending on where you start from, that determines what kind of product you end up with.
[Damien Blenkinsopp]: So it’s kind of like you’re just trying to measure the volume of free radicals by what happens when they hit other thing and –
[Josh Fessel]: That’s right. That’s exactly right. Yeah because, by their nature, free radicals are fairly evanescent things. They’re reactive and they don’t last long. There are techniques to actually measure the radicals themselves and those rely on techniques like electron paramagnetic resonance measurements and that sort thing. So they’re specialized techniques and they’re really kind of research only sorts of deals. So if you really want to know about the radicals themselves that’s what you end up doing. But for most of us and again if you’re thinking about oxidant injury in particular, I actually find it more useful to look at the byproducts of reactions that we know to be fairly uncontrolled reactions because, in my mind, that conceptually gets you back to a process that’s injury as opposed to a deliberate signal. So you can look at anything from – we mentioned 8-oxo guanosine. That’s a product of free radical interaction with DNA. You can look at malondialdehyde, which comes from lipids and can come from some protein oxidation. There are protein carbonyl assays you can look at and they all tell you some information. The reason that we’ve settled on F2 isoprostanes and related compounds is that we know a lot about the chemistry of formation. We know from the moment the inciting radical is generated, we can walk through the reactions that lead to F2 isoprostane formation. And this is through work that Jack did. When these things were first discovered in the 1990’s, we know that once they’re formed, they hang around in a more or less unchanged structure – a more or less unchanged form. And further when they do get metabolized, we know what the metabolites are. So there’s no source of spurious generation. When you look at things like malondialdehyde or like the TBARS assay, the thiobarbituric reacting substance – the problem with assays like that is that they tend to generate some signal in the process of the measurement of itself and so it’s hard to know, except in a relative sense, how much of what you’re measuring was there to start with and how much of it came about as a result of the measurement itself. By contrast, I’ve heard Jack tell this story a few times of when they discovered the isoprostanes back in the early 90’s, they did an experiment where they took a beaker of urine and sat and measured the level of isoprostanes in the urine and then sat the beaker of urine on a hotplate for about 72 hours which ought to – any spurious generation’s going to happen, that’ll do it and the levels were exactly the same as they had been 3 days before.
[Damien Blenkinsopp]: Wow.
[Josh Fessel]: Yeah, so really robust and –
[Damien Blenkinsopp]: Yeah. So that means you could ship it around the world. So you’re talking about urine samples here?
[Josh Fessel]: Yes, yes.
[Damien Blenkinsopp]: Right. So that’s also very accessible –
[Josh Fessel]: Correct.
[Damien Blenkinsopp]: Compared to blood. Yeah.
[Josh Fessel]: That’s correct, yeah. So exactly what you say has been done. We’ve analyzed urine samples from the deep jungles of Southeast Asia looking at measurements in patients with malaria and all that kind of stuff. So it really is robust in that regard. There’s also a series of studies actually that are sort of interesting reading called the Biomarkers of Oxidative Stress Study or the BOSS study. And this was published in four or five installments. It was a study sponsored by the National Institute of Environmental Health Sciences and the NIHS wanted to know exactly the question that you’re asking. What are the best markers of oxidative stress or oxidant injury in a living system and so they did head to head comparisons of a variety of different biomarkers in a bunch of different contexts starting with different oxidants, looking at different biologic samples and the isoprostanes emerged as of one of the most robust. I don’t want to overstate – it’s certainly not the only thing that’s useful to look at. But in the BOSS studies, the isoprostanes emerged as one of the most robust across a variety of context, samples, that kind of thing. But the BOSS studies are NIH sponsored. They’re publicly available. They’re kind of interesting reading actually.
[Damien Blenkinsopp]: Great. Yeah, we’ll definitely link to all of this stuff in the show notes. One of the big things I understood was there was a difference between in vivo and in vitro. Could you talk a little bit about that because sometimes people go and read studies or they go to a link for a study and it’ll be in vitro. They just assume that it’s going to be exactly the same in the body. So, first of all in vivo means inside the body and in vitro basically means in a test tube.
[Josh Fessel]: In a living system.
[Damien Blenkinsopp]: Right.
[Josh Fessel]: That’s right. So most of the time when people talk about in vitro they’re talking about something up to cells growing in a dish. So, it might pure chemicals in a test tube, it might be cells growing in a dish, something like that. In vivo is referring to in some intact living system. Sometimes as simple as a worm or a fly, but it’s an intact organism. Worm, fly, mouse, human, something like that. So the distinction is really important. You can make lots of things happen in a test tube or in cells in a dish that may never happen in a living system for a thousand different reasons. Just as one sort of easy example to grasp, if you’ve got cells growing in a dish, they have a very limited capacity to respond to any insult you throw at them and you know that’s not true of an intact human being for example. You’ve got all sorts of immune responders and chemical antioxidants and the liver and the kidneys eliminate toxins and this and that. So there’s interplay of a hundred different systems in an intact organism that may run counter to or may enhance the effect that you’re looking at and so to extrapolate from a test tube or cells in a dish to a person or even a mouse in a cage, that’s a long stretch. Now what we constantly do in our research is exactly that. We find something interesting in a very simplified system in vitro and then we say can we find any echo for this in the living system, can we see the same thing, or how was it modified between the cells and the dish and the person in the lab.
[Damien Blenkinsopp]: Great, great. And in terms of these oxidant injury markers, I’m trying to adopt your expression there, what did you find in terms of the markers? Were there some of them which were working better with in vivo? Because I mean at the end of the day we want to know what’s going on in the body of course.
[Josh Fessel]: That’s exactly right. One of other reasons we really like lipid peroxidation products in general or that I really like lipid peroxidation products in general and isoprostanes in particular and related compounds is that every cell with a membrane is fair game for study. So, for example if you wanted to measure DNA oxidation products, well there are are cells in your body that lack DNA. Red blood cells, for example, have no DNA in them. Platelets have little shreds of DNA. But every cell has a membrane, so every cell is fair game for study and it lets you really refine your question. It also means that if I can get ahold of the membrane, I can study it in vivo even down to the subcellular level. So I can take a sample of liver tissue, skeletal muscle, whatever and get the mitochondria out of it and measure the levels of isoprostanes or isofurans or whatever in the mitochondrial membrane and I can tell you something about what happened to that level of detail in a living system and so that’s how we try to bridge that gap between things that are very simplified in vitro and move into in vivo. But there are lots of things you can do in that regard. There’s a lot of literature for example on looking at oxidized DNA floating around in the plasma as a marker, not only of oxidant injury, but of cellular injury. So people are looking at the DNA contained within mitochondria, for example, and looking not only at how much is there floating around in the plasma because it’s not really supposed to be there in it’s free form, but of that how much of it is oxidized and how extensively. And you can get a really pretty granular view of what must be going on at the cellular level. Now, it doesn’t tell you things like is it in one specific spot in the body or is this a whole body thing, but you can get pretty detailed information in a living human. From a research standpoint, a living human is a really complex and sort of filthy place to do your research, right. It’s very uncontrolled. There are a million variables that you can’t do anything about and yet that’s what you have to do and the techniques are such that we, in a research setting, we can get pretty detailed.
[Damien Blenkinsopp]: Yeah because I mean the body has so many variables. If you’re just thinking about it. It has a long dynamic equation – some crazy calculous. There’s so many variable that to do science is actually really difficult because you can’t control so many different variables that are going on. So, you have to appreciate the efforts people are making to study how we work just in the incredible in-complexity. We’ve looked at hormesis quite a bit, which I think illustrates quite well the concept you’re explaining here about in vivo being different where we have things like our hormetic curcumin for example. You put it into the body and it ends up creating some kind of anti-stress kind of like an antioxidant effect. Although the mechanism as we understand it today is actually a small oxidant kind of injury as I understand it. So there you see it’s causing the opposite of what you thought. I’m sorry – It’s very illustrative of the importance of focusing on the in vivo. So, okay we understand why you like isoprostane. What kind of things have you seen our reduced high levels of isoprostane if anything? You mentioned caloric restriction as being seen. Are there any other things that have been seen that have some kind of impact on it?
[Josh Fessel]: Yep. You can supplement dietary antioxidant intake and see a measurable effect on isoprostanes and there are a number of studies that have done that using various dietary sources. Regular exercise is a pretty clear – it’s interesting and this may get to that idea of hormesis. There was a study where they took people – and this maybe isn’t surprising when you say it out loud. They took ultra-marathoners and measured their levels of isoprostanes right before and right after an ultramarathon and then maybe up to a week later. And not surprisingly, right after the run and obviously these are extremely fit people, right after the run their levels of isoprostanes were incredibly high.
[Damien Blenkinsopp]: Sky high, yeah.
[Josh Fessel]: Yeah.
[Damien Blenkinsopp]: Cancer patient levels.
[Josh Fessel]: Right, right or more. I mean if you just looked at the numbers and didn’t know what had happened, you’d say oh my God, what’s going on with these people. But as you say, it’s the biological of that which doesn’t kill you makes you stronger and so clearly these are fit and when you look at their baseline levels, their baseline levels were quite low. So regular exercise we know improves the efficiency of the machinery that tends to leak free radicals or improves the ability to respond and maybe both. So it’s a lot of the things that you might guess at anyway. The healthy diet that’s low in fat and high in fresh fruits and vegetables, that kind of thing. Oh, the other really big thing is we know from a number of studies that smokers are under a huge constant oxidant stress. It not only enhances the formation of free radicals and masking goes hand in hand with this, depletes levels of multiple different endogenous antioxidants. So, the other thing that we know is beneficial is if you smoke, please stop.
[Damien Blenkinsopp]: Alright. So, you’re talking about glutathione and –
[Josh Fessel]: Yep. Glutathione, ascorbate. I can’t remember if there was a measurable effect on vitamin E or not. Lipoic acids – many of the usual suspects and they were all depleted in the smokers.
[Damien Blenkinsopp]: Great, great. So, I guess increasing your glutathione or having low glutathione is going to have an impact on your isoprostane levels just because you’re indigenous antioxidant system is different. You brought a very important aspect of it there. They weren’t for a run for a few hours and they completely changed their isoprostane levels. So then we have to think about, okay we really have to control. If this can change that rapidly – give that that was quite an extreme circumstance. But what kind of things do we have to control for it to make sure that we’re not getting some kind of useful reading with isoprostanes.
[Josh Fessel]: Yeah, that’s a really good question. So, we know that people who are heavier – who are overweight or obese – have higher levels. So you got to control for that. As I say, we know that smokers have higher levels, so you have to control for variables like that. It ends up being a lot of the variables that you would control for in a fitness type of study anyway. It turns out that the specifics of – at least in a short time window – the specifics of dietary composition aren’t as important as you would think. So, year’s back we actually did an experiment in the lab where a bunch of us – because we wanted to know is it possible that what you’re measuring when you measure a plasma level of isoprostanes for example is coming in with the food you’re eating. A bunch of us in the lab went and got a very high fat meal from a popular fast food chain and measured our levels.
[Damien Blenkinsopp]: I wish you would say the name, but we can guess.
[Josh Fessel]: I won’t necessarily say the name.
[Damien Blenkinsopp]: Have they been in the news lately?
[Josh Fessel]: Almost certainly. So we measure our levels beforehand – blood and urine. And then ate a very fatty meal and then I think it was something like 6 to 8 hours later, measured plasma and urine levels and they really didn’t change. Which was kind of a surprise, but it was very reassuring. It suggested that what you’re measuring is more reflective – or at least, if it’s not more reflective of a steady state, it’s at least not so sensitive that you can tip with –
[Damien Blenkinsopp]: With just one meal.
[Josh Fessel]: That’s right.
[Damien Blenkinsopp]: Right, right. Okay.
[Josh Fessel]: But, overall dietary composition is something you would want to know something about if you were doing a controlled measurement.
[Damien Blenkinsopp]: Is there anything about time of day or with a lot of blood tests we do fasting. Will it make any difference if we fast say 6 or 8 hours or 12 hours and then do it in the morning? Or is it okay to do in the evening – to take your sample then if urine for example? Are those kind of influences important? How about like summer or winter? Are these good questions because if I imagine if I’m interested in tracking this just say for aging or for some other aspect, then I want to know that I’m not just going to get hectic data basically. Like one day up, one day down. One season up, one season down and basically can I be completely fooling myself that I’m tracking anything useful?
[Josh Fessel]: That’s exactly the right question to ask. So, as far as we know – at least in plasma levels – there’s no diurnal variation and that’s true actually of a lot of the different measures, not just isoprostanes. If you’re measuring anything in urine, in general, the best time to measure is the first morning urine. Not necessarily because you get diurnal variation, but what happens is you’re awake throughout the day. You tend to take in fluid and that’s going to tend to dilute your sample. But that’s true of almost literally anything you would measure in the urine.
[Damien Blenkinsopp]: Well that’s a great rule that you just gave use there.
[Josh Fessel]: Yeah. And then as far as seasonable variation – that’s a really interesting question. To the best of our ability to determine, no there isn’t any seasonal variation. I actually did a study when I was in graduate school to see if sun exposure had any impact because you’re delivering radiation to a large area of the body if you’re out in the sun and radiation is ionizing and creates free radicals and so I wanted to know was there any acute effective of sun exposure and the short answer is no there isn’t. So, for all those reasons, these tend to be pretty robust measurements and like I say, some measures are going to be a little more noisy than others, but in general these are things that – the one thing that would have an impact on the acute measurement of any index of oxidant injury would be if you had some sort of acute illness. So, if you had that flu for example. We know that people who are acutely ill have – and we’ve probably best studied oxidant injury in the setting of acute illness. We know that people who are acutely ill will have higher levels and the sicker you are the higher they’ll tend to be. So, if you were doing any kind tracking of any biomarker really over time, you’d want any individual measurement to be fairly representative of how you are on a day to day basis.
[Damien Blenkinsopp]: Absolutely. So I actually ran into this problem very early in my tracking. I was tracking high sensitivity of the C reactive protein. And the second time I ever tracked it – this is going back like 8 years or so – very early – and I actually had an injury to my coccyx by falling – I can’t remember – falling over something. Very painful, it was really horrible.
[Josh Fessel]: That sounds awful.
[Damien Blenkinsopp]: Yeah, yeah. It was because you can’t sit down. It’s very difficult. But anyway, I took my CRP and it was like much, much higher of course. I can’t remember the levels. I think it was 8 or something, which it was completely off the chart compared to what it was. I honestly had to look and it really wasn’t worth me spending my money on that CRP this time just to find that yes, you have a coccyx injury or any other injury, you kind of expect these kind of things. So very, very important point there.
So just wind of the isoprostane discussion. So we didn’t’ really talk about TBARS. The thing about TBARS and the MDA is when you look at, for instance, supplements and things like this, you often see that they talk about the TBARS as supporting evidence that it’s lowering lipid peroxidation. Do you feel like it’s reasonable to trust statements from backing supplements and stuff? Should we really be looking at the isoprostane levels? And can we trust – if we’re reading stuff on supplements and it seems that lowering lipid peroxidation, would you trust that or what issues would you see with trusting that TBARS method?
[Josh Fessel]: Yeah, that’s a great question. So, what I often tell my patients when they ask about supplements is remember the job of the person who printed that label is to sell you the supplement. So know that whether they’re making a claim about TBARS and MDA or isoprostanes or protein carbon meals – so know that. The question, I guess, is to dig in and find out what are the quality of the data that they’re sighting? And it seems like you’re speaking to a really engaged and educated audience here and so my advice would be dig into it and see do they site a study? And if so, go find the study and look at it. And if it doesn’t make sense, go talk to your physician or whoever – somebody that you know has some background to help you pick through it and say – because some of the studies that are out there that have looked at TBARS and malondialdehyde and all that – they’re fine studies. They’re well designed and you’re going to get relative quantifications that probably do tell you something. There are plenty of studies of isoprostanes out there that are not as well designed and probably not as informative as better design study of TBARS. So whether you trust the claim or not – I always go in with skepticism and my first question is okay well let me see if I can find the study they’re actually talking about. If I can, I’ll look at it and say okay this is actually pretty good or this has some problems. And then the other thing is independent of that, I’ll look for other investigations of the same thing. So maybe the study they site isn’t that good, but there are 10 other studies that have been better done and they actually seem to suggest yeah there’s something here or the conclusion is no, there’s really nothing here. So I say take each on a case by case basis, but get as much data as you can before you spend your hard earned money and educate yourself on the front end.
[Damien Blenkinsopp]: Great. Is there anything in particular which would, if you were reading a study and it had TBARS in it, is there anything in particular you would look at for that marker which you’d be like, “Ah that could be an issue.
[Josh Fessel]: Yeah. Sometimes it’s hard to pick out what can be the issues. If I’m reading a study – this happened once. I was reading a study that were analyzing samples that were 10 years old and that gave me pause because anything that sits around long enough, unless it’s stored under really rigorous conditions will show generation of malondialdehyde and isoprostanes and all the other products of oxidant injury or oxidative stress just by virtue of sitting around. So, when I saw that it was red flag to me that oh, I need to interpret this data cautiously. Are they making comparisons between groups and how comparable are those groups, really? Exactly as you eluded to? You’re controlling for the things that could influence that. Did they study? Was there intervention in a group who, on average, was 10 or 20 years younger than their control group? Well that’s a problem for reasons that we’ve already discussed. So, I look for things and these may sound goofy. Like of course they would control for that, but sometimes they don’t or can’t or won’t or didn’t or whatever and so you just look for things like that. That’s true not just for TBAR’s measurements, but for anything.
[Damien Blenkinsopp]: So there’s nothing specific that you highlight that you know is a weakness of the TBARS?
[Josh Fessel]: Not really. I’ll say that the one caveat I guess with TBARS, Is that the more complex the sample that they’re measuring, the more cautiously I’d interpret the data. So, for example, if it’s a study of TBARS in urine, urine is a biological sample. It’s pretty simple. It’s got salt and a little bit of protein and few other things and that’s about it. Plasma on the other hand, is really complex. It’s got proteins and lipids and a few cells. So if you were making measurements using the TBARS protocol in urine, I would tend to hang a little more validity on that than if you were in the plasma. I think it’s a dirtier biological matrix.
[Damien Blenkinsopp]: That’s interesting because I think most people assume that blood’s the ultimate measure. So, just of now, does an isoprostane – does urine correlate well with the blood sample levels? So, are they pretty much exactly the same?
[Josh Fessel]: They’ll tell you the same information. And the nice thing with isoprostanes is that – because we’ve had it come up before where people say, “Well how do you know they aren’t being made in the kidney and that’s really what you’re measuring?” That’s a fair question. So the one nice thing about isoprostanes is that we also have defined metabolites that are excreted in the urine. So the only way you can get that is if you formed the compound, released it in the blood, and then the enzymes that metabolize isoprostanes have a chance to work on it. So, you can measure urinary metabolites and they’re very stable compounds and say there’s no way this was generated in the kidney, this had to come from the total body pool. But in general, yes, they do correlate.
[Damien Blenkinsopp]: Great, great. Thank you very much. Okay, so I know that you’ve been starting to get involved in a project that’s going on. We have someone who wanted to change something in their life and so I brought that up and it’s very interesting case study to bring up on the program. So, it’s called Feeding Danny. Could you give us a quick background about it?
[Josh Fessel]: Sure. I’d be happy to. Thanks for asking about it. Yeah, so this is a project that started with my friend and my wife’s friend, Danny. Danny, like a lot of people has struggled with his weight over time and Danny is very overweight. In medical terms, you would say he’s morbidly obese. He carries a lot of extra weight. I’m guessing and I don’t know for sure – I’m guessing he weighs he weighs somewhere around 350-400 pounds. He’s a big dude and has health problems associated with his weight. He’s got joint problems, sleep apnea, asthma, all sorts of things. And so he has tried many different ways to get a handle on this and has had a lot of trouble and like I said, he’s clearly not alone in that. And so what came about is two friends of his approached him with the idea that they wanted to stage what you might describe as a dietary intervention. They said, “If you’ll allow us to do it, we will take over your diet for a year’s time and change everything about what you’re eating. We will make sure that the only thing going into this system are all natural, organic, pesticide-free, hormone-free foods and that by doing that we feel certain that you will, not only lose weight, but you’ll see improvements on any number of health related measures and act scenes.” And so when I heard about this I said I would love to help out if I can because I love my friend Danny and I want to help him, but beyond that I thought this was a really interesting concept on a single person as you say case study and that’s really what it is. Can you do this dramatic intervention and see a positive change. What I thought I could offer was to bring the medical perspective to things just in terms of overall fitness, but also bring the science perspective because I come from a slightly different place than the women that are doing this. Their names are Leilani and Vanessa. I tend to think about things in a very sort of pragmatic, low level kind of way. I think this will work because if you’re eating a diet like they’re describing – and it does include meat and that sort of thing as we discussed. This is not a strict vegan diet or anything like that. But I think if you’re eating a diet that’s high in fruits and vegetables and whole grains and lower in saturated fats and all that kind of stuff, you’re going to lose weight because your caloric intake is going to go down. I suspect what we’re going to learn is that as we go along they are thinking more along the lines of eliminating toxins from the diet and that sort of thing and I always halt a little at that because as I say, just as I don’t like the term oxidative stress because it’s nonspecific, I don’t like the idea of toxins because that’s nonspecific. What do you mean -What toxin, can I measure it, what are the levels, that kind of thing. And so, it doesn’t really matter who’s right as long as it works and so I’m excited to participate in this. What they’re proposing to do is to do this intervention for a year. They’ve uprooted their lives in Chicago and have moved to Nashville. They just got here about a week ago. What they want to do is do this for a year and document it on film and hopefully at the end of it have a true representation of what happens over the course of that year.
[Damien Blenkinsopp]: Alright. Those things are great – documentaries – because they can be inspiring for people, often more inspiring than this show when we’re talking about scientific data like this one for a lot of people. So, they’re really, really great, but it would also be like really cool if there were some controls in place to kind of understand a little bit like what really did happen. So, my understanding is that the intervention is basically a diet of organic foods, right. So they’re going to be buying specifically organic, certified organic produce and probably they’re going to basically eliminate all of the stuff in the middle of the supermarket. So you’ll walk around the edges and you’ll grab all the vegetables, fruits, meats and so on, but most of the stuff in packages isn’t going to be included in the diet.
[Josh Fessel]: That’s correct and ideally they’ll actually, in as many instances as possible, eliminate the supermarket and go to the farm where it’s being raised. And Nashville’s actually a good place to do that. There are a lot of certified organic farms and you can locally source just about everything. So this is kind of an ideal place to try what they’re proposing.
[Damien Blenkinsopp]: I guess somebody other kind of confounders in terms of diet because the diet world is so complex in terms of all the people have different opinions. Whether it’s grass-fed meat or its grain-fed meat, there’s a whole question of grains. In this case it seems like grains isn’t the issue. But like we were just talking before like it’s just important to define exactly what the diet intervention are in it – what limitations are and what the limitations aren’t to kind of get started. What kind of other things would you feel would be worthwhile controlling for? I understand the budget probably isn’t going to be really high, right, in terms of testing and things like that? But there’s probably some things they could track and it would probably maybe help the documentary or just be useful to kind of look at afterwards and be like yeah. So maybe we can say that toxins did play a role or – although I haven’t come across so far a kind of generic marker of toxins like you’re kind of alluding to. I’m not sure it is a generic toxin marker unless you want to say oxidant injury potentially. So what would be your thoughts on kind of if you wanted to get a baseline today before everything started and to see where things are at and then I know what kind of time scale would control certain things and at the end, in one year’s time, what would you like to control for if you could?
[Josh Fessel]: Yeah, that’s a great question and this is something that we’re in discussions about right now because, you’re exactly right, budget is going to be limiting and so there are some things that I think we’ll need to do just from a general sort of health monitoring standpoint. There are some things I’d like to do that we may or may not be able to do, but all of it is in service to trying to figure out did anything actually work. Where my thinking is, is that we’re going to need to look at some really standard, basic measures of health, particularly metabolic health, and this is real simple stuff like cholesterol, like hemoglobin A1C, blood sugar, triglyceride levels in the blood, if I had basic kidney and liver function, that kind of thing. If I had a complete wish list, I’d probably want to know about thyroid function and that kind of thing. And then to branch out from the traditional, clinical indices as far as biomarkers and thinking about what else I would want to know. I would actually be really interested to know what the circulating levels of isoprostanes were and compare that with circulating malondialdehyde or TBARS. I would love to know high sensitivity CRP. I would love to know what plasma levels of ascorbate and vitamin E and all the other small molecule antioxidants. I think that would all be fascinating and to see how those change with this fairly profound diet modification that’s going to happen. How much of that we’ll be able to do I don’t really know. Since some of those things make sense clinically, some of those things are more on the research side and this is an interesting case study, but in the strictest terms this is not a research study. So, we’re going to have to be a little judicious in how we go about these things. But nonetheless, I think what we’ll end up doing is certainly hitting all the things that we need to look at just from a basic health and safety standpoint and then I hope that there’s additional funds available to dig into some of these other things, not only to get a baseline, but hopefully to measure them periodically over time and see what did we really do.
[Damien Blenkinsopp]: Yeah. That’s great. And I think you’ve mentioned a lot of different things and I think especially for people to get the value out of the markers they’re tracking and given how most things are still pretty expensive today. Some of the things you mentioned I thought particularly kind of practical are blood sugar regulation. You mean just taking like the blood sugar reading.
Recently, had a conversation with Bob Troia on The Quantified Body. He was on the one of the recent podcasts and he tracked his blood sugar every day for a long time. It was interesting to see it went up and down all time based on what he’d been doing the night before and everything. so the problem that I realize is like sometimes when I’m having my blood panels, I’ll get my fasting blood sugar taken and I realized I’m kind of wasting my time because, unless I’ve been very careful about what I’m doing the night before, in terms of exercise and intake and everything. But on the other hand, there’s a pretty cheap method. It’s the Precision Extra pinprick blood sugar devices where you can take a couple of reading. It’s pretty cheap. Unfortunately you have to prick your finger and you have to think about okay is Danny going to want to prick his finger like once every day or maybe once a week or like whatever you’re trying to control for. Obviously, blood sugar regulation’s one thing that’s going to fit with the research that there’s definitely going to be some changes there. One of the things I was thinking of is cardiovascular risk. Is that something he’s worried about? Given the weight and everything, we worry about that a lot. There’s one other test out there that I’ve been meaning to get someone on the show for, for a while is the LDL particle number, which the research has been looking at more sharply because it correlates better. They are looking at some other things they are using CRP which is one you mentioned too. So, just kind of figuring some of the other things I thought would be interesting and of course like a weighing scale because in terms – like I think one of the great things about this project is that you could take pictures every day and obviously there’s going to be video footage, which is going to motivating for other people, but sometimes you can’t see it yourself as well when you’re measuring. But if you got a scale and you’re just jumping on it every day, that’s a very easy thing to keep you motivated to see that something is happening. We have to be aware of something that you said earlier in our conversation today. Which is that there were benefits being seen with caloric restriction before any of the pounds were coming off in your example, right. So we have to also be aware that although sometimes maybe the weight isn’t’ coming off, there are other improvements that are going on inside our bodies.
[Josh Fessel]: That’s absolutely true and that’s why I hope we’ll be able to quantify as many different parameters as possible as you say. In terms of a quantified body, a quantified life a bathroom scale is probably one of the most useful things you can have. But you’re exactly right in that let’s say that weight loss – let’s be pessimistic and say there isn’t as much weight loss as we there’s going to be, we might still have one real victory, but you’ve got to know what to look for. You got to be able to look for it. And so for exactly that reason I think the more carefully selected data we can have in this case – and this is true, not just in the case of Feeding Danny, but in a broader sense I think that’s useful. My clinical life is in part spent in the intensive care unit taking care of critically ill patients and that’s about as quantified as you can get on an acute basis and all of that information can be really helpful, not only as individual data points and not only as trends, but also as a gestalt of what’s going on with the person. And i think this maybe a similar conceptual exercise over a much longer time scale. So I’m hopeful that we’ll be financially able to look at all these things. But if nothing else, like you say, daily weights and looking at blood sugar over time and things like -one of the things that I hope we’ll be able to do – one of the sort of quantified self-measures that I haven’t personally gotten into, but that I think has a lot of potential utility for not much investment is looking at actigraphy things like the fitness trackers and whatever. But just getting a sense of over days/weeks, what is your activity level? What are you really doing? And patterns emerge that you would never observe as you say on a day to day basis.
[Damien Blenkinsopp]: That will be interesting for this project as well because like I’m sure as your weight goes down your activity naturally tends to rise.
[Josh Fessel]: That would be my hypothesis.
[Damien Blenkinsopp]: And then as a benefit that most people aren’t going to think of like straight away, but it would be great – just have a Fitbit – be wearing a Fitbit. We discussed on one of our last episodes about the whole market and basically the Fitbit tends to be one of the better trackers at the moment. Or another one as long as it’s giving you directional info, it would be really interesting just to see that. So I think these projects are great, like I said, for inspiring other people for change. So good luck with that. In terms of your own personal life, just always interested to find out what people are doing with themselves. Are there any biomarkers or personal data you track on any kind of routine basis or monitor just related to health, longevity or performance, anything about your body really?
[Josh Fessel]: Yeah. So, the bathroom scale is there. So I track my weight every day and I track that pretty closely. At times I’ve even charted it out, made graphs, that sort of thing. That’s been really informative. I’m a pretty careful calorie counter. I keep a really close count on a daily basis of the calories going in and –
[Damien Blenkinsopp]: Is that just by kind of eyeballing? Like that’s roughly 200 I’m consuming right there.
[Josh Fessel]: It’s about that. I mean I spend a lot of time reading labels and that kind of thing. I’ve had periods where I had the flexibility in my schedule to actually weigh foods and that sort of stuff and carefully measure out serving sizes and I love being able to do that. In terms of satisfying the practical demands of every day, it’s a lot of times by eye, but I’ve been doing it for a while and so actually have a pretty good database built up of “Oh okay I know that this is going to be this many calories and so on”. And I do that essentially on a daily basis.
[Damien Blenkinsopp]: Okay, great. So you kind of track roughly how much you consumed in a day of calories and you track your weight. Has anything interesting come out of that for you whether it be accountability? What kind of value have you got out of that?
[Josh Fessel]: Yeah, absolutely. Like so many people, I’ve struggled with my weight for a long time too and so at my heaviest I was probably about 230, 240 pounds.
[Damien Blenkinsopp]: Just out of interest, how are you now?
[Josh Fessel]: So now I weight between 145 – 150.
[Damien Blenkinsopp]: Okay. So like a big deal, a lot of difference.
[Josh Fessel]: Yeah. So I lost a lot of weight. Some of it was diet modification, some of it was activity, most of it was diet actually. But by being very careful about tracking calories and tracking daily weights and that sort of thing, I’ve been able to take that weight off and keep it off and that’s worked really well for me. It’s also made me very conscious about the dietary choices that I make. So, in general, I’m – lazy isn’t the right word – but I like to spend mental energy on particular things. And one of the things that I don’t love to spend a lot of time thinking about is what am I going to eat for any given meal? Or, if I’m hungry and I want a snack, I want to sort of check that box and get on with whatever it is I’m actually interested in doing. And so that coupled with being careful about calorie accounts has really had a great positive impact on my diet because the things that you can mindlessly eat without destroying your daily calorie count, tend to be pretty healthy things. So that’s worked really well for me and I’ve had some patients that that’s worked really well for. Others are much more exercise oriented and that’s the area that I’ve started more recently tracking my exercise over time with following either how many calories burned in any given workout session or I’m mostly doing treadmill and cardio aerobic kind of stuff.
[Damien Blenkinsopp]: So you’re using the machines or using your own device?
[Josh Fessel]: I use the machines typically. I haven’t yet invested in, like I say, an actigraph or a Fitbit or anything like that, which I think would be really interesting. But I’ve started tracking what kind of distance do I do and to motivate myself a little bit because I know that the piece that I am personally missing is regular physical activity. I think the data are really solid that that has health benefits beyond weight control and that sort of thing. So I’m trying to live by example as when I tell my patients to do this – and these are people – so I’m a pulmonary doctor by specialization. So the patients that I see all have lung disease. So here I am telling these people that have difficulty drawing breath to go exercise and it’s pretty hypocritical of me if I don’t make the effort myself.
[Damien Blenkinsopp]: Great, thank you for that. Okay, so last question. We’re talking about data on this show. So, do you have one recommendation? Like what’s the most important insight you have about using data in a way that’s going to be valuable to improve health, longevity, or performance? What would recommendation would it be?
[Josh Fessel]: If I were going to say anything about using data to guide performance, health status, anything, it would be to pay close attention to know what it is that the data are telling you or going to tell you before you get it and know what you’re going to do about it before you get it. This gets to the whole actionable thing. So, not all data are useful. If you don’t know what the data are really telling you, not useful. And if you know what they’re telling you, but you can’t do anything about it, not useful. And this is true in really any context I think. So before I would get a test results or order any kind of assay or whatever, I would want to know. And I do this in my research lab, I do this in my clinical practice. Before you order a test, before you run an experiment, have an idea of what it’s going to tell you and what you’re going to do with the likely or the potential outcomes. If it’s this, then I’ll do this. If it’s that then I’ll do this other thing. And if you can’t set that up on the front end, that’s not going to be a useful piece of data to you, so don’t waste your time or spend your money.
[Damien Blenkinsopp]: Great and we talk often about things being actionable, which is kind of like a jargon. It’s a bit of a jargon word, so I really liked the explanation you just gave, which was very clear and it was kind of like an exercise. It’s like before, plan what action you’re going to take once you find out the data is this, once you find out the data is that. And that’s a way of learning if it’s actionable – that it’s actually going to be valuable. But I think a lot of people don’t think about it. So I think that’s really a great piece of advice. It’s a great exercise before anything you’re going to think through that way. It will kind of force you to understand if it’s going to be of value to you in terms of taking action on it.
[Josh Fessel]: Well thank you. Yeah, that’s exactly right. That’s why I force myself to do it because if you don’t know – if you can’t make a plan, then it’s probably not actionable. And so maybe wait until you have other information or maybe discard it entirely and change the line of inquiry.
[Damien Blenkinsopp]: Well Josh, like final thing. Where can we reach you, get in contact? Are you on Twitter? Are you on a website? Where can people find you?
[Josh Fessel]: That’s a great question. No, I’m kind of a lead eye. I don’t even have a Facebook page, but I’m pretty findable. So, google search for Josh Fessel will find me. I’m on the faculty at Vanderbilt University. So, I’m that Josh Fessel. And I think there are a couple other people out there with the same name, but a google search and if you include Vanderbilt you’ll find me. That will link to my faculty page that talks about my particular background and my research interests and that sort of thing. And I think email addresses are there too. So, I can be reached any number of ways. I’ve spared the world my thoughts a 140 characters at a time. So, like I said, I’m a little behind the times there. But, yeah, I’m pretty findable online and that’s probably the best way to do it.
[Damien Blenkinsopp]: Great. Well Josh, thank you so much for your time today. I really appreciate it. It’s been a great discussion.
[Josh Fessel]: Oh, no. Damien, thank you. It’s a pleasure.

Leave a Reply

This episode is about experimenters in the field of biohacking, the people actually in the trenches doing stuff. We’re focusing on wearable devices such as watches, shirts, bracelets, necklaces and on and on.
We’re focusing on wearable devices such as watches, shirts, bracelets, necklaces and on an on. Basically, anything that you can put on your body that can give you data on your performance.

Wearables are here to stay and there are more coming out to track different aspects of our biology, of our health and our fitness, and so on. Which of these devices give us the most accurate data? How can we make good use of the data and improve our lives instead of just letting all those numbers cause confusion and distraction?

“You really have to get this intersection of who is the user. How much data do they want? Are we giving them enough data and is it accurate data?”
– Troy Angrignon

Troy Angrignon is an emerging technologies consultant with expertise in marketing strategies and segmentation for wearables. Troy spends a lot of his time testing several of the latest wearables while doing a range of relatively extreme athletics and feats, including military style training like that done by SealFit. He reviews and compares the products then maps them all out into big ‘x and y’ diagrams simplify data and make test easier to understand.

The show notes, biomarkers, and links to the apps, devices and labs and everything else mentioned are below. Enjoy the show and let me know what you think in the comments!

itunes quantified body

Show Notes

  • Troy’s interest in wearables started with early generation sports watches that could tell the user how much recovery time they would need after a particular workout. (4:05).
  • Improvements in utility of wearable devices over the past 10 years from sport watches to fitness trackers, to activity trackers to smart watches. (6:25).
  • Value of wearable tech depends on the user’s activity level and goals – Troy Angrigon’s 5-tier approach ranging from the semi-active user who needs little more than a watch with a timer to measure how long or how fast they ran to the pro athlete looking for clinical data. (7:33).
  • Devices currently available that cater to the tracking needs of elite-level endurance athletes: Garmin 920Xt and Fenix. (11:10).
  • Discussion of accuracy of wearable devices – Damien notes that tests have shown the degrees of error to be roughly the same between manufacturers. (13:10).
  • Devices currently available that are accurate enough for optimizing performance at a high level (17:10).
  • Problems with current software that misinterprets sedentary activity such as watching t.v. and reports it as sleeping. (20:32).
  • Fitbit Surge design advantages – combines GPS with optical heart rate monitoring (21:42).
  • Design areas where Troy Angrignon thinks manufacturers are excelling: Fitbit has good tracking for lower level users, Jawbone offers good customer service and good apps, and areas that still need work: understanding the customer, how they live and what they are going to use the tool for. (22:45).
  • Devices for lower activity level users: Fitbit, Jawbone and Body Media (23:47).
  • Devices for mid-level users: Fitbit Surge HR, Garmin Vivoactive, Garmin FR620 (27:14).
  • Devices for high-level users: Garmin 920XT, Fenix and Epix models (29:10).
  • Platform compatibility issues between manufacturers – users with several devices from different manufacturers can’t pool or cross correlate their data easily(29: 58).
  • Application issues with EEG devices: Muse, Emotive; collect data but few apps have been developed for converting the data into usable or actionable information. (30:40).
  • Meditation as a tool for improving mental and physical performance. Damien mentions using meditation in conjunction with the Muse (32:05).
  • Discussion of sleep tracking devices for different user/quantification levels: level 2 analysis reports how many hours in bed and of that how many hours spent sleeping vs. tossing and turning; level 3 reports deep vs. light sleep phases, records snoring, level 4 provides clinically verified data, level 5 provides raw sensitive data. (35:04).
  • Troy and Damien describe techniques they’ve each used to improve their sleep quality: cover bedroom window with blanket to darken the room, turn off all screens, programmable lights; devices to use: Basis, Jawbone, Fitbit Sealfit Unbeatable Mind, Lumen Trails. (39:48).
  • Price ranges of wearable devices (50:00).
  • Risks associated with EMF exposure from wearable devices. Damien mentions that most people aren’t aware of potential detrimental health effects of EMF’s. Topic is discussed in the book 4-Hour Body by Tim Ferris. (52:55).
  • Sleep coaching tool: Sleepio.com. Troy mentions this tool, which educates the user on the complexities of sleep and identifies the user’s particular sleep issues. (56:30).
  • Troy Angrignon’s prediction for the direction wearable device technology is going in the next 5-10 years: we are currently at an immature stage in being able to collect and analyze data. He hopes we can compress the maturation period of this technology and not have to wait 30 years until we can turn data into actionable intelligence (57:55).
  • The biomarkers Troy Angrignon tracks on a routine basis to monitor and improve his health, longevity and performance include sleep via Sleepio.com, heart rate variability with the Garmin Forerunner 920xt and recovery levels through RestWise.com.
  • Troy Angrignon’s one biggest recommendation on using body data to improve your health, longevity and performance is to decide on the one thing that would make the biggest difference to you and track it.

Thank Troy Angrignon on Twitter for this interview.
Click Here to let him know you enjoyed the show!

Troy Angrignon

The Tracking

Biomarkers

  • Sleep-Related Biomarkers: Measure sleep in total time (hours and minutes) and percentage of time spent in different sleep phases:
    • REM (Rapid Eye Movement) sleep : Characterized by random eye movements and is physiologically distinct from non-REM phases of sleep. Troy mentions that the Basis watch measures the amount of REM sleep.
    • Deep Sleep: Characterized by slow, synchronized brain activity and is the most restful phase of sleep. Mentioned by Damien in relation to inability of the Basis watch to track properly.
    • Light Sleep: Also known as stage 1 sleep, a non-REM sleep stage that forms the transition from wakefulness into deeper stages of sleep. Mentioned by Troy in context of the Basis sleep tracking watch.

  • Heart Rate Variability (HRV): Mentioned by Troy as an indicator for over-training. HRV is a physiological phenomenon whereby the heart rate changes to accommodate physiological, mental or emotional stressors.
  • VO2 Max: Mentioned by Damien as a test available through fitness labs. Measures an athlete’s maximum oxygen consumption rate and is used to gauge aerobic fitness levels.

Lab Tests, Devices and Apps

  • Colored LED Lights: Damien mentions using these to help with sleep.
  • Apple Watch: Smart watch with fitness tracking capability.
  • Basis Watch: Smart watch with sleep tracking. Mentioned by Damien for its inability to distinguish sleep from sedentary activity.
  • Beddit: Sleep tracking device. Troy mentions that version 1 was offered in consumer or pro models, with the consumer model being cumbersome to operate.
  • Beddit Misfit: Under mattress sleep tracker.
  • Body Media Fit : Mentioned by Troy as having a loyal customer base. Strap-on style device worn on arm.
  • EEG (electroencephalogram) Devices : Measure brain wave activity, used to determine sleep cycles. Mentioned by Damien in relation to tracking sleep.
    • Emotiv: EEG monitor Troy mentions that he hasn’t tried yet.
    • Muse Headband: Contains an EEG device.

  • Fitbit Products
    • Fitbit Surge: Fitness watch that offers GPS tracking, heart rate monitor, all-day tracking, sleep tracking, and wireless syncing. Troy mentioned it in relation to its optical heart rate detector.
    • Fitbit Charge HR: Fitness watch with automatic monitoring.

  • Garmin Products
    • Garmin Fenix: Mentioned by Troy as a durable device, good for competitive and endurance athletes.
    • Garmin Forerunner 920xt: Mentioned by Troy as a durable device, good for competitive and endurance athletes.
    • Garmin Vivoactive: Good for running, cycling and swimming but not able to track transitions in triathlons
    • Garmin Epix: Similar to the 920XT and Fenix plus a larger screen with high-reolution color and apps.

  • Jawbone Up : A line of activity trackers. Mentioned by Troy as being problematic for its clip-on style and not being waterproof.
  • Lumen Trails: Tracker app Troy uses to simplify tracking for many things.
  • Sleep Tracking Devices
    • ResMed S-Plus: Sleep tracker with connections to Phillips Corp.
    • SleepRate: Sleep tracker mentioned by Troy as having a different scoring algorithm than Jawbone.
    • Sleepio: Sleep tracker mentioned by Troy in relation to its scoring algorithm.

  • Restwise: App Troy uses to track post-workout recovery.
  • Suunto: A Finnish manufacturer of measuring instruments that carries a range of sport watches. Troy mentioned their products as having excellent hardware but cumbersome software.

Other People, Books & Resources

People

  • Dr. Greg Welk: A Kinesiology Professor at Iowa State University where he oversees the Physical Activity and Health Promotion lab. Listen to Damien’s interview with Dr. Welk on the accuracy of fitness trackers in episode 18.
  • Dave Asprey: author of The Bulletproof Diet Mentioned by Troy in regards to brain training for increasing focus and blood flow to the pre-frontal cortex.
  • Ben Greenfield: Mentioned by Troy in relation to sleep improvement tips. Maintains a fitness website and blog.
  • Ray at DCRainmaker.com: Triathlete who maintains a website and blog. Mentioned by Troy for his extensive product reviews.
  • Dr. Kirk Parsley: Sleep clinician for Navy SEALs. Associated with performance program called Sealfit Unbeatable Mind.

Organizations

Books

  • The 4-Hour Body: The book by Tim Ferriss mentioned by Damien in relation to health effects of EMF’s.

Full Interview Transcript

Click Here to Read Transcript
[Damien Blenkinsopp]: Troy, thank you so much for joining us on the show.

[Troy Angrignon]: Hey Damien. Thanks, great to be here.

[Damien Blenkinsopp]: So, you have the absolute, most comprehensive review of wearable technologies, wearable devices I’ve ever seen. It looks like something from my consulting background years where I was paid big money to create those kinds of things.

So when I saw it I was like, yeah I definitely have to get this guy on the show. He’s put so much time and effort to looking at it from a user; what people actually need and the functionality out there. How did you get into this? Where did your interest in wearable devices start from?

[Troy Angrignon]: I’ve always been interested in them. I’ve always looked in the very early days at running watches, all the sport watches in the early days. The Suunto’s and the Garmins’s and things like that and even in the early incarnations, you could see some kind of cool things that were happening.

They would have interesting features in them. It would say, ‘you have to recover four hours after this workout’ and then say, ‘oh wow, that’s really cool. How are they figuring that out?’ So I got interested in some of the early sport watch stuff and really followed it through that. I’m a nerd and kind of a geek in general.

Anyway I like data. I’ve been involved in data based industries and loved doing sports. It really came from probably the sport watch side of things in the early days.

[Damien Blenkinsopp]: Great. So how long have you been doing this because the sport watch has been around for quite a while now?

[Troy Angrignon]: They have, right. Probably ten plus years and I really got into; I’d say what we know as this current generation of wearables or near-ables. You want to use that phrase.

Really about four years ago when I started looking at sleep issues; I was having sleep issues from working on a start-up and getting no sleep, and all those things. So I started looking at better sleep practices, a lot of stuff that you and I both went through in the bio-hacking space.

And looking at sleep practices as well as tools, so I started looking at a lot of tools and from there that was kind of the beginning. I think you were probably very aware of it at the same time. The sleep tools were happening and the activity trackers were starting to come out and things like that. That was probably 2011, 2010?

[Damien Blenkinsopp]: Right. Absolutely. What it is though, is sleeping activity is a big area? It’s interesting. Have you got a lot of data from over ten years reflected from all of these watches and things?

[Troy Angrignon]: No. Especially in the early days a lot of it, it’s hard to get the data off or it just comes off into space and you could look at it on some desktop application or something. So no, I think my largest, continuous data set is probably three years. I was just looking at it actually, all my workouts, probably for the last three years.

It’s spotty. There were sections where things didn’t track or I lost data or whatever else. Probably the last three years has been pretty rigorous.

[Damien Blenkinsopp]: I think you’re probably got pretty much on top of what’s been actionable and what’s been most useful for you over that time. How have you seen the curve of utility go up for you personally, because obviously you’ve been testing different devices and it’s been ten plus years?

In the beginning, was it useful or was it like trying to get some value out of this and getting a little bit but not so much? Like how to use scales on like one to ten, how has it changed over the last then plus years?

[Troy Angrignon]: Well I think two things have changed. There’s how have I changed. I own an approach to thinking about the data and I’ve kind of gone through my own levels of maturity in thinking about it. And then the technology, of course, is changing.

You and I have talked about this before where I kind of do think in that ‘x and y’ and I think that the market has evolved. We’ve gone from just sport watches to now, we’ve got fitness trackers, activity trackers and I can get into definitions of those things. Smart watches.

Some of the fashion companies; they’re with traditional fashion watches are now getting into smart watches. And so you’re getting this kind of bigger fragmentation and more features being developed. At the same time as what I want data has definitely changed and matured and mutated over time. So it has been definitely a change in both ways.

[Damien Blenkinsopp]: Great. Thanks. And who do you see is getting real value from the wearables tech on the market today? I mean you can take yourself as an example. What are you getting real value out of today and who else do you see getting real value out of these wearable tech today?

[Troy Angrignon]: That’s a tough question. I think a lot of different people of different skill sets can get value and it really comes down to what they are trying to do. So I think, maybe it will help set the stage probably for the rest of the call and give us a framework. Why don’t we talk through what we discussed the other day?

But I tend to think of user types as kind of a zero to five in a very gross, coarse way. So a zero would say, ‘I don’t care about data. I’m not going to use any of these tools. I’m just going to go run. I want to just feel the wind in my hair and get outside.’ Where a one would start to ask for some data, like I just want a watch that shows me the time. Like how long did I run? How far did I run? Maybe something basic.

A two would say, ‘well I want that but I want a little bit more data. Give me a few more fields.’ And a three really starts to say, ‘I want to know my time, my splits, my cadence, my running dynamics, my vertical oscillation. They start to get pretty technical in terms of what they’re looking for.

And the fours, they’re really looking for that. They want it to be trusted. They want to know that the data that they’re getting in those devices or applications truly is actually legitimate data. Where the threes are ok, just give me the number and I’ll kind of look at the numbers Is it going up or going down. I don’t really care if it’s super accurate.

And then the fives, you’re really talking Olympic athletes to that point. You’re talking people getting clinical, grave data. And so if you think about kind of the levels and you can apply those levels to the level of athlete too; zero probably doing nothing, one just starting, a two sort of semi-active, a three quite active, four pro-amateur level and five being a lead athlete.

And so if you think about those levels and then you think about what they do. Is this a wellness client who’s saying, ‘I just want to feel better, eat a little better, lose a little more’ or are they kind of a fitness type person that’s saying, ‘well I jog a bit, I run a bit, I cycle. I do a couple of things, I dance, I do yoga whenever. Or they’re really starting to get into the endurance in space.

So, I do run. I do marathons. I do long distance cycling. And then all the way up to what I call to the right on my charts where you’re beginning to know super competitive endurance and ultra-distance stuff. And ultimately you’re getting into like the outdoor, backcountry stuff where they’re like, ‘I’m going to go, put my watch on and go ten days into the back country.’

That’s a different animal. It’s a different kind of an athlete. So I tend to think of it kind of an ‘x by y’. And that’s a long back story to answer your question. But I think that people from, kind of the ones to the fives, on the y axis. And then everything from the sitting on the couch and just trying to get a little more active, all the way to the outdoor backcountry folks.

There are pockets of people in there who are getting a lot of value but I think it’s less about them and less about their specific technology and more about the process. So, are they clear on what they’re trying to figure out? Have they chosen the right tool? Does the tool give them the data and can they look at the data and have a feedback loop and say, ‘ok, I got what I needed. I’m going to improve my running speed or I’m going to back off and train less hard because I’m over-trained or whatever else.’

So, that’s a really fuzzy way of saying some people are getting useful stuff out of it and a lot of people are just looking at stuff and they don’t know why.

[Damien Blenkinsopp]: Right. And what we were talking about is a critical need the other day. You were talking about competitive athletes who want to shave off a few seconds off of their times or whatever.

This is critical needs and I guess these are the guys that would be using the fours and the fives that exist today. What kind of devices out there are there that provide that level of detail today, if there are any?

[Troy Angrignon]: Yeah, up in the competitive endurance space. I would look at, these are folks who are doing pretty aggressive, marathons, triathlons, cycling races, multi-sport, even obstacle course racing, which as you know is pretty popular these days, Spartan racing, those kinds of things.

And it’s less about those sports and more the level at which they compete in them. So we’re talking upper 50 percentile, upper 25 percentile folks. Now we are either looking at their times, very aggressive about their times. So once you get into those environments, your use case is pretty tough for a device manufacture.

You can throw a FitBit on these people. And then a lot of my friends bought Jawbones or Fitbits or whatever. What I would can an activity tracker, meaning something with an accelerometer in it and they last about a day because you get them wet, you cover them in mud, you get them in the ocean. Whatever happens, they short out.

So those kinds of users that are really competitive and endurance athletes, they’re hard on their toys. And they really need devices and apps, in fact they don’t even carry their phone with them cause they just trash them. So, you’re really looking at things like Garmin 920xt’s are a great example in the triathlon space or the Fenix, which is the new Garmin in the Fenix Backcountry watch.

Suunto has some excellent hardware, although their data is really hard to move around so I’m not a big fan of them for that reason. So yes, there are definitely tools that work in that space.

[Damien Blenkinsopp]: Great. And in the general where do you see most people using today? Is it in the level one? We were talking with Greg Welk who’s done ongoing studies on the accuracy of these devices and we got into this discussion of how they’re not accurate, most of them to varying degrees. They’re biased.

However, they’re roughly the same wrong every time. So you can check, the relative is difference to what you did yesterday. Consistently one direction wrong or the other so you will talk about the usefulness of at least I know had more activity or I was faster than yesterday at the very least. Is that how you look at that whole area right now? I mean it’s more of a relative difference you can use it for.

[Troy Angrignon]: Absolutely. And again, think of the ones to fives. Kind of drawing a picture in your head of kind of the ones to fives on the left side and then really the bottom of the chart, consumer wellness on the left and all the way through fitness, recreational endurance, competitive endurance and outdoor tactical on the right.

And so I think your question really gets to who uses these, let’s say activity trackers, like Jawbones, Fitbits, these little things that you can clip on. I don’t like clip on ones cause you just throw them in the wash and lose them and break them.

But let’s say the bands you can put on. And you nailed it; they’re not that accurate but if you’re a one you don’t really care. All you’re looking for is step data. And so, did I move a little bit more than I did yesterday? Is it consistently capturing the step data? Is it good enough?

And I have met so many people who say, ‘oh I’ve got my first one and I love it because I used to do 2000 steps and now I do 3000 steps.’ And does it matter that it was 3500 or 2500? No, it’s irrelevant. What they know is they a feedback loop which gives them some objective measure and it’s better than what they had before, which was nothing.

So I think that there’s still a lot of value there. There’s a really interesting company I was actually looking at it yesterday after you and I talked. Diva Metrics I think is the name and I think they’re in Montreal. I may have the city wrong, or Calgary.

And they’ve gone through a really rigorous analysis on how inaccurate all these tools are and making data correction tools. So they’ll say, ‘well this thing is 92% accurate so we’ll just take the data and just up it by the requisite 8% to reality.

[Damien Blenkinsopp]: That’s interesting.

[Troy Angrignon]: So, it’s pretty cool.

[Damien Blenkinsopp]: They can be selling that to the companies who design the devices.

[Troy Angrignon]: So I think there’s still a lot of value in just having some kind of indicator. Calories, I could go on a rant about calories for days. The shorter version is that I think calories in and calories out is a dead model. But a basic summary, whether it’s steps or calories, is it a number that’s higher or lower than it was yesterday.

That’s a great indicator for people that just didn’t have awareness of that before.

[Damien Blenkinsopp]: It’s definitely kind of how serious you are about doing what you’re doing. So if you take an example of sleep. That’s what we were talking about this last time and we’re both fans of sleep, obviously.

I was really interested in the Basis Watch when they were bringing the sleep tracking out because I wanted to understand my deep sleep versus other areas of sleep. And I really just wanted to know I was hitting my eight hours that I wanted and trying to push it up to nine for a while.

I was pretty disappointed because it was saying I was asleep a lot of the time and I wasn’t able to trust that data because if I was sitting around watching TV, or even working on my computer sometimes, it would be like yeah you were asleep in the middle of the day.

So I couldn’t actually use that for just an estimate of how long I was asleep and because I didn’t trust that, I didn’t trust how much it was saying I had in deep sleep either. I didn’t feel like I could do any of the experiments, like to increase your deep sleep because that’s one of the things that I was interested in doing.

I gave up on those experiments and trying to optimize that. By having these biases, it really limits the kinds of experiments and what you can do. If we’re just trying to get a little bit better, like say with the activity trackers. Its fine, we just want to make sure we’re moving. The Basis Watch I’m sure, loads of others, you can point out would be ok for that.

But if we want to actually go to the next stage and optimize it to another level, to a higher level, a more competitive level and get more out of that performance, whatever that angle is. If it’s sleep or running, it’s not quite there yet.

Or are there devices which you feel are there in certain areas, whether it’s sleep or running or areas where you can really optimize pretty well and move to the next level?

[Troy Angrignon]: There are and it’s interesting and I’ve really been wrestling with this a lot. I’ve looked at and broken everything out there or bought and given it away. I’ve tested pretty much everything I’ve ever written about.

You can definitely get more data. You just gave a great example with the Basis and it’s a bit my favorite whipping horse because it’s got some weirdness in the way they develop product. But essentially they try to give these really advance, what I would call QS level, quantified self-level for type of graphs.

A graph is pretty complex and you would expect a person in a pretty deep understanding of visualization and data analytics in order for them to use it. But yet a whole watch was really aimed at couch to 5k, people who are walking and maybe cycling.

In fact, that’s all it will even track, actually. It will self-identify activities. And then in the sleep arena, as you said it had things like deep sleep, REM sleep, light sleep and activity but everybody I know who has one said, ‘yes, they always tell me I’m sleeping when I’m sitting at the opera,’ which is probably true but that’s not relevant.

I don’t really want it showing that I’m sleeping at the opera. Or I’m watching TV or I’m sitting down to dinner. It was trying to do automatic sleep categorization. We’re running into really tough to build hardware and software that does auto-sensing and auto-identification of activity, whether that’s sleep or running or cycling or anything else.

You tease apart all of these issues, what it really comes down to is, as a vendor these guys have to get together and say, ‘well who really is our user and what level are they at? What use case are they using it for? Are they a triathlete and if they’re a triathlete, are they a one, two, three, four, or five?’

In my view, I know triathletes who don’t use watches. They literally just have a Timex. They don’t care about anything else. They don’t use complex sport watches. I would call them almost a QS-1, a quantified self-level one, but serious competitive triathlete.

You really have to get this intersection of who is the user. How much data do they want? Are we giving them enough data and is it accurate data? There’s this really complex landscape out there, which you and I talked about. This is why people are so confused right now.

[Damien Blenkinsopp]: Your charts are amazing. It’s amazing how many devices are there, already. And there is obviously a lot of money going into this space. What I guess is interesting is if you take the Basis as an example, again and I guess the Apple iWatch which is coming out.

Applications like that are trying to give people at home a very generic tracker, which is going to have a broad spectrum of things it’s tracking. But it sounds like you’re saying that just because the hardware isn’t there yet in terms of actually getting data from us, that the software can’t handle figuring out what we’re up to.

If you’re trying to track everything like are you asleep, are you moving, what are you up to, all of these kinds of things, yet the hardware isn’t accurate enough to be able to take that data and use some software to interpret it.

But if, like you said, we focus on a narrow use case, where the conditions we understand a lot more closely because it’s just one area of use rather than trying to track someone’s whole life. And that’s working and you can see that it’s possible that we can get there this time even though the hardware is not quite there yet. Is that kind of your viewpoint?

[Troy Angrignon]: Yes. I think it’s a reasonable summary, especially when we started with things like 3D accelerometers. They really don’t do much. They just give you rotation and space and G-Force, and that sort of stuff.

It’s pretty hard to extract really clean signal out of that and figure out what the heck is really going on. Is this person running or jogging or doing cycling. That was a big issue. There just wasn’t enough data or the sensors were even terrible and there weren’t enough of them.

Then we started to do things like, a great example I think that I was quite impressed by, is Fitbit Surge, their new heart rate based one. It has GPS for location, it has optical heart rate on the back, so it’s shining right into the skin, in the tissue just above the wrist and reading your heart rate which is pretty challenging to do.

They have the 3D accelerometer and they can use all of that combined so the GPS will be shut down. It will say, you’re not moving or it will actually just be shut off. It will say heart beat is low and there is no motion in the body and it’s late at night.

So it’s starting to get easier and easier for them to identify that you’re going to sleep and to pick that pattern out, or to just show that you’re active. I can see you’re active. Your arm is moving, your body is pumped up and I’ve got a lot of very heavy heart rate, sustain heavy heart rate. You’re probably doing something.

Now they don’t try to self-identify, which I think was the right move. You can mark it and tell it that you’re doing yoga or doing a workout. I think it’s all trending in the right direction.

[Damien Blenkinsopp]: So if you were would like to point out on the landscape right now what manufacturers are doing right and what needs work, in specific areas, where is your pet peeves and where are the areas where it’s doing a really good job?

[Troy Angrignon]: I think my biggest pet peeve across the board is just not understanding your customer. It goes back to what I said a few minutes ago. Know who your customer is. Know how they live and what the use cases are that they are going to put the tool through.

That really helps the vendor narrow down to what features does it have to have, how rugged does it have to be, how much battery life does it have to have. I have not been traditionally a fan of Fitbit. I know they are the 800 lb. gorilla here in North America. I think they had 67% of the market share in 2013 and I’m not sure that’s a ’14 number, but they have a broad spectrum of product.

[Damien Blenkinsopp]: So which devices do you see as being the most effective, the best buys right now, doing a really great job for users?

[Troy Angrignon]: Again, it depends on who you are, but I think there are some ones that are standing out. Moving left to right again and from ones to fives, lower left to upper right if you keep that chart pictured in your head that we talked about earlier.

The folks that want to just get a little more active than they were or they’re lucky to move a little more, track a little more and ones and twos in terms of tracking and they’re not really hard on their toys. Any of the new Fitbits (they’ve launched a whole new line) I think are doing a pretty good job.

They’re number one for a reason. I think what’s going to be interesting in that space is Jawbone. Jawbone I lost and or broke and destroyed a bunch of them and they were very good in Customer Service and kept sending me new ones.

I like their apps. They’ve got a good partner network. They’ve got a new one coming out; the Up 3 and they’re actually integrating some of the technology they bought from Body Media and I know that people who have Body Media’s, you can’t pry them off of their cold dead bodies.

It’s pretty interesting. They are rabidly loyal fans. That was the big one you strap on your arm basically. A lot of people are really attached to that and so they’ve taken some of that technology, like the bio impedance sensors and things and put it into the new Jawbone Up 3. I haven’t tested it but I have a pretty strong belief that they’re going to do a pretty good job at that low end of the activity tracker section. It will be interesting to see and that should be out March or April.

[Damien Blenkinsopp]: With those two devices, what kind of things do you think people could reasonably do? What kind of functionality are people thinking they just want to know they are doing more? How far do you think they can push those devices and get useful decision making out of them, using them to maximize something?

[Troy Angrignon]: You really can’t do a ton. They do basic activity tracking. They basically show you how active are you; you’re active parts of your day. They’ll give you calorie data and it’s totally inaccurate, so I wouldn’t use that. I would use the steps as just an indicator like you and I talked about. Am I doing more or am I doing less? That’s really what you want to look for, just for trend data day to day.

The Fitbit has sleep tracking. The low end of their stuff you still have to push a button or mark it. I think that’s a non-starter. That’s not sustainable because people forget. As you move up into their new ones like their Charge HR, which stands for heart rate and a Surge HR which has a screen and also does heart rate, you’re getting into more into the fitness tracker space.

Now you can track your day to day activities, see trending patterns. You can actually auto-sense your sleep or it will auto-sense your sleep. It’ doesn’t give you very deep sleep data. It just shows you are you restless or are you awake or are you asleep. It’s really three states essentially

If you’re really a nerd like you or I and you want to see deep sleep and light sleep and all that, it really doesn’t do that. Jawbone actually has always done that, although they’ve only done it through the 3D accelerometers. I’ve never really trusted that data.

With the inclusion of the new stuff, the new technology they bought from Body Media, I suspect they’re going to start to be able to pick up because they can sample the heart rate through the night and do things like figure out your morning resting heart rate which is a nice thing to know.

So I think that’s going to be an interesting entry in the higher end of that low end, if that makes sense, the activity trackers. And then as you get into the middle range, I’d say fitness folks who are doing a couple of sports, maybe they dance or running or the odd bit of cycling, but nothing ongoing, then the Fitbit Surge HR.

I sound like a Fitbit rep which is funny because I’ve never been a big fan. But I think they’re doing a good job and you can mark different sports. It’s pretty good actually. The accuracy is even surprisingly high when I cross reference it to some of the higher end tools I use.

Really to me, it’s kind of one of the only successful ones in that middle of the road fitness tracker space; Garmin is releasing something called a Vivoactive which will be squarely in that spot. It’s for running and cycling and swimming but this is a key point- not for triathlon because that’s a whole other use case where you need to connect those sports together in a block, like a swim and a transition and a bike and a transition and a run.

That’s a multi-sport thing which really you find at the high end. So I would say in the fitness tracker stuff in the middle, you’re looking at the Fitbit Surge HR, maybe the Garmin Vivoactive. I have not tested it. I’ve seen it and I’ve used it and I find the touch screen a bit finicky.

Maybe the Garmin FR620, which is their running watch, is pretty nice in that space; clear, bright screen, auto-upload on WI-FI and Bluetooth. So literally you do your run and then that’s it. It just synchronizes and it sends the data up which I think for these things to be sustainable, all of this stuff has to happen automatically.

You and I talked a lot about that. It’s like how much overhead can we take away. We shouldn’t be saying to the user, ‘you need to mark sleep, you need to do this, you need to do that.’ We’ve got enough on our plates. They don’t want to adopt a baby. It’s not a Tamagotchi watch.

I think that the watch can do, the better. And then at the high end, definitely these days I would really lean to the Garmin lineup. They release three new ones at CES, the Consumer Electronic Show, which I was quite impressed with because I think they’ve done a very good job of understanding the use case.

They’ve got a 920XT for the triathletes and multi-sport folks, a Phoenix which is that plus the backcountry stuff and then their Epix, which is all of that plus a great big screen with high-resolution color and apps on it.

I think the Fenix and the 920 are the winners out there because they’ve got the same thing; auto-upload on WI-FI and Bluetooth. And to me the big deal is data. Is it automatic, is it easy to use, is it automatic, does the data go somewhere and can you get the data to other places. Does that make sense?

[Damien Blenkinsopp]: Yes, absolutely. There are different platforms, like the Basis is a closed one, or not?

[Troy Angrignon]: It’s an island and so is Suunto. They’re off in space, Timex is the same thing. And anybody who’s an island, it doesn’t make any sense anymore because people have something like, I’m making this number up, but crazy numbers of 20 or 30 fitness apps on their phone and they want all that stuff to connect.

[Damien Blenkinsopp]: And it’s also a trust factor I think. Because with the Basis you can’t extract the information so where do these numbers come from. So I think there’s also that angle when you’re talking about people who are getting more involved in it.

They can’t take the data off of it. They’re wondering what the data is inside of it and how it’s calculated and things like that. I know that’s been a big frustration with Basis users. Another interesting model is the Muse, like the Muse Calm, they had that EEG device where basically you have an open API and they’re bringing this hardware to market and anyone can connect to it, develop aps on it, although no one seems to be doing that yet, so I’m wondering how that’s going to go.

[Troy Angrignon]: I talked to Muse and have not used the Muse. The Emotive is another one. And any of these EEG things essentially they are saying it’s something you put on your head. It’s this thing that looks like it’s from the future. It has all these touch points on your skull and it picks up your brain waves or brain wave patterns.

I think the big question I always have is, to do what. What’s the application and so I understand you have the hardware and I understand you have some kind of open API application programming interface, some way for me to get the data out, but ultimately what am I doing with it.

I tested another one. I picked up one from Dave Asprey’s Bullet Proof site which was a brain trainer, focus trainer which is ostensibly teaches you to move more blood flow in the pre-frontal cortex. I have it and I could actually do it. It’s actually pretty cool because you can put this little film on and you can fly over the mountains and you can actually control it with your brain, which is really cool for about ten minutes.

[Damien Blenkinsopp]: But it was, I was at this bullet proof live conference so I did it there and it’s a lot of fun but it’s a nice fast game. It’s not integrating with your life I guess. It’s something like meditation that you have to take time out for.

[Troy Angrignon]: which I’m a huge fan of. I think meditation, I do it every if not every day, every second day. I know a lot of people, especially athletes who are really, really find that critical piece of their training. But I don’t think that these tools are necessarily getting you there.

I think they’re kind of early attempts to say, ‘look at the pattern in your brain’ and you’re like, ‘great, what do I do with it’. I don’t know what to do with that information.

[Damien Blenkinsopp]: My personal experience from the Muse so far, I’m meditating every day and I’m using that. I’m playing around with different things and different types of meditation, for instance.

Dan [unclear 0:32:45:5] and so on, and I have managed to shift it. Basically you have an index . You don’t exactly know what that is so that’s a bit worrying to me because it’s their index that they’ve given you.

[Troy Angrignon]: Again, it’s another made up number

[Damien Blenkinsopp]: Rather than some standard that you can rely on more easily. So I think that’s another concern I have about a lot of these devices. Some of the manufacturers come up with an index which is 1 to 100.

It’s not based on any standard and you’re left wondering, I hope it’s doing what I want to because otherwise I’m spending of time meditating and hoping that I’m getting better but I might actually be getting worse.

I definitely want to dig more into what that data means and how it’s calculated. Now I’ve spent enough time on ‘I have to get around to looking at this’. So I think people have that concern at this stage too. And it’s kind of this transparency thing again. If you can just pull the data off and you can see exactly what it is then it would give you that comfort factor.

[Troy Angrignon]: Well, let’s step through that though, back to the beginning of the conversation. A level one person, in this case a quantified self, level one person, they only want that number because they don’t really know and don’t want to know the complexity underneath the numbers.

So I understand why the manufacturers do that, to look at the slave tools. They’ll give you a score. Your sleep score was 85%. Now Jawbone’s sleep score is not the same as Sleep Rates sleep score, or Sleepio’s sleep score. Those are all different sleep scores. And they have different algorithms underneath.

Some are transparent, some are not. But ultimately the user just wants to know, ‘hey it was 85 yesterday, its 90 today’. I’m trending up and that’s a good thing. And they’re good, that’s fine as long as that’s all they want then they’re already ok.

But I think you and I, we’re not ones. You’re definitely not a one. You’re a five.

[Damien Blenkinsopp]: Hey, you’re a five too.

[Troy Angrignon]: I’m a five, you’re a five.

[Damien Blenkinsopp]: Don’t stop for any fives around.

[Troy Angrignon]: So, we’re not that user and I think we need to be cognizant that a one doesn’t want the level of data that you and I want. And that’s ok because they’re just in a different place. And it doesn’t mean also that we’re a badass athlete and they’re not.

You can find world class athletes who are ones. Who are like just give me my Timex watch, I don’t want to know anything else. So I think that those are two separate dimensions. So to get to your point, yes, a lot of people are doing these roll up scores.
In my mind that’s a thing you deliver to the users who are ones and then if you’re delivering product to be also available to the twos, the quantified self, level twos, then you say, ‘hey, here’s your sleep score. It’s 85%.’ Underneath that means is, you were in bed eight hours but only six and a half of that you were sleeping and an hour and a half of that you were tossing and turning.

That’s kind of a level two analysis. And a level three analysis would be; well actually you had deep sleep, light sleep, here are the different phases. Here’s how many times you were interrupted and maybe here’s a recording of you snoring. Sleep rate does that, which is a little bit creepy.

And a level four would be that plus all of that is trusted, absolutely, clinically verified. And then a five would be the raw sensitive data. Put me in a lab and hook me up to 50 machines, which I’m sure you do.

[Damien Blenkinsopp]: I’m tempted. I haven’t done it as much as I’ve wanted to yet. I bet you’ve been doing it for a long time.

[Troy Angrignon]: No, I do actually show up to something with three or four devices on me. I was at a heart zone training session in this last week and I showed up with all of these devices on my arms and everyone was like, ‘why do you have so many watches’.

[Damien]: Because I don’t trust anyone of these.

[Troy Angrignon]: I’m cross referencing them all.

[Damien Blenkinsopp]: Which one do I trust today. Just out of interest, you were talking about labs, you’ve done VO2 Max or any of these kinds of measures. I know you can go to fitness labs and do those kinds of things.

[Troy Angrignon]: No surprise. I love to do more of that lab type testing. In fact, I’m actually doing one this week with a start-up that’s in stealth mode around heart zone training and threshold analysis. I would love to do more of that.

Most of mine has been with these consumer grade tools. Really just looking to see which one is the most accurate of the bunch because I am not at the level with my own training and with my own coaches where I need to be within, for heart rate threshold analysis, I don’t need to be within one beat. It’s not material useful for my training.

[Damien Blenkinsopp]: For most of my stuff I’m there. I’d say like the most critical thing I have is sleep. And I’d really love to know exactly how many hours I’m sleeping. And it’s more, for me its accountability. It’s just like if I get a little alarm and it’s like you only slept five hours the last few days, then I’m going to act on it. That’s the big thing and that will change my life, just that little thing there.

[Troy Angrignon]: I think it would change everybody’s life. I fell into this rabbit hole. You and I both came to this from having health issues. I was having sleep issues. That was my big thing at the time. I’m sure a lot of your listeners know your back story.

So I came into it from the sleep angle of going, ‘man, I’m not sleeping,’ and I’d like to prove that. I learned a lot from the bio hacking community and the bullet proof executive and Ben Greenfield and all of these guys.

And I was like, ‘ok, I need to make the room black and I need to go to bed early and turn off my screens at night’. All the stuff that we now know is good sleep discipline. There is another word.

[Damien Blenkinsopp]: Sleep discipline is a good word because all of things take a little bit of effort to do them, that’s all. Once you’ve got a routine and you’re doing them, then it’s great.

[Troy Angrignon]: Right, and so coming into it I think that everybody kind of vectors in on these things like what is your one thing that you’re working on. Actually, that’s a good thing to talk about here which is, what is your one thing? What’s the one thing you want to change the most?

Do you want to increase your time or do a race and just finish or do a race and be top ten? Or just sleep better? And that helps you pick the universe of possibilities of things you might use as a tracker, maybe you just pick the one thing that will help you get to that step and don’t try and boil the ocean.

[Damien Blenkinsopp]: So you’re saying don’t just try to attempt to track everything? When I got the Basis I wanted to have it all. I’m not picking on Basis here, it’s just that when I happened to jump on to it a couple of years back so I had the most experience of it. And it didn’t do that and the Jawbone or the Fitbit didn’t do it at the time. So what you’re saying is decide that one thing and that’s going to decide what device you get and you’re going to get that value out of it, if that’s the most important thing to you, whatever you want to change.

[Troy Angrignon]: Right. And I think that that’s a really good object lesson for all of us. I’ve been through all of these things so I ultimately I always come back and think about it. Now that I’ve tested it and I can talk to other people about it, that’s fine. But for me, what am I working on next and therefore what is the right tool for me, today or this week?

[Damien Blenkinsopp]: Well cool, let’s talk about some quick case scenarios then and the market and where it is today. What would you do? Let’s start with sleeping. If we’re just trying to improve our sleep or get some accountability behind it, which device would you choose right now, and you think it would do the job? Would you think it would do the job?

[Troy Angrignon]: Yes. So I wouldn’t even get a device. Actually I would just listen to Ben Greenfield’s podcast that he did, a long presentation, a bunch of Q&A that he did at Sealfit Unbeatable Mind, I think you and I talked about Sealfit. He was down there for a conference. He’s published the podcast and it’s an excellent podcast. I highly recommend it.

[Damien Blenkinsopp]: Cool, is this on sleep or is it Q&A?

[Troy Angrignon]: Well inside there he has this whole how to bio hack your whole life. He goes through 4000 things you can do and so many at the end rightfully said. ‘Look dude, my brain exploded. Where do I start?’ And he came to the same thing. He was like, ‘pick one thing. Pick one area that you would like to improve, one metric in that area and look for the right tool.’

To go back to your question, the right first device to fix your sleep is not a device. It’s reading up on the basics of sleep, understanding what good sleep discipline is, doing things like blacking out your room. Maybe the first device is a big hairy blanket you hang from your window. That’s probably the best device. The cheapest thing that you can buy that’s going to have the biggest impact.

[Damien Blenkinsopp]: You’re laughing about that but that’s exactly how I started. I just got a big furry blanket and I’m guessing you did too. I had come to visit my parents and I all of a sudden read this stuff. This is years ago and I grabbed a blanket and put it up and they were like, ‘what the hell are you doing?’ And they really didn’t like it because it’s just not done, I guess.

[Troy Angrignon]: Somewhere I read was like, ‘tinfoil doesn’t pass any light through’, so I completely tin foiled my window and the very next day the building manager came up and said, ‘you need to take that down, you look like a crazy person.’

[Damien Blenkinsopp]: Some of these things, if you go this route, is a pain to take down. Otherwise you just leave it up. You’re like, ‘well I’m not in that room during the day anyway.’ But other people aren’t so [unclear 0:41:56:3]

[Troy Angrignon]: Exactly. I think there’s a lot of work and we don’t need to go down that. This is more about devices. There are a lot of things you can do. I would say black out the room, put things like ‘F LUX F. LUX’ on your computer at night. It dims the screen. There’s a lot of stuff about not having blue light at night. This is all well documented at Ben Greenfield or Dave Aspreys Bulletproof podcast.

[Damien Blenkinsopp]: Well the one thing I have done, because I didn’t trust the Basis data, was I have this little tiny app which tracks all manor of things. It’s just like a little tracker app. It’s called Lumen Trails. There are probably plenty of others like that, but for some reason three years ago when I started tracking a lot of stuff, that was the one out there.

And it just allows you to put data in and it just allows me to press a button which says I’m going to sleep and then when I wake up, press it again and now I’m awake and then I know how long I slept. That’s really the most reliable measure I had and I’ve got huge chunks of data like months where I was doing that.

And I found that useful although it’s not automatic, it’s a pain. But at least it gave me some kind of register. Because I found out I really don’t know sometimes what time I, especially if was tired if I went to sleep, I won’t really remember at what time I went to sleep and what time I’m waking up unless I’ve actually gotten it written down somewhere.

[Troy Angrignon]: And I think you just nailed it. You’re a very quantified guy and it was still a pain and we need to get away from that stuff. This whole thing of you have to click a button, it doesn’t matter how small that motion is, we have too much going on to make the users do that.

I’m coming back to being a PR dude for Fitbit here, but I think the Charge HR does this as well but I know that the Fitbit Surge HR does this. It just automatically figures it out and unlike Basis, which would say I slept five blocks of 30 minutes, which is just insane.

The Fitbit Surge actually does a really good job of saying, you went to bed now and you got up then and it was eight hours and you were actually asleep for six and a half. It doesn’t give you any depth below that, so it’s kind of a quantified self, level two answer.

Eight hours with six and a half with real sleep inside there and there are no phases or anything else, but it’s automatic. I don’t have to think about it. I’m quite willing to make that trade off because I could get more data but then I would have to think about it and I don’t want to think about it. I have enough tools in my life.

[Damien Blenkinsopp]: And for 99% of people, that data is going to be actionable. That’s going to tell them what they need to know.

[Troy Angrignon]: Absolutely. Because you can look at it and see, ‘oh well, gee, I got four hours, four hours, four hours, four hours. And it actually displays your actual sleep time. So it’s been showing me things like three and a half hours. I’ll be in bed for five or six and it will say three and a half. What do you mean three and a half?!

It’s showing the actual time that I’m not moving and I’m really dead to the world. I have to laugh about that. I think finding a basic device like that is good, but something that’s automatic I think is also helpful.

If you have real sleep issues, sleep is a really critical issue and we are all as a population lacking in good quality sleep, I think this is worth investing time and energy and focus on, because it improves everything. There’s hormonal issues and weight loss and moods, just a million things. In my book it’s foundational so I think it’s the place everybody should start.

[Damien Blenkinsopp]: Sleep and meditation I think, are the two things that I want to get done every day. We are always thinking about these huge lists of task, but I’ve really tried to start putting these two things at the top. So if I don’t do anything else at least I’ve slept and I did my meditation.

[Troy Angrignon]: Yes, if more people would prioritize that. Down at Sealfit Unbeatable Mind there’s a really great fellow there, Dr. Kirk Parsley. He is a Sleep Clinician for Navy Seals and he said, ‘my biggest challenge is, a) they don’t sleep that much because they’re training all the time and b) I have a hard time in getting their heads around the fact that sleep is fundamental and foundational to everything they do. And that lesson is not just for them. That’s for all of us.

[Damien Blenkinsopp]: So you fixed your sleep. What did you find that the main things were that you’re doing and that worked for you just since that’s something that you worked on a lot?

[Troy Angrignon]: The big things were I had to make changes at work. I had a very great team that I was working with at the time and I said, ‘look these are all the things going on and we need to shift some stuff.’ There were work changes, darkening the room, putting timers on my phone that would alert me to say it’s 9 o’clock and start winding down.

One of the big things that I did, which has made a huge material difference, is as soon the Phillips Hue light
ing came out where you could change all the bulbs and control them from your phone. I put timers on them. Back to the whole ‘don’t have blue light at night thing’, I put timers on them and I basically set the entire house and the whole thing dims from normal lightening and deep submarine red lightening.

It feels like I’m in the Hunt for Red October movie. Feels like I’m in a submarine. But the whole house dims to basically 10% deep red by 9 o’clock. So really it’s fantastic and it sends this signal.

[Damien Blenkinsopp]: I bought some Amazon lights and I was doing that myself at one point but depending on my location it hasn’t been convenient. But have it set up at your homeand automatic, that’s really amazing. If it’s done automatically it’s going to happen.

[Troy Angrignon]: For a while I was doing it manually. I would turn certain lights off or I would do various things. Again, back to the overhead, I don’t want to think about this. I have enough going on in my life. We all do.

[Damien Blenkinsopp]: Well right because you say you were re-organizing your work. I would just be interested to know, you’re basically talking about stress loads here. For me I’ve been subscribing to the fact that if you have too many things in your head, we’re talking about adding things in terms of I’ve got to track this, I’ve got to track that.

That’s not going to be an easy way forward for us because it’s just too much. We already have too many items based in our heads. I don’t know if you did this for your work, but for my work I’ve been hiring a lot more people and systematizing a lot of stuff and basically knocking things off my table.

So just, even if I’m still working the 40, 50, 60 hours, at least I’m only working on four things. And I find that helps tremendously with sleep and just general stress levels. I don’t know if you’ve seen something similar.

[Troy Angrignon]: It does. I think you’ve nailed it and I think that this is all very self-reinforcing and everything is connected to everything. So your sleep supports your work and your work impacts your sleep. And this we could talk for days on this subject. So I think there are basic things that I did.

[Damien Blenkinsopp]: So it’s hard to actually see the quantitative impact in your sleep I guess. I don’t know if you were able to see that. Well you just feel better. You were able to see more hours slept or were there anything that you were able to see that and changed?

[Troy Angrignon]: No, absolutely. I went from two hours to near panic attack sleep to eight, nine hours of solid sleep and it took probably a year to make that change.

[Damien Blenkinsopp]: That’s something I didn’t have as serious as you. I was waking up at 4 o’clock in the morning and I there was nothing I could do about it. I would go to bed at 12 and I would wake up at 4 every day. I’d start working in the dark.

Luckily, I lived in Mexico at the time so I was looking out at the light, the sunrise on the beach and it was amazing. But my girlfriend wasn’t a huge fan of me waking her up at 4 o’clock in the morning when I left. So for me gradually the hours increased.

I think this is kind of funny; I was tracking it for a long time then I stopped tracking and I knew it was fixed because I wasn’t concerned about it anymore because now I’m sleeping seven or eight or nine hours consistently and it doesn’t feel like a problem for me anymore and so I haven’t tracked it for maybe six months.

[Troy Angrignon]: And that’s a really good point. You had an issue amongst all the other issues that you were working on and then when you got to a point where this isn’t really a problem anymore. I don’t need the extra overhead and headache of waking up, finding my phone, clicking this button, doing these things, tracking these numbers. You don’t care at that point. You’re not working on it anymore.

And that’s why it’s kind of like peeling the onion. Pick the one biggest thing, the one biggest boulder and pick one thing that you can do about it and start there.
[Damien Blenkinsopp]: And it’s not necessarily going to be the same thing that you’re going to be doing for the next year. Maybe you’ll work on it for three months, you’ll fix it and then you will say, what’s next. Hopefully you don’t have to buy a new device, depending on your budget.

Let’s talk quickly about budget, actually. I’m guessing the Garmin’s are some of the more expensive ones. I haven’t looked at the prices myself, but what do you think of the pricing at the moment? For the things I’m buying it’s relatively accessible, I think. They’re around $100 or $150, tops.

[Troy Angrignon]: There’s such a huge range. Before we jump to there, I’ll come right back. But before we leave the sleep subject, just so we can wrap up on the devices. There are a lot of devices ultimately after you get through figuring out what you want to do and fix, there are a bunch of devices as you know that will help you track sleep.

It could be as simple as a sleep cycle on your phone. I’m not a fan of that unless you put your phone on the Airplane Mode because you’ve got this EMF blasting a hundred meters of Wi-Fi right beside you.

[Damien Blenkinsopp]: Did you trust the data on that, because I used it for a little bit.

[Troy Angrignon]: No I didn’t really think the data was any good because it’s too hard to pick it up from the accelerometer on the phone and it’s sitting there beside you. It seems like a bit of a dorky way to do it. But again, if it’s better than it was yesterday, it’s consistently probably inaccurate, back to our beginning conversation.

[Damien Blenkinsopp]: I think that app is a couple of dollars, or is it free?

[Troy Angrignon]: Exactly, it’s a cheap way to get your toes in the water. And then going up a step from there, you could look at some of these low end, Fitbit or equivalent things that kind of clip on. Withings had one which was really dorky.

You’d have to find the sleeve and stick this thing in the sleeve and put the sleeve on and the sleeve would fall off. It was ridiculous. It was unsustainable. So I think anything that’s just really easy that you can put on and hopefully have to push one button and hopefully you don’t even have to push that button in the morning.

That’s a better case. The best case is you’re always wearing it and it just automatically knows you’ve gone to bed and it automatically knows you’ve gotten up. So, if and when you go to check the data, the data is already there and you didn’t think about it.

[Damien Blenkinsopp]: So after you looked at the Beddit and there’s a Phillips one as well. Or they’ve basically have got things placed on the mattress?

[Troy Angrignon]: The Beddit comes in multiple versions. The Beddit V1 came in two versions- consumer and pro, it was Bluetooth legacy, so it was a huge headache. So the process, very briefly was, go find your phone, turn on the phone, open it up, open the app, connect to the sensor, sit there and wait for it to connect to the sensor. Eventually it would connect and you would select the sensor.

Then you would open the app and you would go through these questions. I wanted to throw my phone out the window I was so stressed trying to go to bed every night. And I hated it and everybody I know who used it, stopped using it.

And Dave Asprey was always saying, ‘oh, I love my Beddit.’ And I couldn’t figure out why so I went and talked to Lasse Holstrum who is the founder and he said, ‘oh he’s got the pro version.’ Apparently they went to Bluetooth, BLE, Bluetooth Low Energy and cleaned that all up so it automatically connects to the sensor. So literally all you do is open the app, it auto-connects and you just say, ‘hey, I’m going to bed.’

[Damien Blenkinsopp]: So just to clarify, is that Bluetooth running all night?

[Troy Angrignon]: It is and that’s Bluetooth Low Energy and the transmitters are hanging off the edge of your bed, but there’s a great podcast that Ben Greenfield did about this one as well recently too. These things are not labeled or marked and for folks that really EMF wary, which I’m becoming more so these days, I’m not a huge fan of that frankly.

I haven’t used the Version 2, which is the one they did in partnership with Misfit. What I heard from the founder they were doing the right things for V2. Ultimately I tossed it in the box and got rid of it. I’ve tried the S-Plus by ResMed, which bought some of the IP from CO and it’s actually downstream from Phillips. I think it’s tied into Phillips Corp.

It’s this contact list that sits there at the edge of your bed and bounces these 10 G HZ signals off of your body and it uses echo location to try and figure out your chest respirations from your chest. I didn’t trust that data at all. They say the gut research data that says it’ as good as a 3D accelerometer, which is not saying much.

[Damien Blenkinsopp]: But what you said about it bouncing waves, so it’s bouncing waves of you all night?

[Troy Angrignon]: Yes. It’s basically just sitting there blasting EMF at you all night long, which seems like a bad idea.

[Damien Blenkinsopp]: That seems like a really bad [idea] especially for sleep. If you want to have good sleep, I’m not sure that’s the best idea.

[Troy Angrignon]: In my building I have 20 visible Wi-Fi access blasting out full-bore 100 meter, 2.4 G so I’m swamped in here anyway. So I wasn’t keen on it, sent that one back and then Withings go so slammed by people who hated their product that their CEO actually apologized for how terrible the product was so I don’t think there’s much there.

Then InFIT is one I saw at CES and it looks interesting. It’s a very heavy strip which sits underneath, not on top of top mattress but in between the top and the second mattress. It scans you through the bed. Again it’s doing some kind of signal through the bed.

This is a problem. Everything swarm you in EMF and pulls this data and broadcast from you and I think we’re going to be paying the price on that one at some point, but I’m not sure.

[Damien Blenkinsopp]: There don’t seem to be many manufacturers who are concerned about that though.

[Troy Angrignon]: They’re too busy in the hay day of wearables.

[Damien Blenkinsopp]: I guess we’re ahead of the curve thinking about EMF. Most people aren’t concerned about EMF. Most people you talk to don’t even realize there’s a problem. Although there’s some books which I appreciate like 4-Hour Body by Tim Ferriss.

He talks about the phone waves and keeping them away from your balls. But it’s little things like that. Ever since I read that, that’s a rule I’ve had. I’ve had my phones switched off for most of the time. We don’t know where it’s going.

That’s why there are all these devices out there and a lot of them have these and it’s the one thing that makes me resistant to play with all of the devices.

[Troy Angrignon]: Yes, because it’s an overload.

[Damien Blenkinsopp]: Yes. Maybe in ten years this is going to be something that I wish I hadn’t pursued so intensely.
[Troy Angrignon]: When you’re growing a third arm out of your forehead and you say how did that happen? I think to wrap this thing up on devices; there are a few different things that I would say, easy, lightweight, relatively inexpensive.

I would look at the Fitbits. It’s not deep data but its ok. I would look at the Jawbone Up24 or the Jawbone Up3, which is the new one coming out in month or two. And I think that those are reasonably good. I think the Jawbone actually does now and will have better sleep tracking with more data in it, if you’re more nerdy. That could be an interesting one.

That’s for now. Then actually I think the coolest thing I’ve seen in the sleep space and I’m actually using their program right now is a little thing called Sleepio., which is a sleep coaching tool. Sleepio.com and they’re in the UK.

And I can’t believe how well-done it is. Essentially you’ll get this little animated, British professor who walks you through the complexities of sleep and what your specific issues are. They’ve got incredibly deep, rich branching logic in behind this thing.

If you say my biggest goal is this and my biggest fear is that and my biggest issue is whatever, then that builds the curriculum from there and every week it pulls in your Fitbit or your Jawbone data and then it reviews it with you and says here’s what we learned. Here’s what we were working on. Here’s what you’re going to work on next week.

It walks you through it and ask you, ‘I will make a commitment to you that I will only give you advice based on these 30 years of scientific research and you need to commit that you will do your best to stick to this program because change is hard and changing sleep habits is hard.’ I thought that was a really interesting addition so it’s not a wearable device but it works with wearable devices.

[Damien Blenkinsopp]: That’s more intelligence side and definitely we need to see more of that. What do you think is going to happen over the next five or ten years because that seems like one of the endpoints where you have near artificial intelligence walking you through step by step and fixing your problems for you?

[Troy Angrignon]: I think that’s an early indicator of the direction that we’re going. The stuff that you and I have had to go through just to figure out a) figure out what we were asking and b) how to collect the data c) how to make sense of it or rationalize it or normalize it.

That was really hard for us because we started so early and d) what does it mean? When you look at it on charts and graphs, ‘well am I learning anything or not.’ How many thousands of hours have you spent looking at graphs thinking ‘I have no idea what that is.’

[Damien Blenkinsopp]: I have. You can Google a presentation of me showing people. It’s ridiculous.

[Troy Angrignon]: I actually had people call me on that. ‘That’s a pretty graph, what does it mean?’ It’s been a lot of work for us to figure that out and yet ultimately I have gotten to a point where I’ve been able to say, ‘I know what data means. I know what this is telling me. I know what these trends and patterns are. I can compare this to my goals and I can see I’m either moving towards or away from my goals.

That was a lot of work. That’s why I was so impressed with Sleepio, that they would come right out up front and say, ‘You’re not alone. A lot of people have these sleep problems. It’s also hard so get ready to dig in and do the work and we’re going to walk you through it.

It’s not artificial intelligence but it’s really well-done branching logic.

[Damien Blenkinsopp]: It’s pretty amazing it’s done that. As you said a lot of their hacks, hacks to fix sleep, hacks to improve different things. They’re just kind of still appearing and we’re just getting to the grips of the science and a lot of things.

This is why we have this show. We can focus on data or the data behind things so that we are acting and making decisions that are good versus we don’t know. It’s just opinion. We see a lot of opinion out there when it comes to fitness, health and all of these areas.

I think that’s part of the challenge with that. Before we can get there we need to accumulate a lot of data and people really need to know for sure that when you do this it equals this. But it sounds like they’ve got a really good job. Do you know where they got the actions, basically the things that they’re recommending from?

[Troy Angrignon]: No. I was going to dig into it and I thought actually that I would try a week or two and just walk through their process to see how that’s handled and I’m so impressed that now at this point I have to go back and dig into what their evidence is. What’s their ‘peer reviewing’ research.

[Damien Blenkinsopp]: Excellent. While I’m in London I might reach out to them Thanks for bringing it up.

[Troy Angrignon]: Actually I would definitely do it. They would be worth having on the show I think. And I think to answer your question, ‘where do we go?’ I had this really interesting conversation with a friend of mine, a colleague from my old industry which is Business Intelligence as well as some military intelligence analyst.

I said it seems like we’ve already seen this movie. We already know how to get from data to actionable intelligence, to smart guidance. To say given you’re trying to do ‘x’ the data says you should do ‘y’. And we already know what that data supply chain looks like.

Like how you get the data, clean the data, analyze the data, run it through some kind of mental model or framework and then that outputs this answer which says you should do ‘x’. Then you do ‘x’ and you run through the whole process again. And you say did that work or not. Where we are, we are just really immature.

We’re way back at step one where we’re collecting a huge pile of data and we’re providing some pretty charts and graphs. They’re not that useful and we’re providing a chart or graph, or five charts or graphs for one sensor.

What you really want is this nice, blended, normalized view of all of your data on one time base where you can just look at it and see, almost like those old biorhythm charts, if you remember those things. It’s like your mood is doing this and your sleep is doing that and you’re food intake is doing something else and your workload from your training is doing something else.

You can see the patterns and do eyeball correlation, like when I sleep really short my productivity really sucks the next day or my mood sucks the next day. We’re early in that process I think so we’re going to go through maturation.

I’m giving a talk on this IOT World, I think here in San Francisco soon. What I’m hoping is we can take those lessons from the other industries and instead of taking 30 years to get to the point where we can take data and turn it into actionable intelligence, maybe we can compress that to ten. I don’t know.

[Damien Blenkinsopp]: You’re absolutely right. It’s already being done so well. When I think about my corporate training, it was all analytics was being the big thing for a while. When I was in management consulting and strategy consulting, a big thing with that when you’re trying to roll it out was the KPI, the Key Performance Indicator.

It is one number which you’re trying to bundle a whole bunch of stuff into and then you had to balance the scorecards. You might have heard of those. Those are another nice way to look at data and make it more useful. So you’re right. It’s just about playing with all of these models that we already have. So much work and literally a decade has been spent on those things.

[Troy Angrignon]: I think we know that stuff. We just need to bring it across and import it from those other industries and hopefully we can do that and not take the same 30 years.

[Damien Blenkinsopp]: At some point. Where should someone look to learn more because you’ve got all of these great charts on your blog? So if someone wants to see the map of the whole wearables devices in 2015, those charts are awesome. Where do they go to get those?

[Troy Angrignon]: I don’t have a short URL for that. I’ll just give you the website and I’ll spell it out for everybody since it is a French complicated name. But its www.troyangrignon.com, that’s my full name, Troy Angrignon. There’s a Wearable section, Health and Fitness section, Market Map section and they are just different views into all of the different blog posts. I would say that’s probably the best place to go. Everything I write and all of my speaking that I do is always posted there as well.

[Damien Blenkinsopp]: We’ll put direct links to all of the charts and stuff and show notes as well as well so the people can find it.

[Troy Angrignon]: Oh yeah, that’s fine too, very good. That’s a great idea. Perfect.

[Damien Blenkinsopp]: I thought it was a French name.

[Troy Angrignon]: I can only swear in French.

[Damien Blenkinsopp]: Do you speak any French? So, besides yourself, are there other people you look to and you learn from in this whole wearable tech area, which are on top of it?

[Troy Angrignon]: Ray at DC Rainmaker. Anybody who has ever done any sports and used any sport device owes Ray a huge debt of gratitude. He has a site called dcrainmaker.com. You looked at my charts and we were laughing.

I said I felt like Russell Crow from Beautiful Minds sitting there in my garage connecting things with strings because everyone looks at this and asks is that in your brain? He’s even more extreme. He will do these reviews that are longer and better than any other review on the planet, but he will preface it by saying, ‘This is just a brief look. I will do my full review later.’

It just makes me laugh. And his real reviews are 30 pages deep of every screen and unboxing and it’s just insanely deep. So I have learned a ton from Ray. I owe him a huge debt of gratitude for getting me up to speed over the last couple of years. I would say he is the leader.

He knows so much about the industry. He gives great presentations at the ANT+ forum each year. You can often Google those and find those presentations. I get a kick out of them because he always starts with his first slide, ‘Why should you listen to me?’

And it says my site is now responsible for $900 million of purchasing decisions and he is not making it up. This isn’t even his day job. This is his side thing he does for fun. I would definitely point at him. The bio hacking stuff, you and I are already pretty big fans of folks like Ben Greenfield or Dave Asprey, lots of folks in there and their camp. Those are probably the biggest ones that I can think of.

[Damien Blenkinsopp]: Great. Thanks very much. Now for you; what are you focused on in terms of data metrics for your own life along routine basis? Maybe you’re doing a lot of projects at the moment but are there other things that you track on a routine basis and pay attention to?

[Troy Angrignon]: Aside from wearing four devices all of the time and cross referencing them, so the data I’m looking for is how good is the data. That’s a different thing. Personally, the things I track day to day are my sleep so I can go visit my little British Sleep Prof over at Sleepio and he can berate me for how little sleep I’m getting and my daily workouts. I throw a heart rate strap on and I put my Garmin 920xt on, which I love. I go do my workouts. I come back in and save it and it uploads and all of that stuff goes into Garmin.

[Damien Blenkinsopp]: Which actual markers do you look at? Do you scan them all or are there ones you pay attention to more? Do you look at HRV for instance?

[Troy Angrignon]: Yes. HRV, Heart rate variability, which we’re not going to go into here obviously, but it’s an indicator of how over-trained you are. I think my biggest ones are really sleep, activity level through my workouts and recovery level. The HRV and I use something called Rest Wise at Restwise.com.

I use Rest Wise, HRV, morning heart rate, muscle soreness and just my own intuition to assess how I am feeling. Am I over training? Do I need to back off or not? To me this has been a really big issue, which is ‘we can see the trees, we can’t see the forest’. Ultimately at the end of the day, I want to train as hard as I can; going up the curve towards some events I have planned.

But I also don’t want to over train and then incur risk of injury. I think we talked a lot about that in our one to one call. I think for me its sleep, recovery, nutrition, training load and stress load, which is an ambient awareness of it.

[Damien Blenkinsopp]: I guess with the sleep is what we were talking about. You just keep an eye on it and the number of hours you’ve slept.

[Troy Angrignon]: That’s a really interesting thing. I used to be very focused on deep and life and one of the pieces of education I got from Sleepio, is they’ve said, ‘we done this 30 years. We’ve realized that the phases inside don’t matter, which was a bit of a surprise to me, frankly.

What really matters is of the ‘x’ hours you spend in bed, what percentage of that time were you asleep. The phases inside that really aren’t material.’ Now I think that that’s a different case if you’re self-medicating yourself to sleep and you’re not getting the phases.

I’m just using Fitbit and Sleepio. It’s giving me a record and it’s giving me an efficiency score and that efficiency score is pretty low. It’s 65%. So I am spending 30-35% of my sleep rolling around.

[Damien Blenkinsopp]: I don’t remember my numbers. With the Basis mine were lower but I don’t know about these devices. That might be average for that device, right?

[Troy Angrignon]: It’s definitely nice having both the accelerometer and the heart rate in there to cross reference that data to get the slightly more accurate sleep analysis.

[Damien Blenkinsopp]: Thank you so much for your time today, Troy. Final Question; what would be your number one recommendation to someone who is trying to use some form of data to make their lives better, basically decisions on their body’s health performance and longevity?

[Troy Angrignon]: I think the number one is really just to know what you’re trying to do first. We talked about it in this call. What is the one thing that would make a real difference to you and what is the one goal you have set there? Is it your sleep or it doesn’t matter? Pick one.

Pick that one thing and do one thing in that arena and track one thing that’s material. That makes a difference. For sleep you want to just track number of hours and percent of time you’re in bed actually asleep. That’s huge. Have a goal and then track something that’s material that makes sense in relation to that goal.

I’ve seen too many people tracking way too much data that’s not material and that’s not useful and doesn’t lead to change. I had a conversation with somebody who literally tracked every meal for three years but didn’t lose a pound.

And they changed their diet and suddenly started shedding the weight because they got more information. For three weeks of not making a change, it should’ve been what I am doing isn’t working. I guess maybe that’s the second fall on point to make. Use the number and test the metric. If it’s not showing up try something new.

[Damien Blenkinsopp]: Absolutely. Keep it simple.

[Troy Angrignon]: And if the change you’re looking for is not happening, you’re probably not changing.

[Damien Blenkinsopp]: You have to give it a little bit of time, a week, two weeks, depending on what that is. And adjust for sure. Well Troy, thank you so much for your time. This has been a great discussion. We’ve pretty much looked at the whole landscape today. Thank you so much for your time.

[Troy Angrignon]: Damien, it’s been great.

Leave a Reply